

Evidence Synthesis

Number 164

Screening for Atrial Fibrillation With Electrocardiography: An Evidence Review for the U.S. Preventive Services Task Force

Prepared for:

Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
5600 Fishers Lane
Rockville, MD 20857
www.ahrq.gov

Contract No. HHSA-290-2015-00011-I, Task Order No. 7

Prepared by:

RTI International–University of North Carolina Evidence-based Practice Center
Research Triangle Park, NC 27709

Investigators:

Daniel E. Jonas, MD, MPH
Leila C. Kahwati, MD, MPH
Jonathan D.Y. Yun, MD
Jennifer Cook Middleton, PhD
Manny Coker-Schwimmer, MPH
Gary N. Asher, MD, MPH

AHRQ Publication No. 17-05236-EF-1
August 2018

This report is based on research conducted by the RTI International–University of North Carolina Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHSA-290-2015-00011-I, Task Order No. 7). The findings and conclusions in this document are those of the authors, who are responsible for its contents, and do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information (i.e., in the context of available resources and circumstances presented by individual patients).

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

None of the investigators has any affiliations or financial involvement that conflicts with the material presented in this report.

Acknowledgments

The authors gratefully acknowledge the following individuals for their contributions to this project: Elisabeth Kato, MD, MRP, and Howard Tracer, MD, AHRQ Medical Officers; Tracy Wolff, MD, MPH, AHRQ Associate Scientific Director; current and former members of the U.S. Preventive Services Task Force who contributed to topic deliberations; expert reviewers David A Fitzmaurice, MBChB, MRCP, MD, Richard Hobbs, MA, Stephen Morgan, MA, MB, BChir, MSc, MRCP, and Larisa G. Tereshchenko, MD, PhD; Federal partner reviewers at the Centers for Disease Control and Prevention; and RTI International–University of North Carolina EPC staff Carol Woodell, BSPH; Josh Green, BA; Christiane Voisin, MSLS; Claire Korzen, BA; Sharon Barrell, and Loraine Monroe.

Suggested Citation

Jonas DE, Leila C. Kahwati LC, Yun JD, Middleton JC, Coker-Schwimmer M, Asher GN. Screening for Atrial Fibrillation With Electrocardiography: An Evidence Review for the U.S. Preventive Services Task Force. Evidence Synthesis No. 164. AHRQ Publication No. 17-05236-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2018.

Structured Abstract

Purpose: To systematically review the evidence on screening for and stroke prevention treatment of nonvalvular atrial fibrillation (AF) in adults age 65 years or older for populations and settings relevant to primary care in the United States.

Data Sources: PubMed/MEDLINE, the Cochrane Library, and trial registries through May 24, 2017; reference lists of retrieved articles; outside experts; and reviewers, with surveillance of the literature through June 6, 2018.

Study Selection: Two investigators selected English-language studies using a priori criteria. Eligible studies included controlled trials of screening for or treatment of AF, controlled prospective cohort studies evaluating detection rates of previously unknown AF or harms of screening or treatment, and systematic reviews of trials evaluating benefits or harms of treatment. Eligible screening tests included electrocardiogram (ECG) screening (e.g., 12-lead ECG, intermittent handheld ECG) or screening with both pulse palpation and ECG for all participants. Eligible treatment studies compared warfarin, aspirin, or novel oral anticoagulants (NOACs: apixaban, dabigatran, edoxaban, or rivaroxaban) with placebo or no treatment. Studies focused on persons younger than age 65 or those with a history of stroke, transient ischemic attack, known heart disease, or heart failure were excluded.

Data Extraction: One investigator extracted data and a second checked accuracy. Two reviewers independently rated quality for all included studies using predefined criteria.

Data Synthesis: Seventeen unique studies (described in 22 publications) were included. No eligible studies evaluated screening compared with no screening and focused on health outcomes. Systematic screening with ECG identified more new cases of AF than no screening (absolute increase with 12-lead ECG, 0.6% [0.1% to 0.98%] over 12 months; absolute increase with twice-weekly single-lead ECG, 2.8% [95% CI, 0.9% to 4.7%] over 12 months), but a systematic approach using ECG did not detect more cases than an opportunistic approach focused on pulse palpation. Warfarin treatment for an average of 1.5 years was associated with a reduced risk of ischemic stroke (pooled relative risk [RR], 0.32 [0.20 to 0.51]) and all-cause mortality (pooled RR, 0.68 [0.50 to 0.93]), and an increased risk of major bleeding (pooled RR, 1.8 [0.85 to 3.7]) compared with controls (5 trials; 2,415 participants). Treatment trial participants were not screen-detected; mean age was 67 to 74 years; very few had a history of TIA or stroke (3%-8%); most had long-standing persistent AF; and baseline stroke risk scores were not reported. For a population of 1,000 adults age 65 or older with an annual stroke risk of 4 percent, this translates to an absolute reduction of 28 ischemic strokes and 16 deaths per year and an absolute increase of five major bleeding events per year. Aspirin treatment for an average of 1.5 years was associated with a reduced risk of ischemic stroke (pooled RR, 0.76 [0.52 to 1.1]) and all-cause mortality (pooled RR, 0.84 [0.62 to 1.14]) compared with controls, but the differences were not statistically significant (3 trials; 2,663 participants). A network meta-analysis found that all treatments reduced the risk of a composite outcome (any stroke and systemic embolism) and all-cause mortality. For NOACs, it found statistically significant associations with reduction in the composite outcome compared with placebo/control (adjusted odds ratios [ORs] from 0.32 to 0.44), and an increased risk of bleeding compared with

placebo/control (adjusted ORs from 1.38 to 2.21), but confidence intervals for the risk of bleeding were wide and differences between groups were not statistically significant.

Limitations: This review is limited in the ability to describe the direct evidence on the effectiveness or harms of screening for AF because we identified no eligible studies that aimed to address the overarching question. For potential harms of screening (e.g., overdiagnosis from misinterpretation of ECGs, subsequent interventions leading to harms), no eligible studies provided information that allowed comparison between screening and no-screening. No eligible stroke prevention treatment studies focused on asymptomatic, screen-detected participants. The included trials that evaluated warfarin benefits and harms had an average of 1.5 years of followup and were stopped early. Estimates for benefits and harms of lifelong anticoagulation and for screen-detected persons were not available.

Conclusions: There is uncertainty about the benefits and harms of screening for AF with ECG. Although screening with ECG can detect previously unknown cases of AF, it has not been shown to detect more cases than opportunistic screening that is focused on pulse palpation. Most older adults with previously unknown AF have a stroke risk above the threshold for anticoagulation. Multiple treatments for AF reduce the risk of stroke and all-cause mortality, and increase the risk of bleeding, but trials have not assessed whether treatment of screen-detected asymptomatic older adults results in better health outcomes than treatment after detection by usual care or after symptoms develop.

Table of Contents

Chapter 1. Introduction.....	1
Scope and Purpose	1
Condition Definition	1
Etiology and Natural History	1
Risk Factors.....	2
Prevalence and Burden.....	2
Rationale for Screening and Screening Strategies	3
Treatment Approaches	3
Recommendations and Clinical Practice in the United States	4
Chapter 2. Methods	6
Chapter 3. Results	10
Literature Search	10
Results by KQ	10
KQ 1. Does Screening for AF With ECG Improve Health Outcomes in Asymptomatic Older Adults?	10
KQ 2. Does Systematic Screening for AF With ECG Identify Older Adults With Previously Undiagnosed AF More Effectively Than Usual Care?	11
KQ 3. What Are the Harms of Screening for AF With ECG in Older Adults?.....	13
KQ 4. What Are the Benefits of Anticoagulation or Antiplatelet Therapy on Health Outcomes in Asymptomatic, Screen-Detected Older Adults With AF?	14
KQ 5. What Are the Harms of Anticoagulation or Antiplatelet Therapy in Asymptomatic, Screen-Detected Older Adults With AF?.....	20
Chapter 4. Discussion	24
Summary of Evidence	24
Evidence for Benefit and Harms of Screening	24
Detection of Previously Undiagnosed AF.....	25
Benefits and Harms of Anticoagulation and Antiplatelet Treatment for Nonvalvular AF	25
Limitations	26
Future Research Needs.....	28
Conclusion	28
References.....	29

Figures

Figure 1. Analytic Framework

Figure 2. Summary of Evidence Search and Selection

Figure 3. Odds of Detecting New Cases of Atrial Fibrillation and Absolute Difference in New Cases Detected, by Comparison

Figure 4. Relative Risk of All-Cause Mortality, Cardiovascular-Related Mortality, All Ischemic Stroke, Moderately to Severely Disabling Stroke, Major Bleeding, Major Extracranial Bleeding, Intracranial Hemorrhage, and All Ischemic Stroke or Intracranial Hemorrhage for Warfarin Compared With Controls

Figure 5. Relative Risk of All-Cause Mortality, Cardiovascular-Related Mortality, All Ischemic Stroke, Major Bleeding, Major Extracranial Bleeding, and All Ischemic Stroke or Intracranial Hemorrhage for Aspirin Compared With Controls

Tables

Table 1. Classification of Atrial Fibrillation

Table 2. Characteristics of Included Randomized, Controlled Trials for KQs 2 and 3

Table 3. Results of Included Randomized, Controlled Trials for KQs 2 and 3

Table 4. Characteristics of Included Randomized, Controlled Trials for KQs 4 and 5: Part 1

Table 5. Characteristics of Included Randomized, Controlled Trials for KQs 4 and 5: Part 2

Table 6. Summary of Evidence for Screening for Atrial Fibrillation With ECG

List of Appendixes

Appendix A. Additional Background, Summary of Guidelines From Other Groups, and Contextual Questions

Appendix B. Detailed Methods

Appendix C. Excluded Studies

Appendix D. Quality and Relevance Assessments

Appendix E. Additional Tables of Study Results

Appendix F. Additional Meta-Analysis Results

Chapter 1. Introduction

Scope and Purpose

The U.S. Preventive Services Task Force (USPSTF) will use this report to inform a recommendation on the topic of screening asymptomatic adults for atrial fibrillation (AF) using an electrocardiogram (ECG). The USPSTF has not previously made a recommendation on AF. This report systematically evaluates the current evidence on screening for and treatment of AF for populations and settings relevant to primary care in the United States.

Condition Definition

AF is a supraventricular tachyarrhythmia characterized by uncoordinated electrical activity and resulting inefficient atrial contraction.¹ On an ECG, AF has the following features: (1) R-R intervals (intervals from the onset of one R wave to the onset of the next one, one complete cardiac cycle) are “irregularly irregular” (i.e., they follow no repetitive pattern) and (2) there are no distinct repeating P waves (the waves on an ECG associated with atrial depolarization), although atrial electrical activity (fibrillatory f waves) may be seen in some leads.² Clinically helpful labels include paroxysmal, persistent, permanent, and nonvalvular (**Table 1**).

Etiology and Natural History

A number of disease pathways and mechanisms can cause structural or electrophysiological abnormalities that alter the atrial tissue, resulting in AF. Underlying heart disease (e.g., ischemic heart disease, valvular heart disease, cardiomyopathies, heart failure) can lead to inflammation, fibrosis, and hypertrophy in the atrial architecture, leading to increased left atrial pressure with subsequent atrial dilation and changes in wall stress.^{3, 4} Multiple electrophysiological mechanisms may contribute to the initiation and perpetuation of AF in an individual with an anatomical vulnerability; the natural history of the condition generally involves a gradual worsening over time.^{5, 6} Factors such as suboptimal ventricular rate control, loss of atrial contraction, variability in ventricular filling, and sympathetic activation can lead to the adverse hemodynamic effects of AF, resulting in reduced cardiac output with potential for fatigue, palpitations, dyspnea, hypotension, syncope, or heart failure.⁷⁻⁹ However, some patients have silent AF, with no obvious symptoms relevant to the disease.¹⁰ Persons may attribute mild symptoms (e.g., fatigue) to other causes.

Before widespread anticoagulant use, AF was associated with a fivefold increase in the risk of stroke, after adjustment for other factors.¹¹ AF reduces cardiac blood flow; along with changes in blood composition involving platelets, other coagulatory proteins, and inflammatory cytokines, a reduction in cardiac blood flow predisposes patients to thrombus formation (particularly in the left atrial appendage) and confers an increased risk of stroke and systemic thromboembolism.¹² Although earlier studies suggest similar risks of stroke for persons with paroxysmal AF compared with those who have persistent or permanent AF,¹³⁻¹⁶ more recent studies show lower

risk for those with paroxysmal AF.¹⁷⁻²³ For example, a recent randomized, controlled trial (RCT) comparing edoxaban with warfarin (21,105 participants in 46 countries) found lower mean annual rates of stroke or systemic embolism (the primary efficacy outcome) for those with paroxysmal AF than those with persistent AF or permanent AF over a median of 2.8 years of followup (1.49% vs. 1.83% vs. 1.95%, $p < 0.05$ for both comparisons with paroxysmal AF).^{17, 18}

Increasing age is an independent predictor of stroke in persons with AF, associated with an increased risk of about 1.5 percent per decade; the annual stroke incidence increases from 1.3 percent in those ages 50 to 59 years to 5.1 percent in those ages 80 to 89 years.²⁴ Strokes due to AF are associated with a poor prognosis as measured by both 28-day and 3-month mortality, disability, and discharge to institution rather than home.²⁵⁻²⁷ Approximately 30 percent of patients with AF who have a stroke die within 1 year of the stroke, and up to 30 percent of survivors are permanently disabled.²⁸

Risk Factors

Risk factors for AF include diabetes, previous cardiothoracic surgery, smoking, prior stroke, age, underlying heart disease, hypertension, sleep apnea, obesity, alcohol/drug use, and hyperthyroidism.²⁹ Models for predicting the risk of future AF have been developed from several large longitudinal study cohorts,³⁰ including the Atherosclerosis Risk in Communities Study³¹ and the Framingham Heart Study, and externally validated in additional population-based cohorts.³⁰ An externally validated risk prediction model derived from the Atherosclerosis Risk in Communities Study, Cardiovascular Health Study, and Framingham Heart Study cohorts includes age, race, height, weight, systolic and diastolic blood pressure, current smoking, use of antihypertensive medication, diabetes, and history of myocardial infarction and heart failure as predictors of future AF risk.^{31, 32}

Prevalence and Burden

AF is the most common arrhythmia. Prevalence increases with age, from less than 0.2 percent for those younger than age 55 years to about 10 percent for those age 85 years or older, and is higher for men than women (**Appendix A Table 1**).³³ In 2013, the estimated prevalence was 8.3 percent for U.S. Medicare beneficiaries.³⁴ About 25 percent of AF is paroxysmal;³⁵ however, assessing the prevalence of AF—particularly paroxysmal AF—is challenging because episodes may be brief and undetected.³⁶

In 2011, AF was mentioned in the death certificates of 116,247 persons in the United States and was listed as the underlying cause of death in 17,729 cases. The National Center for Health Statistics reported 479,000 hospitalizations in 2010 with AF as the primary diagnosis. According to Medicare and MarketScan databases from 2004–2006, persons with AF are approximately twice as likely to be hospitalized as age- and sex- matched control individuals (37.5 vs. 17.5%). This analysis also revealed that care for AF adds approximately \$8,700 per year to the cost of a patient's health care and accounts for \$26 billion in U.S. health care expenditures annually.³⁷

Rationale for Screening and Screening Strategies

Because patients may not notice any symptoms of AF before a serious first event, such as stroke, identifying asymptomatic persons for treatment may reduce risk for future morbidity and mortality. Of patients who have a stroke because of AF, it is estimated that 20 percent or more are diagnosed with AF at the time of the stroke or shortly thereafter.³⁸⁻⁴⁰ For subclinical AF, screening with ECG could identify patients with asymptomatic AF who might benefit from treatment to reduce the risk for thromboembolic events, reduce frequency or severity of future symptoms related to AF, and reduce overall mortality.

To characterize the potential yield of screening for AF with ECG or pulse palpation, a 2013 systematic review found an overall incidence of screen-detected, previously unknown AF of 1 percent (95% confidence interval [CI], 0.89% to 1.04%; 14 studies, 67,772 participants) and an incidence of 1.4 percent (95% CI, 1.2% to 1.6%; 8 studies, 18,189 participants) for those age 65 years or older.⁴¹ However, the review did not require studies to have control groups, so it may have overestimated the added yield beyond usual medical care.

Screening for AF could potentially use a variety of approaches, including 12-lead ECG, devices that record fewer than 12 leads (including handheld ECG), pulse oximetry, ambulatory pulse monitors, consumer-directed devices (e.g., smartphone applications), or pulse palpation. A 2015 systematic review evaluated the accuracy of methods for identifying an irregular pulse and found that pulse palpation had the lowest accuracy among various methods, largely because of its lower specificity.⁴² Health care professionals, including medical assistants, nurses, and physicians, often perform pulse measurement and/or palpation using automated or manual approaches during routine or acute care encounters. When an irregular pulse is detected during usual medical care, a diagnostic evaluation that includes a standard 12-lead ECG typically is performed and may result in AF case-finding. This approach assumes that the patient is in AF at the time of the 12-lead ECG and may not identify patients with paroxysmal AF. Further, some patients have tremors or other rate or rhythm disturbances that make interpretation of ECG challenging.⁴³

Treatment Approaches

Oral anticoagulant medications can prevent thromboembolic events in AF patients by reducing the formation of clots in the left atrium or atrial appendage.⁴⁴ Oral anticoagulants to prevent stroke and reduce all-cause mortality in persons with AF include warfarin (a vitamin K antagonist) and the newer target-specific anticoagulants, direct thrombin and Factor Xa inhibitors.¹ Dabigatran etexilate (Pradaxa) is the only currently available oral direct thrombin inhibitor in the United States. Oral Factor Xa inhibitors include apixaban (Eliquis), edoxaban (Savaysa), and rivaroxaban (Xarelto).¹ Reviews of current global treatment practices for stroke prevention in AF, including those in the United States, reported underuse of anticoagulation and antiplatelet therapy in AF patients at every level of stroke risk.^{45, 46} Aspirin, an antiplatelet agent, might be considered as a treatment option for persons with AF who have a low risk of stroke (i.e., those who do not warrant anticoagulation).

Randomized trials have shown anticoagulant therapies to be more effective than antiplatelet

therapies in reducing stroke; however, their use is associated with an increased risk of bleeding.^{47, 48} Individualized assessment of the balance of potential benefits (i.e., risk reduction in stroke or embolism) versus potential harms (i.e., risk increase in major bleeding) is recommended when choosing a therapeutic strategy. Validated risk prediction tools (**Appendix A Tables 2 and 3**) for stroke risk (e.g., the Congestive heart failure, Hypertension, Age ≥ 75 years [doubled], Diabetes mellitus, prior Stroke or TIA or thromboembolism [doubled], Vascular disease, Age 65-74 years, Sex category [CHA₂DS₂-VASc] score) and bleeding risk (e.g., HAS-BLED, HEMORR₂HAGES¹) have been developed to aid in this assessment, which is complicated because many risk factors for anticoagulation-related bleeding are also risk factors for stroke in patients with AF.

A U.S. Food and Drug Administration–approved device, the WATCHMAN™, offers a nonpharmacologic alternative to oral anticoagulation.⁴⁹ In patients with nonvalvular AF at increased risk for embolism (based on the Congestive heart failure, Hypertension, Age ≥ 75 years, Diabetes mellitus, prior Stroke or TIA or thromboembolism [CHADS₂] or CHA₂DS₂-VASc scores) and eligible for treatment with warfarin, this catheter-delivered heart implant is designed to reduce the risk of thromboembolism by closing off the left atrial appendage.

Therapies for rate or rhythm control are also routinely used in clinical practice, primarily to prevent and treat hemodynamic consequences of AF. Rate control therapies include beta blockers and nondihydropyridine calcium channel blockers. When pharmacologic therapy is inadequate to control symptoms, atrioventricular (AV) nodal ablation with ventricular pacing is an option. Rhythm control strategies (i.e., direct current or pharmacologic cardioversion or radiofrequency catheter ablation) may be appropriate for select persons (e.g., persons who have persistent symptoms, are not able to achieve rate control, or are young¹); however, RCTs have not demonstrated a mortality benefit for rhythm control over rate control strategies.^{50, 51} Neither rate nor rhythm control of AF is intended to prevent strokes.

Recommendations and Clinical Practice in the United States

In recent years, several U.S. and international professional organizations have issued recommendations for managing AF and preventing stroke (**Appendix A Table 4**). Some organizations recommended screening for AF in selected patients. The 2014 guidelines from the American Heart Association and the American Stroke Association recommended conducting active screening with pulse palpation (followed by ECG as appropriate) in older adults.^{52, 53} Similarly, guidelines from the European Society of Cardiology (ESC), the Royal College of Physicians of Edinburgh (one of the founding groups of the Scottish Intercollegiate Guidelines Network), European Primary Care Cardiovascular Society, and others recommended opportunistic screening with pulse taking for persons age 65 years or older.⁵⁴⁻⁵⁷ The guidelines recommending screening for AF usually state that screening should be performed with pulse palpation and the diagnosis confirmed by ECG.⁵³⁻⁵⁹ No recommendations are given for screening frequency except for the EPCCS, which recommends at least yearly pulse palpation.⁵⁹ The ESC, European Heart Rhythm Association, and AF-SCREEN recommended that pulse taking *or* ECG (rhythm strip or single-lead) could be used for screening. Guidelines from the ESC, EHRA, and AF-SCREEN recommend that systematic ECG screening be considered in patients age 75 years

or older or for those at high stroke risk.^{59, 60}

Professional organizations have consistently recommended the use of risk prediction tools to guide the appropriate use of therapy in patients with AF. Recent guidelines recommend using the CHA₂DS₂-VASc score. In general, guidelines recommend no antithrombotic therapy or antiplatelet therapy for those at lowest risk of stroke (CHA₂DS₂-VASc score=0) and recommend anticoagulant therapy for those at high risk (CHA₂DS₂-VASc score \geq 2). Recent guidelines are mixed in their recommendations for those with a CHA₂DS₂-VASc score of 1, with some recommending anticoagulant therapy⁶¹⁻⁶³ and others recommending treatment based on risk and patient preference.^{1, 54, 60, 64} Older guideline recommendations based on the CHADS₂ score differ somewhat in their recommendations.⁶⁵⁻⁶⁸

Chapter 2. Methods

Key Questions and Analytic Framework

The Evidence-based Practice Center (EPC) investigators, USPSTF members, and Agency for Healthcare Research and Quality (AHRQ) Medical Officers developed the scope and key questions (KQs). **Figure 1** shows the analytic framework and KQs that guided the review. Five KQs were developed for this review:

1. Does screening for atrial fibrillation with ECG improve health outcomes (i.e., reduce all-cause mortality or reduce morbidity or mortality from stroke) in asymptomatic older adults? 1.a. Does improvement in health outcomes vary for subgroups defined by stroke risk (e.g., based on CHA₂DS₂-VASc score), age, sex, or race/ethnicity?
2. Does systematic screening for atrial fibrillation with ECG identify older adults with previously undiagnosed atrial fibrillation more effectively than usual care?
3. What are the harms of screening for atrial fibrillation with ECG in older adults? 3.a. Do the harms of screening vary for subgroups defined by stroke risk (e.g., based on CHA₂DS₂-VASc score), age, sex, or race/ethnicity?
4. What are the benefits of anticoagulation or antiplatelet therapy on health outcomes in asymptomatic, screen-detected older adults with atrial fibrillation? 4.a. Do the benefits of anticoagulation or antiplatelet therapy vary for subgroups defined by stroke risk (e.g., based on CHA₂DS₂-VASc score), age, sex, or race/ethnicity?
5. What are the harms of anticoagulation or antiplatelet therapy in asymptomatic, screen-detected older adults with atrial fibrillation?
5a. Do the harms of anticoagulation or antiplatelet therapy vary for subgroups defined by stroke risk (e.g., based on CHA₂DS₂-VASc score), age, sex, or race/ethnicity?

our KQs, we looked for evidence related to three contextual questions that focused on the prevalence of previously unrecognized or undiagnosed AF among asymptomatic adults by age, the stroke risk in asymptomatic older adults with previously unrecognized or undiagnosed AF, and the recommendations on and frequency of use of rate or rhythm control treatments for AF in asymptomatic adults ages 65 years or older. These contextual questions were not a part of our systematic review. They are intended to provide additional background information. Literature addressing these questions is summarized in **Appendix A**.

Data Sources and Searches

We searched PubMed/MEDLINE and the Cochrane Library for English-language articles published through May 24, 2017. We used Medical Subject Headings as search terms when available and keywords when appropriate, focusing on terms to describe relevant populations, tests, interventions, outcomes, and study designs. Complete search terms and limits are detailed in **Appendix B1**. We conducted targeted searches for unpublished literature by searching ClinicalTrials.gov and the World Health Organization International Clinical Trials Registry Platform. To supplement electronic searches, we reviewed reference lists of pertinent articles,

studies suggested by reviewers, and comments received during public commenting periods. Since May 2017, ongoing surveillance was conducted through article alerts and targeted searches of journals to identify major studies published in the interim that may affect the conclusions or understanding of the evidence and the related USPSTF recommendation. The last surveillance was conducted on June 6, 2018 and identified no additional eligible studies.

Study Selection

We developed inclusion and exclusion criteria for populations, interventions, comparators, outcomes, settings, and study designs with input from the USPSTF (**Appendix B2**). We included English-language studies focused on adults ages 65 years or older conducted in countries categorized as “very high” on the Human Development Index. We excluded studies focused on children, adolescents, adults younger than age 65, and adults with a history of stroke or transient ischemic attack (TIA).

For KQs 1 (direct evidence that screening improves health outcomes), 2 (detection of undiagnosed AF), and 3 (harms of screening), we required studies to enroll unselected or explicitly asymptomatic older adults or those selected for increased risk of nonvalvular AF (e.g., those with obesity, smoking, alcohol use, or hypertension). Studies of mixed asymptomatic and symptomatic populations were eligible if the results were reported separately for asymptomatic adults or if less than 10 percent of the sample was symptomatic. We tracked whether any studies were excluded because of the 10 percent threshold so that we could conduct sensitivity analyses by adding studies in which 10 to 50 percent of the population was symptomatic; however, no such studies were identified. Studies consisting of mostly symptomatic adults, those with a known history of AF, and those with mitral valve disease or repair/replacement were not eligible. Eligible screening tests for KQs 1, 2, and 3 included systematic ECG screening (e.g., in-office, single-application 12-lead ECG, continuous ECG, intermittent use of handheld ECG) or systematic screening with both pulse palpation and ECG for all participants in a given study. We excluded studies whose interventions were limited to physical examination (including pulse palpation), blood pressure monitoring, pulse oximetry, and other technologies. Eligible comparisons included screened versus unscreened groups, systematic screening versus opportunistic screening, and systematic screening versus usual care (which may include pulse palpation, automated blood pressure measurement, or cardiac auscultation during the course of a physical examination, or examination for another reason, with subsequent ECG if an irregular heart beat or pulse is noted). For KQ 1, RCTs and controlled clinical trials were eligible. For KQs 2 and 3, prospective cohort studies were also eligible.

For KQs on benefits (KQ 4) and harms (KQ 5) of treatment, we excluded studies of adults with known heart disease, heart failure, and/or previous stroke or TIA. Eligible studies compared medical treatment with aspirin or oral anticoagulants (warfarin, apixaban, dabigatran, edoxaban, or rivaroxaban) versus no treatment (with or without placebo). We excluded all nonpharmacologic treatments and forms of treatment or management of AF for reasons other than prevention of stroke (e.g., rate or rhythm control, cardioversion, ablation). RCTs and controlled clinical trials of older adults with AF were eligible. Systematic reviews of trials were also eligible if they were directly relevant (i.e., met our eligibility criteria, focused on primary

prevention studies, included the relevant aspirin or oral anticoagulant trials, and had not been updated). **Appendix D Table 7** details our assessment of the relevance of potentially eligible systematic reviews. For KQ 5, prospective cohort studies were also eligible.

Two investigators independently reviewed titles and abstracts; those marked for potential inclusion by either reviewer were retrieved for evaluation of the full text. Two investigators independently reviewed the full text to determine final inclusion or exclusion. Disagreements were resolved by discussion and consensus.

Quality Assessment and Data Abstraction

For each included study, one investigator extracted pertinent information about the methods, populations, interventions, comparators, outcomes, timing, settings, and study designs. A second team member reviewed all data extractions for completeness and accuracy.

We assessed the quality of studies as good, fair, or poor, using predefined criteria developed by the USPSTF and adapted for this topic (**Appendix B3**). Two independent investigators assigned quality ratings for each study. Disagreements were resolved by discussion. We included only studies with good or fair quality.

Data Synthesis and Analysis

We qualitatively synthesized findings for each KQ by summarizing the characteristics and results of included studies in tabular and narrative format. To determine whether meta-analyses were appropriate, we assessed the clinical and methodological heterogeneity of the studies following established guidance.⁶⁹ We qualitatively assessed the populations, tests, treatments, comparators, outcomes, and study designs, looking for similarities and differences.

For KQ 2, fewer than three studies were available for each comparison, and absolute risk differences and odds ratios were calculated for detection of unknown AF. For KQs 4 and 5, when at least three similar studies were available, quantitative synthesis was conducted with random-effects models using the inverse-variance weighted method (DerSimonian and Laird) to estimate pooled effects.⁷⁰ We calculated relative risks and 95 percent CIs for all-cause mortality, cardiovascular-related mortality, all ischemic stroke, moderately to severely disabling stroke, TIA, major bleeding, major extracranial bleeding, intracerebral hemorrhage, minor bleeding, and a composite outcome of all ischemic stroke or intracerebral hemorrhage. Results for the composite outcome, which includes a benefit and a harm, are provided in KQ 4. Statistical significance was assumed when 95 percent CIs of pooled results did not cross the null. All testing was two-sided. For all quantitative syntheses, the I^2 statistic was calculated to assess statistical heterogeneity in effects between studies.^{71, 72} An I^2 from 0 to 40 percent might not be important; 30 to 60 percent may represent moderate heterogeneity; 50 to 90 percent may represent substantial heterogeneity; and 75 percent or greater represents considerable heterogeneity.⁷³ We conducted sensitivity analyses by adding one trial rated as poor quality that evaluated aspirin.⁷⁴ The results of the sensitivity analyses are provided in appendices of this

report; estimates of effect were similar to main analyses, and statistical significance (or lack thereof) did not change. Quantitative analyses were conducted using Comprehensive Meta-Analysis version 3.3 (Biostat, Inc.) and Stata version 14 (StataCorp).

We assessed the overall strength of the body of evidence for each KQ as high, moderate, low, or insufficient using methods developed for the USPSTF (and the EPC program), based on the overall quality of studies, consistency of results between studies, precision of findings, and risk of reporting bias.⁷⁵ We also assessed the applicability of the findings to U.S. primary care populations and settings.

Expert Review and Public Comment

A draft report was reviewed by content experts, representatives of Federal partners, USPSTF members, and AHRQ Medical Officers and was revised based on comments, as appropriate. It was also posted for public comment and revised based on public comments. Based on the comments received we revised the report to include the recently published REHEARSE-AF study. REHEARSE-AF was published after the original search cutoff date but was captured by surveillance during the public comment period. Minor edits were also made to the report to be more consistent and clear when describing “opportunistic” screening. At the request of reviewers, the list of recommendations from other groups was updated to include additional groups.

USPSTF Involvement

This review was funded by AHRQ. AHRQ staff and members of the USPSTF participated in developing the scope of work and reviewed draft reports, but the authors are solely responsible for the content.

Chapter 3. Results

Literature Search

We identified 4,121 unique records and assessed 389 full-text articles for eligibility (**Figure 2**). We excluded 367 studies for various reasons, detailed in **Appendix C** and included 17 unique studies (described in 22 publications) of good or fair quality. Of the included studies, one RCT reported some eligible outcomes for KQ 1 (although the study was focused on KQ 2 outcomes), three RCTs (described in 7 publications) addressed detection of previously undiagnosed AF (KQ 2), and one of those two (described in 5 publications) was also included for KQ 3 (harms of ECG screening). Six RCTs (described in 7 publications) and eight systematic reviews addressed the benefits (KQ 4) and/or harms (KQ 5) of anticoagulation or antiplatelet therapy. Details of quality assessments of included studies and studies excluded because of poor quality are in **Appendix D Tables 1-6**.

Results by KQ

KQ1. Does Screening for AF With ECG Improve Health Outcomes in Asymptomatic Older Adults?

We found no eligible studies that focused on this question and have reported results. One fair-quality RCT of 1,001 participants and a primary outcome of time to diagnosis of AF (a KQ 2 outcome), Assessment of REmote HEArt Rhythm Sampling using the AliveCor heart monitor to scrEen for Atrial Fibrillation (REHEARSE-AF), reported limited information on health outcomes but was not designed or powered to evaluate them.⁷⁶ The trial is described in more detail in KQ 2. For all-cause mortality, the authors reported three deaths in the screening group and five in the no screening group ($p=0.51$). For a composite of stroke, TIA, or systemic embolism, there were 6 versus 10 events, respectively (hazard ratio [HR] 0.6 [95% CI, 0.2 to 1.7]; $p=0.34$).

We identified another RCT, the STROKESTOP Study, that is currently ongoing and has not yet reported results for the outcomes and comparisons eligible for our review.⁷⁷⁻⁷⁹ The primary outcome listed in clinicaltrials.gov is reduced incidence of stroke among 75-year-old subjects, with a planned time frame of 5 years (and interim analysis after 3 years). The estimated study completion date is March 2019.⁷⁹ The STROKESTOP study randomized 28,768 persons ages 75 to 76 years in two regions in Sweden to screening program invitations for AF or to no invitations. More than half of those invited (53.8%) participated in the screening. The screening program used an initial ECG and then a handheld one-lead ECG recorder for intermittent recordings over 2 weeks (average of 26 completed recordings per participant). The handheld recorder uses an integrated mobile transmitter to send 30-second ECG strips to a database. Participants were instructed to place their thumbs on the device twice daily and whenever they noticed palpitations. The detection rate for previously unknown AF was 3 percent (95% CI, 2.7 to 3.5; 218/7,173 participants) in the intervention group; incidence data for AF in the control

group has not yet been reported. Of the new cases detected in the intervention group, few of them were identified on the initial ECG (37/218=17%). More than 90 percent of the new cases of AF accepted initiation of oral anticoagulant therapy.

KQ2. Does Systematic Screening for AF With ECG Identify Older Adults With Previously Undiagnosed AF More Effectively Than Usual Care?

Characteristics of Included Trials

We included three fair-quality RCTs (described in 7 articles).^{76, 80-85} The characteristics of the included studies are summarized in Error! Reference source not found., and the results are summarized in Error! Reference source not found.. Two trials compared systematic screening with opportunistic screening;⁸⁰⁻⁸⁵ one of those also compared systematic screening with no screening.⁸⁰⁻⁸⁴ The third trial compared systematic, twice-weekly screening using a handheld ECG versus no screening.⁷⁶

The Screening for Atrial Fibrillation in the Elderly (SAFE) study was a multicenter cluster randomized trial (14,802 participants) that randomized 50 primary care practices to screening versus no screening.⁸⁰⁻⁸⁴ Within the 25 practices randomized to screening, individual participants were randomized to systematic screening or opportunistic screening. Those in the systematic screening arm were invited by mail to attend a nurse-led screening clinic where their radial pulse was palpated, and a 12-lead ECG was performed. For those in the opportunistic arm, paper or computer flags were placed in their notes to encourage pulse recording; those with an irregular pulse were invited to attend a screening clinic and have a 12-lead ECG. For the screening practices, primary care physicians and other members of the health care team attended educational days covering the importance of detecting AF and available treatment options. The second trial randomized 3,001 participants from four primary care practices to systematic screening or opportunistic screening.⁸⁵ Those in the systematic screening arm were invited by mail to attend a nurse-led screening clinic where their radial pulse was palpated and a lead II rhythm strip was performed. Those unable to attend the clinic were offered screening at home. For those in the opportunistic arm, a reminder flag was placed in their notes. Nurses or physicians who assessed the pulse during routine care of the patient were asked to indicate on the flag whether the pulse was suspicious of AF and whether they wished to investigate further with an ECG. Nurses conducting screenings received 2 hours of training in the clinical assessment of the pulse rhythm. The third trial, REHEARSE-AF, randomized 1,001 participants with a CHA₂DS₂-VASc score of 2 or more to a twice-weekly screening with a single-lead ECG using a handheld device or to no screening.

All three trials were conducted in the United Kingdom. Followup lasted 12 months for the SAFE study and for REHEARSE-AF and 6 months for the other trial. All trials enrolled patients age 65 years or older; the mean age of participants was 72 to 75 years. More than half of participants were women in all three trials (53% to 59%). None of the trials reported information about the race or ethnicity of participants. Only REHEARSE-AF reported the baseline prevalence of hypertension (54%), diabetes (27%), heart failure (1.4%), or the proportion of participants with a history of TIA or stroke (6.5%). Only REHEARSE-AF reported baseline stroke risk scores for

participants; the mean (SD) CHA₂DS₂-VASc score was 3 (1). The SAFE study reported the CHADS₂ scores for the 149 newly identified cases of AF.⁸¹ More cases in the systematic screening arm had scores of 2 or more than in the opportunistic arm, but the difference was not statistically significant (43.2% [95% CI, 32.6% to 54.6%] vs. 29.3% [20.2% to 40.4%], p=0.077).

Results of Included Trials

All three trials focused on detection of AF. In the SAFE study, two cardiologists masked to allocation assessed whether ECGs showed AF; a third arbitrated any disagreements. The trial that randomized 3,001 participants reported AF ascertainment by a single observer (masking not reported) who reviewed medical records. In REHEARSE-AF, an unmasked study cardiologist confirmed all AF diagnoses. The trials did not find a significant difference between systematic and opportunistic screening for detection of new cases of AF (**Figure 3** and Error! Reference source not found.). The SAFE study reported about a 60 percent increase in the odds of detecting new cases with either screening approach compared with no screening (**Figure 3** and Error! Reference source not found.). REHEARSE-AF also reported that more new cases of AF were detected in those undergoing screening compared with no screening (19 vs 5; HR, 3.9 [95% CI, 1.4 to 10.4]; risk difference, 2.8% [95% CI, 0.9% to 4.7%]; odds ratio [OR], 3.9 [95% CI, 1.5 to 10.6]).

The SAFE study reported that more new cases of AF were detected in those undergoing screening (systematic or opportunistic) than in the no screening group (149 vs. 47; 1.63% vs. 1.04%; OR, 1.58 [95% CI, 1.12 to 2.22]). There was no difference in detection of new cases between opportunistic and systematic screening groups (75 vs. 74; 1.64% vs. 1.62%; OR, 0.99 [95% CI, 0.7 to 1.4]). The trial that used lead II rhythm strips found no statistically significant difference between systematic and opportunistic screening groups, although there were few new cases and the CI was wide (12 vs. 7; 0.8% vs. 0.5%; OR, 1.7 [95% CI, 0.7 to 4.4]).

The SAFE study reported subgroup analyses by sex and age for systematic or opportunistic screening compared with no screening. The subgroup analyses show that screening may not increase detection of new cases among women. Men in the systematic (44 vs. 16; OR, 2.68 [95% CI, 1.52 to 4.73]) and opportunistic screening groups (38 vs. 16; OR, 2.33 [95% CI, 1.30 to 4.15]) had greater odds of having AF diagnosed than men in the no screening group. The odds were not significantly increased for women in either screening group compared with no screening (30 vs. 31; OR, 0.98 [95% CI, 0.59 to 1.61] and 37 vs. 31; OR, 1.20 [95% CI, 0.74 to 1.92], respectively). Patients ages 65 to 74 years and those older than 75 had similar odds of having AF diagnosed in both the systematic screening (30 vs. 18; OR 1.62 [95% CI, 0.91 to 2.88] and 44 vs. 29; OR, 1.56 [95% CI, 0.98 to 2.49], respectively) and opportunistic screening arms (31 vs. 18; OR, 1.63 [95% CI, 0.92 to 2.89] and 44 vs. 29; OR, 1.60 [95% CI, 1.00 to 2.56], respectively), compared with no screening.

KQ3. What Are the Harms of Screening for AF With ECG in Older Adults?

KQ3a. Do the Harms of Screening Vary for Subgroups Defined by Stroke Risk, Age, Sex, or Race/Ethnicity?

We identified no eligible studies assessing labeling or harms of subsequent procedures or interventions initiated because of screening with ECG (e.g., subsequent ablation with complications). One of the trials included for KQ 2, the SAFE study, assessed anxiety associated with screening. It did not, however, collect anxiety data from patients within the no screening arm of the study, which would have allowed for a comparison between screening and no screening. As a result, we cannot make conclusions about whether screening causes more or less anxiety than usual care.

The SAFE study used the Spielberger Six-Item Anxiety Questionnaire (S6AQ) to evaluate anxiety in the opportunistic and systematic screening arms at three different time points.⁸⁰ To allow for baseline score adjustment later in the study, 750 patients (out of more than 9,000 in the screening groups) were sent the S6AQ before randomization into either the opportunistic or screening arm. Patients who underwent ECGs in both screening arms were sent the S6AQ immediately after ECG screening. Seventeen months after baseline, investigators sent the S6AQ to all patients who screened positive and all 750 patients who had received the questionnaire before randomization.^{51, 83} Of the 750 questionnaires sent to patients before randomization, 620 (84%) were returned and 493 were completed (66%). Investigators provided S6AQs to all 2,595 patients who underwent ECG screening immediately after ECG screening, and 1,940 were returned (response rate 75%). Of the 777 questionnaires sent to patients 17 months after baseline, 535 were returned (response rate 69%).⁸³

Anxiety levels were not significantly different between the opportunistic and systematic screening arms at baseline (Mean Spielberger State Anxiety inventory 35.78 [95% CI, 33.80 to 37.76] vs. 36.44 [95% CI, 34.35 to 38.53], $p=0.695$). The two arms had similar results on the questionnaires administered immediately after screening (28.77 [95% CI, 28.27 to 29.26] vs. 28.25 [95% CI, 26.78 to 29.73], unadjusted $p=0.732$). Mean scores for the systematic and opportunistic screening arms were also similar at 17 months (35.92 [95% CI, 34.29 to 37.55] vs. 37.50 [95% CI, 35.82 to 39.18], $p=0.844$ adjusted for baseline scores). When comparing screen-positive and screen-negative respondents, anxiety scores collected 17 months after initial chart review were significantly different ($p=0.028$), with screen-positive participants having higher mean anxiety scores (38.12 [95% CI, 35.89 to 40.35]) than screen-negative participants (34.61, 95% CI, 32.41 to 36.81) (unadjusted $p=0.028$), although relatively few participants were included in that analysis (142 screen-positive and 128 screen-negative participants).⁸³

Potential harms of screening include overdiagnosis (e.g., from misinterpretation of ECGs) and overtreatment (e.g., warfarin for someone without AF). An analysis of 2,595 participants in the SAFE study from 49 general practices assessed the accuracy of general practitioners and interpretive software for diagnosing AF.⁸² General practitioners missed 20 percent of AF cases on 12-lead ECG and misinterpreted 8 percent of sinus rhythm cases (as AF) compared with reference standard cardiologists (sensitivity 79.8 [95% CI, 70.5 to 87.2]; specificity 91.6 [90.1 to

93.1]; 79 out of 99 AF cases detected; misinterpreted sinus rhythm as AF for 114 out of 1,355). False-positive rates varied from 0 to 44 percent for individual general practitioners (standard deviation, 13%). Combining general practitioners' interpretations with those of interpretive software increased the sensitivity (91.9 [86.6 to 97.3]), but specificity was about the same (91.1 [89.6 to 92.6]). Use of single-lead or limb-lead ECGs resulted in slightly lower specificity.

KQ4. What Are the Benefits of Anticoagulation or Antiplatelet Therapy on Health Outcomes in Asymptomatic, Screen-Detected Older Adults With AF?

Although we aimed to determine the benefits of treatment for asymptomatic, screen-detected older adults with AF, we found no trials or systematic reviews that focused on asymptomatic, screen-detected participants. We included six RCTs of people who were not screen-detected; most had long-standing persistent nonvalvular AF; few had a history of TIA or stroke (<8%); prevalence of baseline or past symptoms (e.g., palpitations, dyspnea) was generally not reported. Three evaluated warfarin,⁸⁶⁻⁸⁸ one evaluated aspirin,⁸⁹ and two (described in 3 articles) evaluated both warfarin and aspirin.⁹⁰⁻⁹² The characteristics of the included RCTs are summarized in Error! Reference source not found. and Error! Reference source not found., and the results are summarized in **Appendix E Tables 1 and 2**. One trial evaluating aspirin was excluded for poor quality but was used in sensitivity analyses.⁷⁴ We included seven systematic reviews (**Appendix E Table 3**): three were traditional systematic reviews with meta-analyses,^{44, 93, 94} three were meta-analyses of individual patient data,⁹⁵⁻⁹⁷ and one was a network meta-analysis.⁹⁸ The systematic reviews included a total of 38 unique studies (including the 6 RCTs in our review). Many of the unique studies included in other systematic reviews were not eligible for this review because they evaluated secondary prevention (i.e., some of the eligible systematic reviews evaluated treatments for people with a history of TIA or stroke in addition to addressing primary prevention) or because they were head-to-head studies (most of the 21 studies included in the network meta-analysis were head-to-head studies).

Warfarin: Characteristics of RCTs

Five trials (described in 6 articles) evaluated warfarin.^{86-88, 90-92} Four of the five trials compared warfarin with a placebo (Atrial Fibrillation, ASpirin, and AntiKoagulation study [AFASAK I],⁹⁰ Canadian Atrial Fibrillation Anticoagulation [CAFA],⁸⁷ Stroke Prevention in Atrial Fibrillation [SPAF I],^{91, 92} Stroke Prevention in Nonrheumatic Atrial Fibrillation [SPINAF]⁸⁸) and one (Boston Area Anticoagulation Trial for Atrial Fibrillation [BAATAF])⁸⁶ compared warfarin with no treatment. BAATAF allowed participants in the no treatment group to take aspirin (and 46% of all patient years in the control group were contributed by participants taking aspirin), but use of aspirin or other antithrombotic medications was not permitted in the four placebo-controlled trials. Two trials (AFASAK I and SPAF I) were three-arm studies that included aspirin arms (in addition to warfarin and placebo or no treatment). Two trials were double-blind (CAFA, SPINAF), and three were open label (AFASAK I, BAATAF, SPAF I). Three trials were conducted in the United States (BAATAF, SPAF I, and SPINAF), one in Canada (CAFA), and one in Denmark (AFASAK I). Mean duration of followup ranged from 1.2 to 2.2 years. All five trials began in the 1980s and were completed by 1992. All five trials were stopped early, primarily because of evidence favoring warfarin for stroke reduction.

None of the trials focused on participants who were detected by screening in primary care or the general population. The mean age of participants ranged from 67 to 74 years. Most participants were men, with four out of five trials enrolling fewer than 30 percent women. Just one trial reported any information about the race or ethnicity of participants (16% were nonwhite in SPAF I). Few participants had a history of TIA or stroke (range 3% to 8%). The baseline prevalence of hypertension and diabetes ranged from 32 to 58 percent and 12 to 18 percent, respectively. AFASAK I and SPINAF did not include participants with paroxysmal AF; the other three trials reported that 7 percent to 34 percent had paroxysmal AF. Most participants in the trials had AF for more than a year. Three trials (CAFA, SPAF I, and BAATAF) reported that between 19 percent and 32 percent had AF for less than a year; SPINAF I reported that 12 percent had AF less than 6 months (and a mean duration of AF of 8 years); and AFASAK I did not report information about the duration of AF prior to enrollment. Baseline stroke risk (e.g., CHADS₂) was not reported by any of the trials because stroke risk scores used in current practice were not yet developed; some future publications have used the baseline characteristics of subjects to estimate that the mean CHADS₂ scores of participants in these trials ranged from 1 to 1.6.⁹⁸

All trials titrated doses of warfarin on the basis of either prothrombin time (PT) or international normalized ratio (INR). The INR target ranges spanned from 1.4 to 4.5. The mean INRs achieved ranged from 2 to 2.6. The reported time in therapeutic range (TTR) spanned from 44 percent (CAFA) to 83 percent (BAATAF), and three trials reported TTR over 70 percent (SPAF I, AFASAK I, and BAATAF).

Warfarin: Results of Meta-Analyses

All-Cause Mortality

Across included trials, the mean annual mortality rate in control groups was 5 percent. Warfarin treatment over an average of 1.5 years was associated with a 32 percent reduction in all-cause mortality compared with controls (pooled RR, 0.68 [95% CI, 0.50 to 0.93]; I²=0%; 5 trials; 2,415 participants) (**Figure 4**).

Cardiovascular-Related Mortality

Across included trials, the mean annual cardiovascular-related mortality rate in control groups was 2.8 percent. Warfarin treatment over an average of 1.5 years was associated with a reduction in cardiovascular-related mortality, but the difference between warfarin and controls was not statistically significant (pooled RR, 0.66 [95% CI, 0.33 to 1.29]; I²=53.3%; 5 trials; 2,415 participants) (**Figure 4**).

All Ischemic Stroke

Across included trials, the mean annual ischemic stroke rate in control groups was 4 percent. Four of the five trials reported a statistically significant reduction in ischemic strokes. Warfarin treatment over an average of 1.5 years was associated with a 68 percent reduction in ischemic strokes compared with controls (pooled RR, 0.32 [95% CI, 0.20 to 0.51]; I²=0%; 5 trials; 2,415 participants) (**Figure 4**).

Moderately to Severely Disabling Stroke

Across included trials, the mean annual event rate in control groups was 1.5 percent. Warfarin treatment over an average of 1.5 years was associated with a 62 percent reduction in moderately to severely disabling stroke compared with controls (pooled RR, 0.38 [95% CI, 0.19 to 0.78]; $I^2=0\%$; 5 trials; 2,415 participants) (**Figure 4**).

TIA

Across included trials, the mean annual event rate in control groups was 0.8 percent. Warfarin was associated with a reduction in TIAs, but the difference between warfarin and controls was not statistically significant (pooled RR, 0.66 [95% CI, 0.26 to 1.68]; $I^2=0\%$; 4 trials; 1,890 participants) (**Appendix E Figure 1**).

All Ischemic Stroke or Intracranial Hemorrhage

Across included trials, the mean annual event rate in control groups was 4.1 percent. Warfarin treatment over an average of 1.5 years was associated with a 62 percent reduction in all ischemic stroke or intracranial hemorrhage compared with controls (pooled RR, 0.38 [95% CI, 0.25 to 0.59]; $I^2=0\%$; 5 trials; 2,415 participants) (**Figure 4**).

Aspirin: Characteristics of RCTs

Our review included three RCTs (described in 4 articles) that evaluated aspirin.⁸⁹⁻⁹² One trial, which was conducted in Spain and evaluated aspirin 125 mg daily versus 125 mg every other day versus control (Low-dose Aspirin, Stroke, Atrial Fibrillation [LASAF] pilot study), was excluded for poor quality but was used in sensitivity analyses.⁷⁴ Two of the three included trials compared aspirin with placebo (AFASAK I⁹⁰ and SPAF I^{91, 92}), and one (Japanese Atrial fibrillation Stroke Trial [JAST])⁸⁹ compared aspirin with a control group taking no antiplatelet or anticoagulant therapy. The doses of aspirin used in the included trials were 75 mg daily (AFASAK I), 325 mg daily (SPAF I), and 150–200 mg daily (JAST). AFASAK I was a three-arm trial that also included a warfarin arm. SPAF I divided participants into two groups based on their eligibility for warfarin (i.e., willingness to take it, bleeding risk, and risk of embolism): those eligible for warfarin were randomized to warfarin, aspirin, or placebo, and those not eligible for warfarin were randomized to aspirin or placebo. Participants from both groups were combined in analyses comparing aspirin with placebo. AFASAK I and SPAF I were double-blind, and JAST was open label. SPAF I was conducted in the United States, AFASAK was conducted in Denmark, and JAST was conducted in Japan. On average, followup lasted 1.2 to 2.1 years. AFASAK I and SPAF I began in the 1980s and were concluded by 1991, and JAST began in 1998 and was stopped in 2002.

None of the trials focused on asymptomatic participants who were screen-detected. AFASAK I did not include participants with paroxysmal AF, but 33 percent of those in SPAF I and 45 percent of those in JAST had paroxysmal AF. The mean age of participants ranged from 65 to 74 years. Most participants in all trials were men; 29 to 46 percent of participants were women. SPAF I reported that 16 percent were nonwhite, and neither JAST nor AFASAK I reported on

the race or ethnicity of their participants. Few participants had a history of TIA or stroke (range 2.5% to 7%). The baseline prevalence of hypertension and diabetes ranged from 32 to 52 percent and 12 to 15 percent, respectively.

Aspirin: Results of Meta-Analyses

All-Cause Mortality

Across included studies, the mean annual mortality rate in control groups was 4.2 percent. Aspirin treatment over an average of 1.5 years was associated with a lower risk of death than controls, but the difference between aspirin and controls was not statistically significant (pooled RR, 0.84 [95% CI, 0.62 to 1.14]; $I^2=0\%$; 3 trials; 2,663 participants) (**Figure 5**).

Cardiovascular-Related Mortality

Across included trials, the mean annual cardiovascular-related mortality rate in control groups was 2.2 percent. Aspirin treatment over an average of 1.5 years was associated with a reduction in cardiovascular-related mortality, but the difference between aspirin and controls was not statistically significant (pooled RR, 0.86 [95% CI, 0.56 to 1.32]; $I^2=0\%$; 3 trials; 2,663 participants) (**Figure 5**).

All Ischemic Stroke

Across included trials, the mean annual ischemic stroke rate in control groups was 3.7 percent. Aspirin treatment over an average of 1.5 years was associated with a reduction in ischemic strokes, but the difference between aspirin and controls was not statistically significant (pooled RR, 0.76 [95% CI, 0.52 to 1.1]; $I^2=15.7\%$; 3 trials; 2,663 participants) (**Figure 5**).

Moderately to Severely Disabling Stroke

Two of the three included trials reported on disabling strokes (AFASAK I and SPAFI). Both reported nonstatistically significant reductions in events for those treated with aspirin (RR 0.57 [95% CI, 0.17 to 1.9] in AFASAK I over an average followup of 1.2 years, with 672 participants; RR 0.64 [95% CI, 0.29 to 1.4] in SPAFI over an average followup of 1.3 years, with 1,120 participants) (**Appendix F Figure 7**).

All Ischemic Stroke or Intracranial Hemorrhage

Across included trials, the mean annual event rate in control groups was 3.9 percent. Aspirin treatment over an average of 1.5 years was associated with a reduction in events, but the difference between aspirin and controls was not statistically significant (pooled RR, 0.81 [95% CI, 0.54 to 1.21]; $I^2=31.7\%$; 3 trials; 2,663 participants) (**Figure 5**).

Results of Previously Published Systematic Reviews and Meta-Analyses

Results of previously published systematic reviews^{44, 93-98} were generally consistent with our

findings and are summarized in **Appendix E Table 3**. Here we highlight the findings from those reviews that provide additional information (beyond what we have described already in this KQ). Overall, the included systematic reviews provide some additional details about subgroups (from individual patient data meta-analyses) and some information about head-to-head comparisons, including comparisons with novel oral anticoagulants (NOACs).

Warfarin vs. Placebo or Control

One systematic review from the Cochrane collaboration evaluated warfarin for primary prevention.⁹³ It included the same five RCTs in our review but obtained unpublished data excluding the 3 to 8 percent of participants with prior stroke or TIA. The findings were very similar to those of our meta-analyses, although they reported ORs (e.g., for all-cause mortality, they reported OR 0.69 [0.50 to 0.94] vs. our pooled result of RR 0.68 [0.50 to 0.93]) (**Appendix E Table 3**).

Aspirin vs. Placebo or Control

One systematic review from the Cochrane collaboration evaluated aspirin for primary prevention.⁹⁴ It included two of the three RCTs (AFASAK I and SPAF I) that were in our main analyses and included LASAF, which we excluded because of poor quality but used in sensitivity analyses. The review authors obtained unpublished data excluding participants with prior stroke or TIA. The findings were very similar to those of our meta-analyses, showing that aspirin treatment was associated with a reduced risk of several outcomes and that the difference between aspirin and controls was not statistically significant (e.g., for all-cause mortality, they reported OR 0.75 [0.54 to 1.04] vs. our pooled result of RR 0.84 [0.62 to 1.14]) (**Appendix E Table 3**). However, they reported one composite outcome that we did not pool data for (all stroke, myocardial infarction, or vascular death) and found a significant reduction in risk with aspirin compared with controls (OR, 0.71 [0.51 to 0.97]).

Subgroups

Three individual patient data meta-analyses used the Atrial Fibrillation Investigators database from clinical trials evaluating warfarin or aspirin.⁹⁵⁻⁹⁷ That database included all five warfarin trials described in this report (AFASAK I, CAFA, SPAF I, SPINAF, BAATAF) and two of the aspirin trials (AFASAK I and SPAF I). One evaluated subgroups based on sex and history of hypertension for both warfarin and aspirin,⁹⁵ one evaluated whether benefits vary by age for both warfarin and aspirin,⁹⁷ and one evaluated multiple subgroups for aspirin.⁹⁶ The aspirin analyses are all limited by not including the JAST study (which was published after these analyses).

The individual patient data meta-analysis that evaluated subgroups based on sex and history of hypertension⁹⁵ used the same five RCTs evaluating warfarin that we included in KQ 4. It reported that the efficacy of warfarin was consistent across subgroups. Warfarin was associated with a reduction in stroke for both men and women, without a statistically significant difference between them (relative risk reduction, 60% [35% to 76%] and 84% [55% to 95%], respectively). For aspirin, the analyses included two of the RCTs (AFASAK I and SPAF I) eligible for our report (JAST was not yet published). Aspirin was associated with a reduction in stroke for both

men and women, without a statistically significant difference between them (relative risk reduction, all participants: 36% [4% to 57%]; $p=0.03$; men: 44% [3% to 68%], $p=0.04$; women: 23% [40% to 58%], $p=0.38$, test for interaction not reported). However, the effect of aspirin was found to vary by history of hypertension. For those with a history of hypertension, aspirin was associated with a reduction in stroke (relative risk reduction [RRR], 59% [28% to 77%]; $p=0.002$), but for those with no history of hypertension, it was not (10% [40% to 100%]; $p=0.76$; and $p=0.02$ for difference in effectiveness between those with and without hypertension).

The individual patient data meta-analysis that evaluated subgroups based on age⁹⁷ used the same five RCTs evaluating warfarin that we included in KQ 4, but also included a secondary prevention trial (European Atrial Fibrillation Trial [EAFT], 439 participants treated with warfarin or placebo).⁹⁹ Warfarin was associated with a reduced risk of ischemic stroke (compared with placebo/control) for all ages; for the assessment of relative benefit with increasing age, the interaction did not reach statistical significance (e.g., HR, 0.22 [95% CI, 0.11 to 0.41] for 50-year-olds; HR, 0.53 [0.35 to 0.81] for 90-year-olds, interaction of age and warfarin, $p=0.07$). For aspirin, the analyses included two of the RCTs (AFASAK I and SPAF I) eligible for our report and one secondary prevention trial (EAFT, 782 participants treated with aspirin or placebo). The relative benefit of aspirin for preventing ischemic stroke decreased significantly with increasing age. At age 50 years, the HR was 0.40 (95% CI, 0.22 to 0.72); by age 77 years, the HR no longer excluded the null; at age 82 years, the HR exceeded 1 (interaction of age and aspirin, $p=0.01$). Although the analyses included EAFT, the authors report conducting sensitivity analyses with serial exclusion of individual studies that did not alter estimates. Neither warfarin nor aspirin interacted significantly for cardiovascular events.

The individual patient data meta-analysis that evaluated multiple subgroups for aspirin⁹⁶ included two of the RCTs (AFASAK I and SPAFI) eligible for our report and a secondary prevention trial (EAFT). The analyses considered age, sex, history of hypertension, systolic blood pressure 160 or lower versus not, history of CHF, and history of diabetes. The analyses reported finding no convincing evidence of specific subgroups for whom aspirin was more effective for reducing the risk of ischemic stroke. Like the individual patient data meta-analysis described above,⁹⁵ the authors reported that those with a history of hypertension had a significant reduction in the risk of ischemic stroke (RR, 0.64 [95% CI, 0.46 to 0.89]), but those without a history of hypertension did not (RR, 0.98 [95% CI, 0.79 to 1.39]). Unlike the individual patient data meta-analysis above, however, the interaction between a history of hypertension and aspirin use was not significant ($p=0.08$). The difference between the two meta-analyses is likely because of including versus not including EAFT. A secondary (post hoc) analysis found that among patients without a previous stroke or TIA (thus excluding EAFT and 6% of participants from AFASAK I and SPAFI), those with a history of hypertension or diabetes had a greater reduction in ischemic stroke risk (RRR, 54% [17% to 74%]) than those without a history of hypertension or diabetes (RRR not reported) (interaction $p=0.02$).

Results of Previously Published Network Meta-Analysis

The one included network meta-analysis used 21 RCTs (96,017 participants) of treatment for nonvalvular AF.⁹⁸ It was not limited to primary prevention populations, but most of the data was from studies in which most of the participants had no history of stroke or TIA. Four of the 21

RCTs reported that more than 35 percent of their participants had a history of stroke or TIA: 100 percent in EAFT (warfarin vs. aspirin vs. placebo), 64 percent in the Japanese Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (rivaroxaban vs. warfarin), 55 percent in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (rivaroxaban vs. warfarin), and 38 percent in SPAF III (low-intensity fixed-dose warfarin adjusted to INR, 1.2–1.5 combined with aspirin 325 mg once daily vs. adjusted-dose warfarin with target INR, 2.0–3.0). The percentage of participants with a history of stroke or TIA was less than 10% in nine trials (AFASAK I, BAATAF, SPAFI, CAFA, SPAF II, AFASAK II, the Primary Prevention of Arterial Thromboembolism in Nonrheumatic Atrial Fibrillation study, Swedish Atrial Fibrillation Trial, and JAST) and ranged from 13 to 28 percent in the other eight included trials. Limitations of the network meta-analysis include (1) the lack of sensitivity analyses removing the studies with greater focus on secondary prevention, (2) limited ability to adjust for population characteristics (because some included studies were older and did not report CHADS₂ scores, and they were estimated from baseline characteristics), and (3) heterogeneity of doses in intervention and control groups.

The primary efficacy outcome was the combination of stroke (of any type) and systemic embolism. All-cause mortality was the secondary efficacy outcome. The authors provided both unadjusted results and results adjusted for population characteristics (CHADS₂ scores, TTR, duration of followup). The analysis found that all treatments (aspirin, vitamin K antagonists [VKAs], all four NOACs, and the Watchman device) reduced the risk of the primary and secondary efficacy outcomes in unadjusted analyses (**Appendix E Table 3**). Effect sizes for VKAs and aspirin compared with placebo/control were nearly identical to those from our pairwise meta-analyses for warfarin and aspirin. For the four NOACs (apixaban, dabigatran, edoxaban, and rivaroxaban), the authors reported statistically significant associations with reduction in the primary outcome compared with placebo/control (unadjusted ORs from 0.27 to 0.38; adjusted ORs from 0.32 to 0.44) (**Appendix E Table 3**), but no statistically significant differences for the four NOACs in comparison to one another. In adjusted analyses, the NOACs were not statistically different from VKAs for either efficacy outcome. VKAs and the NOACs showed greater reduction in risk of the primary outcome compared with aspirin.

KQ5. What Are the Harms of Anticoagulation or Antiplatelet Therapy in Asymptomatic, Screen-Detected Older Adults With AF?

All six RCTs described in KQ 4 for benefits of warfarin or aspirin also reported harms.⁸⁶⁻⁹² As for KQ 4, we found no trials or systematic reviews that focused on asymptomatic, screen-detected participants. Error! Reference source not found. and Error! Reference source not found. summarize the characteristics of the included studies and **Appendix E Tables 1 and 2** summarize the results. We also included seven systematic reviews (**Appendix E Table 3**): four were traditional systematic reviews with meta-analyses,^{44, 93, 94, 100} two were individual patient data meta-analyses,^{95, 97} and one was a network meta-analysis.⁹⁸

Warfarin: Results of Meta-Analyses

Major Bleeding

Across trials, 31 major bleeding events occurred, 20 in warfarin groups and 11 in control groups. Warfarin treatment over an average of 1.5 years was associated with an increased risk of major bleeding compared with controls, but the CI was wide, and the difference between groups was not statistically significant (pooled RR, 1.8 [95% CI, 0.85 to 3.7]; $I^2=0\%$; 5 trials; 2,415 participants) (**Figure 4**).

Major Extracranial Bleeding

Across trials, 23 events occurred, 14 in warfarin groups and 9 in control groups. Warfarin treatment over an average of 1.6 years was associated with an increased risk of major extracranial bleeding compared with controls, but the CI was wide, and the difference between groups was not statistically significant (pooled RR, 1.6 [95% CI, 0.67 to 3.6]; $I^2=0\%$; 4 trials; 1,744 participants) (**Figure 4**).

Intracranial Hemorrhage

Eight intracranial hemorrhages occurred, six in warfarin groups and two in control groups. Warfarin treatment over an average of 1.5 years was associated with an increased risk of intracranial hemorrhage compared with controls, but the CI was wide, and the difference between groups was not statistically significant (pooled RR, 1.9 [95% CI, 0.56 to 6.7]; $I^2=0\%$; 5 trials; 2,415 participants) (**Figure 4**).

Minor Bleeding

A total of 222 minor bleeding events occurred, 136 in warfarin groups and 86 in control groups. Warfarin treatment over an average of 1.6 years was associated with an increase in minor bleeding compared with controls (pooled RR, 1.6 [95% CI, 1.2 to 2.0]; $I^2=0\%$; 4 trials; 1,744 participants) (**Appendix F Figure 2**).

Aspirin: Results of Meta-Analyses

Major Bleeding

In the included trials, 34 major bleeding events occurred, 18 in aspirin groups and 16 in control groups. Aspirin treatment over an average of 1.5 years was associated with an increased risk of major bleeding compared with controls, but the CI was wide, and the difference between groups was not statistically significant (pooled RR, 1.5 [95% CI, 0.44 to 5.0]; $I^2=45\%$; 3 trials; 2,663 participants) (**Figure 5**).

Major Extracranial Bleeding

In the included trials, 24 major extracranial bleeding events occurred, 12 in aspirin groups and 12

in control groups. Aspirin treatment over an average of 1.5 years was associated with an increased risk of major extracranial bleeding compared with controls, but the CI was wide, and the difference between groups was not statistically significant (pooled RR, 1.4 [95% CI, 0.32 to 5.8]; $I^2=31.5\%$; 3 trials; 2,663 participants) (**Figure 5**).

Intracranial Hemorrhage

Ten intracranial hemorrhages occurred, six in aspirin groups and four in control groups (**Appendix F Figure 9**). AFASAK I reported no events in either group. SPAF I reported two events in both groups (RR, 1.0 [95% CI, 0.15 to 7.3]), and JAST reported four events in the aspirin group and two events in the control group (RR, 2.1 [95% CI, 0.38 to 11.4]).

Previously Published Systematic Reviews and Meta-Analyses

Results of previously published systematic reviews^{44, 93-95, 97, 98, 100} were generally consistent with our findings and are summarized in **Appendix E Table 3**. Here we highlight the findings from those reviews that provide additional information (beyond what we have described already in this KQ). Overall, the included systematic reviews provide some additional details about subgroups (from individual patient data meta-analyses) and some information about head-to-head comparisons, including comparisons with NOACs.

Warfarin vs. Placebo or Control

One systematic review from the Cochrane collaboration evaluated warfarin for primary prevention.⁹³ It included the same five RCTs in our review but obtained unpublished data excluding the 3 to 8 percent of participants with prior stroke or TIA. The findings were very similar to those of our meta-analyses, although they reported ORs (e.g., for intracranial hemorrhage, they reported OR 2.38 [95% CI, 0.54 to 10.5] vs. our pooled result of RR 1.94 [95% CI, 0.56 to 6.68]) (**Appendix E Table 3**).

Aspirin vs. Placebo or Control

One systematic review from the Cochrane collaboration evaluated aspirin for primary prevention.⁹⁴ It included two of the three RCTs (AFASAK I and SPAF I) that were in our main analyses and included LASAF, which we excluded because of poor quality but used in sensitivity analyses. The review authors obtained unpublished data excluding participants with prior stroke or TIA. The findings were very similar to those of our meta-analyses, showing that aspirin treatment was associated with an increased risk of bleeding compared with controls, but the CIs were wide and the difference between groups was not statistically significant (e.g., for major extracranial bleeding, they reported OR 1.14 [95% CI, 0.44 to 2.98] vs. our pooled result of RR, 1.4 [95% CI, 0.32 to 5.8]) (**Appendix E Table 3**).

Subgroups

Two of the individual patient data meta-analyses described in KQ 4 provided information about whether the risk of harms varies for subgroups.^{95, 97} Both used the Atrial Fibrillation

Investigators database of clinical trials evaluating warfarin or aspirin. That database included all five warfarin trials described in this report (AFASAK I, CAFA, SPAFI, SPINAF, BAATAF) and two of the aspirin trials (AFASAK I and SPAFI). The aspirin analyses are all limited by not including the JAST study (which was published later).

One meta-analysis of individual patient data concluded that the small number of patients with intracranial bleeding does not allow for reliable conclusions about whether the risk varies for subgroups.⁹⁵ They also reported that the six warfarin-treated patients who had intracranial bleeding had higher blood pressure than warfarin-treated patients who did not have intracranial bleeding (169/93 vs. 141/83 mm Hg, $p=0.001$ for systolic and $p=0.016$ for diastolic). The mean age for patients with intracranial bleeding events was higher than for those without bleeding, but the difference between groups was not statistically significantly different (73 vs. 69 years, p not significant and not reported).

The other individual patient data meta-analysis evaluated subgroups based on age for risk of serious hemorrhage (intracranial hemorrhages or major bleeding).⁹⁷ The analyses used the same five RCTs evaluating warfarin that we included, but also included a secondary prevention trial (EAFT). They found that neither warfarin nor aspirin interacted significantly with patient age for serious hemorrhage (data not reported; shown in figures only).

Results of Previously Published Network Meta-Analysis

The one included network meta-analysis used 21 RCTs (96,017 participants) of treatment for nonvalvular AF and is described in KQ 4.⁹⁸ The primary safety outcome was major bleeding (the combination of major extracranial bleeding and intracranial hemorrhage). The authors provided both unadjusted results and results adjusted for population characteristics (CHADS₂ scores, TTR, duration of followup). Effect sizes for VKAs and aspirin compared with placebo/control were nearly identical to those from our pairwise meta-analyses for warfarin and aspirin. Aspirin was associated with an increased risk of major bleeding compared with placebo/control, but the CI was wide, and the difference between groups was not statistically significant (adjusted OR, 1.65 [95% CI, 0.77 to 3.51]). Similarly, for the four NOACs (apixaban, dabigatran, edoxaban, and rivaroxaban), the authors reported associations with an increased risk of bleeding, but the CIs were wide, and differences between groups were not statistically significant (adjusted ORs from 1.38 to 2.21) (**Appendix E Table 3**), and there were no statistically significant differences between any of the four NOACs. Compared with VKAs, three of the NOACs (apixaban, dabigatran, and edoxaban) were associated with a lower risk of bleeding (range of ORs [95% CIs] from 0.64 [95% CI, 0.46 to 0.90] to 0.85 [95% CI, 0.65 to 1.11]), but the difference was only statistically significant for edoxaban (OR, 0.64 [95% CI, 0.46 to 0.90]) (**Appendix E Table 3**). For rivaroxaban compared with VKAs, the odds of major bleeding was 1.03 (95% CI, 0.68 to 1.57).

Chapter 4. Discussion

Summary of Evidence

Error! Reference source not found. provides a summary of findings in this evidence review. This table is organized by KQ and provides a summary of the main findings along with a description of consistency, precision, quality, limitations, strength of evidence, and applicability.

Evidence for Benefit and Harms of Screening

We did not identify any eligible studies evaluating screening for AF with ECG compared with no screening that focused on health outcomes (i.e., no eligible studies focused on the overarching question, KQ 1). We identified one ongoing RCT, the STROKESTOP study, that aims to do so and is estimated to be completed by March 2019.^{77, 79} It randomized 28,768 older adults to screening program invitations for AF or to no invitations. The screening program involves an initial 12-lead ECG and then a handheld 1-lead ECG for intermittent recordings over 2 weeks. The primary outcome is incidence of stroke.

For harms of screening, no eligible studies provided information that allowed comparison between screening and no screening. The SAFE study provided limited evidence showing that anxiety may be increased among people who undergo ECG and screen positive compared with those who undergo ECG and screen negative; relatively few participants were included in the analysis (270 of the 14,802 participants in the trial). Although the difference was statistically significant, it is unclear whether the difference between groups was clinically meaningful (mean S6AQ score at 17 months: 38.1 [35.9 to 40.4] vs. 34.6 [32.4 to 36.8], $p=0.028$). Though it may be expected that anxiety would be slightly higher after a positive screen (than after a negative screen) because it is associated with a new diagnosis of AF.

Potential harms of screening with ECG include overdiagnosis, misdiagnosis (e.g., from misinterpretation of ECGs), and overtreatment (e.g., with anticoagulation for someone without AF, with rate or rhythm control agents when not indicated) for asymptomatic persons who either do not have AF or who would never have had symptoms of or problems from AF. Some evidence suggests that many primary care providers cannot accurately detect AF on ECG.⁸² For example, an analysis of 2,595 participants from 49 general practices in central England participating in the SAFE study assessed the accuracy of general practitioners and interpretive software for diagnosing AF.⁸² General practitioners missed 20 percent of AF cases on 12-lead ECG and misinterpreted 8 percent of sinus rhythm cases (as AF) compared with reference standard cardiologists (sensitivity 79.8 [95% CI, 70.5 to 87.2]; specificity 91.6 [90.1 to 93.1]; 79 out of 99 AF cases detected; misinterpreted sinus rhythm as AF for 114 out of 1,355). False-positive rates varied from 0 to 44 percent for individual general practitioners (standard deviation, 13%). Combining general practitioners' interpretations with those of interpretive software increased the sensitivity (91.9 [86.6 to 97.3]), but specificity was about the same (91.1 [89.6 to 92.6]). Use of single-lead or limb-lead ECGs resulted in slightly lower specificity. The analysis did not evaluate the accuracy of primary care providers for other ECG findings (e.g., findings

that may suggest ischemia and could lead to subsequent testing). Another study using a database from a U.S. hospital that evaluated 2,298 ECGs (from 1,085 patients) with a computerized interpretation of AF found that 442 (19%) ECGs from 382 (35%) patients had been misinterpreted.⁴³ For 92 patients, physicians did not correct the computerized misinterpretation and initiated inappropriate and potentially harmful treatments, and they pursued unnecessary additional testing. Potential harms could also result from additional testing (e.g., unnecessary stress tests or angiographies that were done because of ECG findings suggestive of ischemia, which turned out to be false positives and resulted in complications).

Detection of Previously Undiagnosed AF

Our review found that both one-time systematic screening with 12-lead ECG and twice-weekly screening with a single-lead ECG identified more new cases of AF than no screening (absolute increase over 12 months, 0.6% [95% CI, 0.1% to 0.9%] and 2.8% [95% CI, 0.9% to 4.7%], respectively), but screening with ECG did not detect more cases than an opportunistic screening approach using pulse palpation. The opportunistic screening approaches used in trials included reminder flags to encourage pulse recording and are therefore not necessarily reflective of routine clinical practice. Extrapolating to the U.S. population of adults age 65 or older (estimated as 46 million in 2016¹⁰¹) suggests that 276,000 additional new cases would be identified if ECG screening programs using one-time screening with 12-lead ECG were implemented in the United States. Studies without control groups (summarized in **Appendix A, Contextual Question 1**) estimated more new cases, although they do not account for differences in detection of undiagnosed AF between screening programs and usual care (i.e., the new cases detected that would be attributable to screening). REHEARSE-AF, STROKESTOP, and some uncontrolled studies^{77, 102, 103} suggest that the number of new AF cases detected is greater with intermittent ECG recordings or continuous ECG recordings over the course of 2 weeks than with one-time ECG.

Most asymptomatic older adults with previously unrecognized or undiagnosed AF have a stroke risk (based on CHADS₂ scores or CHA₂DS₂-VASc scores) above the threshold for initiating anticoagulation (**Appendix A Table 2; Appendix A, Contextual Question 2**). Seven studies that described CHA₂DS₂-VASc scores reported a range of mean scores from 3.1 to 3.8, scores that would typically be associated with initiation of anticoagulation (in the absence of contraindications). In STROKESTOP, over 90 percent of new cases of AF were offered and accepted initiation of oral anticoagulant therapy.⁷⁷ The SAFE study reported that 78 percent of new cases identified with systematic screening had CHADS₂ scores of 1 or more and that 43 percent had scores of 2 or more.⁸¹ Of note, if screening programs were implemented, they could be limited to people age 65 or older who have CHA₂DS₂-VASc scores of 2 or higher (to avoid screening people for whom anticoagulation would not be indicated).

Benefits and Harms of Anticoagulation and Antiplatelet Treatment for Nonvalvular AF

Our review found consistent evidence that anticoagulation reduces the risk of stroke and all-cause mortality and increases the risk of bleeding for people with nonvalvular AF who do not

have a history of stroke or TIA (i.e., for primary prevention). Warfarin treatment (mean 1.5 years) was associated with a 68 percent reduction in ischemic stroke (pooled RR, 0.32 [95% CI, 0.20 to 0.51]) and 32 percent reduction in all-cause mortality (pooled RR, 0.68 [95% CI, 0.50 to 0.93]) compared with controls. For a population with baseline annual stroke risk of 4 percent (e.g., such as those with CHADS₂ scores of 2), warfarin was associated with a corresponding NNT of 24 (95% CI, 17 to 36) to prevent one ischemic stroke over an average of 1.5 years of followup. For a population of 1,000 adults age 65 or older with an annual stroke risk of 4 percent, the results translate to an absolute reduction of approximately 28 ischemic strokes per year, an absolute reduction of 16 deaths per year, and an absolute increase of five major bleeding events per year. Aspirin was associated with reduction in mortality and ischemic stroke, but differences between aspirin and controls were not statistically significant. Of note, aspirin for the treatment of AF is either not recommended or is only recommended if the stroke risk is low (CHA₂DS₂-VASc score=1) (**Appendix A Table 2**). A previously published network meta-analysis⁹⁸ included in our review found that NOACs (apixaban, dabigatran, edoxaban, and rivaroxaban) were not statistically different from VKAs for a composite outcome (any stroke and systemic embolism) or for all-cause mortality. VKAs and the NOACs showed greater reduction in risk of the composite outcome compared with aspirin.

Although we aimed to determine the benefits of treatment for asymptomatic, screen-detected older adults with nonvalvular AF, we found no trials or systematic reviews that focused on this population, and it is uncertain whether benefits of medications vary for symptomatic people and those who have never had symptoms (asymptomatic screen-detected people).

Limitations

This review is limited in the ability to describe the direct evidence on the effectiveness or harms of screening for AF because we identified no eligible studies designed to address the overarching question (KQ 1). Therefore, we attempted to review literature that might establish an indirect chain of evidence from multiple questions that link screening to health outcomes (KQs 2 through 5). **Table 6** provides a summary of key limitations of the evidence for each KQ.

We did not systematically review the evidence regarding the diagnostic accuracy of screening tests for AF or the accuracy of a 12-lead ECG conducted and interpreted within primary care settings. A 2017 health technology assessment synthesized studies conducted in a variety of settings (e.g., primary care, preoperative clinics, cardiology practices) that were related to diagnostic accuracy for AF.¹⁰⁴ Based on data from seven studies, a 12-lead ECG interpreted by a nurse, general practitioner, or the ECG machine's automated algorithm had a sensitivity of 92.7 percent (95% CI, 85.9% to 96.8%) and a specificity of 97.4% (95% CI, 95.0% to 98.9%) when compared with a reference standard of cardiologist interpretation. The authors derived these estimates from a hierarchical summary receiver operating characteristics curve. Across individual studies, sensitivity ranged from 68 percent to 100 percent and specificity ranged from 76 percent to 100 percent.

We did not systematically review all the evidence on rate control or rhythm control for AF; however, we summarized the recommendations on rate and rhythm control and the main

evidence cited by those recommendations in **Appendix A (Contextual Question 3a)**. Briefly, rhythm control is not recommended for asymptomatic adults with AF. Some guidelines, including those of the American Heart Association/American College of Cardiology/Heart Rhythm Society, recommend rate control to achieve a resting heart rate under 110 beats per minute for asymptomatic patients with AF based on the results from one trial (Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison between Lenient versus Strict Rate Control II [RACE II]) that concluded noninferiority of a lenient (<110 bpm) versus a strict (<80 bpm resting HR) rate control strategy in patients with permanent AF (for up to 12 months prior to enrollment).⁵¹ RACE II compared strict (<80 bpm resting HR) versus lenient (<110 bpm) rate control strategies in patients with permanent AF (for up to 12 months prior to enrollment). Forty-three percent of the study population was asymptomatic at baseline (defined as no palpitations, dyspnea, or fatigue), although it is not clear how many were never symptomatic (i.e., how many did not have symptoms around the time of their AF diagnosis or prior to it).

We did not include head-to-head trials of treatments for AF because our intention was to provide evidence on benefits of treatments compared with placebo/no treatment for the USPSTF rather than to assess the comparative effectiveness of treatments. Nevertheless, we did include and summarize a previously published network meta-analysis that provides comparative effectiveness estimates.

For KQs 4 and 5, all five included trials that evaluated warfarin began in the 1980s and were completed by 1992. Baseline population rates of stroke may have decreased since then with the increased use of statins and antihypertensive medications. Therefore, the absolute benefits of anticoagulation compared with placebo/control might be less in current clinical practice than in the RCTs, although the relative benefits would not be expected to have changed. Also, the current clinical approach to anticoagulation has evolved since the trials were conducted. Target INR ranges in current practice are typically 2 to 3 for patients with nonvalvular AF. The INR target ranges in the included trials were 2.8 to 4.2 (AFASAK I), 1.5 to 2.7 (BAATAF), 2 to 3 (CAFA), 2 to 4.5 (SPAFI), and 1.4 to 2.8 (SPINAF). In three of the trials (BAATAF, SPAFI, and SPINAF), PT was used to adjust warfarin doses, and the corresponding INR target ranges and mean INRs achieved were estimated. There is some uncertainty about the INR target ranges of these three trials because they used PT targets and conversion of PT to INR cannot be done precisely because of uncertain sensitivity of thromboplastin agents. In addition, trials enrolled somewhat selected participants and followed protocols (e.g., for warfarin dosing); routine clinical practice may not be as rigorous, and whether the results apply to routine clinical practice might be questioned. However, observational studies of anticoagulation suggest that the results are applicable to routine clinical practice.¹⁰⁵ Finally, the trials included in KQs 4 and 5 that evaluated warfarin had a mean duration of followup from 1.2 to 2.2 years (on average, 1.5 years of followup) and were stopped early. It is possible that estimates for reduction in strokes and all-cause mortality are not accurate for lifelong anticoagulation.

The aspirin evidence may be somewhat limited by heterogeneity of doses used. Just one (SPAFI) of the trials evaluating aspirin used a full-dose aspirin (325 mg daily), and it found benefit for stroke reduction, unlike the pooled data.

Future Research Needs

To better understand the potential benefits and harms of screening for AF with ECG, randomized trials of asymptomatic persons that directly compare screening with usual care and assess health outcomes are needed (i.e., trials that address KQ 1, the overarching question, and KQ 3 on harms). The ongoing STROKESTOP study may help fill this evidence gap. Other relevant ongoing RCTs are focused on detecting AF (KQ 2) as the primary outcome; these include SCREEN-AF (NCT02392754), IDEAL-MD (NCT02270151), D₂AF,¹⁰⁶ and mSToPS.¹⁰⁷ SCREEN-AF plans to randomize 822 Canadians age 75 or older with hypertension to screening with Zio XT Patch (2-week continuous ECG monitoring) plus home blood pressure monitoring or to no screening. The primary outcome is new diagnosis of AF or atrial flutter within 6 months. Secondary outcomes include stroke, TIA, and major bleeding. IDEAL-MD is a cluster randomized trial in the Netherlands aiming to enroll 16,000 participants (from 42 general practices randomized to screening vs. usual care) age 65 or older. In the screening arm, a single lead handheld ECG recorder (for up to 1 minute) will be used at every visit to the practice for 1 year. The primary outcome is new diagnosis of AF over 1 year. Secondary outcomes include major cardiovascular events and all-cause mortality over 1 year. Finally, the Detecting and Diagnosing Atrial Fibrillation (D₂AF) trial (listed in The Netherlands Trial Register, NTR4914) is a multicenter cluster randomized trial that will compare different approaches to case finding among adults 65 or older.¹⁰⁶ The case finding protocol includes pulse palpation, sphygmomanometer with automated AF detection, and handheld single-lead ECG. Participants with a positive test and a random sample of those with negative tests will undergo 12-lead ECG. Participants without AF on 12-lead ECG will undergo additional continuous Holter monitoring and use the handheld single-lead ECG at home for 2 weeks. The primary outcome is the difference in detection rate of new AF over 1 year (compared with usual care).

Conclusion

There is uncertainty about the benefits and harms of screening for AF with ECG, and screening can potentially lead to harms that have not been well studied. Although screening can detect previously unknown cases of AF, it has not been shown to detect more cases than opportunistic screening that is focused on pulse palpation. Most older adults with previously unknown AF have a stroke risk above the threshold for anticoagulation. Multiple treatments for AF reduce the risk of stroke and all-cause mortality, and increase the risk of bleeding, but trials have not assessed whether treatment of screen-detected asymptomatic older adults results in better health outcomes than treatment after detection by usual care or after symptoms develop.

References

1. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. 2014 Dec 02;64(21):e1-76. doi: 10.1016/j.jacc.2014.03.022. PMID: 24685669.
2. Cheng A, Kumar K. Overview of atrial fibrillation. 2015. <http://www.uptodate.com/contents/overview-of-atrial-fibrillation>.
3. Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. *J Am Coll Cardiol*. 2008 Feb 26;51(8):802-9. doi: 10.1016/j.jacc.2007.09.064. PMID: 18294563.
4. Kistler PM, Sanders P, Fynn SP, et al. Electrophysiologic and electroanatomic changes in the human atrium associated with age. *J Am Coll Cardiol*. 2004 Jul 7;44(1):109-16. doi: 10.1016/j.jacc.2004.03.044. PMID: 15234418.
5. Allessie M, Ausma J, Schotten U. Electrical, contractile and structural remodeling during atrial fibrillation. *Cardiovasc Res*. 2002 May;54(2):230-46. PMID: 12062329.
6. Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. *Circ Arrhythm Electrophysiol*. 2008 Apr;1(1):62-73. doi: 10.1161/CIRCEP.107.754564. PMID: 19808395.
7. Ikeda T, Murai H, Kaneko S, et al. Augmented single-unit muscle sympathetic nerve activity in heart failure with chronic atrial fibrillation. *J Physiol*. 2012 Feb 1;590(Pt 3):509-18. doi: 10.1113/jphysiol.2011.223842. PMID: 22144576.
8. Segerson NM, Sharma N, Smith ML, et al. The effects of rate and irregularity on sympathetic nerve activity in human subjects. *Heart Rhythm*. 2007 Jan;4(1):20-6. doi: 10.1016/j.hrthm.2006.09.017. PMID: 17198984.
9. Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. *Europace*. 2009 Apr;11(4):423-34. doi: 10.1093/europace/eun369. PMID: 19153087.
10. Savelieva I, Camm AJ. Clinical relevance of silent atrial fibrillation: prevalence, prognosis, quality of life, and management. *J Interv Card Electrophysiol*. 2000 Jun;4(2):369-82. PMID: 10936003.
11. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke*. 1991 Aug;22(8):983-8. PMID: 1866765.
12. Watson T, Shantsila E, Lip GY. Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. *Lancet*. 2009 Jan 10;373(9658):155-66. doi: 10.1016/S0140-6736(09)60040-4. PMID: 19135613.
13. Banerjee A, Taillandier S, Olesen JB, et al. Pattern of atrial fibrillation and risk of outcomes: the Loire Valley Atrial Fibrillation Project. *Int J Cardiol*. 2013 Sep 10;167(6):2682-7. doi: 10.1016/j.ijcard.2012.06.118. PMID: 22795403.
14. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. *Eur Heart J*. 2010 Apr;31(8):967-75. doi: 10.1093/eurheartj/ehn599. PMID: 19176537.

15. Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. *J Am Coll Cardiol*. 2000 Jan;35(1):183-7. PMID: 10636278.
16. Hohnloser SH, Pajitnev D, Pogue J, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. *J Am Coll Cardiol*. 2007 Nov 27;50(22):2156-61. doi: 10.1016/j.jacc.2007.07.076. PMID: 18036454.
17. Link MS, Giugliano RP, Ruff CT, et al. Stroke and mortality risk in patients with various patterns of atrial fibrillation: results from the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). *Circ Arrhythm Electrophysiol*. 2017 Jan;10(1)doi: 10.1161/circep.116.004267. PMID: 28077507.
18. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2013 Nov 28;369(22):2093-104. doi: 10.1056/NEJMoa1310907. PMID: 24251359.
19. Al-Khatib SM, Thomas L, Wallentin L, et al. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. *Eur Heart J*. 2013 Aug;34(31):2464-71. doi: 10.1093/eurheartj/eh135. PMID: 23594592.
20. Steinberg BA, Hellkamp AS, Lokhnygina Y, et al. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial. *Eur Heart J*. 2015 Feb 1;36(5):288-96. doi: 10.1093/eurheartj/ehu359. PMID: 25209598.
21. Lip GY, Frison L, Grind M. Stroke event rates in anticoagulated patients with paroxysmal atrial fibrillation. *J Intern Med*. 2008 Jul;264(1):50-61. doi: 10.1111/j.1365-2796.2007.01909.x. PMID: 18266660.
22. Takabayashi K, Hamatani Y, Yamashita Y, et al. Incidence of Stroke or Systemic Embolism in Paroxysmal Versus Sustained Atrial Fibrillation: The Fushimi Atrial Fibrillation Registry. *Stroke*. 2015 Dec;46(12):3354-61. doi: 10.1161/strokeaha.115.010947. PMID: 26514188.
23. Vanassche T, Lauw MN, Eikelboom JW, et al. Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. *Eur Heart J*. 2015 Feb 1;36(5):281-7a. doi: 10.1093/eurheartj/ehu307. PMID: 25187524.
24. Stroke Risk in Atrial Fibrillation Working G. Independent predictors of stroke in patients with atrial fibrillation: a systematic review. *Neurology*. 2007 Aug 7;69(6):546-54. doi: 10.1212/01.wnl.0000267275.68538.8d. PMID: 17679673.
25. Dulli DA, Stanko H, Levine RL. Atrial fibrillation is associated with severe acute ischemic stroke. *Neuroepidemiology*. 2003 Mar-Apr;22(2):118-23. doi: 68743. PMID: 12629277.
26. Lamassa M, Di Carlo A, Pracucci G, et al. Characteristics, outcome, and care of stroke associated with atrial fibrillation in Europe: data from a multicenter multinational hospital-based registry (The European Community Stroke Project). *Stroke*. 2001 Feb;32(2):392-8. PMID: 11157172.
27. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation. The Framingham Study. *Stroke*. 1996 Oct;27(10):1760-4. PMID: 8841325.

28. Menke J, Luthje L, Kastrup A, et al. Thromboembolism in atrial fibrillation. *Am J Cardiol*. 2010 Feb 15;105(4):502-10. doi: 10.1016/j.amjcard.2009.10.018. PMID: 20152245.
29. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. *Circulation*. 2016 Jan 26;133(4):e38-e360. doi: 10.1161/CIR.0000000000000350. PMID: 26673558.
30. Schnabel RB, Sullivan LM, Levy D, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. *Lancet*. 2009 Feb 28;373(9665):739-45. doi: 10.1016/S0140-6736(09)60443-8. PMID: 19249635.
31. Chamberlain AM, Agarwal SK, Folsom AR, et al. A clinical risk score for atrial fibrillation in a biracial prospective cohort (from the Atherosclerosis Risk in Communities [ARIC] study). *Am J Cardiol*. 2011 Jan;107(1):85-91. doi: 10.1016/j.amjcard.2010.08.049. PMID: 21146692.
32. Alonso A, Krijthe BP, Aspelund T, et al. Simple risk model predicts incidence of atrial fibrillation in a racially and geographically diverse population: the CHARGE-AF consortium. *J Am Heart Assoc*. 2013 Apr;2(2):e000102. doi: 10.1161/JAHA.112.000102. PMID: 23537808.
33. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA*. 2001 May 9;285(18):2370-5. PMID: 11343485.
34. Centers for Medicare & Medicaid Services. Medicare Beneficiary Prevalence for Chronic Conditions for 2004 Through 2013. 2015. https://www.ccwdata.org/web/guest/medicare-charts/medicare-chronic-condition-charts/#b2_cardio_2004_2013.
35. Harris K, Edwards D, Mant J. How can we best detect atrial fibrillation? *J R Coll Physicians Edinb*. 2012;42 Suppl 18:5-22. doi: 10.4997/JRCPE.2012.S02. PMID: 22518390.
36. Moran PS, Flattery MJ, Teljeur C, et al. Effectiveness of systematic screening for the detection of atrial fibrillation. *Cochrane Database Syst Rev*. 2013(4):Cd009586. doi: 10.1002/14651858.CD009586.pub2. PMID: 23633374.
37. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. *Circulation*. 2015 Jan 27;131(4):e29-322. doi: 10.1161/CIR.0000000000000152. PMID: 25520374.
38. Wolf PA, Kannel WB, McGee DL, et al. Duration of atrial fibrillation and imminence of stroke: the Framingham study. *Stroke*. 1983 Sep-Oct;14(5):664-7. PMID: 6658948.
39. Lin HJ, Wolf PA, Benjamin EJ, et al. Newly diagnosed atrial fibrillation and acute stroke. The Framingham Study. *Stroke*. 1995 Sep;26(9):1527-30. PMID: 7660392.
40. Hannon N, Sheehan O, Kelly L, et al. Stroke associated with atrial fibrillation--incidence and early outcomes in the north Dublin population stroke study. *Cerebrovasc Dis*. 2010;29(1):43-9. doi: 10.1159/000255973. PMID: 19893311.
41. Lowres N, Neubeck L, Redfern J, et al. Screening to identify unknown atrial fibrillation. A systematic review. *Thromb Haemost*. 2013 Aug;110(2):213-22. doi: 10.1160/th13-02-0165. PMID: 23595785.
42. Taggar JS, Coleman T, Lewis S, et al. Accuracy of methods for detecting an irregular pulse and suspected atrial fibrillation: A systematic review and meta-analysis. *Eur J Prev Cardiol*. 2016 Aug;23(12):1330-8. doi: 10.1177/2047487315611347. PMID: 26464292.

43. Bogun F, Anh D, Kalahasty G, et al. Misdiagnosis of atrial fibrillation and its clinical consequences. *Am J Med.* 2004 Nov 1;117(9):636-42. doi: 10.1016/j.amjmed.2004.06.024. PMID: 15501200.
44. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med.* 2007 Jun 19;146(12):857-67. PMID: 17577005.
45. Ogilvie IM, Newton N, Welner SA, et al. Underuse of oral anticoagulants in atrial fibrillation: a systematic review. *Am J Med.* 2010 Jul;123(7):638-45 e4. doi: 10.1016/j.amjmed.2009.11.025. PMID: 20609686.
46. Ogilvie IM, Welner SA, Cowell W, et al. Characterization of the proportion of untreated and antiplatelet therapy treated patients with atrial fibrillation. *Am J Cardiol.* 2011 Jul 1;108(1):151-61. doi: 10.1016/j.amjcard.2011.02.353. PMID: 21545990.
47. Cameron C, Coyle D, Richter T, et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation (Provisional abstract). *Database of Abstracts of Reviews of Effects.* 2014(2):e004301. PMID: DARE-12014036609.
48. Dogliotti A, Paolasso E, Giugliano RP. Current and new oral antithrombotics in non-valvular atrial fibrillation: a network meta-analysis of 79 808 patients. *Heart.* 2014 Mar;100(5):396-405. doi: 10.1136/heartjnl-2013-304347. PMID: 24009224.
49. U.S. Food and Drug Administration. WATCHMAN LAA Closure Technology approval letter. 2015.
<http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfTopic/pma/pma.cfm?num=p130013>. Accessed February 8, 2016.
50. Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. *J Am Coll Cardiol.* 2004 Apr 7;43(7):1201-8. doi: 10.1016/j.jacc.2003.11.032. PMID: 15063430.
51. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. *N Engl J Med.* 2002 Dec 5;347(23):1834-40. doi: 10.1056/NEJMoa021375. PMID: 12466507.
52. Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* 2014 Dec;45(12):3754-832. doi: 10.1161/STR.0000000000000046. PMID: 25355838.
53. Bushnell C, McCullough LD, Awad IA, et al. Guidelines for the prevention of stroke in women: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* 2014 May;45(5):1545-88. doi: 10.1161/01.str.0000442009.06663.48. PMID: 24503673.
54. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. *Eur Heart J.* 2012 Nov;33(21):2719-47. doi: 10.1093/eurheartj/ehs253. PMID: 22922413.
55. Stott DJ, Dewar RI, Garratt CJ, et al. RCPE UK Consensus Conference on 'Approaching the comprehensive management of atrial fibrillation: evolution or revolution?'. *J R Coll*


- Physicians Edinb.* 2012;42(Suppl 18):3-4. doi: 10.4997/JRCPE.2012.S01. PMID: 22518389.
56. Murphy A, Banerjee A, Breithardt G, et al. The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation. *Glob Heart.* 2017 Dec;12(4):273-84. doi: 10.1016/j.ghheart.2017.01.015. PMID: 28336387.
 57. Kirchhof P, Breithardt G, Bax J, et al. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. *Europace.* 2016 Jan;18(1):37-50. doi: 10.1093/europace/euv304. PMID: 26481149.
 58. Mairesse GH, Moran P, Van Gelder IC, et al. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). *Europace.* 2017 Oct 1;19(10):1589-623. doi: 10.1093/europace/eux177. PMID: 29048522.
 59. Hobbs FR, Taylor CJ, Jan Geersing G, et al. European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care. *Eur J Prev Cardiol.* 2016 Mar;23(5):460-73. doi: 10.1177/2047487315571890. PMID: 25701017.
 60. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J.* 2016 Oct 7;37(38):2893-962. doi: 10.1093/eurheartj/ehw210. PMID: 27567408.
 61. Culebras A, Messe SR, Chaturvedi S, et al. Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology.* 2014 Feb 25;82(8):716-24.
 62. Scottish Intercollegiate Guidelines Network (SIGN). SIGN 129: Antithrombotics: Indications and Management. Edinburgh: Healthcare Improvement Scotland; 2013.
 63. Lip GY, Ramsay SG. Consensus conference on approaching the comprehensive management of atrial fibrillation. *Expert Rev Cardiovasc Ther.* 2012;10(6):697-700.
 64. National Institute for Health and Care Excellence. Atrial Fibrillation: The Management of Atrial Fibrillation National Institute for Health and Care Excellence (UK). London: 2014.
 65. Antithrombotic Agents for the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation Canadian Agency for Drugs and Technologies in Health. Ottawa (ON): 2013.
 66. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest.* 2012;141(2 Suppl):e513S-75S.
 67. Verma A, Cairns JA, Mitchell LB, et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. *Can J Cardiol.* 2014;30(10):1114-30.
 68. Lindsay MP, Gubitz G, Bayley M, et al. Canadian Best Practice Recommendations for Stroke Care (Update 2010). On behalf of the Canadian Stroke Strategy Best Practices and Standards Writing Group Canadian Stroke Network. Ottawa (ON): 2010.

69. West SL, Gartlehner G, Mansfield AJ, et al. Comparative Effectiveness Review Methods: Clinical Heterogeneity. Report No.: 10-EHC070-EF. Rockville, MD: Agency for Healthcare Research and Quality; Sep 2010.
70. Nyaga VN, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. *Arch Public Health*. 2014;72(1):39. doi: 10.1186/2049-3258-72-39. PMID: 25810908.
71. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*. 2002 Jun 15;21(11):1539-58. doi: 10.1002/sim.1186. PMID: 12111919.
72. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. *BMJ*. 2003 Sep 06;327(7414):557-60. doi: 10.1136/bmj.327.7414.557. PMID: 12958120.
73. Higgins JPT, Green S. *Cochrane Handbook for Systematic Reviews of Interventions: The Cochrane Collaboration*. London: The Cochrane Collaboration; March 2011.
74. Posada IS, Barriaes V. Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. *Am Heart J*. 1999 Jul;138(1 Pt 1):137-43. PMID: 10385777.
75. U.S. Preventive Services Task Force. U.S. Preventive Services Task Force, Procedure Manual, Appendix VI. Rockville, MD: U.S. Preventive Services Task Force; 2015. <https://www.uspreventiveservicestaskforce.org/Page/Name/methods-and-processes> Accessed May 17, 2017.
76. Halcox JPJ, Wareham K, Cardew A, et al. Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study. *Circulation*. 2017 Nov 7;136(19):1784-94. doi: 10.1161/circulationaha.117.030583. PMID: 28851729.
77. Svennberg E, Engdahl J, Al-Khalili F, et al. Mass screening for untreated atrial fibrillation: the STROKESTOP Study. *Circulation*. 2015 Jun 23;131(25):2176-84. doi: 10.1161/circulationaha.114.014343. PMID: 25910800.
78. Friberg L, Engdahl J, Frykman V, et al. Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP). *Europace*. 2013 Jan;15(1):135-40. doi: 10.1093/europace/eus217. PMID: 22791299.
79. Karolinska University Hospital. Systematic ECG Screening for Atrial Fibrillation Among 75 Year Old Subjects in the Region of Stockholm and Halland, Sweden. In: ClinicalTrials.gov [Internet]. Bethesda, MD: National Library of Medicine (US). [cited 2017]. <https://ClinicalTrials.gov/show/NCT01593553>. NLM Identifier: NCT01593553.
80. Fitzmaurice DA, Hobbs FD, Jowett S, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. *BMJ*. 2007 Aug 25;335(7616):383. doi: 10.1136/bmj.39280.660567.55. PMID: 17673732.
81. Fitzmaurice DA, McCahon D, Baker J, et al. Is screening for AF worthwhile? Stroke risk in a screened population from the SAFE study. *Fam Pract*. 2014 Jun;31(3):298-302. doi: 10.1093/fampra/cmu011. PMID: 24728774.
82. Mant J, Fitzmaurice DA, Hobbs FD, et al. Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial. *BMJ*. 2007 Aug 25;335(7616):380. doi: 10.1136/bmj.39227.551713.AE. PMID: 17604299.
83. Hobbs FD, Fitzmaurice DA, Mant J, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over.

- The SAFE study. *Health Technol Assess*. 2005 Oct;9(40):iii-iv, ix-x, 1-74. PMID: 16202350.
84. Swancutt D, Hobbs R, Fitzmaurice D, et al. A randomised controlled trial and cost effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in the over 65s: (SAFE) [ISRCTN19633732]. *BMC Cardiovasc Disord*. 2004 Jul 29;4:12. doi: 10.1186/1471-2261-4-12. PMID: 15283871.
 85. Morgan S, Mant D. Randomised trial of two approaches to screening for atrial fibrillation in UK general practice. *Br J Gen Pract*. 2002 May;52(478):373-4, 7-80. PMID: 12014534.
 86. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. *N Engl J Med*. 1990 Nov 29;323(22):1505-11. doi: 10.1056/nejm199011293232201. PMID: 2233931.
 87. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. *J Am Coll Cardiol*. 1991 Aug;18(2):349-55. PMID: 1856403.
 88. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. *N Engl J Med*. 1992 Nov 12;327(20):1406-12. doi: 10.1056/nejm199211123272002. PMID: 1406859.
 89. Sato H, Ishikawa K, Kitabatake A, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. *Stroke*. 2006 Feb;37(2):447-51. doi: 10.1161/01.STR.0000198839.61112.ee. PMID: 16385088.
 90. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. *Lancet*. 1989 Jan 28;1(8631):175-9. PMID: 2563096.
 91. Stroke Prevention in Atrial Fibrillation Study Group Investigators. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. *N Engl J Med*. 1990 Mar 22;322(12):863-8. doi: 10.1056/nejm199003223221232. PMID: 2407959.
 92. Stroke Prevention in Atrial Fibrillation Study. Final results. *Circulation*. 1991 Aug;84(2):527-39. PMID: 1860198.
 93. Aguilar Maria I, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. *Cochrane Database of Systematic Reviews*. 2005(3)doi: 10.1002/14651858.CD001927.pub2. PMID: CD001927.
 94. Aguilar M, Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. *Cochrane Database Syst Rev*. 2005 Oct 19(4):CD001925. doi: 10.1002/14651858.CD001925.pub2. PMID: 16235290.
 95. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. *Arch Intern Med*. 1994 Jul 11;154(13):1449-57. PMID: 8018000.
 96. Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. *Arch Intern Med*. 1997 Jun 9;157(11):1237-40. PMID: 9183235.

97. van Walraven C, Hart RG, Connolly S, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. *Stroke*. 2009 Apr;40(4):1410-6. doi: 10.1161/strokeaha.108.526988. PMID: 19182090.
98. Tereshchenko LG, Henrikson CA, Cigarroa J, et al. Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis. *J Am Heart Assoc*. 2016 May;5(5)doi: 10.1161/jaha.116.003206. PMID: 27207998.
99. EAFT Study Group (European Atrial Fibrillation Trial). Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. *Lancet*. 1993;342:1255.
100. Coleman CI, Sobieraj DM, Winkler S, et al. Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation (Structured abstract). *Int J Clin Pract*. 2012;66(1):53-63. PMID: DARE-12012000802.
101. Mather M. Fact Sheet: Aging in the United States. Washington, DC: Population Reference Bureau; 2016. Accessed May 16, 2017.
102. Engdahl J, Andersson L, Mirskaya M, et al. Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. *Circulation*. 2013 Feb 26;127(8):930-7. doi: 10.1161/circulationaha.112.126656. PMID: 23343564.
103. Turakhia MP, Ullal AJ, Hoang DD, et al. Feasibility of extended ambulatory electrocardiogram monitoring to identify silent atrial fibrillation in high-risk patients: the Screening Study for Undiagnosed Atrial Fibrillation (STUDY-AF). *Clin Cardiol*. 2015 May;38(5):285-92. doi: 10.1002/clc.22387. PMID: 25873476.
104. Welton NJ, McAleenan A, Thom HH, et al. Screening strategies for atrial fibrillation: a systematic review and cost-effectiveness analysis. *Health Technol Assess*. 2017 May;21(29):1-236. doi: 10.3310/hta21290. PMID: 28629510.
105. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? *JAMA*. 2003 Nov 26;290(20):2685-92. doi: 10.1001/jama.290.20.2685. PMID: 14645310.
106. Uittenbogaart SB, Verbiest-van Gurp N, Erkens PM, et al. Detecting and Diagnosing Atrial Fibrillation (D2AF): study protocol for a cluster randomised controlled trial. *Trials*. 2015;16:478. doi: 10.1186/s13063-015-1006-5. PMID: 26499449.
107. Steinhubl SR, Mehta RR, Ebner GS, et al. Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: The mHealth Screening to Prevent Strokes (mSToPS) trial. *Am Heart J*. 2016;175:77-85. doi: 10.1016/j.ahj.2016.02.011. PMID: CN-01142287.

Figure 1. Analytic Framework




Abbreviations: CHA₂DS₂-VASc=Congestive heart failure, Hypertension, Age≥75 years (doubled), Diabetes mellitus, prior Stroke or TIA or thromboembolism (doubled), Vascular disease, Age 65-74 years, Sex category; ECG=electrocardiography; KQ=key question.

Key Questions to Be Systematically Reviewed

1. Does screening for atrial fibrillation with ECG improve health outcomes (i.e., reduce all-cause mortality or reduce morbidity or mortality from stroke) in asymptomatic older adults?
 - a. Does improvement in health outcomes vary for subgroups defined by stroke risk (e.g., based on CHA₂DS₂-VASc score), age, sex, or race/ethnicity?
2. Does systematic screening for atrial fibrillation with ECG identify older adults with previously undiagnosed atrial fibrillation more effectively than usual care?
3. What are the harms of screening for atrial fibrillation with ECG in older adults?
 - a. Do the harms of screening vary for subgroups defined by stroke risk (e.g., based on CHA₂DS₂-VASc score), age, sex, or race/ethnicity?
4. What are the benefits of anticoagulation or antiplatelet therapy on health outcomes in asymptomatic, screen-detected older adults with atrial fibrillation?
 - a. Do the benefits of anticoagulation or antiplatelet therapy vary for subgroups defined by stroke risk (e.g., based on CHA₂DS₂-VASc score), age, sex, or race/ethnicity?
5. What are the harms of anticoagulation or antiplatelet therapy in asymptomatic, screen-detected older adults with atrial fibrillation?
 - a. Do the harms of anticoagulation or antiplatelet therapy vary for subgroups defined by stroke risk (e.g., based on CHA₂DS₂-VASc score), age, sex, or race/ethnicity?


Figure 2. Summary of Evidence Search and Selection



^a We also used one study rated poor quality in sensitivity analyses.⁷⁴

Abbreviations: SR=systematic review; WHO ICTRP=World Health Organization International Clinical Trials Registry Platform.


Figure 3. Odds of Detecting New Cases of Atrial Fibrillation and Absolute Difference in New Cases Detected, by Comparison



Analyses for this figure used the full study denominators. If using smaller denominators that exclude persons determined to have a prior history of AF, the results were almost identical.

Abbreviations: CI=confidence interval; G=group; ICU=intensive care unit; IG=intervention group; INR=international normalized ratio; No.=number; OR=odds ratio; RD=risk difference; SAFE=Screening for Atrial Fibrillation in the Elderly.

Figure 4. Relative Risk of All-Cause Mortality, Cardiovascular-Related Mortality, All Ischemic Stroke, Moderately to Severely Disabling Stroke, Major Bleeding, Major Extracranial Bleeding, Intracranial Hemorrhage, and All Ischemic Stroke or Intracranial Hemorrhage for Warfarin Compared With Controls




All-cause mortality: SPINAF includes only those without a history of stroke. AFASAK includes data from a previously published meta-analysis that they obtained data from the original study authors.

Major bleeding: AFASAK did not specify bleeding severity of most bleeding events; it reported 1 fatal intracerebral hemorrhage in the warfarin group and only reported bleeding events leading to withdrawal from study, 21 for warfarin and 0 for placebo. BAATAF defines major bleeding as intracranial bleeding, fatal bleeding, or bleeding that led to a blood transfusion (four or more units of blood within 48 hours). SPAF I defines major bleeding as bleeding that involved the central nervous system, management requiring hospitalization with transfusion and/or surgery, or permanent residual impairment. CAFA defines major bleeding as life-threatening bleeding. SPINAF defines major bleeding as bleeding that required a blood transfusion, an emergency procedure, or removal of a hematoma or bleeding that led to ICU admission.

Intracranial Hemorrhage: SPAF I events included one fatal intracerebral hemorrhage and one subdural hematoma with full recovery in the warfarin group, and two subdural hematomas with full recovery in the placebo group.

Abbreviations: AFASAK=Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation study; BAATAF=Boston Area Anticoagulation Trial for Atrial Fibrillation; CAFA=Canadian Atrial Fibrillation Anticoagulation study; CG=control group; CI=confidence interval; ICU=intensive care unit; IG=intervention group; INR=international normalized ratio; No.=number; RR=risk ratio; SPAF=Stroke Prevention in Atrial Fibrillation Study; SPINAF=Stroke Prevention in Nonrheumatic Atrial Fibrillation study; yr=year.

Figure 5. Relative Risk of All-Cause Mortality, Cardiovascular-Related Mortality, All Ischemic Stroke, Major Bleeding, Major Extracranial Bleeding, and All Ischemic Stroke or Intracranial Hemorrhage for Aspirin Compared With Controls



All-cause mortality: AFASAK includes data from a previously published meta-analysis that they obtained from the original study authors.

Major bleeding: AFASAK did not specify the severity of most bleeding events; it only reported that there were two aspirin bleeding episodes that required a blood transfusion and zero bleeding episodes in the placebo group. SPAF I defined major bleeding as bleeding that involved the central nervous system, management requiring hospitalization with transfusion and/or surgery, or permanent residual impairment. JAST defined major bleeding as fatal bleeding, bleeding that required hospital admission for treatment, bleeding that required a blood transfusion, or a decrease of hemoglobin concentration by more than 4g/dL.

Abbreviations: AFASAK=Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation study; CG=control group; CI=confidence interval; g/dL=grams per deciliter; JAST=Japan Atrial Fibrillation Stroke Trial; IG=intervention group; INR=international normalized ratio; No.=number; RR=risk ratio; SPAF=Stroke Prevention in Atrial Fibrillation Study; yr=year.

Table 1. Classification of Atrial Fibrillation

Type of AF	Definition
Paroxysmal	AF that terminates spontaneously or with intervention within 7 days of onset; episodes may recur with variable frequency.
Persistent	Continuous AF for more than 7 days.
Long-standing persistent	Continuous AF for more than 12 months.
Permanent	AF when the patient and clinician make a joint decision to stop further attempts to restore and/or maintain sinus rhythm; does not reflect a pathophysiological attribute of AF.
Nonvalvular	AF in the absence of rheumatic mitral valve disease, mitral valve repair, or valve replacement.

Source: Adapted from 2014 American Heart Association/American College of Cardiology/Heart Rhythm Society guidelines.¹

Abbreviation: AF=atrial fibrillation.

Table 2. Characteristics of Included Randomized, Controlled Trials Evaluating Detection of Previously Undiagnosed Atrial Fibrillation (KQ 2)

First Author, Year Trial Name	G1 (N) G2 (N) G3 (N)	Screening Approaches	Source of Patients	Country	Duration of Study, Months	Mean Age	% F	Quality
Fitzmaurice, 2014 ⁸¹ ; Fitzmaurice, 2007 ⁸⁰ ; Mant, 2007 ⁸² ; Hobbs, 2005 ⁸³ ; Swancutt, 2004 ⁸⁴ SAFE	Opportunistic screening (4,933) Systematic screening (4,933) No screening (4,936)	Opportunistic screening: Nurses and physicians encouraged to record pulse during routine visits; patients with irregular pulses invited to attend a nurse-led screening clinic and have 12-lead ECG Systematic screening: Patients invited by letter to attend a nurse-led screening clinic where their radial pulse was palpated, and a 12-lead ECG was performed	50 primary care practices; cluster RCT with randomization at the practice level	United Kingdom	12	75.3	57.4	Fair
Halcox, 2017 ⁷⁶ REHEARSE-AF	Systematic screening (500) No screening (501)	Systematic screening: Twice-weekly 30-second, single-lead ECG using a handheld device, plus additional recordings if symptomatic No screening: followed up as normal by their general practitioner	General practices	United Kingdom	12	72.6	53.4	Fair
Morgan, 2002 ⁸⁵	Opportunistic screening (1,502) Systematic screening (1,499)	Opportunistic screening: Nurses and physicians were encouraged to record pulse during routine visits; if pulse was suspicious for atrial fibrillation, they decided whether to request ECG depending on the history and clinical context Systematic screening: Patients invited by letter to attend a nurse-led screening clinic where their radial pulse was palpated, and a lead II rhythm strip was performed	4 general practices	United Kingdom	6	75.5	58.8	Fair

Abbreviations: ECG=electrocardiogram; F=Female; G=group; N=sample size; SAFE=Screening for Atrial Fibrillation in the Elderly.

Table 3. Results of Included Randomized, Controlled Trials for KQs 2 and 3

First Author, Year Trial Name	G1 (N) G2 (N) G3 (N)	Atrial Fibrillation G1 N (%) G2 N (%) G3 N (%) Between-Group Difference or OR (95% CI)	Anxiety G1 N (%) G2 N (%) Mean State Anxiety (95% CI), p-Value (Unadjusted Except Where Indicated), Response Rate (Questionnaires Completed/Sent)
Fitzmaurice, 2014 ⁸¹ ; Fitzmaurice, 2007 ⁸⁰ ; Mant, 2007 ⁸² ; Hobbs, 2005 ⁸³ ; Swancutt, 2004 ⁸⁴ SAFE	Opportunistic screening (4,933) Systematic screening (4,933) No screening (4,936)	New cases identified (percentage of those randomized; percentage if excluding those with a history of atrial fibrillation and those with missing notes from the denominator): 75 (1.5; 1.64) 74 (1.5; 1.62) 47 (0.95; 1.04) <i>Screening (either approach) vs. no screening</i> Between-group difference: 0.59% (0.20% to 0.98%); the difference was similar and statistically significant for both opportunistic vs. no screening and systematic vs. no screening ($p \leq 0.02$ for both) OR: 1.58 (1.12 to 2.22), $p=0.01$ without accounting for baseline prevalence OR: 1.61 (1.14 to 2.29), $p=0.0085$ accounting for baseline prevalence <i>Opportunistic screening vs. systematic screening</i> Between-group difference: 0.02% (-0.5% to 0.5%) OR: 0.99 (0.72 to 1.37), $p=0.95$	<i>Systematic vs. opportunistic</i> Baseline: 35.78 (33.80 to 37.76) vs. 36.44 (34.35 to 38.53), $p=0.695$, 66% (493/750) Postscreening: 28.77 (28.27 to 29.26) vs. 28.25 (26.78 to 29.73), $p=0.732$, 75% (1940/2595) After 17 months: 35.92 (34.29 to 37.55) vs. 37.50 (35.82 to 39.18), $p=0.089$, $p=0.844$ (adjusted), 69% (535/777) <i>Screen positive (n=142) vs. screen negative (n=128) (after 17 months):</i> 38.12 (35.89 to 40.35) vs. 34.61 (32.41 to 36.81), $p=0.028$
Halcox, 2017 ⁷⁶ REHEARSE-AF	Systematic screening (500) No screening (501)	<i>New cases identified</i> 19 5 Hazard ratio, 3.9; 95% CI, 1.4 to 10.4, $p=0.007$	Study was rated as poor quality for anxiety outcomes
Morgan, 2002 ⁸⁵	Opportunistic screening (1,502) Systematic screening (1,499)	<i>New cases identified</i> 7 (0.5) 12 (0.8) OR: 1.7 (0.68 to 4.4), $p=0.25$ <i>All cases identified (most of these had a prior diagnosis of atrial fibrillation)</i> 19 (1.3) 67 (4.5) Between-group difference: 3.2% (2.0% to 4.4%), $p<0.001$	NR

Abbreviations: CI=confidence interval; G=group; n=number (of patients); N=sample size; NR=not reported; OR=odds ratio; SAFE=Screening for Atrial Fibrillation in the Elderly.

Table 4. Characteristics of Included Randomized, Controlled Trials for KQs 4 and 5: Part 1

First Author, Year Trial Name	G1 (N) G2 (N) G3 (N)	Source of Patients	Country	Mean Follow up, yr	Mean Age	% F	% Non-white
Petersen, 1989 ⁹⁰ AFASAK	Warfarin, adjusted dose (335) Aspirin 75 mg daily (336) Placebo (336)	Those with chronic AF from 2 outpatient ECG laboratories	Denmark	1.2	74 (median)	46	NR
The Boston Area Trial for Atrial Fibrillation Investigators, 1990 ⁸⁶ BAATAF	Warfarin, adjusted dose (212) Control ⁹ (208)	32 centers and 3 private medical offices	United States	2.2	68	28	NR
Stroke Prevention in Atrial Fibrillation Investigators, 1990 & 1991 ^{91, 92} SPAF I	<u>Group 1 (anti-coagulation candidates)</u> Warfarin, adjusted dose (210) Aspirin 325 mg/day (206) Placebo (211) <u>Group 2 (non-anticoagulation candidates)</u> Aspirin 325 mg/day (346) Placebo (357)	15 centers	United States	1.3	67	29	16
Connolly, 1991 ⁸⁷ CAFA	Warfarin, dose adjusted per subject (187) Placebo (191)	11 centers (hospitals, outpatient laboratories, and direct physician referrals)	Canada	1.3	68	25	NR
Ezekowitz et al, 1992 ⁸⁸ SPINAF	Warfarin, adjusted dose (4- mg/day and adjusted to meet PT ratios) (260) Placebo (265) ^b	16 Department of Veterans Affairs medical centers	United States	1.7	67	0	NR
Sato et al, 2006 ⁸⁹ JAST	Aspirin 150-200 mg/day (426) Control (445)	13 centers and 76 affiliated hospitals	Japan	2.1	65	30	NR

Table 5. Characteristics of Included Randomized, Controlled Trials for KQs 4 and 5: Part 2

First Author, Year Trial Name	% TIA % Stroke	% HF % Heart Valve dz % CAD % HTN % DM	Target INR (PT)	TTR%
Petersen, 1989 ⁹⁰ AFASAK	2 4	52 NR 8 prior MI 32 12	2.8 to 4.2 (NR)	73
The Boston Area Trial for Atrial Fibrillation Investigators, 1990 ⁸⁶ BAATAF	NR 3	26 23 MR>1+ 52 51 15	1.5 to 2.7 (1.2 to 1.5)	83
Stroke Prevention in Atrial Fibrillation Investigators, 1990 & 1991 ^{91, 92} SPAF I	7 Stroke or TIA	19 6 MVP 8 with prior MI 52 16	G1: 2 to 4.5 (1.3 to 1.8)	71 within target PT
Connolly, 1991 ⁸⁷ CAFA	4 Stroke or TIA	22 NR 13 prior MI 39 12	2 to 3 (NR)	44
Ezekowitz et al, 1992 ⁸⁸ SPINAF	NR 8	30 15 MR>1+ 19 prior MI 58 18	1.4 to 2.8 (1.2 to 1.5)	56
Sato et al, 2006 ⁸⁹ JAST	2.5	9 NR 0 38 14	NA	NA

^a Control group was allowed to take aspirin.

^b Study reported findings separately for patients with and without previous cerebral infarctions. Patients with previous cerebral infarction: warfarin (21) vs. control (25).

Abbreviations: AF=atrial fibrillation; AFASAK=Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation study; BAATAF=Boston Area Anticoagulation Trial for Atrial Fibrillation; CAD=coronary artery disease; CAFA=Canadian Atrial Fibrillation Anticoagulation study; DM=diabetes mellitus; dz=disease; ECG=electrocardiogram; F=female; G=group; HF=heart failure; HTN=hypertension; INR=international normalized ratio; JAST=Japan Atrial Fibrillation Stroke Trial; mg=milligrams; MI=myocardial infarction; MR=mitral regurgitation; N=sample size; MR=mitral regurgitation; MVP=mitral valve prolapse; NA=not applicable; NR=not reported; OR=odds ratio; PT=prothrombin time; SPAF=Stroke Prevention in Atrial Fibrillation Study; SPINAF=Stroke Prevention in Nonrheumatic Atrial Fibrillation study; TIA=transient ischemic attack; TTR=time in therapeutic range; yr=year.

Table 6. Summary of Evidence for Screening for Atrial Fibrillation With ECG

Key Question and Topic	No. of Studies Study Design	No. of Participants	Summary of Main Findings (Including Consistency and Precision)	Quality	Limitations (Including Reporting Bias)	Strength of Evidence	Applicability
1: Benefits of screening	1 RCT	1,001	Study was not designed or powered to evaluate health outcomes (it was designed for KQ 2). Composite of stroke, TIA, or systemic embolism: 6 vs. 10 events; HR, 0.61; 95% CI, 0.22 to 1.69; consistency unknown; imprecise.	Fair	Moderate risk of measurement bias; lack of masking; reporting bias not detected.	Insufficient	NA
2: Identifying new cases of atrial fibrillation	3 RCTs	18,804	No significant difference between systematic screening with ECG and opportunistic screening approaches focused on pulse palpation; RDs were -0.02% (95% CI, -0.5% to 0.5%) and 0.3% (-0.2% to 0.9%); consistent, imprecise. Systematic screening with 12-lead ECG identified more new cases than no screening (absolute increase over 12 months, 0.6% [95% CI, 0.1% to 0.98%]) as does twice-weekly screening with single-lead ECG (absolute increase over 12 months, 2.8% [95% CI, 0.9% to 4.7%]); consistent ^a ; imprecise.	Fair	Allocation concealment was inadequate or not reported; limited reporting of baseline characteristics to allow assessment for baseline differences in 2 studies (studies reported only age and sex); ⁸⁰⁻⁸⁵ potential ascertainment bias for previous atrial fibrillation diagnoses in 1 study (done by 1 person and masking to allocation was NR); ⁸⁵ moderate risk of ascertainment bias with lack of masking and uncertain workup to confirm AF in 1 study; ⁷⁶ reporting bias not detected.	Low	Adults age 65 or older without a known history of atrial fibrillation Questionable applicability to women
3: Harms of screening	1 RCT	False positives: 2,595 Anxiety: 1,940 ^b (of the 14,802 participants in the SAFE study)	General practitioners misinterpreted 8% of sinus rhythm cases as AF compared with reference standard cardiologists (sensitivity 79.8 [95% CI, 70.5 to 87.2]; specificity 91.6 [90.1 to 93.1]). Mean anxiety (S6AQ) scores were not significantly different for systematic and opportunistic screening arms postscreening (28.8 [95% CI, 28.3 to 29.3] vs. 28.3 [26.8 to 29.7], p=0.73) or after 17 months (35.9 [34.3 to 37.6] vs. 37.5 [35.8 to 39.2], p=0.84 adjusted for baseline scores). Mean scores were higher for screen-positive vs. screen-negative respondents at 17 months (38.1 [35.9 to 40.4] vs. (34.6 [32.4 to 36.8], p=0.03); consistency unknown (single study); precise.	Fair	Relatively few participants were included in the analysis of screen-positive vs. screen-negative respondents (270 participants). <i>Screening vs no screening:</i> no anxiety data collected from no-screening group to allow comparison between screening and no-screening arms. Reporting bias not detected.	Low for false positives; low for anxiety for systematic vs. opportunistic and screen-positive vs. negative Insufficient for other harms and screening vs. no screening for all harms	Adults age 65 or older who were screened with an ECG

Table 6. Summary of Evidence for Screening for Atrial Fibrillation With ECG

Key Question and Topic	No. of Studies Study Design	No. of Participants	Summary of Main Findings (Including Consistency and Precision)	Quality	Limitations (Including Reporting Bias)	Strength of Evidence	Applicability
4: Benefits of treatment	6 RCTs and 7 SRs	4,531 in the RCTs and 108,942 in the SRs	<p>Warfarin treatment (mean 1.5 years) was associated with reduced all-cause mortality (pooled RR, 0.68 [0.50 to 0.93]) and ischemic stroke (pooled RR, 0.32 [0.20 to 0.51]) compared with controls (5 trials; 2,415 participants). Findings were consistent and precise. Aspirin was associated with reduced all-cause mortality and ischemic stroke compared with controls, but differences were not statistically significant.^c</p> <p>Network meta-analysis (previously published⁹⁸) found that all treatments (aspirin, VKAs, and all four NOACs)^d reduced the risk of a primary outcome (composite of any stroke and systemic embolism) and all-cause mortality. For NOACs, it found statistically significant associations with reduction in the primary outcome compared with placebo/control (unadjusted ORs from 0.27 to 0.38; adjusted ORs from 0.32 to 0.44).^e</p>	Fair	<p>All warfarin trials were stopped early; 3 of the 5 warfarin trials were open label; 4 of the 5 warfarin trials had inadequate or unclear methods of allocation concealment. Reporting bias not detected.</p> <p>Limitations of the network meta-analysis include (1) the lack of sensitivity analyses removing the studies with greater focus on secondary prevention, (2) limited ability to adjust for population characteristics (because some included studies were older and did not report CHADS₂ scores, and they were estimated from baseline characteristics), and (3) heterogeneity of doses in intervention and control groups.</p>	Moderate	<p>Adults with nonvalvular atrial fibrillation and no history of stroke or TIA; uncertain whether the results are applicable to asymptomatic screen-detected people with AF.</p> <p>Most participants had AF for more than a year and few had paroxysmal AF. Warfarin trials were mean 1.5 years; estimates for lifelong benefits are not available.</p>

Table 6. Summary of Evidence for Screening for Atrial Fibrillation With ECG

Key Question and Topic	No. of Studies Study Design	No. of Participants	Summary of Main Findings (Including Consistency and Precision)	Quality	Limitations (Including Reporting Bias)	Strength of Evidence	Applicability
5: Harms of treatment	6 RCTs and 7 SRs	4,531 in the RCTs and 116,496 in the SRs	<p>Warfarin treatment for an average of 1.5 to 1.6 years was associated with increased risk of major bleeding (pooled RR, 1.8 [0.85 to 3.7]) and intracranial hemorrhage (pooled RR, 1.9 [0.56 to 6.7]) compared with controls, but confidence intervals were wide and differences between groups were not statistically significant (5 trials; 2,415 participants). Findings were consistent and imprecise. Aspirin was associated with increased risk of bleeding compared with controls; confidence intervals were wide, and differences were not statistically significant.^f</p> <p>Network meta-analysis (previously published^{g,h}) found that the four NOACs were associated with increased risk of bleeding compared with placebo/controls (adjusted ORs from 1.38 to 2.21); confidence intervals were wide and differences between groups were not statistically significant).^h</p>	Fair	<p>All warfarin trials were stopped early; 3 of the 5 warfarin trials were open label; 4 of the 5 warfarin trials had inadequate or unclear methods of allocation concealment; reporting bias not detected.</p> <p>Limitations of the network meta-analysis include 1) the lack of sensitivity analyses removing the studies with greater focus on secondary prevention, 2) limited ability to adjust for population characteristics (because some included studies were older and did not report CHADS₂ scores, and they were estimated from baseline characteristics), and 3) heterogeneity of doses in intervention and control groups.</p>	Moderate ^g	Adults with nonvalvular AF and no history of stroke or TIA

^a Consistent when considering the studies described in Appendix A for Contextual Question 1 and considering that the results were consistent for systematic screening versus no screening when compared with those for opportunistic screening versus no screening.

^b This was a subset of the 14,802 participants in the SAFE study. The number of participants may be slightly greater than 1,940 because the study did not report the total number of unique individuals who completed the Spielberger 6-item Anxiety Questionnaire (S6AQ) and it is unclear whether everyone in the baseline and end-of-study samples were also in the post-ECG screening sample. The study reported that 493 participants completed the baseline S6AQ, 1,940 completed the postscreening S6AQ, and 535 returned the end-of-study S6AQ. REHEARSE-AF also reported some information about anxiety, but it was not included because those outcomes were rated poor quality because of high risk of measurement bias (for not using a valid and reliable measure and lack of masking).

^c Aspirin treatment for an average of 1.5 years was associated with a reduction in all-cause mortality (pooled RR, 0.84 [0.62 to 1.14]) and ischemic stroke (pooled RR, 0.76 [95% CI, 0.52 to 1.1]) compared with controls, but the differences were not statistically significant; 3 trials; 2,663 participants. Findings were consistent and imprecise.

^d The four NOACs are apixaban, dabigatran, edoxaban, and rivaroxaban.

^e The network meta-analysis also found no statistically significant differences for the four NOACs in comparison to one another. In adjusted analyses, the NOACs were not statistically different from VKAs for the primary outcome or for all-cause mortality. VKAs and the NOACs showed greater reduction in risk of the primary outcome compared with aspirin.

^f Aspirin treatment for an average of 1.5 years was associated with an increased risk of major bleeding compared with controls, but the confidence interval was wide and the difference between groups was not statistically significant (pooled RR, 1.5 [95% CI, 0.44 to 5.0]; 3 trials; 2,663 participants).

^g Although findings were imprecise and quality was fair, we graded the strength of evidence as Moderate considering evidence on dose response (with higher INRs increasing bleeding risk) and evidence on treatment of other conditions showing consistent evidence of bleeding risk.

^h The network meta-analysis also found no statistically significant differences for the four NOACs in comparison to one another. Compared with VKAs, three of the NOACs (apixaban, dabigatran, and edoxaban) were associated with a lower risk of bleeding (range of ORs [95% CIs] from 0.64 [0.46 to 0.90] to 0.85 [0.65 to 1.11]), but the difference was only statistically significant for edoxaban (0.64 [0.46 to 0.90]). For rivaroxaban compared with VKAs, the odds of major bleeding was 1.03 (95% CI, 0.68, 1.57).

Abbreviations: CHADS₂=Congestive heart failure, Hypertension, Age≥75 years, Diabetes mellitus, prior Stroke or TIA or thromboembolism; CI=confidence intervals; ECG=electrocardiogram; HR=hazard ratio; INR=international normalized ratio; NA=not applicable; No.=number; NOAC=novel oral anticoagulant; NR=not reported; OR=odds ratio; RCT=randomized control trial; RD=risk difference; REHEARSE-AF=Assessment of REmote HEArt Rhythm Sampling using the AliveCor heart monitor to scrEen for Atrial Fibrillation; RR=relative risk; S6AQ=Spielberger 6-item Anxiety Questionnaire; SR=systematic review; TIA=transient ischemic attack; VKA=vitamin K antagonist.

Prevalence

On the basis of 1990s data from 1.89 million adult members of a health maintenance organization in California, the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study reported a prevalence of diagnosed AF among the general population of 0.95 percent, increasing with age (**Appendix A Table 1**).¹ The ATRIA study also identified differences in AF prevalence based on race. Although African American and white patients between 50 and 59 years of age patients had similar rates of AF, higher rates were reported among white patients in older age groups: 1.8 percent versus 1.3 percent in patients ages 60 to 69 years, 5.2 percent versus 4.4 percent in patients ages 70 to 79 years, and 9.9 percent versus 7.7 percent among those age 80 years or older.¹

Age Band (years)	Prevalence in Women (%)	Prevalence in Men (%)
<55	0.1	0.2
55–59	0.4	0.9
60–64	1.0	1.7
65–69	1.7	3.0
70–74	3.4	5.0
75–79	5.0	7.3
80–84	7.2	10.3
≥85	9.1	11.1

Abbreviation: ATRIA=AnTicoagulation and Risk factors In Atrial fibrillation.

Appendix A Table 2. Validated Risk Prediction Tools for Stroke Risk

Risk Factor Category	Stroke Risk Tool				
	CHADS ₂ ²	CHA ₂ DS ₂ -VASc ³	R ₂ CHADS ₂ ⁴	QStroke ⁵	ATRIA ^{a,6}
	Scoring/Points				
Congestive heart failure	1 (recent)	1 (or LV dysfunction)	1 (recent)	Y/N	1
Hypertension	1 (history of)	1	1 (history of)	Continuous (SBP)	1
Age (years)	1 (75+)	1 (65–74) 2 (75+)	1 (75+)	Range, 25–84	6/9 (85+) 5/7 (75–84) 3/7 (65–74) 0/8 (<65)
Diabetes mellitus	1	1	1	Y/N (T1DM, T2DM)	1
Stroke/TIA/TE	2	2	2		
Renal dysfunction			2 (creatinine clearance <60 mL/min)		1 (proteinuria) 1 (eGFR <45 mL/min/1.73 m ² or ESRD)
Sex		1 (female)		Separate models for MF	1 (female)
Vascular disease		1 (prior MI, PAD, or aortic plaque)			
Valvular heart disease				Y/N	
Family history CHD				Y/N	
TC:HDL C ratio				Continuous	
Atrial fibrillation				Y/N	
Rheumatoid arthritis				Y/N	
BMI				Continuous	
Smoking status				5 categories	
Ethnicity				9 categories	
Deprivation				Continuous (TDI score)	

^a Scored for age categories with/without prior stroke.

Abbreviations: ATRIA=Anticoagulation and Risk factors In Atrial fibrillation; BMI=body mass index; CHADS₂= Congestive heart failure, Hypertension, Age≥75 years, Diabetes mellitus, Prior stroke or TIA or thromboembolism; CHA₂DS₂-VASc=Congestive heart failure (or left ventricular systolic dysfunction), Hypertension, Age≥75 years, Diabetes mellitus, Prior stroke or TIA or thromboembolism, Vascular disease, Age 65–74 years, Sex category; CHD=coronary heart disease; eGFR=estimated glomerular filtration rate; ESRD=end stage renal disease; HDLC=high density lipoprotein cholesterol; LV=left ventricular; m²=square meters; M/F=male/female; MI=myocardial infarction; min=minute; mL=milliliters; PAD=peripheral artery disease; R₂CHADS₂=Renal Dysfunction, Congestive Heart Failure, Hypertension, Age, Diabetes, Stroke/Transient Ischemic Attack; SBP=systolic blood pressure; T1DM=type 1 diabetes mellitus; T2DM=type 2 diabetes mellitus; TC=total cholesterol; TDI=Townsend deprivation index; TE=thromboembolism; TIA=transient ischemic attack; Y/N=yes/no.

Appendix A Table 3. Validated Risk Prediction Tools for Bleeding Risk

Risk Factor Category	Bleeding Risk Tool		
	HAS-BLED ^{a,7}	HEMORR ₂ HAGES ⁸	ATRIA ⁹
	Scoring/Points		
Hypertension	1	1 (uncontrolled)	1
Age (years)	1 (65+ or frail)	1 (75+)	2 (75+)
Stroke	1	1	
Hepatic and/or renal dysfunction	1 or 2	1	3 (severe renal disease)
Ethanol abuse	1	1	
Anemia		1	3
Bleeding-associated factors	1 (bleeding tendency or predisposition)	1 (reduced platelet count/function) 2 (rebleeding risk)	1 (prior hemorrhage)
Malignancy		1	
Genetic factors (CYP2C9 SNP)		1	
Excessive fall risk		1	
Labile INRs (if on warfarin)	1		
Drugs (e.g., anti-platelet or NSAIDs)	1		

^a 2013 review by the AHRQ Effective Health Care Program found that, based on limited evidence, the HAS-BLED tool best discriminates the bleeding risk in patients with AF;¹⁰ recent guidelines from the United Kingdom, Europe, and Canada also recommend its use for the stratification of bleeding risk in AF patients before treatment decisions.¹¹⁻¹³

Abbreviations: ATRIA=Anticoagulation and Risk factors In Atrial fibrillation; CYP2C9 SNP=Gene variant (single nucleotide polymorphism) affecting drug metabolism; HAS-BLED=Hypertension, Abnormal renal and liver function, Stroke, Bleeding, Labile international normalized ratios, Elderly, Drugs or alcohol; HEMORR₂HAGES=Hepatic or renal disease, ethanol abuse, Malignancy, Older age, Reduced platelet count or function, Rebleeding risk, Hypertension, Anemia, Genetic factors, Excessive fall risk, Stroke; INR=International Normalized Ratio, assay used to determine clotting tendency; NSAID=non-steroidal anti-inflammatory drug.

Appendix A Table 4. Recent Recommendations (2010 or newer) on Primary Prevention of Stroke (Including Screening and/or Treatment) in Patients With Atrial Fibrillation

Society or Professional Organization, Year Scope	Screening	Anticoagulation^a	Antiplatelet^a
AF-SCREEN, 2017 ¹⁴ Screening for AF	Age >65 years, opportunistic pulse then ECG, single-lead ECG, or patient-activated twice-daily intermittent screening for 2 weeks (for age ≥75 years or those at high stroke risk),	OAC ^b	Not recommended
WHF, 2017 ¹⁵ Management of AF	Age ≥65 years, opportunistic pulse palpation, with ECG as appropriate	VKA or NOAC ^b	Not recommended
EHRA, 2016-7 ^{16, 17} Screening for AF	Support the ESC 2016 recommendations; age ≥65 years, opportunistic screening by pulse taking or ECG rhythm strip; systematic ECG screening may be considered in patients ≥75 years or those at high stroke risk	VKA or NOAC ^b	Not recommended
ESC, 2016 ¹⁸ Management of AF	Age ≥65 years, opportunistic screening by pulse taking or ECG rhythm strip; systematic ECG screening may be considered in patients ≥75 years or those at high stroke risk	VKA or NOAC ^b	Not recommended
EPCCS, 2016 ¹⁹ Prevention of stroke in AF	Age ≥65 years, opportunistic case finding with pulse palpation at least yearly, with ECG as appropriate (alternative approach could use modified sphygmomanometers or single-lead ECG devices if they have been subject to validation with 12-lead ECG)	VKA or NOAC ^b	Not recommended
UK NSC, 2014 ²¹ Screening for AF	Age ≥65 years, screening not recommended	Not addressed	Not addressed
NICE, 2014 ¹³ Management of AF	Not directly addressed, pulse palpation for symptoms and ECG when AF is suspected because of irregular pulse (symptomatic or not)	VKA or NOAC ^b	Not recommended
AHA/ACC/HRS, 2014 ²² Management of AF	Not addressed	VKA or NOAC ^b	Low stroke risk only ^c
AHA/ASA 2014 ²³ Prevention of stroke	Age ≥65 years, pulse with ECG as appropriate	VKA or NOAC ^b	Low stroke risk only ^c
AAN, 2014 ²⁴ Prevention of stroke in NVAf	Not addressed	VKA or NOAC ^d	Low stroke risk only ^c
CCS, 2014 ²⁵ Stroke prevention in AF	Not addressed	NOAC > VKA ^f	Low stroke risk only
CADTH, 2013 ²⁶ Antithrombotic agents in AF	Not addressed	VKA or NOAC ^e	Not addressed
SIGN, 2013 ²⁷ Antithrombotic indications	Not addressed	VKA or NOAC ^{f, g}	Limited to persons refusing VKA/NOAC
ACCP, 2012 ²⁸ Antithrombotic therapy for AF	Not addressed	NOAC > VKA ^f	Low stroke risk ^c or patients refusing VKA/NOAC
AHA/ASA, 2012 ²⁹ Antithrombotic agents in NVAf	Not addressed	VKA or NOAC	Low stroke risk only
RCPE, 2012 ³⁰ Management of AF	Age ≥65 years, pulse with ECG as appropriate	VKA or NOAC ^g	Not recommended
ACCF/AHA 2010 ³¹ CV risk in asymptomatic adults	Consider resting ECG in adults with HTN or DM (not specific to AF)	Not addressed	Not addressed
CSN, 2010 ³² Prevention of stroke	Not addressed	VKA or NOAC ^f	Low stroke risk only ^h

^a All treatment recommendations are for patients found to be appropriate candidates for treatment based on risk stratification

^b Recommended for patients with CHA₂DS₂-VASc score ≥2, variable recommendations for score=1

^c Consider for patients with CHA₂DS₂-VASc score=1

Appendix A Table 4. Recent Recommendations (2010 or newer) on Primary Prevention of Stroke (Including Screening and/or Treatment) in Patients With Atrial Fibrillation

^d Recommended for elderly patients (older than 75 years of age) with no history of recent unprovoked bleeding, variable for patients with dementia or occasional falls

^e NOAC for patients with a CHADS₂ score ≥ 1 who are unable to achieve adequate anticoagulation with warfarin

^f Recommended for patients \geq age 65 or with CHADS₂ score ≥ 1

^g Recommended for patients with CHA₂DS₂-VASc score ≥ 1

^h Recommended for patients with CHADS₂ score ≥ 1

Abbreviations: AAN=American Academy of Neurology; ACC=American College of Cardiology; ACCF=American College of Cardiology Foundation; ACCP=American College of Chest Physicians; AF=atrial fibrillation; AF-SCREEN=acronym not defined; AHA=American Heart Association; ASA=American Stroke Association; CADTH=Canadian Agency for Drugs and Technologies in Health; CCS=Canadian Cardiovascular Society; CSN=Canadian Stroke Network; CV=cardiovascular; DM=diabetes mellitus; ECG=electrocardiogram; EHRA=European Heart Rhythm Association; EPCCS=European Primary Care Cardiovascular Society; ESC=European Society of Cardiology; HRS=Heart Rhythm Society; HTN=hypertension; NICE=National Institute for Health and Care Excellence; NOAC=novel oral anticoagulants; NSC=National Screening Committee; NVAf=non-valvular atrial fibrillation; OAC=oral anticoagulant; RCPE=Royal College of Physicians of Edinburgh; SIGN=Scottish Intercollegiate Guidelines Network; UK=United Kingdom; VKA=vitamin K antagonists; WHF=World Heart Federation.

CQ 1. What is the prevalence of previously unrecognized or undiagnosed atrial fibrillation among asymptomatic adults, by age (groups), in primary care and community settings?

We identified 19 studies that reported on the prevalence of previously undiagnosed atrial fibrillation (AF) among adults. **Appendix A Table 5** [CQ1] summarizes the study populations, detection method used, and findings from these studies. Ten studies were conducted among population-based samples or participants recruited from community settings, and nine studies were conducted among participants recruited from primary care clinical settings. A variety of approaches to detecting AF were used in these studies. Six studies used one-time single-lead ECG via handheld devices for intervals between 10 and 30 seconds.³³⁻³⁸ Nine studies used a single, resting 12-lead ECG.³⁹⁻⁴⁷ The remaining studies used intermittent^{48, 49} or continuous⁵⁰ single-lead ECG over a period of 2 weeks or a combination approach of a single-lead ECG with a followup confirmatory 12-lead ECG.⁵¹ Studies that included both younger and older adults did not provide results stratified by age. The pooled prevalence of previously undiagnosed AF among clinic-based populations is 1.23 percent (95% CI, 0.85% to 1.77%; $I^2=85\%$; 9 studies; 21,919 participants, **Appendix A Figure 1**), and the pooled prevalence among community-based populations is 1.29 percent (95% CI, 0.82% to 2.03%; $I^2=98\%$; 10 studies; 74,003 participants; **Appendix A Figure 1**). These data provide an estimate of the total burden of undiagnosed AF but do not offer evidence about differences in detection of undiagnosed AF between routine screening and usual care. This is addressed in KQ 2 of this review.

Appendix A Table 5. Summary of Studies Published Since 2000 Reporting the Prevalence of Previously Undiagnosed Atrial Fibrillation (CQ1)

ID; Author, Year; Trial Name (if applicable)	Study Design	Sample Size	Country	Study Population	Method of Detection	Previously Undiagnosed Atrial Fibrillation Prevalence (95% CI)
Population or Community-Based Samples						
Chan et al, 2016 ³³	Uncontrolled trial	8,797	Hong Kong	Population-based sample of adults age 18 years or older. Mean age 64.7 (SD 13.4) 71.5% men 38.2% HTN 14.8% DM 0.7 % heart failure 2.2 coronary heart disease 2.7 cardiothoracic surgery	One-time single-lead ECG for 30-second interval using handheld device with smartphone application (AliveCor device). Detection based on presence of full 30-second interval of AF.	1.1% (NR)
Svennberg et al, 2015, STROKESTOP ⁴⁸	Uncontrolled trial	7,173	Sweden	Population-based sample of 75- and 76-year-old adults. % men NR No clinical characteristics reported for the overall study population.	12-lead ECG at index visit followed by intermittent single-lead ECG with handheld device twice daily and whenever palpitations occurred over 2 weeks. Detection based on AF or atrial flutter at index visit, during intermittent monitoring or in subsequent follow up Holter monitoring or 12-lead ECGs.	3.0% (95% CI, 2.7% to 3.5%) (218 cases total, 37 diagnosed at the index visit; 140 diagnosed with intermittent ECG, and 41 required Holter monitor or other repeat 12-lead ECG; 8 cases were atrial flutter)
Lowres et al, 2014, SEARCH-AF ³⁷	Uncontrolled trial	1,000	Australia	Community-based sample of adults age 65 years or older recruited from community pharmacies. Mean age 76 (SD 7) 44% men	Pulse palpation and one-time single lead via handheld device connected to smartphone. Criteria for detection NR.	1.0% (95% CI, 0.5% to 1.8%) (Of the 10 cases of new AF, 2 had paroxysmal AF that reverted to sinus rhythm by the time of confirmation with 12-lead ECG)
Engdahl et al, 2013 ⁴⁹	Uncontrolled trial	767	Sweden	Population based sample of 75- and 76-year-old adults. 43% men 4% heart failure 53% hypertension 11% diabetes 10% stroke/TIA	Stepwise screening approach, initial 12-lead ECG, if normal and CHADS ₂ equal to 2 or more (i.e., 1 risk factor besides age) then intermittent single-lead ECG via handheld device twice daily for 2 weeks (55% of study population qualified for this second step). Detection based on 30-second interval of AF or two separate intervals at least 10 seconds.	5.2% (3.8 to 7.7) (40 cases total, 10 cases identified on initial 12-lead ECG, 30 cases identified on intermittent monitoring)

Appendix A Table 5. Summary of Studies Published Since 2000 Reporting the Prevalence of Previously Undiagnosed Atrial Fibrillation (CQ1)

ID; Author, Year; Trial Name (if applicable)	Study Design	Sample Size	Country	Study Population	Method of Detection	Previously Undiagnosed Atrial Fibrillation Prevalence (95% CI)
Frewen et al, 2013, TILDA ⁴⁴	Cohort study	4,890	Ireland	Population-based sample of community-dwelling adults age 50 years or older from a longitudinal study on ageing. Mean age NR 54% men	12-lead ECG (lasting 10 minutes). Detection of AF by two independent clinicians according to European Society of Cardiology guidelines, with adjudication by a cardiologist.	0.9% (NR)
Claes et al, 2012 ³⁸	Uncontrolled trial	10,758	Belgium	Community-based sample of adults 40 years or older recruited through media advertisements. Mean age 59 (SD, 11) 38% men	One-time single-lead ECG via a handheld device. Detection based on RR intervals, absence of p waves, and variable atrial cycle length.	1.5% (NR)
Schnabel et al, 2012 ⁴⁰	Cohort study	5,000	Germany	Population-based sample of adults between ages 35 and 74 years. Mean age 52 (SD 11) 49.9% men 45.4% hypertension 6.0% diabetes 17.7% heart failure 1.5% stroke	12-lead ECG; detection based on confirmed AF by two independent cardiologists.	0.5% (NR)
Meschia et al, 2010 ⁴¹	Cohort study	29,861	USA	Racially and ethnically diverse population-based sample of adults age 45 years or older. Median age 74 (IQR 69 to 79) 45% men 11% stroke 59% hypertension 221% diabetes	12-lead ECG or 7-lead ECG obtained during in-home visit and interpreted centrally. Detection based on presence of AF on ECG.	0.6% (NR)
Doliwa et al, 2009 ³⁴	Diagnostic accuracy study	606	Sweden	Community-based sample of adults age 18 years or older. 49% were age 60 or older 64% men	One-time single-lead ECG via handheld device for 10-second interval. Detection criteria NR.	1.0% (NR)
Furberg et al, 1994 ⁴⁵	Cohort study	5,151	USA	Population recruited from Medicare eligibility lists of adults age 65 or older from four U.S. communities. Mean age 73 (NR) 43% men 94.7% white	One time, 12-lead ECG, interpreted centrally.	1.5% (NR)

Appendix A Table 5. Summary of Studies Published Since 2000 Reporting the Prevalence of Previously Undiagnosed Atrial Fibrillation (CQ1)


ID; Author, Year; Trial Name (if applicable)	Study Design	Sample Size	Country	Study Population	Method of Detection	Previously Undiagnosed Atrial Fibrillation Prevalence (95% CI)
Clinic-Based Samples						
Bury et al, 2015 ⁵¹	Uncontrolled trial	566	Ireland	Convenience sample of patients age 70 or older from 25 general practices. Mean age 78 (SD NR) 40% men 48.2% hypertension 10.6% diabetes 22.5% coronary heart disease 2.6% stroke 3.1% other heart surgery or cardiac procedures	One-time 3-lead ECG using the ECG component of an automated external defibrillator followed by confirmatory 12-lead ECG. Criteria for detection NR but included both AF and atrial flutter.	2.1% (NR) (2 of 12 cases were atrial flutter)
Kaasenbrood, 2016 ³⁵	Uncontrolled trial	3,269	The Netherlands	Patients age 60 or older recruited from 10 general practices at the time of yearly flu vaccination. Mean age 69.4 (SD 8.9) 49.0% men	One-time single lead ECG via handheld device for 60 seconds. Detection based on positive signal confirmed by cardiologist(s).	1.1% (NR)
Turakhia et al, 2015, STUDY-AF ⁵⁰	Uncontrolled trial	75	USA	Single Veteran's Health Administration clinic-based sample of adults age 55 years or older with 2 or more AF risk factors including CHD, heart failure, hypertension, diabetes, and sleep apnea. Mean age 69 (SD 8.0) 100% men 95% with hypertension 17% with heart failure 77% with coronary artery disease 56% with diabetes	Continuous single-lead ECG via a wearable patch-based device for 2 weeks. AF based on presence of 30 seconds or more interval of AF.	5.3% (NR)
Clua-Espuny et al, 2013 ⁴²	Cross-sectional study	1,043	Spain	Patients recruited from primary care clinics. Mean age 78.9 (SD 7.3) % men NR	ECG in clinic setting, further details NR. Detection based on cardiologist confirmation of AF.	2.2% (NR)
Deif et al, 2012 ³⁹	Uncontrolled trial	2,802	Australia	Ambulatory adults age 40 or older undergoing preoperative evaluation for minor procedures or elective surgery. Mean age 65 (SD 13) 50% men	"Routine" ECG; detection criteria NR.	0.4% (NR) all participants 0.7% (NR) in participants age 65 years or older

Appendix A Table 5. Summary of Studies Published Since 2000 Reporting the Prevalence of Previously Undiagnosed Atrial Fibrillation (CQ1)

ID; Author, Year; Trial Name (if applicable)	Study Design	Sample Size	Country	Study Population	Method of Detection	Previously Undiagnosed Atrial Fibrillation Prevalence (95% CI)
Fitzmaurice et al, 2007; SAFE study ⁴³	Cluster RCT	9,137	UK	Patients age 65 or older from 50 general practices. Mean age 75.3 (SD 7.2) 42.8% men	Practices were allocated to screening or control, and screening practices were subsequently allocated to systematic (invitation to attend screening clinic with 12-lead ECG) or opportunistic screening (pulse check at usual care visits with referral to screening clinic if abnormal). Detection based on AF on 12-lead ECG.	1.6% (in practices allocated to screening) 1.0% (in practices allocated to control)
Morgan et al, 2002 ³⁶	Parallel group RCT with two active comparators	3,001	UK	Patients ages 65 to 100 from four general practices. Mean age 75 (SD NR) 41% men	Systematic pulse and single-lead (II) ECG vs. opportunistic screening (reminder placed on patient chart to perform pulse screening). Detection based on AF on confirmatory ECG (in systematically screened arm).	Yield of new AF cases in systematically screened arm: 0.8% (NR) (systematically screened) 0.5% (NR) (opportunistic screened)
Wheeldon et al, 1998 ⁴⁷	Uncontrolled trial	1,207	UK	Patients age 65 or older from four general practices. Mean age NR % Men NR	Single 12-lead ECG in clinic setting. Detection based on interpretation by cardiologist.	0.4% (NR)
Hill et al, 1987 ⁴⁶	Uncontrolled trial	819	UK	Symptomless patients age 65 or older from a single general practice. Mean age	Single 12-lead ECG in clinic setting. Detection based on interpretation by two physicians.	1.2% (NR)

Abbreviations: AF=atrial fibrillation; CHD=coronary heart disease; CI=confidence interval; DM=diabetes mellitus; ECG=electrocardiogram; HTN=hypertension; ID=identification number; IQR=interquartile range; NR=not reported; RCT=randomized, controlled trial; RR= relative risk; SAFE =Screening for AF in the elderly; SD=standard deviation; STUDY-AF=Screening Study for Undiagnosed Atrial Fibrillation; TIA=transient ischemic attack; TILDA= The Irish Longitudinal Study on Ageing ; UK=United Kingdom; USA=United States of America.

Appendix A Figure 1. Meta-Analysis of Studies Assessing Proportion of Participants With Undiagnosed Atrial Fibrillation



Abbreviations: AF=atrial fibrillation; CI=confidence interval; ECG=electrocardiogram; N=number; NR=not reported.

CQ 2. What is the stroke risk in asymptomatic older adults with previously unrecognized or undiagnosed atrial fibrillation?

Incidence of Stroke for Incidentally Detected AF

Limited evidence was found regarding the incidence of stroke in asymptomatic older adults with unrecognized or undiagnosed AF conducted among the general population. Martinez et al. identified 5,555 persons with incidentally detected AF (and reportedly asymptomatic based on review of Read Medical Codes and ICD codes) through hospital and general practice databases.⁵² These were not screen detected as far as the article reports but rather seem to have been detected in the course of usual care. Just over half were treated with oral anticoagulant therapy with or without antiplatelet therapy. The cohort included people with a history of CAD without MI (10.6%), MI (4.2%), and stroke or TIA (9.2%). Mean CHA₂DS₂-VASc score was 2.5 (SD, 1.5, and 73% had a score of 2 or greater) and mean CHADS₂ score was 1.3 (1.1). Limitations of the study include that patients were not screen detected and that using Read Medical Codes and ICD codes has limitations regarding the ability to identify asymptomatic people and to accurately identify previously undiagnosed AF. The study reported stroke incidence rates per 1,000 person-years over a maximum of 3 years by age group for those with incidentally detected AF as follows:

- Ages 18 to 49 years: 0 (95% CI, 0 to 6.5)
- Ages 50 to 64 years: 9.1 (95% CI, 5.9 to 13.4)
- Ages 65 to 74 years: 16.5 (95% CI, 13.1 to 20.6)
- Ages 75 to 84 years: 29.6 (95% CI, 25.1 to 34.7)

The study also provided data for a matched comparison group of people without AF (but not comparing asymptomatic vs. symptomatic people). Stroke incidence rates per 1,000 were 19.4 (17.1 to 21.9) for those with incidentally detected AF (all ages) and 8.4 (7.7 to 9.1) for the matched controls without AF.

Predicted Stroke Risk

Fitzmaurice et al. compared CHADS₂ scores among persons with newly diagnosed AF (149 cases) identified through either opportunistic screening or systematic screening in the SAFE study (described in KQ 2).⁵³ The proportion with scores greater than or equal to 1 was similar (82.7% [95% CI, 72.6 to 89.6] opportunistic screening group; 78.4% [95% CI, 67.7 to 86.2] systematically screened group; p=0.51). The proportion with scores of 2 or more was slightly lower in the opportunistic arm, but the difference was not statistically significant (29.3% [95% CI, 20.2 to 40.4] opportunistic arm vs. 43.2% [95% CI, 32.6 to 54.6] in the systematic screening arm; p=0.077). Eight of the 19 studies described in CQ 1 provided data on the mean predicted risk of stroke among persons with previously unrecognized or undiagnosed AF;^{33, 35, 37, 39, 49-51} findings are summarized in **Appendix A Table 6 (CQ 2)**. The range of mean CHADS₂ scores was 1.8 to 2.2 (3 studies), and the range of mean CHA₂DS₂-VASc scores was 3.1 to 3.8 (7 studies), ranges that would typically be associated with initiation of anticoagulation (in the absence of contraindications).

Relative Risk of Stroke in Asymptomatic AF vs. Symptomatic AF

Four cohort studies provide information related to the relative risk of stroke among persons with asymptomatic AF compared with persons with symptomatic AF. Study details and limitations

Appendix A. Contextual Question 2

are summarized in **Appendix A Table 7**. These studies were conducted among different patient populations using different approaches to ascertain AF, and some reported a higher absolute incidence of stroke among persons with asymptomatic AF compared with persons with symptomatic AF. Adjusted analyses in two of the four studies showed no statistically significant difference between those with asymptomatic and symptomatic AF. Although some of the studies adjusted for known differences in baseline characteristics, the potential for residual confounding in these studies is high because asymptomatic and symptomatic persons differed on baseline characteristics across all studies for which this information was available. Some studies did not consider important risk factors for stroke in their adjusted analyses (e.g., CHA₂DS₂-VASc score or its components, smoking). Further, although some information about rates of anticoagulation treatment among persons with asymptomatic AF was provided, differences in treatment to prevent stroke between groups cannot be ruled out. The risk of selection bias in most of these studies is high, because many identified patients were from cardiology or AF registries, and may not be representative of patients seen in primary care. Over 60 percent of participants in two of the studies had heart disease at baseline, and one study did not report baseline descriptive information (published as abstract only). Risk of ascertainment bias for determining symptom status (i.e., whether people were asymptomatic) is also a concern because the studies typically reported limited information about methods for ascertainment, and they relied on retrospective chart reviews or claims to determine whether patients were asymptomatic. Only one clearly distinguished fully asymptomatic (no current or past symptoms of AF) patients (Boriani et al, 2015) from patients who are currently asymptomatic, indicating a more appropriately detailed ascertainment of symptom status;⁵⁴ it reported no difference in outcomes for symptomatic and asymptomatic patients in adjusted analyses.

Appendix A Table 6. Mean Predicted Stroke Risk Among Persons With Previously Unrecognized Atrial Fibrillation (CQ2)

Author, Year	n Previously Undiagnosed AF/ N Total Study Sample	Risk Instrument/ Mean (SD) Predicted Stroke Risk
Chan et al. (2016) ³³	101/8,797	CHA ₂ DS ₂ -VASc 3.1 (1.3)
Bury et al. (2015) ⁵¹	12/566	CHA ₂ DS ₂ -VASc (median) 4
Kaasenbrood et al. (2015) ³⁵	37/3,269	CHA ₂ DS ₂ -VASc 3.4 (1.9)
Turakhia et al. (2015) ⁵⁰	4/75	CHA ₂ DS ₂ -VASc ≥ 2 in all 4 participants
Engdahl et al. (2013) ⁴⁹	10/767	CHA ₂ DS ₂ 1.8 (NR)
Dief et al. (2012) ³⁹	10/1,459	Among persons age 65 or older CHA ₂ DS ₂ 2.2 (1.5) CHA ₂ DS ₂ -VASc 3.8 (SD 2.0)
Svennberg et al. (2015) ⁴⁸	218/7,173	CHA ₂ DS ₂ -VASc 3.5 (1.2)
Low res et al. (2013) ³⁷	15/1,000	CHA ₂ DS ₂ 1.9 (1.1) CHA ₂ DS ₂ -VASc 3.7 (1.1)

Abbreviations: AF=atrial fibrillation; CHA₂DS₂-VASc=Congestive heart failure, Hypertension, Age ≥ 75 years [doubled], Diabetes mellitus, prior Stroke or TIA or thromboembolism [doubled], Vascular disease, Age 65-74 years, Sex category; CQ=contextual question; n=number of patients; N=number of patients in sample; NR=not reported; SD=standard deviation.

Appendix A Table 7. Stroke Incidence in People With Asymptomatic, Previously Unrecognized AF vs. People With Symptomatic AF, Reported by Observational Studies

Author, Year Country	Study Population and Setting	Stroke Incidence	Study Limitations
Potpara, 2013 ⁵⁵ Serbia	146 asymptomatic patients with initial AF diagnosis between 1997 and 2007 diagnosed with 12-lead ECG during period medical exam based on registry of patients with AF. (Total cohort=1,100 individuals with AF) 47.9% were placed on aspirin and 40.4% were placed on oral anticoagulants after diagnosis	14 (9.6%) vs. 44 (5.6%) with ischemic stroke during mean follow up of 9.9 years Adjusted HR 1.8 (95% CI, 1.0 to 3.4, p=0.051) compared with individuals in cohort with symptomatic AF (adjustment for age, sex, and treatment at baseline)	-High potential for confounding (e.g., no adjustment for smoking status and other relevant imbalances between symptomatic and asymptomatic individuals at baseline) -Limited information regarding ascertainment of AF symptoms -60% had prior heart disease, so not applicable to general population
Tsang, 2011 ⁵⁶ US	1,152 asymptomatic adults (mean age 74 years) with ECG-confirmed diagnosis of first AF between 1980 and 2000 in Olmsted County, Minnesota, based on medical record review (Total cohort=4,618)	Number (%) of events NR for either group. Compared with persons with symptomatic AF, persons with asymptomatic AF were three times more likely to have sustained an ischemic stroke prior to their diagnosis after adjustment for age, sex, and other stroke risk factors (p<0.0001)	-Data published in abstract format only, limiting assessment of risk of bias -No information to assess whether groups were similar at baseline or what specific stroke risk factors were included in analysis (it reported adjusting for age, sex, and "multiple other stroke risk factors"). -Methods of ascertaining symptom status NR (other than stating that medical records were used)
Siontis, 2016 ⁵⁷ US	161 asymptomatic adults (mean age 69.2) from among 1,000 randomly selected patients from a total cohort of 3,344 adults with incident AF between 2000 and 2010 in Olmsted County, Minnesota	Total of 59 strokes (among the 1,000). Persons with asymptomatic AF had higher incidence of stroke over median follow up of 5.6 years compared with persons with typical AF (adjusted HR 2.6, 95% CI 1.10 to 6.11, adjusted for CHA ₂ DS ₂ -VASc score, age, BMI, smoking status, COPD, eGFR, dementia, malignancy, warfarin use and time in therapeutic range)	-Potential for residual confounding due to unmeasured differences in baseline characteristics among persons with typical, atypical, and asymptomatic AF as these groups were clearly different on numerous measured baseline characteristics -Symptom status ascertained retrospectively by medical records review (by trained abstractors looking for information about palpitations, atypical symptoms, etc.)
Boriani, 2015 ⁵⁴ Europe	1,237 persons with asymptomatic AF (mean age 72; 520/1,237 with "fully asymptomatic" AF, indicating absence of current and previous symptoms) in a AF registry from those presenting to cardiology practices from 9 countries. Most asymptomatic patients had valvular heart disease (64.5%), chronic heart failure (44.3%), or CAD (40.1%). (Total cohort=3,119 in the EORP-AF)	Mean follow up about 1 year 112/1064 (10.5%) vs. 80/1409 (5.7%) events for a composite incidence of stroke/TIA/peripheral embolism or death higher in asymptomatic AF compared to symptomatic AF at 1 year (p < 0.0001) in unadjusted analyses. Multivariate analyses found no significant association with symptom status for mortality or for the composite of stroke/TIA/peripheral embolism or death ^a	-High potential for residual confounding; asymptomatic patients were more likely to be older, male, and had a higher proportion of related comorbidities, including history of thromboembolic complications and stroke -Analyses did not focus on the 520 "fully asymptomatic" persons for the comparisons reported -Limited applicability to the key questions of this review because most participants had known heart disease

^a Outcomes compared the 1,237 currently asymptomatic people (but not the fully asymptomatic) with symptomatic people.

Abbreviations: AF=atrial fibrillation; BMI=body mass index; CAD=coronary artery disease; CI=confidence interval; COPD=chronic obstructive pulmonary disease; CVD=cardiovascular disease; ECG= electrocardiogram; eGFR=estimated glomerular filtration rate; EORP=EurObservational Research Programme – Atrial Fibrillation; HR=hazard ratio; NR=not reported; TIA=transient ischemic attack; US=United States.

3a. What are the recommendations on use of rate or rhythm control for the treatment of atrial fibrillation in asymptomatic adults age 65 years or older?

We found no recommendations that specifically address the use of rhythm control for asymptomatic adults (it is recommended for selected patients with symptoms); some guidelines recommend rate control to achieve a resting heart rate under 110 beats per minute (bpm) for asymptomatic patients because prolonged rapid ventricular rates increase the risk of cardiomyopathy.^{58, 59} There has been an ongoing debate on the use of rate versus rhythm control strategies for patients with AF. However, rate control is now generally preferred for multiple reasons: several clinical trials have not found either rate or rhythm control to be clearly superior for benefits, rate control medications are familiar to a larger number of providers, and evidence shows an increased risk of adverse events with antiarrhythmic agents.⁶⁰⁻⁶²

According to the AHA/ACC/HRS guidelines, for rate control, beta-blockers are the most commonly used agents, followed by nondihydropyridine calcium channel blockers (e.g., diltiazem), digoxin, and amiodarone.⁶³ Rhythm control strategies aiming to restore and maintain sinus rhythm include electrical cardioversion, pharmacological cardioversion using antiarrhythmic agents, and surgical or catheter ablation, used either singly or in combination. A meta-analysis of eight RCTs⁶⁴ (7,499 AF patients, mean age 68 years) by Caldeira et al. concluded there were no differences in a variety of outcomes between rate and rhythm control strategies: all-cause mortality (RR, 0.95; 95% CI, 0.68 to 1.05; 8 studies), cardiovascular mortality (RR, 0.99; 95% CI, 0.97 to 1.13, 7 trials), arrhythmic and sudden death (RR, 1.12; 95% CI, 0.91 to 1.38; 5 trials), ischemic stroke (RR, 0.89; 95% CI, 0.52 to 1.53; 4 trials), systemic embolism (RR, 0.89; 95% CI, 0.69 to 1.14; 6 trials), and major bleeding (RR, 1.10; 95% CI, 0.89 to 1.36; 5 trials). Sensitivity analysis including studies with more than 50 percent of participants having heart failure demonstrated fewer systemic embolic events with rate control strategies (RR, 0.43; 95% CI, 0.21 to 0.89; 3 trials). For patients with mean age ≥ 65 years (5 trials), there were no differences between treatment strategies for all of the previously mentioned outcomes, with the exception of arrhythmic and sudden deaths, which were not reported. For these analyses, two studies—AFFIRM (n=4060) and AF-CHF (n=1376)—provided most of the data (weight, 95.3%). AFFIRM,⁶⁵ the largest of the RCTs to compare rate versus rhythm control, enrolled 4,060 patients age 65 years or older with AF and risk factors for stroke or death. After 5 years of observation following randomization to either rate or rhythm control strategies, the study found no difference in mortality between the groups (HR, 1.15; 95% CI, 0.99 to 1.34). Visual inspection of the Kaplan-Meier curves, however, suggests an apparent separation of the two groups that appears to widen over time (trending toward favoring a possible benefit for rate control). In a re-analysis of AFFIRM using propensity-matched scoring for participants ages 70 to 80 years, mortality was greater in the rhythm control arm (HR, 1.30; 95% CI, 1.06 to 1.59).⁶⁶

Guidelines for treatment of AF recommend initial rate control strategies for most symptomatic patients with a stepwise approach to rhythm control strategies in those patients who have persistent symptoms or are unable to be treated using rate control alone.^{63, 67, 68} The AHA/ACC/HRS recommendations are based largely on the results of two RCTs, which demonstrate the lack of superiority of one strategy over the other,^{61, 69} as well as an increase in hospitalizations for rhythm control strategies.⁶⁰ The NICE guidelines include a systematic review and meta-analysis of eight RCTs, which drew similar conclusions to the meta-analysis by

Appendix A. Contextual Questions 3a and 3b

Caldeira et al. The NICE guidelines acknowledge moderate-quality evidence supporting the mortality and bleeding outcomes but low- or very low-quality evidence for other outcomes comparing rate versus rhythm control.

While no guideline made a specific recommendation for asymptomatic adults age 65 years or older, the mean age of participants across trials was 61 to 72 years. The AHA/ACC/HRS guideline includes a single recommendation for a lenient rate-control strategy (resting heart rate <110 bpm) when patients remain asymptomatic and left ventricular systolic function is preserved, which is based on a single study (RACE II).⁶⁹ RACE II compared strict (<80 bpm resting HR) versus lenient (<110 bpm) rate control strategies in patients with permanent AF (for up to 12 months prior to enrollment). Forty-three percent of the study population was asymptomatic at baseline (defined as no palpitations, dyspnea, or fatigue), although it is not clear how many were never symptomatic (i.e., how many did not have symptoms around the time of their diagnosis or prior to it). RACE II concluded noninferiority between the two strategies for prevention of major cardiac events.⁷⁰

The AHA/ACC guidelines recommend rhythm-control strategies for AF patients with persistent symptoms and with select factors such as inadequate rate control, younger age, tachycardia-mediated cardiomyopathy, first AF episode, AF precipitated by an acute illness, and patient preference.⁶³ Because AF can progress from paroxysmal to persistent, resulting in electrical and structural remodeling that becomes irreversible over time, the guidelines note that when considering a rhythm control strategy, early intervention may be most beneficial to prevent AF progression.

According to a Cochrane review by Mead et al, electrical cardioversion did not result in any greater reduction in mortality than rate control strategies (OR, 0.83; 95% CI, 0.48 to 1.43; 3 trials, 927 patients) and may increase the risk of stroke (OR, 1.9; 95% CI, 0.99 to 3.64; 3 trials).⁷¹ However, physical function, physical role function, and vitality were better in the cardioversion group. The mean age of participants across the three trials was 60 to 68 years. Other studies report that some patients spontaneously revert to AF within weeks or months, and up to 25 percent will revert within 1 year, which may explain the possible increase in risk of stroke because many patients who are cardioverted often cease taking anticoagulation or antiplatelet agents used to prevent stroke.^{72, 73} The AHA/ACC guidelines recommend direct current cardioversion as an option when pursuing a rhythm-control strategy for symptomatic patients and those refractory to pharmacological therapies; they do not make a specific recommendation for asymptomatic patients.⁶³

Although the ESC acknowledges the efficacy of pharmacologic cardioversion using antiarrhythmic agents, they also note the elevated adverse event and mortality rates associated with using these agents.⁶⁷ Accordingly, they recommend antiarrhythmic drug therapy only in patients with resistant symptoms due to recurrent AF. The AHA/ACC guidelines note that antiarrhythmic drug efficacy is modest, and AF recurrences are common. Lafuente-Lafuente et. al. concluded in a meta-analysis of 59 studies (21,305 patients) that several classes of antiarrhythmic agents were moderately effective at maintaining sinus rhythm after conversion of AF (OR, 0.19 to 0.77; number-needed-to-treat (NNT), 3 to 16), but most agents increased adverse events and mortality (OR, 2.23 to 2.39; number needed to harm 109 to 169).⁷⁴

Concerning catheter ablation, the ESC notes that large trials of ablation therapy are pending and that the risks associated with the procedure need to be carefully weighed against potential for

Appendix A. Contextual Questions 3a and 3b

symptomatic benefit.⁶⁷ Although the guideline authors note that catheter ablation is more effective than antiarrhythmic drug therapy, its use as first-line therapy should currently be limited to those with paroxysmal AF preferring interventional treatment and who have a low-risk profile for procedure-associated complications. The AHA recommends AV nodal ablation only sparingly noting that the procedure leads to pacemaker dependency, and is therefore usually reserved for elderly patients.⁶³ Guidelines from both organizations recommend catheter ablation as a second line treatment in patients who are candidates for first line treatment with antiarrhythmic agents who experience failure or intolerance with these agents.⁷⁵ Two recent Cochrane reviews address the question of catheter ablation for AF. However, neither review addressed the use of ablation techniques in screen-detected, asymptomatic patients. Chen et al. assessed the benefits and harms of catheter ablation versus medical therapy for patients with either paroxysmal or persistent AF (32 RCTs, 3,560 patients).⁷⁶ They concluded that compared with medical therapy, ablation had a better effect for inhibiting AF recurrence (RR, 0.27; 95% CI, 0.18 to 0.41; 7 trials, 767 patients), and they found no differences between treatments for mortality (RR, 0.50; 95% CI, 0.04 to 5.65), fatal and nonfatal embolic complications (RR, 1.01; 95% CI, 0.18 to 5.68), or thrombo-embolic-specific mortality (RR, 3.04; 95% CI, 0.13 to 73.43). Significant heterogeneity was noted for the comparison of ablation versus medical therapies, and overall, RCTs were small in size and poor quality. Nyong et al. assessed the use of both surgical and catheter ablation in patients with nonparoxysmal AF (3 RCTs, 261 patients with mean age of 60 years).⁷⁷ They concluded that radio-frequency catheter ablation was superior to antiarrhythmic agents for achieving freedom from atrial arrhythmias (RR, 1.84; 95% CI, 1.17 to 2.88), reducing further cardioversion (RR, 0.62; 95% CI, 0.47 to 0.82) and reducing cardiac-related hospitalization (RR, 0.27; 95% CI, 0.10 to 0.72). Trials were rated as low or unclear risk of bias, and strength of evidence for these findings was low (hospitalizations) to moderate. Additionally, they identified three ongoing studies comparing catheter ablation to either rate control, electrical cardioversion, or both rate and rhythm control drug treatments. They identified no comparative studies of surgical ablation.

3b. How often are such treatments used in the United States in asymptomatic adults age 65 years or older?

We did not find any data that specifically address how often these treatments are used in asymptomatic adults. The existing data do not describe symptom status of the treated patients. One retrospective administrative claims analysis (using claims from January 1, 2008 through September 30, 2010) of 48,814 patients with a diagnosis of AF reported that 38,502 (79%) received treatment.⁷⁸ Of those treated, the majority received rate control medications (67% received beta blockers) and rhythm control medications were used in the initial regimens for 12 percent (and 24% received rhythm control medications at any time). Direct current cardioversion was used in the initial treatment for 8.5 percent (and 18% at any time). Catheter ablation was used in 5 percent of patients and was typically not a first line treatment.

The National Disease and Therapeutic Index is a survey of about 3,000 office-based physicians that collects diagnosis and treatment information on all patient visits over a randomly selected 2-day period in each calendar year. National estimates for treatments by diagnoses are calculated using survey *drug mentions* as a surrogate for actual drug treatments. Between October 1999 and September 2003, mention of digoxin treatment for patients with AF declined from 29 percent to 17 percent, while mentions of beta blockers rose from about 8 percent to 11 percent and

Appendix A. Contextual Questions 3a and 3b

mentions of calcium channel blockers remained stable around 8 percent.⁷⁹ When stratified by age, mention of digoxin was more common among patients age 60 years or older (24% vs. 17%), while the use of beta blockers was slightly more common among patients younger than 60 years (13% vs. 10%). Among patients age 60 years or older, 11 percent of visits mentioned use of an anti-arrhythmic agent. Amiodarone was the most commonly cited agent among this age group (5.6%), followed by sotalol, class 1c, and 1a agents. No information was reported from this survey about symptomatic versus asymptomatic treatment. Based on the National Hospital Discharge Survey (NHDS), rates of catheter ablation to treat AF have risen by 15 percent per year between 1990 (0.06% of patients with AF) and 2005 (0.79%). Across all age groups, the rate of increase was similar, including patients older than 80 years (0.00% in 1990 vs. 0.26% in 2005). Overall, 0.42 percent of hospitalized patients (1,144/269,471) identified in NHDS underwent catheter ablation, corresponding to a national estimate of 133,000 ablations in 32 million hospitalizations over the 15-year period.⁸⁰

Appendix B1. Original Search Strategies

PubMed, 7/12/16

Search	Query	Items Found
#1	Search ("Atrial Fibrillation"[Mesh] OR atrial fibril*[tiab] OR atrium fibrillation*[tiab] OR a-fib[tiab] OR atrial flutter*[tiab])	60865
#2	Search ("Electrocardiography"[Mesh] OR electrocardiography[tiab] OR EKG[tiab] OR ECG[tiab])	209997
#3	Search (#1 and #2)	13398
#4	Search ("Mass Screening"[Mesh] OR screen*[tiab])	591510
#5	Search (#3 and #4)	314
#6	Search (((randomized[title/abstract] OR randomised[title/abstract]) AND controlled[title/abstract] AND trial[title/abstract]) OR (controlled[title/abstract] AND trial[title/abstract]) OR "Controlled Clinical Trial"[publication type] OR "Randomized Controlled Trial"[Publication Type] OR "Single-Blind Method"[MeSH] OR "Double-Blind Method"[MeSH] OR "Random Allocation"[MeSH])	642006
#7	Search (#5 and #6)	22
#8	Search ("Cohort Studies"[Mesh] OR "Epidemiologic Studies"[Mesh] OR "Follow-up Studies"[Mesh] OR "prospective cohort" OR "prospective studies"[MeSH] OR (prospective*[All Fields] AND cohort[All Fields] AND (study[All Fields] OR studies[All Fields])))	1902550
#9	Search (#5 and #8)	128
#10	Search (#7 or #9)	140
#11	Search (#7 or #9) Filters: Humans	138
#12	Search (#7 or #9) Filters: Humans; English	132
#13	Search (#7 or #9) Filters: Humans; English; Adult: 19+ years	126
#14	Search ("Anticoagulants"[Mesh] OR anticoagulant*[tiab] OR "Warfarin"[Mesh] OR warfarin OR noac* OR ("Dabigatran"[Mesh] OR Dabigatran OR Pradaxa) OR apixaban OR Eliquis OR "Rivaroxaban"[Mesh] OR Rivaroxaban[tiab] OR Xarelto[tiab])	103597
#15	Search (#1 and #14)	10286
#16	Search ("Factor Xa Inhibitors"[Mesh] OR "factor xa"[tiab])	7468
#17	Search (#1 and #16)	839
#18	Search ("Antithrombins"[Mesh] OR antithrombin*[tiab] OR thrombin inhibit*[tiab])	22731
#19	Search (#1 and #18)	1348
#20	Search ("Aspirin"[Mesh] OR aspirin[tiab] OR anti-platelet*[tiab] OR antiplatelet*[tiab] OR Plavix[tiab] OR ASA[tiab] OR "acetylsalicylic acid"[tiab] OR "Aspirin, Dipyridamole Drug Combination"[Mesh] OR Aggrenox[tiab] OR "Dipyridamole"[Mesh] OR Dipyridamole[tiab] OR "clopidogrel"[Supplementary Concept] OR clopidogrel[tiab])	104013
#21	Search (#1 and #20)	2998
#22	Search (#15 or #17 or #19 or #21)	11039
#23	Search (#22 and #6)	798
#24	Search (#22 and #8)	2431
#25	Search (("review"[Publication Type] AND "systematic"[tiab]) OR "systematic review"[All Fields] OR ("review literature as topic"[MeSH] AND "systematic"[tiab]) OR "meta-analysis"[Publication Type] OR "meta-analysis as topic"[MeSH Terms] OR "meta-analysis"[All Fields])	180177
#26	Search (#22 and #25)	438
#27	Search (#22 and #25) Filters: Publication date from 2011/01/01 to 2016/12/31	294
#28	Search (#23 or #24 or #27)	3191
#29	Search (#23 or #24 or #27) Filters: Humans	3060
#30	Search (#23 or #24 or #27) Filters: Humans; English	2785
#31	Search (#23 or #24 or #27) Filters: Humans; English; Adult: 19+ years	2378
#32	Search (#30 not #13)	2358

Appendix B1. Original Search Strategies

PubMed, 5/22/17

Search	Query	Items Found
#1	Search ("Atrial Fibrillation"[Mesh] OR atrial fibril*[tiab] OR atrium fibrillation*[tiab] OR a-fib[tiab] OR atrial flutter*[tiab])	65870
#2	Search (("Electrocardiography"[Mesh] OR electrocardiography[tiab] OR EKG[tiab] OR ECG[tiab]))	215045
#3	Search (#1 and #2)	14014
#4	Search (("Mass Screening"[Mesh] OR screen*[tiab]))	629166
#5	Search (#3 and #4)	352
#6	Search (((randomized[title/abstract] OR randomised[title/abstract]) AND controlled[title/abstract] AND trial[title/abstract]) OR (controlled[title/abstract] AND trial[title/abstract]) OR "Controlled Clinical Trial"[publication type] OR "Randomized Controlled Trial"[Publication Type] OR "Single-Blind Method"[MeSH] OR "Double-Blind Method"[MeSH] OR "Random Allocation"[MeSH])	671738
#7	Search (#5 and #6)	27
#8	Search ("Cohort Studies"[Mesh] OR "Epidemiologic Studies"[Mesh] OR "Follow-up Studies"[Mesh] OR "prospective cohort" OR "prospective studies"[MeSH] OR (prospective*[All Fields] AND cohort[All Fields] AND (study[All Fields] OR studies[All Fields])))	2020073
#9	Search (#5 and #8)	138
#10	Search (#7 or #9)	155
#11	Search (#7 or #9) Filters: Humans	150
#12	Search (#7 or #9) Filters: Humans; English	144
#13	Search (#7 or #9) Filters: Humans; English; Adult: 19+ years	137
#14	Search (#7 or #9) Filters: Publication date from 2016/01/01 to 2017/12/31; Humans; English; Adult: 19+ years	8
#15	Search ("Anticoagulants"[Mesh] OR anticoagulant*[tiab] OR "Warfarin"[Mesh] OR warfarin OR noac* OR ("Dabigatran"[Mesh] OR Dabigatran OR Pradaxa) OR apixaban OR Eliquis OR "Rivaroxaban"[Mesh] OR Rivaroxaban[tiab] OR Xarelto[tiab])	108637
#16	Search (#1 and #15)	11590
#17	Search (("Factor Xa Inhibitors"[Mesh] OR "factor xa"[tiab]))	7957
#18	Search (#1 and #17)	1003
#19	Search (("Antithrombins"[Mesh] OR antithrombin*[tiab] OR thrombin inhibit*[tiab]))	23617
#20	Search (#1 and #19)	1571
#21	Search (("Aspirin"[Mesh] OR aspirin[tiab] OR anti-platelet*[tiab] OR antiplatelet*[tiab] OR Plavix[tiab] OR ASA[tiab] OR "acetylsalicylic acid"[tiab] OR "Aspirin, Dipyridamole Drug Combination"[Mesh] OR Aggrenox[tiab] OR "Dipyridamole"[Mesh] OR Dipyridamole[tiab] OR "clopidogrel"[Supplementary Concept] OR clopidogrel[tiab]))	108308
#22	Search (#1 and #21)	3234
#23	Search (#16 or #18 or #20 or #22)	12388
#24	Search (#23 and #6)	864
#25	Search (#23 and #8)	2756
#26	Search (((("review"[Publication Type] AND "systematic"[tiab]) OR "systematic review"[All Fields] OR ("review literature as topic"[MeSH] AND "systematic"[tiab]) OR "meta-analysis"[Publication Type] OR "meta-analysis as topic"[MeSH Terms] OR "meta-analysis"[All Fields]))	204884
#27	Search (#23 and #26)	527
#28	Search (#24 or #25 or #27)	3749
#29	Search (#24 or #25 or #27) Filters: Humans	3579
#30	Search (#24 or #25 or #27) Filters: Humans; English	3260
#31	Search (#24 or #25 or #27) Filters: Humans; English; Adult: 19+ years	2731
#32	Search (#24 or #25 or #27) Filters: Publication date from 2016/01/01 to 2017/12/31; Humans; English; Adult: 19+ years	260
#33	Search (#32 NOT #14)	259

Appendix B1. Original Search Strategies

Cochrane Library, 7/12/16

ID	Search	Hits
#1	[mh "Atrial Fibrillation"] or ("atrial fibril*" or "atrium fibrillation*" or a-fib or afib or "atrial flutter*")	7088
#2	[mh Electrocardiography] or electrocardiography or EKG or ECG	13719
#3	#1 and #2	1171
#4	[mh "Mass Screening"] or screen*	37027
#5	#3 and #4	115
#6	((randomized or randomised) and controlled and trial) or (controlled and trial) or "Controlled Clinical Trial" or "Randomized Controlled Trial" or [mh "Single-Blind Method"] or [mh "Double-Blind Method"] or [mh "Random Allocation"]	675537
#7	#5 and #6 Publication Year from 2011 to 2016	72
#8	[mh "Cohort Studies"] or [mh "Epidemiologic Studies"] or [mh "Follow-up Studies"] or "prospective cohort" or [mh "prospective studies"] or (prospective* and cohort and (study or studies))	139074
#9	#5 and #8	35
#10	[mh Anticoagulants] or anticoagulant* or [mh Warfarin] or warfarin or noac* or [mh Dabigatran] or Dabigatran or Pradaxa or apixaban or Eliquis or [mh Rivaroxaban] or Rivaroxaban or Xarelto	9813
#11	#1 and #10	1591
#12	[mh "Factor Xa Inhibitors"] or "factor xa"	782
#13	#1 and #12	160
#14	[mh Antithrombins] or antithrombin* or "thrombin inhibit"	2295
#15	#1 and #14	215
#16	[mh Aspirin] or aspirin or "anti-platelet*" or antiplatelet* or Plavix or ASA or "acetylsalicylic acid" or [mh "Aspirin, Dipyridamole Drug Combination"] or Aggrenox or [mh Dipyridamole] or Dipyridamole or clopidogrel	23614
#17	#1 and #16	754
#18	#11 or #13 or #15 or #17	1809
#19	#18 Publication Year from 2011 to 2016, in Cochrane Review s (Review s and Protocols) and Other Review s	192
#20	#18 and (#6 or #8)	1374
#21	#20 not #19	1227
#22	#21 Publication Year from 2011 to 2016	701

Appendix B1. Original Search Strategies

Cochrane Library, 5/23/17

ID	Search	Hits
#1	[mh "Atrial Fibrillation"] or ("atrial fibril*" or "atrium fibrillation*" or a-fib or afib or "atrial flutter*")	8442
#2	[mh Electrocardiography] or electrocardiography or EKG or ECG	14832
#3	#1 and #2	1354
#4	[mh "Mass Screening"] or screen*	42666
#5	#3 and #4	149
#6	((randomized or randomised) and controlled and trial) or (controlled and trial) or "Controlled Clinical Trial" or "Randomized Controlled Trial" or [mh "Single-Blind Method"] or [mh "Double-Blind Method"] or [mh "Random Allocation"]	767332
#7	#5 and #6 Publication Year from 2016 to 2017	48
#8	[mh "Cohort Studies"] or [mh "Epidemiologic Studies"] or [mh "Follow-up Studies"] or "prospective cohort" or [mh "prospective studies"] or (prospective* and cohort and (study or studies))	149954
#9	#5 and #8	42
#10	[mh Anticoagulants] or anticoagulant* or [mh Warfarin] or warfarin or noac* or [mh Dabigatran] or Dabigatran or Pradaxa or apixaban or Eliquis or [mh Rivaroxaban] or Rivaroxaban or Xarelto	11249
#11	#1 and #10	2038
#12	[mh "Factor Xa Inhibitors"] or "factor xa"	954
#13	#1 and #12	229
#14	[mh Antithrombins] or antithrombin* or "thrombin inhibit"	2505
#15	#1 and #14	260
#16	[mh Aspirin] or aspirin or "anti-platelet*" or antiplatelet* or Plavix or ASA or "acetylsalicylic acid" or [mh "Aspirin, Dipyridamole Drug Combination"] or Aggrenox or [mh Dipyridamole] or Dipyridamole or clopidogrel	25992
#17	#1 and #16	938
#18	#11 or #13 or #15 or #17	2297
#19	#18 Publication Year from 2016 to 2017, in Cochrane Review s (Review s and Protocols)	59
#20	#18 and (#6 or #8)	1834
#21	#20 not #19	1775
#22	#21 Publication Year from 2016 to 2017	418

Gray Literature Searches, July 15-22, 2016

ClinicalTrials.gov Searches

Advanced Search

Limit to

Adults

Last Updated 01/01/2011 – 12/31/2016

Screening

CONDITION box: atrial fibril* OR atrium fibrillation* OR a-fib OR atrial flutter*

INTERVENTION box: electrocardiography OR EKG OR ECG

Translates to in CT.gov:

atrial fibril* OR atrium fibrillation* OR a-fib OR atrial flutter* | electrocardiography OR EKG OR ECG |

Adult | Studies updated from 01/01/2011 to 12/31/2016

81 studies, all imported

Treatment

CONDITION box: atrial fibril* OR atrium fibrillation* OR a-fib OR atrial flutter*

INTERVENTION box: anticoagulant* OR "Warfarin" OR warfarin OR noac* OR Dabigatran OR Pradaxa OR apixaban OR Eliquis OR Rivaroxaban OR Xarelto OR "factor xa" OR antithrombin* OR thrombin inhibit* OR aspirin OR anti-platelet* OR antiplatelet* OR Plavix OR ASA OR "acetylsalicylic acid" OR Aggrenox OR Dipyridamole OR clopidogrel

232 studies, 230 imported

Appendix B1. Original Search Strategies

REDONE WITH SENIORS:

Screening:

atrial fibril* OR atrial fibrillation OR atrium fibrillation* OR a-fib OR atrial flutter* | electrocardiography OR EKG OR ECG | Adult, Senior | Studies updated from 01/01/2011 to 12/31/2016

85 results, all imported

Treatment:

atrial fibril* OR atrial fibrillation OR atrium fibrillation* OR a-fib OR atrial flutter* | anticoagulant* OR "Warfarin" OR warfarin OR noac* OR Dabigatran OR Pradaxa OR apixaban OR Eliquis OR Rivaroxaban OR Xarelto OR "factor xa" OR antithrombin* OR thrombin inhibit* OR aspirin OR anti-platelet* OR antiplatelet* OR Plavix OR ASA OR "acetylsalicylic acid" OR Aggrenox OR Dipyridamole OR clopidogrel | Adult, Senior | Studies updated from 01/01/2011 to 12/31/2016

239 results, 237 imported. 2 were duplicates with the screening search.

WHO ICRTRP Advanced searches, July 15-22, 2016

Screening:

Recruitment status: ALL

Date of registration is between 01/01/2011 – 31/12/2016

Condition box: atrial fibril* OR atrium fibrillation* OR a-fib OR atrial flutter*

Intervention box: electrocardiography OR EKG OR ECG

0 results.

Tried searching the intervention terms in Title box: electrocardiography OR EKG OR ECG

Condition box: atrial fibril* OR atrium fibrillation* OR a-fib OR atrial flutter*

1 result, imported

Treatment:

In Title box:

anticoagulant* OR "Warfarin" OR warfarin OR noac* OR Dabigatran OR Pradaxa OR apixaban OR Eliquis OR Rivaroxaban OR Xarelto OR "factor xa" OR antithrombin* OR thrombin inhibit* OR aspirin OR anti-platelet* OR antiplatelet* OR Plavix OR ASA OR "acetylsalicylic acid" OR Aggrenox OR Dipyridamole OR clopidogrel

In Condition box:

atrial fibril* OR atrium fibrillation* OR a-fib OR atrial flutter*

19 results, 9 imported

Gray Literature Searches, May 24, 2017

ClinicalTrials.gov Searches

Advanced Search

Limit to

Adults

Last Updated 01/01/2016 – 12/31/2017

Screening

CONDITION box: atrial fibril* OR atrium fibrillation* OR a-fib OR atrial flutter*

INTERVENTION box: electrocardiography OR EKG OR ECG

Translates to in ClinicalTrials.gov

atrial fibril* OR atrium fibrillation* OR a-fib OR atrial flutter* | electrocardiography OR EKG OR ECG |

Adult, Senior | Studies updated from 01/01/2016 to 12/31/2017

22 studies, all imported

Treatment:

CONDITION box: atrial fibril* OR atrium fibrillation* OR a-fib OR atrial flutter*

INTERVENTION box: anticoagulant* OR "Warfarin" OR warfarin OR noac* OR Dabigatran OR Pradaxa OR apixaban OR Eliquis OR Rivaroxaban OR Xarelto OR "factor xa" OR antithrombin* OR thrombin

Appendix B1. Original Search Strategies

inhibit* OR aspirin OR anti-platelet* OR antiplatelet* OR Plavix OR ASA OR "acetylsalicylic acid" OR Aggrenox OR Dipyridamole OR clopidogrel
Translates to in ClinicalTrials.gov
atrial fibril* OR atrial fibrillation OR atrium fibrillation* OR a-fib OR atrial flutter* | anticoagulant* OR "Warfarin" OR warfarin OR noac* OR Dabigatran OR Pradaxa OR apixaban OR Eliquis OR Rivaroxaban OR Xarelto OR "factor xa" OR antithrombin* OR thrombin inhibit* OR aspirin OR anti-platelet* OR antiplatelet* OR Plavix OR ASA OR "acetylsalicylic acid" OR Aggrenox OR Dipyridamole OR clopidogrel | Adult, Senior | Studies updated from 01/01/2016 to 12/31/2017
71 results, 70 imported

WHO ICRTTRP Advanced searches, May 24, 2017

Advanced search, Recruitment status: ALL

Date of registration is between 01/01/2016 – 12/31/2017

Screening:

Condition box: atrial fibril* OR atrium fibrillation* OR a-fib OR atrial flutter*

Intervention box: electrocardiography OR EKG OR ECG

21 results, all imported

Also performed the search with the intervention terms in Title box: electrocardiography OR EKG OR ECG

Condition box: atrial fibril* OR atrium fibrillation* OR a-fib OR atrial flutter*

6 results, 1 imported

Treatment:

In Title box:

anticoagulant* OR "Warfarin" OR warfarin OR noac* OR Dabigatran OR Pradaxa OR apixaban OR Eliquis OR Rivaroxaban OR Xarelto OR "factor xa" OR antithrombin* OR thrombin inhibit* OR aspirin OR anti-platelet* OR antiplatelet* OR Plavix OR ASA OR "acetylsalicylic acid" OR Aggrenox OR Dipyridamole OR clopidogrel

In Condition box:

atrial fibril* OR atrium fibrillation* OR a-fib OR atrial flutter*

74 results, all imported

Appendix B2. Eligibility Criteria

	Include	Exclude
Condition definition	Atrial fibrillation (paroxysmal or persistent)	Other cardiac arrhythmias, nonarrhythmia-related CVD (e.g., coronary heart disease, hypertension)
Populations	<p>KQs 1–3: Unselected or explicitly asymptomatic older adults (age 65 years or older); older adults selected for increased risk of nonvalvular atrial fibrillation (e.g., those with obesity, smoking, alcohol use, hypertension); studies of mixed populations of asymptomatic and symptomatic persons are eligible if results are reported separately for asymptomatic persons or less than 10% of the sample is symptomatic.</p> <p>KQs 4, 5: Older adults with atrial fibrillation. To approximate screen-detected persons with atrial fibrillation, we will aim to stratify analyses based on whether participants are asymptomatic/screen-detected vs. symptomatic (if possible); however, knowing that most studies enroll mixed populations or do not clearly enroll screen-detected or asymptomatic populations, we will not exclude studies based on whether participants were screen detected. To approximate “screening” vs. “disease management” populations, we will limit our analyses to studies of individuals not selected because of known heart disease, heart failure, and/or previous stroke or transient ischemic attack</p>	<p>KQs 1–3: Symptomatic adults; adults with known (history of) atrial fibrillation; children, adolescents, and adults age 65 years or older; adults at high(est) risk for atrial fibrillation (including but not limited to those with mitral valve disease or repair/replacement); and adults with history of stroke or transient ischemic attack</p> <p>KQs 4, 5: Adults needing antiplatelet or anticoagulation medications for conditions other than atrial fibrillation; adults with atrial fibrillation and known heart disease, heart failure, and/or previous stroke or transient ischemic attack</p>
Screening test or intervention	<p>KQs 1–3: Systematic ECG screening using any approach (e.g., in-office single-application 12-lead ECG, continuous ECG, intermittent use of handheld ECG); systematic screening with both pulse palpation and ECG for all participants</p> <p>KQs 4, 5: Medical treatment with antiplatelet agents (aspirin) or anticoagulants (apixaban, dabigatran, edoxaban, rivaroxaban, warfarin). Results will be stratified by type of medication.</p>	<p>KQs 1–3: Physical examination (including pulse palpation); blood pressure monitoring; pulse oximetry; all other technologies (e.g., consumer devices, such as smartphones); studies that only use ECG for participants with irregular pulse (as opposed to all participants)</p> <p>KQs 4, 5: Nonpharmacologic treatment to prevent stroke (e.g., implantable devices), treatment or management of atrial fibrillation for reasons other than prevention of stroke (e.g., rate or rhythm control, cardioversion, ablation), combinations of treatment (e.g., aspirin plus warfarin)</p>
Comparisons	<p>KQs 1–3: Screened vs. nonscreened groups, systematic screening vs. opportunistic screening (as defined by the primary study), systematic screening vs. usual care (which may include pulse palpation, automated blood pressure measurement, or cardiac auscultation during the course of a physical examination, or examination for another reason, with subsequent ECG if an irregular heart beat or pulse is noted)</p> <p>KQs 4, 5: No treatment</p>	<p>All KQs: No comparison, nonconcordant historical control</p> <p>KQs 4, 5: Active treatment (i.e., antiplatelet or anticoagulation medications)</p>

Appendix B2. Eligibility Criteria

	Include	Exclude
Outcomes	KQ 1: All-cause mortality, stroke, and stroke-related morbidity or mortality KQ 2: Comparative/relative yield (i.e., number of persons diagnosed with atrial fibrillation in one group vs. another [unscreened/differently screened] group) KQ 3: Anxiety, labeling, harms of subsequent procedures or interventions initiated as a result of screening (e.g., subsequent ablation with complications) KQ 4: All-cause mortality, cardioembolic stroke, and cardioembolic stroke-related morbidity or mortality KQ 5: Any harms requiring unexpected or unwanted medical attention (e.g., hemorrhagic stroke, major bleeding, allergic reaction)	KQs 3, 5: Nonserious events (e.g., bleeding not requiring or resulting in medical attention)
Study designs	All KQs: Randomized, controlled trials and controlled clinical trials KQs 2, 3: Large prospective cohort studies are also eligible KQ 4: Systematic review ^a s of trials are also eligible KQ 5: Systematic review ^a s of trials, systematic review ^a s of observational studies, and large prospective cohort studies are also eligible	All other designs, narrative reviews, case reports, case series, editorials, letters, cross-sectional studies, case-control studies, and retrospective cohort studies
Setting	KQs 1–3: Studies performed in primary care settings KQs 4, 5: Studies performed in primary care or specialty settings	KQs 1–3: Studies performed in specialty settings, studies of patients undergoing preoperative evaluation, and inpatient settings KQs 4, 5: Studies conducted primarily in inpatient settings
Country	Studies conducted in countries categorized as “Very High” on the 2014 Human Development Index (as defined by the United Nations Development Program)	Studies conducted in countries that are not categorized as “Very High” on the 2014 Human Development Index
Language	English	Non-English
Study quality	Good or fair	Poor (according to design-specific USPSTF criteria)

^a We assessed the relevance of systematic reviews (as described in the Methods) to address KQs 4 and 5 to determine their eligibility.

Abbreviations: CVD=cardiovascular disease; ECG=electrocardiogram; KQ=key question; USPSTF=U.S. Preventive Services Task Force.

Randomized, Controlled Trials and Cohort Studies

Criteria

- Initial assembly of comparable groups
- Randomized, controlled trials (RCTs)—adequate randomization, including concealment and whether potential confounders were distributed equally among groups; cohort studies—consideration of potential confounders with either restriction or measurement for adjustment in the analysis; consideration of inception cohorts
- Maintenance of comparable groups (includes attrition, crossovers, adherence, and contamination)
- Important differential loss to followup or overall high loss to followup
- Measurements that are equal, reliable, and valid (includes masking of outcome assessment)
- Clear definition of interventions
- Important outcomes considered
- Analysis: Adjustment for potential confounders for cohort studies or intention-to-treat analysis for RCTs; for cluster RCTs, correction for correlation coefficient

Definition of Ratings Based on Above Criteria

- Good:** Meets all criteria: Comparable groups are assembled initially and maintained throughout the study (followup $\geq 80\%$); reliable and valid measurement instruments are used and applied equally to the groups; interventions are spelled out clearly; important outcomes are considered; and appropriate attention is given to confounders in analysis. In addition, intention-to-treat analysis is used for RCTs.
- Fair:** Studies will be graded “fair” if any or all of the following problems occur, without the important limitations noted in the “poor” category below: Generally comparable groups are assembled initially, but some question remains on whether some (although not major) differences occurred in followup; measurement instruments are acceptable (although not the best) and generally applied equally; some but not all important outcomes are considered; and some but not all potential confounders are accounted for. Intention-to-treat analysis is lacking for RCTs.
- Poor:** Studies will be graded “poor” if any of the following major limitations exist: Groups assembled initially are not close to being comparable or maintained throughout the study; unreliable or invalid measurement instruments are used or not applied equally among groups (including not masking outcome assessment); and key confounders are given little or no attention. Intention-to-treat analysis is lacking for RCTs.

Sources: U.S. Preventive Services Task Force. U.S. Preventive Services Task Force, Procedure Manual, Appendix VI. Rockville, MD: U.S. Preventive Services Task Force; 2015⁸¹; Harris et al, 2001.⁸²

Systematic Reviews

Criteria

- Comprehensiveness of sources considered/search strategy used
- Standard appraisal of included studies
- Validity of conclusions
- Recency and relevance (especially important for systematic reviews)

Definition of Ratings Based on Above Criteria

Good: Recent, relevant review with comprehensive sources and search strategies; explicit and relevant selection criteria; standard appraisal of included studies; and valid conclusions

Fair: Recent, relevant review that is not clearly biased but lacks comprehensive sources and search strategies

Poor: Outdated, irrelevant, or biased review without systematic search for studies, explicit selection criteria, or standard appraisal of studies

Sources: U.S. Preventive Services Task Force. U.S. Preventive Services Task Force, Procedure Manual, Appendix VI. Rockville, MD: U.S. Preventive Services Task Force; 2015⁸¹; Harris et al, 2001.⁸²

Appendix C. Excluded Studies

- X1: Non-English
- X2: Ineligible population
- X3: Ineligible screening or treatment
- X4: Ineligible or no comparator
- X5: No relevant outcome reported
- X6: Ineligible setting
- X7: Ineligible study design
- X8: Ineligible country
- X9: Meets all criteria but abstract only
- X10: Outdated publication superseded by more recent data
- X11: Systematic Review that did not meet relevance criteria
- X12: Poor quality rating

1. Cost-Effectiveness of antiarrhythmic drugs for prevention of thromboembolism in patients with paroxysmal atrial fibrillation. *Jpn Circ J.* 2001 Sep;65(9):765-8. PMID: 11548872. Exclusion Code: X3.
2. Summaries for patients. What is the appropriate level of blood-thinning medication for elderly people with atrial fibrillation? *Ann Intern Med.* 2004 Nov 16;141(10):I38. PMID: 15545670. Exclusion Code: X7.
3. Summaries for patients. Net benefit of warfarin in atrial fibrillation. *Ann Intern Med.* 2009 Sep 1;151(5):I36. PMID: 19721014. Exclusion Code: X7.
4. Irbesartan did not reduce cardio events in atrial fibrillation patients. *Australian Journal of Pharmacy.* 2011;92(1095):83. PMID: CN-00893899. Exclusion Code: X7.
5. Aspirin and renal insufficiency progression in patients with atrial fibrillation and chronic kidney disease. *International Journal of Cardiology.* 223 (pp 619-624), 2016. Date of Publication: 15 Nov 2016. 2016doi: 10.1016/j.ijcard.2016.08.224. PMID: CN-01194146. Exclusion Code: X4.
6. Risk of bleeding and thrombosis in patients 70 years or older using Vitamin K antagonists. *JAMA Internal Medicine.* 176 (8) (pp 1176-1183), 2016. Date of Publication: August 2016. 2016doi: 10.1001/jamainternmed.2016.3057. PMID: CN-01195175. Exclusion Code: X2.
7. Adam SS, McDuffie JR, Ortel TL, et al. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review (Structured abstract). *Ann Intern Med.* 2012;157(11):796-807. PMID: DARE-12012045713. Exclusion Code: X4.
8. Agarwal S, Hachamovitch R, Menon V. Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis (Structured abstract). *Arch Intern Med.* 2012;172(8):623-31. PMID: DARE-12012014674. Exclusion Code: X4.
9. Aguilar Maria I, Hart R, Pearce Lesly A. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. *Cochrane Database of Systematic Reviews.* 2007(3)doi: 10.1002/14651858.CD006186.pub2. PMID: CD006186. Exclusion Code: X4.
10. Akao M, Chun YH, Esato M, et al. Inappropriate use of oral anticoagulants for patients with atrial fibrillation. *Circ J.* 2014;78(9):2166-72. PMID: 24976391. Exclusion Code: X4.
11. Albertsen IE, Rasmussen LH, Overvad TF, et al. Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis. *Stroke.* 2013 May;44(5):1329-36. doi: 10.1161/strokeaha.113.000883. PMID: 23482597. Exclusion Code: X4.
12. Alexander J, Andersson U, Lopes R, et al. Apixaban 5 mg twice daily and clinical outcomes in patients with atrial fibrillation and advanced age, low body weight, or high creatinine: a secondary analysis of a randomized clinical trial. *JAMA cardiology.* 2017;1(6):673-81. PMID: CN-01308892. Exclusion Code: X4.

Appendix C. Excluded Studies

13. Amin A, Boulanger L, Gatt E, et al. Exposure to warfarin and the risks of stroke and bleeding events among patients with non-valvular atrial fibrillation: Real-world vs. Clinical trial. *Circ Cardiovasc Qual Outcomes*. 2012;5(3 suppl. 1) PMID: CN-01023993. Exclusion Code: X7.
14. Amin A, Stokes M, Wu N, et al. Application of randomized clinical trial data to actual practice: apixaban therapy for reduction of stroke risk in non-valvular atrial fibrillation patients. *Curr Med Res Opin*. 2013 Oct;29(10):1253-61. doi: 10.1185/03007995.2013.818967. PMID: 23796193. Exclusion Code: X4.
15. Angoulvant D, Villejoubert O, Bejan-Angoulvant T, et al. Effect of Active Smoking on Comparative Efficacy of Antithrombotic Therapy in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project. *Chest*. 2015 Aug;148(2):491-8. doi: 10.1378/chest.14-3006. PMID: 25812113. Exclusion Code: X4.
16. Apenteng PN, Murray ET, Holder R, et al. An international longitudinal registry of patients with atrial fibrillation at risk of stroke (GARFIELD): the UK protocol. *BMC Cardiovasc Disord*. 2013;13:31. doi: 10.1186/1471-2261-13-31. PMID: 23617744. Exclusion Code: X5.
17. Ashburner JM, Go AS, Reynolds K, et al. Comparison of frequency and outcome of major gastrointestinal hemorrhage in patients with atrial fibrillation on versus not receiving warfarin therapy (from the ATRIA and ATRIA-CVRN cohorts). *Am J Cardiol*. 2015 Jan 1;115(1):40-6. doi: 10.1016/j.amjcard.2014.10.006. PMID: 25456871. Exclusion Code: X4.
18. Assiri A, Al-Majzoub O, Kanaan AO, et al. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation (Provisional abstract). *Clin Ther*. 2013;35(7):967-84.e2. PMID: DARE-12013042121. Exclusion Code: X11.
19. Avgil Tsadok M, Jackevicius CA, Rahme E, et al. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. *JAMA*. 2012 May 9;307(18):1952-8. doi: 10.1001/jama.2012.3490. PMID: 22570463. Exclusion Code: X7.
20. Azoulay L, Dell'Aniello S, Simon T, et al. The concurrent use of antithrombotic therapies and the risk of bleeding in patients with atrial fibrillation. *Thromb Haemost*. 2013 Mar;109(3):431-9. doi: 10.1160/th12-08-0542. PMID: 23306435. Exclusion Code: X7.
21. Bai Y, Chen H, Yang Y, et al. Safety of antithrombotic drugs in patients with atrial fibrillation and non-end-stage chronic kidney disease: Meta-analysis and systematic review. *Thromb Res*. 2016 Jan;137:46-52. doi: 10.1016/j.thromres.2015.11.020. PMID: 26610746. Exclusion Code: X2.
22. Bajorek BV, Krass I, Ogle SJ, et al. Optimizing the use of antithrombotic therapy for atrial fibrillation in older people: a pharmacist-led multidisciplinary intervention. *J Am Geriatr Soc*. 2005 Nov;53(11):1912-20. doi: 10.1111/j.1532-5415.2005.53564.x. PMID: 16274372. Exclusion Code: X3.
23. Baker WL, Phung OJ. Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation. *Circ Cardiovasc Qual Outcomes*. 2012 Sep 1;5(5):711-9. doi: 10.1161/circoutcomes.112.966572. PMID: 22912382. Exclusion Code: X4.
24. Banerjee A, Clementy N, Haguenoer K, et al. Prior history of falls and risk of outcomes in atrial fibrillation: the Loire Valley Atrial Fibrillation Project. *Am J Med*. 2014 Oct;127(10):972-8. doi: 10.1016/j.amjmed.2014.05.035. PMID: 24929021. Exclusion Code: X4.
25. Banerjee A, Fauchier L, Vourc'h P, et al. A prospective study of estimated glomerular filtration rate and outcomes in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. *Chest*. 2014 Jun;145(6):1370-82. doi: 10.1378/chest.13-2103. PMID: 24356875. Exclusion Code: X4.
26. Barrios V, Escobar C, Calderon A, et al. Use of antithrombotic therapy according to CHA2DS2-VASc score in patients with atrial fibrillation in primary care. *Rev Esp Cardiol (Engl Ed)*. 2014 Feb;67(2):150-1. doi: 10.1016/j.rec.2013.07.009. PMID: 24795129. Exclusion Code: X5.

Appendix C. Excluded Studies

27. Baruch L, Gage BF, Horrow J, et al. Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified? *Stroke*. 2007 Sep;38(9):2459-63. doi: 10.1161/strokeaha.106.477133. PMID: 17673721. Exclusion Code: X4.
28. Bath PM, Prasad A, Brown MM, et al. Survey of use of anticoagulation in patients with atrial fibrillation. *BMJ*. 1993 Oct 23;307(6911):1045. PMID: 8166802. Exclusion Code: X7.
29. Baxter J, Crabtree L, Hildreth A, et al. Atrial fibrillation. *Lancet*. 1998 Dec 5;352(9143):1858. doi: 10.1016/s0140-6736(05)79924-4. PMID: 9851411. Exclusion Code: X7.
30. Benito L, Coll-Vinent B, Gómez E, et al. EARLY: a pilot study on early diagnosis of atrial fibrillation in a primary healthcare centre. *Europace*. 2015;17(11):1688-93. doi: 10.1093/europace/euv146. PMID: CN-01257576. Exclusion Code: X12.
31. Biase L, Burkhardt JD, Santangeli P, et al. Silent thromboembolic lesions following catheter ablation for atrial fibrillation using radiofrequency energy: Results from a sub-study of the "compare" randomized trial. *Circulation*. 2013;128(22 suppl. 1) PMID: CN-01062460. Exclusion Code: X3.
32. Biondi-Zoccai G, Malavasi V, D'Ascenzo F, et al. Comparative effectiveness of novel oral anticoagulants for atrial fibrillation: evidence from pair-wise and warfarin-controlled network meta-analyses (Provisional abstract). *HSR Proceedings in Intensive Care and Cardiovascular Anesthesia*. 2013;5(1):40-54. PMID: DARE-12013029969. Exclusion Code: X4.
33. Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. *Stroke*. 2006 Apr;37(4):1070-4. doi: 10.1161/01.STR.0000208294.46968.a4. PMID: 16528001. Exclusion Code: X7.
34. Bjorck S, Palaszewski B, Friberg L, et al. Atrial fibrillation, stroke risk, and warfarin therapy revisited: a population-based study. *Stroke*. 2013 Nov;44(11):3103-8. doi: 10.1161/strokeaha.113.002329. PMID: 23982711. Exclusion Code: X7.
35. Blin P, Dureau-Pournin C, Lassalle R, et al. A population database study of outcomes associated with Vitamin K antagonists in atrial fibrillation before DOAC. *Br J Clin Pharmacol*. 2016;81(3):569-78. doi: 10.1111/bcp.12807. PMID: CN-01137679. Exclusion Code: X7.
36. Bo M, Li Puma F, Badinella Martini M, et al. Health status, geriatric syndromes and prescription of oral anticoagulant therapy in elderly medical in-patients with atrial fibrillation: a prospective observational study. *Int J Cardiol*. 2015;187:123-5. doi: 10.1016/j.ijcard.2015.03.334. PMID: 25828331. Exclusion Code: X4.
37. Bo S, Valpreda S, Scaglione L, et al. Implementing hospital guidelines improves warfarin use in non-valvular atrial fibrillation: a before-after study. *BMC Public Health*. 2007;7:203. doi: 10.1186/1471-2458-7-203. PMID: 17692112. Exclusion Code: X3.
38. Bonde AN, Lip GY, Kamper AL, et al. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study. *J Am Coll Cardiol*. 2014 Dec 16;64(23):2471-82. doi: 10.1016/j.jacc.2014.09.051. PMID: 25500231. Exclusion Code: X7.
39. Bonnet-Zamponi D, Aumont MC, Comets E, et al. Heparin bridging therapy and bleeding events in octogenarian inpatients with atrial fibrillation starting anticoagulation: results of an ancillary study. *J Am Geriatr Soc*. 2011 Nov;59(11):2174-8. doi: 10.1111/j.1532-5415.2011.03649.x. PMID: 22098039. Exclusion Code: X6.
40. Bosch RF, Kirch W, Theuer JD, et al. Atrial fibrillation management, outcomes and predictors of stable disease in daily practice: prospective non-interventional study. *Int J Cardiol*. 2013 Aug 10;167(3):750-6. doi: 10.1016/j.ijcard.2012.03.053. PMID: 22475841. Exclusion Code: X5.
41. Bover R, Perez-Gomez F, Maluenda MP, et al. Long-term follow-up of atrial fibrillation patients in the NASPEAF study. Prospective evaluation of different antiplatelet treatments. *Rev Esp Cardiol*. 2009 Sep;62(9):992-1000. PMID: 19712620. Exclusion Code: X4.

Appendix C. Excluded Studies

42. Bruins Slot Karsten MH, Berge E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database of Systematic Reviews. 2013(8)doi: 10.1002/14651858.CD008980.pub2. PMID: CD008980. Exclusion Code: X4.
43. Burton CD, Hamilton KE, Isles CG, et al. Warfarin for nonvalvular atrial fibrillation in primary care--another example of the age paradox? *J Cardiovasc Risk*. 2001 Oct;8(5):307-9. PMID: 11702037. Exclusion Code: X3.
44. Bury G, Swan D, Cullen W, et al. Screening for atrial fibrillation in general practice: a national, cross-sectional study of an innovative technology. *Int J Cardiol*. 2015 Jan 15;178:247-52. doi: 10.1016/j.ijcard.2014.10.037. PMID: 25464263. Exclusion Code: X4.
45. Cadth. Dabigatran for stroke prevention in atrial fibrillation: a review of the evidence on safety (Structured abstract). Health Technology Assessment Database: Canadian Agency for Drugs and Technologies in Health (CADTH); 2012. Exclusion Code: X4.
46. Caldeira D, Barra M, Pinto FJ, et al. Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis (Provisional abstract). Database of Abstracts of Reviews of Effects. 2014(2):epub. PMID: DARE-12014051415. Exclusion Code: X4.
47. Caldeira D, Costa J, Fernandes RM, et al. Performance of the HAS-BLED high bleeding-risk category, compared to ATRIA and HEMORR2HAGES in patients with atrial fibrillation: a systematic review and meta-analysis (Provisional abstract). Database of Abstracts of Reviews of Effects. 2014(2):277-84. PMID: DARE-12014045687. Exclusion Code: X3.
48. Cameron C, Coyle D, Richter T, et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation (Provisional abstract). Database of Abstracts of Reviews of Effects. 2014(2):e004301. PMID: DARE-12014036609. Exclusion Code: X11.
49. Capodanno D, Capranzano P, Giacchi G, et al. Novel oral anticoagulants versus warfarin in non-valvular atrial fibrillation: a meta-analysis of 50,578 patients (Provisional abstract). *Int J Cardiol*. 2013;167(4):1237-41. PMID: DARE-12013055125. Exclusion Code: X4.
50. Caro JJ, Flegel KM, Orejuela ME, et al. Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice. *CMAJ*. 1999 Sep 7;161(5):493-7. PMID: 10497604. Exclusion Code: X12.
51. Casciano JP, Dotiwala ZJ, Martin BC, et al. The costs of warfarin underuse and nonadherence in patients with atrial fibrillation: a commercial insurer perspective. *J Manag Care Pharm*. 2013 May;19(4):302-16. doi: 10.18553/jmcp.2013.19.4.302. PMID: 23627576. Exclusion Code: X7.
52. Cha MJ, Oh GC, Hahn S, et al. Thromboembolic risk evaluation in patients with atrial fibrillation using a modified CHADS(2) scoring system. *J Cardiovasc Electrophysiol*. 2012 Feb;23(2):155-62. doi: 10.1111/j.1540-8167.2011.02181.x. PMID: 21955174. Exclusion Code: X4.
53. Chan N-y, Choy C-c. Screening for atrial fibrillation in 13 122 Hong Kong citizens with smartphone electrocardiogram. *Heart*. 2016 October 12, 2016doi: 10.1136/heartjnl-2016-309993. Exclusion Code: X4.
54. Chatterjee S, Sardar P, Biondi-Zoccai G, et al. New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation (Provisional abstract). *JAMA Neurology*. 2013;70(12):1486-90. PMID: DARE-12013063998. Exclusion Code: X4.
55. Chen T, Yang YM, Tan HQ, et al. Baseline characteristics and 1-year follow-up of Chinese atrial fibrillation patients according to age: a registry study. *Pacing Clin Electrophysiol*. 2014 Oct;37(10):1392-403. doi: 10.1111/pace.12443. PMID: 25039463. Exclusion Code: X4.
56. Cheng HY. The association of warfarin use with osteoporotic fracture in elderly patients with atrial fibrillation. *Arch Intern Med*. 2006 Jul 24;166(14):1525; author reply doi: 10.1001/archinte.166.14.1525-a. PMID: 16864765. Exclusion Code: X7.

Appendix C. Excluded Studies

57. Chishaki A, Kumagai N, Takahashi N, et al. Non-valvular atrial fibrillation patients with low CHADS2 scores benefit from warfarin therapy according to propensity score matching subanalysis using the J-RHYTHM Registry. *Thromb Res*. 2015 Aug;136(2):267-73. doi: 10.1016/j.thromres.2015.06.009. PMID: 26092429. Exclusion Code: X4.
58. Christow S, Seidl K, Diener HC, et al. Increased rate of previous stroke in asymptomatic/minimally symptomatic versus symptomatic patients with newly detected atrial fibrillation in western Europe - results from the GLORIA - AF registry. *EP Europace*. 2017;19(suppl_3):iii355-iii6. doi: 10.1093/ehjci/eux159.005. Exclusion Code: X4.
59. Claes N, Van Laethem C, Goethals M, et al. Prevalence of atrial fibrillation in adults participating in a large-scale voluntary screening programme in Belgium. *Acta Cardiol*. 2012 Jun;67(3):273-8. doi: 10.2143/ac.67.3.2160714. PMID: 22870733. Exclusion Code: X5.
60. Clemens A, Fraessdorf M, Friedman J. Cardiovascular outcomes during treatment with dabigatran: Comprehensive analysis of individual subject data by treatment. *Vascular Health and Risk Management*. 2013;9(1):599-615. doi: 10.2147/VHRM.S49830. PMID: CN-00979960. Exclusion Code: X4.
61. Coleman CI, Straznitskas AD, Sobieraj DM, et al. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable. *Am J Cardiol*. 2012 Apr 1;109(7):1020-5. doi: 10.1016/j.amjcard.2011.11.034. PMID: 22221944. Exclusion Code: X4.
62. Connolly BJ, Pearce LA, Kurth T, et al. Aspirin therapy and risk of subdural hematoma: meta-analysis of randomized clinical trials. *J Stroke Cerebrovasc Dis*. 2013 May;22(4):444-8. doi: 10.1016/j.jstrokecerebrovasdis.2013.01.007. PMID: 23422345. Exclusion Code: X2.
63. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Newly identified events in the RE-LY trial. *N Engl J Med*. 2010 Nov 04;363(19):1875-6. doi: 10.1056/NEJMc1007378. PMID: 21047252. Exclusion Code: X4.
64. Connolly SJ, Pogue J, Hart RG, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. *N Engl J Med*. 2009 May 14;360(20):2066-78. doi: 10.1056/NEJMoA0901301. PMID: 19336502. Exclusion Code: X4.
65. Connolly SJ, Wallentin L, Ezekowitz MD, et al. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. *Circulation*. 2013 Jul 16;128(3):237-43. doi: 10.1161/circulationaha.112.001139. PMID: 23770747. Exclusion Code: X4.
66. Cullen MW, Kim S, Piccini JP, Sr., et al. Risks and benefits of anticoagulation in atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry. *Circ Cardiovasc Qual Outcomes*. 2013 Jul;6(4):461-9. doi: 10.1161/circoutcomes.113.000127. PMID: 23759473. Exclusion Code: X7.
67. Daacke IM. Systematic review and critical appraisal of the statistical methods used in published studies to indirectly compare novel anticoagulants (NOACS) with warfarin for the prevention of stroke in patients with atrial fibrillation (AF). *Value Health*. 2014;17(7):A579. doi: 10.1016/j.jval.2014.08.1958. PMID: CN-01023379. Exclusion Code: X4.
68. Dagres N, Nieuwlaet R, Vardas PE, et al. Gender-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Heart Survey on Atrial Fibrillation. *J Am Coll Cardiol*. 2007 Feb 6;49(5):572-7. doi: 10.1016/j.jacc.2006.10.047. PMID: 17276181. Exclusion Code: X3.
69. Darkow T, Vanderplas AM, Lew KH, et al. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system. *Curr Med Res Opin*. 2005 Oct;21(10):1583-94. doi: 10.1185/030079905x61956. PMID: 16238898. Exclusion Code: X7.
70. Das AK, Willcoxson PD, Corrado OJ, et al. The impact of long-term warfarin on the quality of life of elderly people with atrial fibrillation. *Age Ageing*. 2007 Jan;36(1):95-7. doi: 10.1093/ageing/af1062. PMID: 16799180. Exclusion Code: X4.

Appendix C. Excluded Studies

71. De Ruijter W, Assendelft WJ, Macfarlane PW, et al. The additional value of routine electrocardiograms in cardiovascular risk management of older people. *Scand J Prim Health Care*. 2008;26(3):147-53. doi: 10.1080/02813430802095812. PMID: 18609253. Exclusion Code: X4.
72. Dentali F, Riva N, Crowther M, et al. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. *Circulation*. 2012 Nov 13;126(20):2381-91. doi: 10.1161/circulationaha.112.115410. PMID: 23071159. Exclusion Code: X4.
73. DeSilvey DL. Risk of anticoagulation for atrial fibrillation in the elderly. *Am J Geriatr Cardiol*. 2007 Sep-Oct;16(5):325-6. PMID: 17786064. Exclusion Code: X7.
74. Dewhurst MJ, Adams PC, Gray WK, et al. Strikingly low prevalence of atrial fibrillation in elderly Tanzanians. *J Am Geriatr Soc*. 2012 Jun;60(6):1135-40. doi: 10.1111/j.1532-5415.2012.03963.x. PMID: 22646732. Exclusion Code: X7.
75. Di Biase L, Burkhardt JD, Mohanty P, et al. Periprocedural stroke and management of major bleeding complications in patients undergoing catheter ablation of atrial fibrillation: the impact of periprocedural therapeutic international normalized ratio. *Circulation*. 2010 Jun 15;121(23):2550-6. doi: 10.1161/circulationaha.109.921320. PMID: 20516376. Exclusion Code: X6.
76. Diederichsen S, Haugan K, Kober L, et al. Atrial fibrillation detected by continuous electrocardiographic monitoring using implantable loop recorder to prevent stroke in individuals at risk (the LOOP study): rationale and design of a large randomized controlled trial. *Am Heart J*. 2017;187:122-32. doi: 10.1016/j.ahj.2017.02.017. PMID: CN-01337357. Exclusion Code: X3.
77. DiMarco JP, Flaker G, Waldo AL, et al. Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. *Am Heart J*. 2005 Apr;149(4):650-6. doi: 10.1016/j.ahj.2004.11.015. PMID: 15990748. Exclusion Code: X3.
78. Dogliotti A, Paolasso E, Giugliano RP. Novel oral anticoagulants in atrial fibrillation: a meta-analysis of large, randomized, controlled trials vs warfarin (Structured abstract). *Clin Cardiol*. 2013;36(2):61-7. PMID: DARE-12013014937. Exclusion Code: X4.
79. Donze J, Clair C, Hug B, et al. Risk of falls and major bleeds in patients on oral anticoagulation therapy. *Am J Med*. 2012 Aug;125(8):773-8. doi: 10.1016/j.amjmed.2012.01.033. PMID: 22840664. Exclusion Code: X4.
80. Duygu H, Barisik V, Kurt H, et al. Prognostic value of plasma soluble CD40 ligand in patients with chronic non-valvular atrial fibrillation. *Europace*. 2008 Feb;10(2):210-4. doi: 10.1093/europace/eum284. PMID: 18184662. Exclusion Code: X4.
81. Echeto Garcia A, Bayon Yusta JC, Gardeazabal Romillo MJ, et al. Systematic review of the pharmacoeconomic evidence of dabigatran for stroke prevention in patients with nonvalvular atrial fibrillation (Provisional abstract). *Database of Abstracts of Reviews of Effects*. 2014(2):25-37. PMID: DARE-12014055285. Exclusion Code: X1.
82. Edvardsson N, Juul-Moller S, Omblus R, et al. Effects of low-dose warfarin and aspirin versus no treatment on stroke in a medium-risk patient population with atrial fibrillation. *J Intern Med*. 2003 Jul;254(1):95-101. PMID: 12823646. Exclusion Code: X3.
83. Edwards SJ, Hamilton V, Nherera L, et al. A mixed treatment comparison (MTC) to compare the efficacy of anti-thrombotic agents in the prevention of stroke and systemic embolism (SE) in patients with non-valvular atrial fibrillation (NVAF). *Value Health*. 2012;15(7):A363. doi: 10.1016/j.jval.2012.08.950. PMID: CN-01004208. Exclusion Code: X4.
84. Ellis M, Avnery O, Derazne E, et al. Bleeding in patients with atrial fibrillation treated with different doses of direct oral anticoagulants and vitamin K antagonists: a population-based study. *Blood*. Conference: 58th annual meeting of the american society of hematology, ASH 2016. United states. Conference start: 20161203. Conference end: 20161206. 2017;128(22) (no pagination) PMID: CN-01335074. Exclusion Code: X4.

Appendix C. Excluded Studies

85. Engdahl J, Andersson L, Mirskaya M, et al. Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. *Circulation*. 2013 Feb 26;127(8):930-7. doi: 10.1161/circulationaha.112.126656. PMID: 23343564. Exclusion Code: X4.
86. Ertas F, Eren NK, Kaya H, et al. The atrial fibrillation in Turkey: Epidemiologic Registry (AFTER). *Cardiol J*. 2013;20(4):447-52. doi: 10.5603/CJ.a2013.0055. PMID: 23677730. Exclusion Code: X5.
87. Evans A, Kalra L. Are the results of randomized controlled trials on anticoagulation in patients with atrial fibrillation generalizable to clinical practice? *Arch Intern Med*. 2001 Jun 11;161(11):1443-7. PMID: 11386894. Exclusion Code: X7.
88. Ezekowitz MD, James KE, Nazarian SM, et al. Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. The Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. *Circulation*. 1995 Oct 15;92(8):2178-82. PMID: 7554199. Exclusion Code: X5.
89. Ezekowitz MD, Levine JA. Preventing stroke in patients with atrial fibrillation. *JAMA*. 1999 May 19;281(19):1830-5. PMID: 10340371. Exclusion Code: X7.
90. Fang MC, Go AS, Chang Y, et al. Thirty-day mortality after ischemic stroke and intracranial hemorrhage in patients with atrial fibrillation on and off anticoagulants. *Stroke*. 2012 Jul;43(7):1795-9. doi: 10.1161/strokeaha.111.630731. PMID: 22539546. Exclusion Code: X2.
91. Fang MC, Go AS, Hylek EM, et al. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. *J Am Geriatr Soc*. 2006 Aug;54(8):1231-6. doi: 10.1111/j.1532-5415.2006.00828.x. PMID: 16913990. Exclusion Code: X7.
92. Fang MC, Singer DE, Chang Y, et al. Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study. *Circulation*. 2005 Sep 20;112(12):1687-91. doi: 10.1161/circulationaha.105.553438. PMID: 16157766. Exclusion Code: X4.
93. Farmakis D, Pipilis A, Antoniou A, et al. Clinical profile and therapeutic management of patients with atrial fibrillation in Greece: results from the Registry of Atrial Fibrillation to Investigate New Guidelines (RAFTING). *Hellenic J Cardiol*. 2013 Sep-Oct;54(5):368-75. PMID: 24100180. Exclusion Code: X5.
94. Fauchier L, Clementy N, Saint-Etienne C, et al. Efficacy of new oral anticoagulants in patients with atrial fibrillation previously treated with warfarin: a meta-analysis of randomized controlled trials (Provisional abstract). *Int J Cardiol*. 2014;173(1):122-4. PMID: DARE-12014021030. Exclusion Code: X4.
95. Fauchier L, Lecoq C, Clementy N, et al. Oral Anticoagulation and the Risk of Stroke or Death in Patients With Atrial Fibrillation and One Additional Stroke Risk Factor: The Loire Valley Atrial Fibrillation Project. *Chest*. 2016 Apr;149(4):960-8. doi: 10.1378/chest.15-1622. PMID: 26425935. Exclusion Code: X5.
96. Flaker GC, Belew K, Beckman K, et al. Asymptomatic atrial fibrillation: demographic features and prognostic information from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. *Am Heart J*. 2005 Apr;149(4):657-63. doi: 10.1016/j.ahj.2004.06.032. PMID: 15990749. Exclusion Code: X3.
97. Forslund T, Wettermark B, Wandell P, et al. Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. *Eur J Clin Pharmacol*. 2014 Dec;70(12):1477-85. doi: 10.1007/s00228-014-1739-1. PMID: 25219360. Exclusion Code: X12.
98. Fosbol EL, Holmes DN, Piccini JP, et al. Provider specialty and atrial fibrillation treatment strategies in United States community practice: findings from the ORBIT-AF registry. *J Am Heart Assoc*. 2013 Aug;2(4):e000110. doi: 10.1161/jaha.113.000110. PMID: 23868192. Exclusion Code: X7.

Appendix C. Excluded Studies

99. Freedman B, Camm J, Calkins H, et al. Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration. *Circulation*. 2017 May 09;135(19):1851-67. doi: 10.1161/circulationaha.116.026693. PMID: 28483832. Exclusion Code: X7.
100. Frewen J, Finucane C, Cronin H, et al. Factors that influence awareness and treatment of atrial fibrillation in older adults. *QJM*. 2013 May;106(5):415-24. doi: 10.1093/qjmed/hct060. PMID: 23504411. Exclusion Code: X4.
101. Friberg L, Engdahl J, Frykman V, et al. Population screening of 75- and 76-year-old men and women for silent atrial fibrillation (STROKESTOP). *Europace*. 2013 Jan;15(1):135-40. doi: 10.1093/europace/eus217. PMID: 22791299. Exclusion Code: X5.
102. Friberg L, Hammar N, Pettersson H, et al. Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). *Eur Heart J*. 2007 Oct;28(19):2346-53. doi: 10.1093/eurheartj/ehm308. PMID: 17670754. Exclusion Code: X5.
103. Friberg L, Hammar N, Rosenqvist M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. *Eur Heart J*. 2010 Apr;31(8):967-75. doi: 10.1093/eurheartj/ehn599. PMID: 19176537. Exclusion Code: X4.
104. Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study. *Circulation*. 2012 May 15;125(19):2298-307. doi: 10.1161/circulationaha.111.055079. PMID: 22514252. Exclusion Code: X4.
105. Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. *Eur Heart J*. 2012 Jun;33(12):1500-10. doi: 10.1093/eurheartj/ehr488. PMID: 22246443. Exclusion Code: X4.
106. Frost L, Johnsen SP, Pedersen L, et al. Atrial fibrillation or flutter and stroke: a Danish population-based study of the effectiveness of oral anticoagulation in clinical practice. *J Intern Med*. 2002 Jul;252(1):64-9. PMID: 12074740. Exclusion Code: X7.
107. Fu W, Guo H, Guo J, et al. Relative efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation by network meta-analysis (Provisional abstract). *Database of Abstracts of Reviews of Effects*. 2014(2):873-9. PMID: DARE-12014063328. Exclusion Code: X4.
108. Gage BF, van Walraven C, Pearce L, et al. Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. *Circulation*. 2004 Oct 19;110(16):2287-92. doi: 10.1161/01.cir.0000145172.55640.93. PMID: 15477396. Exclusion Code: X3.
109. Gallagher AM, Setakis E, Plumb JM, et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients. *Thromb Haemost*. 2011;106(5):968-77. doi: 10.1160/TH11-05-0353. PMID: CN-00889921. Exclusion Code: X4.
110. Gallagher AM, van Staa TP, Murray-Thomas T, et al. Population-based cohort study of warfarin-treated patients with atrial fibrillation: incidence of cardiovascular and bleeding outcomes. *BMJ Open*. 2014;4(1):e003839. doi: 10.1136/bmjopen-2013-003839. PMID: 24468720. Exclusion Code: X7.
111. Gamst J, Christiansen CF, Rasmussen BS, et al. Pre-existing atrial fibrillation and risk of arterial thromboembolism and death following pneumonia: a population-based cohort study. *BMJ Open*. 2014;4(11):e006486. doi: 10.1136/bmjopen-2014-006486. PMID: 25398678. Exclusion Code: X7.
112. Ganjehei L, Wilson JM. Anticoagulants for stroke prevention in nonvalvular atrial fibrillation: New agents and an updated understanding. *Tex Heart Inst J*. 2012;39(4):517-25. PMID: CN-01004668. Exclusion Code: X7.
113. Ghatta SR, Biskupiak J, Ye X, et al. All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation. *J Manag Care Pharm*. 2011 Nov;17(9):672-84. doi: 10.18553/jmcp.2011.17.9.672. PMID: 22050392. Exclusion Code: X7.

Appendix C. Excluded Studies

114. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? *JAMA*. 2003 Nov 26;290(20):2685-92. doi: 10.1001/jama.290.20.2685. PMID: 14645310. Exclusion Code: X4.
115. Gold JA. Warfarin encouraged for stroke prevention in atrial fibrillation. *Wis Med J*. 1996 Jan;95(1):42-3. PMID: 8650954. Exclusion Code: X5.
116. Gomes T, Mamdani MM, Holbrook AM, et al. Rates of hemorrhage during warfarin therapy for atrial fibrillation. *CMAJ*. 2013 Feb 5;185(2):E121-7. doi: 10.1503/cmaj.121218. PMID: 23184840. Exclusion Code: X4.
117. Gomes T, Mamdani MM, Holbrook AM, et al. Persistence with therapy among patients treated with warfarin for atrial fibrillation. *Arch Intern Med*. 2012 Nov 26;172(21):1687-9. doi: 10.1001/archinternmed.2012.4485. PMID: 23090098. Exclusion Code: X4.
118. Gomez-Outes A, Lagunar-Ruiz J, Terleira-Fernandez A-I, et al. Causes of Death in Anticoagulated Patients With Atrial Fibrillation. *J Am Coll Cardiol*. 2017;68(23):2508-21. doi: 10.1016/j.jacc.2016.09.944. PMID: CN-01301532. Exclusion Code: X4.
119. Gomez-Outes A, Terleira-Fernandez AI, Calvo-Rojas G, et al. Dabigatran, rivaroxaban, or apixaban versus warfarin in patients with nonvalvular atrial fibrillation: a systematic review and meta-analysis of subgroups (Provisional abstract). *Thrombosis*. 2013;2013(2):640723. PMID: DARE-12014008211. Exclusion Code: X4.
120. González Blanco V, Pérula de Torres LÁ, Martín Rioboó E, et al. Opportunistic screening for atrial fibrillation versus detecting symptomatic patients aged 65 years and older: A cluster-controlled clinical trial. *Med Clin (Barc)*. 2017 1/6;148(1):8-15. doi: <http://dx.doi.org/10.1016/j.medcli.2016.07.036>. Exclusion Code: X2.
121. Gonzalez-Juanatey JR, Alvarez-Sabin J, Lobos JM, et al. Cost-effectiveness of dabigatran for stroke prevention in non-valvular atrial fibrillation in Spain. *Rev Esp Cardiol (Engl Ed)*. 2012 Oct;65(10):901-10. doi: 10.1016/j.recesp.2012.06.006. PMID: 22958943. Exclusion Code: X7.
122. Gorin L, Fauchier L, Nonin E, et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1. *Thromb Haemost*. 2010 Apr;103(4):833-40. doi: 10.1160/th09-10-0746. PMID: 20135077. Exclusion Code: X7.
123. Gorzelak P, Zyzak S, Krewko, et al. [Frequency of use of oral vitamin K antagonists in patients with atrial fibrillation and cognitive function disturbances]. *Polski merkuriusz lekarski: organ Polskiego Towarzystwa Lekarskiego*. 2014;36(215):302-6. PMID: CN-00999004. Exclusion Code: X1.
124. Goto S, Bhatt DL, Rother J, et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. *Am Heart J*. 2008 Nov;156(5):855-63. doi: 10.1016/j.ahj.2008.06.029. PMID: 19061698. Exclusion Code: X4.
125. Granziera S, Nante G, Manzato E, et al. Prescription of vitamin K inhibitors in low-risk patients with atrial fibrillation. *J Thromb Thrombolysis*. 2011 May;31(4):501-2. doi: 10.1007/s11239-010-0518-9. PMID: 20865300. Exclusion Code: X4.
126. Greenhalgh J, Bagust A, Boland A, et al. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of technology appraisal no.90): a systematic review and economic analysis (Structured abstract). *Health Technol Assess*. 2011;15(31):1-178. PMID: DARE-12011006378. Exclusion Code: X2.
127. Guo Y, Pisters R, Apostolakis S, et al. Stroke risk and suboptimal thromboprophylaxis in Chinese patients with atrial fibrillation: would the novel oral anticoagulants have an impact? *Int J Cardiol*. 2013 Sep 20;168(1):515-22. doi: 10.1016/j.ijcard.2012.09.187. PMID: 23103146. Exclusion Code: X8.
128. Guo Y, Wang H, Tian Y, et al. Time Trends of Aspirin and Warfarin Use on Stroke and Bleeding Events in Chinese Patients With New-Onset Atrial Fibrillation. *Chest*. 2015 Jul;148(1):62-72. doi: 10.1378/chest.14-2018. PMID: 25501045. Exclusion Code: X7.

Appendix C. Excluded Studies

129. Gupta D, Giugliano R, Ruff C, et al. The Prognostic Significance of Cardiac Structure and Function in Atrial Fibrillation: The ENGAGE AF-TIMI 48 Echocardiographic Substudy. *J Am Soc Echocardiogr*. 2016;29(6):537-44. doi: 10.1016/j.echo.2016.03.004. PMID: CN-01158351. Exclusion Code: X2.
130. Hannon N, Callaly E, Moore A, et al. Improved late survival and disability after stroke with therapeutic anticoagulation for atrial fibrillation: a population study. *Stroke*. 2011 Sep;42(9):2503-8. doi: 10.1161/strokeaha.110.602235. PMID: 21778447. Exclusion Code: X2.
131. Hanon O, Vidal JS, Pisica-Donose G, et al. Therapeutic management in ambulatory elderly patients with atrial fibrillation: the S.AGES cohort. *J Nutr Health Aging*. 2015 Feb;19(2):219-27. doi: 10.1007/s12603-015-0444-9. PMID: 25651449. Exclusion Code: X5.
132. Hansen ML, Sorensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. *Arch Intern Med*. 2010 Sep 13;170(16):1433-41. doi: 10.1001/archinternmed.2010.271. PMID: 20837828. Exclusion Code: X4.
133. Harenberg J, Marx S, Diener HC, et al. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. *Int Angiol*. 2012 Aug;31(4):330-9. PMID: 22801398. Exclusion Code: X4.
134. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. *Ann Intern Med*. 1999 Oct 05;131(7):492-501. PMID: 10507957. Exclusion Code: X10.
135. Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. *Stroke*. 2012 Jun;43(6):1511-7. doi: 10.1161/strokeaha.112.650614. PMID: 22492518. Exclusion Code: X7.
136. Hart RG, Pearce LA, Miller VT, et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents in the stroke prevention in atrial fibrillation studies. *Cerebrovasc Dis*. 2000 Jan-Feb;10(1):39-43. doi: 16023. PMID: 10629345. Exclusion Code: X4.
137. Healey JS, Crystal E, Lamy A, et al. Left Atrial Appendage Occlusion Study (LAAOS): results of a randomized controlled pilot study of left atrial appendage occlusion during coronary bypass surgery in patients at risk for stroke. *Am Heart J*. 2005 Aug;150(2):288-93. doi: 10.1016/j.ahj.2004.09.054. PMID: 16086933. Exclusion Code: X3.
138. Heidinger KS, Bernardo A, Taborski U, et al. Clinical outcome of self-management of oral anticoagulation in patients with atrial fibrillation or deep vein thrombosis. *Thromb Res*. 2000 May 15;98(4):287-93. PMID: 10822075. Exclusion Code: X3.
139. Hendriks JM, Stromberg A. Integrated nurse-led oral anticoagulation management. *Kardiovaskulare Medizin*. 2015;18(1):9-15. PMID: CN-01084188. Exclusion Code: X3.
140. Ho CW, Ho MH, Chan PH, et al. Ischemic stroke and intracranial hemorrhage with aspirin, dabigatran, and warfarin: impact of quality of anticoagulation control. *Stroke*. 2015 Jan;46(1):23-30. doi: 10.1161/strokeaha.114.006476. PMID: 25406148. Exclusion Code: X7.
141. Ho LY, Siu CW, Yue WS, et al. Safety and efficacy of oral anticoagulation therapy in Chinese patients with concomitant atrial fibrillation and hypertension. *J Hum Hypertens*. 2011 May;25(5):304-10. doi: 10.1038/jhh.2010.57. PMID: 20596062. Exclusion Code: X4.
142. Hohnloser S, Yusuf S, Eikelboom J, et al. Apixaban in patients with atrial fibrillation and their risk for cardiovascular hospitalization: insights from the AVERROES trial. *Eur Heart J*. 2011;32 (Abstract Supplement)(671):Abstract 3904. PMID: CN-00872660. Exclusion Code: X4.
143. Hollerl F, Stollberger C, Finsterer J. Renal function, P-gp-affecting drugs and new anticoagulants for stroke prevention. *Int J Cardiol*. 2013 Sep 20;168(1):576-7. doi: 10.1016/j.ijcard.2013.01.013. PMID: 23394894. Exclusion Code: X7.

Appendix C. Excluded Studies

144. Holster IL, Valkhoff VE, Kuipers EJ, et al. New oral anticoagulants increase risk for gastrointestinal bleeding: a systematic review and meta-analysis. *Gastroenterology*. 2013 Jul;145(1):105-12.e15. doi: 10.1053/j.gastro.2013.02.041. PMID: 23470618. Exclusion Code: X4.
145. Huang B, Yang Y, Zhu J, et al. Clinical characteristics and prognostic significance of chronic obstructive pulmonary disease in patients with atrial fibrillation: results from a multicenter atrial fibrillation registry study. *J Am Med Dir Assoc*. 2014 Aug;15(8):576-81. doi: 10.1016/j.jamda.2014.04.009. PMID: 24894999. Exclusion Code: X4.
146. Humphries KH, Kerr CR, Connolly SJ, et al. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. *Circulation*. 2001 May 15;103(19):2365-70. PMID: 11352885. Exclusion Code: X12.
147. Hunter RJ, McCready J, Diab I, et al. Maintenance of sinus rhythm with an ablation strategy in patients with atrial fibrillation is associated with a lower risk of stroke and death. *Heart*. 2012 Jan;98(1):48-53. doi: 10.1136/heartjnl-2011-300720. PMID: 21930724. Exclusion Code: X3.
148. Hurley V, Ireson R, Fletcher K, et al. A cross-sectional study of hypertension in an elderly population (75 years and over) with atrial fibrillation: secondary analysis of data from the Birmingham Atrial Fibrillation in the Aged (BAFTA) randomised controlled trial. *Int J Cardiol*. 2007 Apr 25;117(2):152-6. doi: 10.1016/j.ijcard.2006.04.061. PMID: 16887213. Exclusion Code: X3.
149. Hussain A, Cox JG. Anticoagulation for nonrheumatic atrial fibrillation: the dilemma. *Stroke*. 1995 Jan;26(1):138. PMID: 7839385. Exclusion Code: X7.
150. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. *Circulation*. 2007 May 29;115(21):2689-96. doi: 10.1161/circulationaha.106.653048. PMID: 17515465. Exclusion Code: X4.
151. Ikeda T, Atarashi H, Inoue H, et al. Study Design and Baseline Characteristics of the EXPAND Study: Evaluation of Effectiveness and Safety of Xa Inhibitor, Rivaroxaban for the Prevention of Stroke and Systemic Embolism in a Nationwide Cohort of Japanese Patients Diagnosed as Non-Valvular Atrial Fibrillation. *Tohoku J Exp Med*. 2016;240(4):259-68. doi: 10.1620/tjem.240.259. PMID: 27904005. Exclusion Code: X5.
152. Imbert P, Pernod G, Jacquet JP, et al. Evaluation of a mobile electronic assistant to aid in fluindione prescription: the INRPlus cluster randomized trial. *Thromb Res*. 2014;133(5):756-61. doi: 10.1016/j.thromres.2014.02.003. PMID: CN-00988586. Exclusion Code: X3.
153. Inoue H, Atarashi H, Okumura K, et al. Impact of gender on the prognosis of patients with nonvalvular atrial fibrillation. *Am J Cardiol*. 2014 Mar 15;113(6):957-62. doi: 10.1016/j.amjcard.2013.11.057. PMID: 24461771. Exclusion Code: X4.
154. Inoue H, Nozawa T, Hirai T, et al. Accumulation of risk factors increases risk of thromboembolic events in patients with nonvalvular atrial fibrillation. *Circ J*. 2006 Jun;70(6):651-6. PMID: 16723782. Exclusion Code: X7.
155. Inoue H, Okumura K, Atarashi H, et al. Target international normalized ratio values for preventing thromboembolic and hemorrhagic events in Japanese patients with non-valvular atrial fibrillation: results of the J-RHYTHM Registry. *Circ J*. 2013;77(9):2264-70. PMID: 23708863. Exclusion Code: X4.
156. Jacobs LG. The sin of omission: a systematic review of antithrombotic therapy to prevent stroke in atrial fibrillation. *J Am Geriatr Soc*. 2001 Jan;49(1):91-4. PMID: 11207849. Exclusion Code: X7.
157. Jahangir A, Lee V, Friedman PA, et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. *Circulation*. 2007 Jun 19;115(24):3050-6. doi: 10.1161/circulationaha.106.644484. PMID: 17548732. Exclusion Code: X4.
158. Johnson BJ, Urrutia V. Stroke Risk Factor Screening in an Inner City Public Market - A Description of the Population - A Better Target for Screening/Education Efforts. *Stroke*. 2010;41(4):E205-E. Exclusion Code: X3.

Appendix C. Excluded Studies

159. Kaasenbrood F, Hollander M, Rutten FH, et al. Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination. *Europace*. 2016 Oct;18(10):1514-20. doi: 10.1093/europace/euv426. PMID: 26851813. Exclusion Code: X4.
160. Kagansky N, Knobler H, Rimon E, et al. Safety of anticoagulation therapy in well-informed older patients. *Arch Intern Med*. 2004 Oct 11;164(18):2044-50. doi: 10.1001/archinte.164.18.2044. PMID: 15477441. Exclusion Code: X6.
161. Kakkar AK, Mueller I, Bassand JP, et al. Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke: perspectives from the international, observational, prospective GARFIELD registry. *PLoS One*. 2013;8(5):e63479. doi: 10.1371/journal.pone.0063479. PMID: 23704912. Exclusion Code: X5.
162. Kamel H, Easton JD, Johnston SC, et al. Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation. *Neurology*. 2012 Oct 02;79(14):1428-34. doi: 10.1212/WNL.0b013e31826d5fe8. PMID: 22993279. Exclusion Code: X2.
163. Kansal AR, Sorensen SV, Gani R, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation. *Heart*. 2012 Apr;98(7):573-8. doi: 10.1136/heartjnl-2011-300646. PMID: 22422743. Exclusion Code: X7.
164. Kansal AR, Zheng Y, Pokora T, et al. Cost-effectiveness of new oral anticoagulants in the prevention of stroke in patients with atrial fibrillation. *Best Pract Res Clin Haematol*. 2013 Jun;26(2):225-37. doi: 10.1016/j.beha.2013.07.012. PMID: 23953910. Exclusion Code: X7.
165. Katona A, Mark L. The Belgian Improvement Study in Oral Anticoagulant Therapy: a randomized clinical trial. *Eur Heart J*. 2006 Jun;27(11):1382. doi: 10.1093/eurheartj/ehi856. PMID: 16595524. Exclusion Code: X7.
166. Khan F, Huang H, Datta YH. Direct oral anticoagulant use and the incidence of bleeding in the very elderly with atrial fibrillation. *J Thromb Thrombolysis*. 2016 Nov;42(4):573-8. doi: 10.1007/s11239-016-1410-z. PMID: 27520093. Exclusion Code: X4.
167. Khumri TM, Idupulapati M, Rader VJ, et al. Clinical and echocardiographic markers of mortality risk in patients with atrial fibrillation. *Am J Cardiol*. 2007 Jun 15;99(12):1733-6. doi: 10.1016/j.amjcard.2007.01.055. PMID: 17560884. Exclusion Code: X3.
168. Klem I, Wehinger C, Schneider B, et al. Diabetic atrial fibrillation patients: mortality and risk for stroke or embolism during a 10-year follow-up. *Diabetes Metab Res Rev*. 2003 Jul-Aug;19(4):320-8. doi: 10.1002/dmrr.386. PMID: 12879410. Exclusion Code: X3.
169. Kodani E, Atarashi H, Inoue H, et al. Beneficial Effect of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation-Results of the J-RHYTHM Registry 2. *Circ J*. 2016;80(4):843-51. doi: 10.1253/circj.CJ-16-0066. PMID: 27001190. Exclusion Code: X12.
170. Komatsu T, Tachibana H, Sato Y, et al. Efficacy of antiarrhythmic drug therapy in preventing recurrence of atrial fibrillation and long-term cardiovascular prognosis in patients with asymptomatic paroxysmal atrial fibrillation. *Int Heart J*. 2010 Mar;51(2):98-104. PMID: 20379042. Exclusion Code: X3.
171. Kong Y, Du X, Tang RB, et al. Whether Warfarin Therapy is Associated with Damage on Renal Function in Chinese Patients with Nonvalvular Atrial Fibrillation. *Chin Med J (Engl)*. 2016 May 20;129(10):1135-9. doi: 10.4103/0366-6999.181970. PMID: 27174319. Exclusion Code: X5.
172. Krishnan S, Chawla N, Ezekowitz MD, et al. Warfarin therapy and systolic hypertension in men with atrial fibrillation. *Am J Hypertens*. 2005 Dec;18(12 Pt 1):1592-9. doi: 10.1016/j.amjhyper.2005.06.001. PMID: 16364831. Exclusion Code: X5.

Appendix C. Excluded Studies

173. Kumar S, Ling LH, Halloran K, et al. Esophageal hematoma after atrial fibrillation ablation: incidence, clinical features, and sequelae of esophageal injury of a different sort. *Circ Arrhythm Electrophysiol*. 2012 Aug 1;5(4):701-5. doi: 10.1161/circep.112.970624. PMID: 22544279. Exclusion Code: X4.
174. Kwong JS, Lam YY, Yan BP, et al. Bleeding of new oral anticoagulants for stroke prevention in atrial fibrillation: a meta-analysis of randomized controlled trials (Provisional abstract). *Cardiovasc Drugs Ther*. 2013;27(1):23-35. PMID: DARE-12013011852. Exclusion Code: X4.
175. Laguna P, Martin A, Del Arco C, et al. Differences among clinical classification schemes for predicting stroke in atrial fibrillation: implications for therapy in daily practice. *Acad Emerg Med*. 2005 Sep;12(9):828-34. doi: 10.1197/j.aem.2005.04.018. PMID: 16141016. Exclusion Code: X3.
176. Lai HM, Aronow WS, Kalen P, et al. Incidence of thromboembolic stroke and of major bleeding in patients with atrial fibrillation and chronic kidney disease treated with and without warfarin. *Int J Nephrol Renovasc Dis*. 2009;2:33-7. PMID: 21694919. Exclusion Code: X7.
177. Lane DA, Kamphuisen PW, Minini P, et al. Bleeding risk in patients with atrial fibrillation: the AMADEUS study. *Chest*. 2011 Jul;140(1):146-55. doi: 10.1378/chest.10-3270. PMID: 21415134. Exclusion Code: X4.
178. Lane DA, Lip GY. Anticoagulation for atrial fibrillation patients with CHADS score of 1. *J Cardiovasc Electrophysiol*. 2010 May;21(5):508-10. doi: 10.1111/j.1540-8167.2009.01687.x. PMID: 20082649. Exclusion Code: X7.
179. Lapner S, Cohen N, Kearon C. Influence of sex on risk of bleeding in anticoagulated patients: a systematic review and meta-analysis. *J Thromb Haemost*. 2014 May;12(5):595-605. PMID: 24977286. Exclusion Code: X4.
180. Larsen TB, Skjoth F, Nielsen PB, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. *BMJ*. 2016 Jun 16;353:i3189. doi: 10.1136/bmj.i3189. PMID: 27312796. Exclusion Code: X4.
181. Lavenson GS, Jr., Pantera RL, Garza RM, et al. Development and implementation of a rapid, accurate, and cost-effective protocol for national stroke prevention screening. *Am J Surg*. 2004 Dec;188(6):638-43. doi: 10.1016/j.amjsurg.2004.08.055. PMID: 15619477. Exclusion Code: X4.
182. Lavitola Pde L, Spina GS, Sampaio RO, et al. Bleeding during oral anticoagulant therapy: warning against a greater hazard. *Arq Bras Cardiol*. 2009 Aug;93(2):174-9. PMID: 19838496. Exclusion Code: X4.
183. Lee BH, Park JS, Park JH, et al. The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1. *J Cardiovasc Electrophysiol*. 2010 May;21(5):501-7. doi: 10.1111/j.1540-8167.2009.01661.x. PMID: 20021521. Exclusion Code: X7.
184. Lee SJ, Shin DH, Hwang HJ, et al. Bleeding risk and major adverse events in patients with previous ulcer on oral anticoagulation therapy. *Am J Cardiol*. 2012 Aug 1;110(3):373-7. doi: 10.1016/j.amjcard.2012.03.036. PMID: 22516526. Exclusion Code: X7.
185. Lega JC, Bertolotti L, Grenillet C, et al. Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation (Provisional abstract). *Database of Abstracts of Reviews of Effects*. 2014(2):e91398. PMID: DARE-12014031370. Exclusion Code: X4.
186. Lega JC, Mismetti P, Cucherat M, et al. Impact of double-blind vs open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta-analysis (Provisional abstract). *J Thromb Haemost*. 2013;11(7):1240-50. PMID: DARE-12013027862. Exclusion Code: X4.
187. Lerner RG, Aronow WS, Sekhri A, et al. Warfarin use and the risk of valvular calcification. *J Thromb Haemost*. 2009 Dec;7(12):2023-7. doi: 10.1111/j.1538-7836.2009.03630.x. PMID: 19793187. Exclusion Code: X5.

Appendix C. Excluded Studies

188. Link MS, Giugliano RP, Ruff CT, et al. Stroke and mortality risk in patients with various patterns of atrial fibrillation: results from the ENGAGE AF-TIMI 48 Trial (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48). *Circ Arrhythm Electrophysiol*. 2017 Jan;10(1):doi: 10.1161/circep.116.004267. PMID: 28077507. Exclusion Code: X4.
189. Lip GY, Frison L, Grind M. Effect of hypertension on anticoagulated patients with atrial fibrillation. *Eur Heart J*. 2007 Mar;28(6):752-9. doi: 10.1093/eurheartj/ehl504. PMID: 17289744. Exclusion Code: X4.
190. Lip GY, Haguenoer K, Saint-Etienne C, et al. Relationship of the SAMe-TT(2)R(2) score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. *Chest*. 2014 Sep;146(3):719-26. doi: 10.1378/chest.13-2976. PMID: 24722973. Exclusion Code: X4.
191. Lip GY, Larsen TB, Skjoth F, et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. *J Am Coll Cardiol*. 2012 Aug 21;60(8):738-46. doi: 10.1016/j.jacc.2012.03.019. PMID: 22575324. Exclusion Code: X7.
192. Lip GY, Rasmussen LH, Olsson SB, et al. Oral direct thrombin inhibitor AZD0837 for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation: a Phase II study of AZD0837 in patients who are appropriate for but unable or unwilling to take vitamin K antagonist therapy. *Thromb Res*. 2011 Feb;127(2):91-9. doi: 10.1016/j.thromres.2010.11.012. PMID: 21172721. Exclusion Code: X4.
193. Lip GY, Rushton-Smith SK, Goldhaber SZ, et al. Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation. *Circ Cardiovasc Qual Outcomes*. 2015 Mar;8(2 Suppl 1):S12-20. doi: 10.1161/circoutcomes.114.001556. PMID: 25714828. Exclusion Code: X5.
194. Lip GY, Skjoth F, Rasmussen LH, et al. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. *J Am Coll Cardiol*. 2015 Apr 14;65(14):1385-94. doi: 10.1016/j.jacc.2015.01.044. PMID: 25770314. Exclusion Code: X7.
195. Liu GJ, Wang YF, Chen PY, et al. The efficacy and safety of novel oral anticoagulants for the preventive treatment in atrial fibrillation patients: a systematic review and meta-analysis. *Drug Deliv*. 2014 Sep;21(6):436-52. doi: 10.3109/10717544.2013.873500. PMID: 24400656. Exclusion Code: X4.
196. Lopes LC, Spencer FA, Neumann I, et al. Bleeding risk in atrial fibrillation patients taking vitamin K antagonists: systematic review and meta-analysis (Provisional abstract). *Clin Pharmacol Ther*. 2013;94(3):367-75. PMID: DARE-12013027705. Exclusion Code: X4.
197. Lopes LC, Spencer FA, Neumann I, et al. Systematic review of observational studies assessing bleeding risk in patients with atrial fibrillation not using anticoagulants. *PLoS One*. 2014;9(2):e88131. doi: 10.1371/journal.pone.0088131. PMID: 24523876. Exclusion Code: X4.
198. Lopez-Lopez JA, Sterne J, Bodalia PN, et al. Network meta-analysis of oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation. *Value Health*. 2015;18(7):A374. PMID: CN-01126898. Exclusion Code: X4.
199. Lowres N, Neubeck L, Redfern J, et al. Screening to identify unknown atrial fibrillation. A systematic review. *Thromb Haemost*. 2013 Aug;110(2):213-22. doi: 10.1160/th13-02-0165. PMID: 23595785. Exclusion Code: X7.
200. Lowres N, Neubeck L, Salkeld G, et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. *Thromb Haemost*. 2014 Jun;111(6):1167-76. doi: 10.1160/th14-03-0231. PMID: 24687081. Exclusion Code: X4.

Appendix C. Excluded Studies

201. Lu D, Zhang Q, Liu Q, et al. Bleeding risks with novel oral anticoagulants during catheter ablation of atrial fibrillation: a systematic review and network meta-analysis. *J Interv Card Electrophysiol*. 2015 Nov;44(2):105-11. doi: 10.1007/s10840-015-0053-x. PMID: 26342485. Exclusion Code: X4.
202. Luik A, Radzewitz A, Kieser M, et al. Cryoballoon Versus Open Irrigated Radiofrequency Ablation in Patients With Paroxysmal Atrial Fibrillation: The Prospective, Randomized, Controlled, Noninferiority FreezeAF Study. *Circulation*. 2015 Oct 6;132(14):1311-9. doi: 10.1161/circulationaha.115.016871. PMID: 26283655. Exclusion Code: X4.
203. Luzzi M, Capucci A, Pasquale G, et al. [The BRIDGE study]. *G Ital Cardiol (Rome)*. 2016;17(1):1-5. doi: 10.1714/2140.23178. PMID: CN-01168203. Exclusion Code: X1.
204. Malek F. Rivaroxaban use in prevention of stroke in patients with non-valvular atrial fibrillation in clinical practice, results of observational studies and our experience. *Vnitr Lek*. 2017;62(10):814-9. PMID: CN-01330031. Exclusion Code: X1.
205. Mantha S, Ansell J. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. *Thromb Haemost*. 2012 Sep;108(3):476-84. doi: 10.1160/th12-02-0093. PMID: 22740145. Exclusion Code: X4.
206. Marijon E, Le Heuzey JY, Connolly S, et al. Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. *Circulation*. 2013 Nov 12;128(20):2192-201. doi: 10.1161/circulationaha.112.000491. PMID: 24016454. Exclusion Code: X4.
207. Martinez C, Katholing A, Freedman SB. Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study. *Thromb Haemost*. 2014 Aug;112(2):276-86. doi: 10.1160/th14-04-0383. PMID: 24953051. Exclusion Code: X7.
208. McCahon D, Fitzmaurice DA, Baker J, et al. Atrial fibrillation: Is screening effective in identifying patients at risk of stroke? *Br J Haematol*. 2014;165:10-1. doi: 10.1111/bjh.12802. PMID: CN-01053067. Exclusion Code: X9.
209. McClennen S, Zimetbaum PJ, Ho KK, et al. Holter monitoring: are two days better than one (Structured abstract). *Am J Cardiol*. 2000;86(5):562-4. PMID: NHSEED-22000001438. Exclusion Code: X7.
210. Mearns ES, White CM, Kohn CG, et al. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression (Provisional abstract). *Database of Abstracts of Reviews of Effects*. 2014(2):14. PMID: DARE-12014045454. Exclusion Code: X4.
211. Mercaldi CJ, Ciarametaro M, Hahn B, et al. Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation. *Stroke*. 2011 Jan;42(1):112-8. doi: 10.1161/strokeaha.110.592907. PMID: 21148442. Exclusion Code: X7.
212. Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation (Structured abstract). *Am J Cardiol*. 2012;110(3):453-60. PMID: DARE-12012036643. Exclusion Code: X4.
213. Minguet J, Sims H, Smith K, et al. The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation. *Expert Rev Clin Pharmacol*. 2017;10(1):5-15. doi: 10.1080/17512433.2016.1258301. PMID: CN-01338057. Exclusion Code: X7.
214. Mitchell SA, Simon TA, Raza S, et al. The efficacy and safety of oral anticoagulants in warfarin-suitable patients with nonvalvular atrial fibrillation: systematic review and meta-analysis (Provisional abstract). *Clin Appl Thromb Hemost*. 2013;19(6):619-31. PMID: DARE-12013028996. Exclusion Code: X4.
215. Monte S, Macchia A, Pellegrini F, et al. Antithrombotic treatment is strongly underused despite reducing overall mortality among high-risk elderly patients hospitalized with atrial fibrillation. *Eur Heart J*. 2006 Sep;27(18):2217-23. doi: 10.1093/eurheartj/ehl208. PMID: 16935869. Exclusion Code: X7.
216. Moran Patrick S, Teljeur C, Ryan M, et al. Systematic screening for the detection of atrial fibrillation. *Cochrane Database of Systematic Reviews*. 2016(6)doi: 10.1002/14651858.CD009586.pub3. PMID: CD009586. Exclusion Code: X7.

Appendix C. Excluded Studies

217. Moran PS, Flattery MJ, Teljeur C, et al. Effectiveness of systematic screening for the detection of atrial fibrillation. *Cochrane Database Syst Rev*. 2013(4):Cd009586. doi: 10.1002/14651858.CD009586.pub2. PMID: 23633374. Exclusion Code: X7.
218. Morilla MA, Tumalak CD, Gulay CB, et al. A meta-analysis on the efficacy of dabigatran versus warfarin among patients with atrial fibrillation (Provisional abstract). *Philipp J Intern Med*. 2012;50(4):1-4. PMID: DARE-12013058012. Exclusion Code: X4.
219. Morimoto T, Crawford B, Wada K, et al. Comparative efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation: A network meta-analysis with the adjustment for the possible bias from open label studies. *J Cardiol*. 2015 Dec;66(6):466-74. doi: 10.1016/j.jjcc.2015.05.018. PMID: 26162944. Exclusion Code: X4.
220. Mortimer CL, Cottrell WN, Comino NJ. Automatic drug use audit in primary care--a pilot evaluation of warfarin use for patients with atrial fibrillation. *Aust Fam Physician*. 2005 Sep;34(9):798-800. PMID: 16184218. Exclusion Code: X3.
221. Naganuma M, Shiga T, Sato K, et al. Clinical outcome in Japanese elderly patients with non-valvular atrial fibrillation taking warfarin: a single-center observational study. *Thromb Res*. 2012 Jul;130(1):21-6. doi: 10.1016/j.thromres.2011.11.005. PMID: 22137743. Exclusion Code: X4.
222. Nagler M, Bachmann LM, Schmid P, et al. Patient self-management of oral anticoagulation with vitamin K antagonists in everyday practice: efficacy and safety in a nationwide long-term prospective cohort study. *PLoS One*. 2014;9(4):e95761. doi: 10.1371/journal.pone.0095761. PMID: 24748062. Exclusion Code: X4.
223. Nair A, Hazell W, Sutton T, et al. Antithrombotic therapy in atrial fibrillation: an assessment of compliance with guidelines. *NZ Med J*. 2005 Jan 28;118(1208):U1258. PMID: 15682210. Exclusion Code: X2.
224. Nguyen TN, Cumming RG, Hilmer SN. Atrial fibrillation in older inpatients: are there any differences in clinical characteristics and pharmacological treatment between the frail and the non-frail? *Intern Med J*. 2016 Jan;46(1):86-95. doi: 10.1111/imj.12912. PMID: 26388116. Exclusion Code: X4.
225. Nielsen PB, Lane DA, Rasmussen LH, et al. Renal function and non-vitamin K oral anticoagulants in comparison with warfarin on safety and efficacy outcomes in atrial fibrillation patients: a systemic review and meta-regression analysis (Provisional abstract). *Database of Abstracts of Reviews of Effects*. 2014(2):epub. PMID: DARE-12014069697. Exclusion Code: X4.
226. Nieuwlaat R, Prins MH, Le Heuzey JY, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. *Eur Heart J*. 2008 May;29(9):1181-9. doi: 10.1093/eurheartj/ehn139. PMID: 18397874. Exclusion Code: X4.
227. Ninios I, Bogossian H, Zarse M, et al. Prevalence, clinical correlates and treatment of permanent atrial fibrillation among the elderly: insights from the first prospective population-based study in rural Greece. *J Thromb Thrombolysis*. 2010 Jul;30(1):90-6. doi: 10.1007/s11239-009-0422-3. PMID: 19921100. Exclusion Code: X4.
228. Nogueras C, Miralles R, Roig A, et al. Polypharmacy as part of comprehensive geriatric assessment: disclosure of false diagnosis of atrial fibrillation by drug revision. *J Am Geriatr Soc*. 2007 Sep;55(9):1476-8. doi: 10.1111/j.1532-5415.2007.01305.x. PMID: 17767695. Exclusion Code: X7.
229. Noseworthy PA, Yao X, Shah ND, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and valvular heart disease. *Int J Cardiol*. 2016 Apr 15;209:181-3. doi: 10.1016/j.ijcard.2016.02.005. PMID: 26896618. Exclusion Code: X2.
230. Ntaios G, Manios E, Synetou M, et al. Prevalence of atrial fibrillation in Greece: the Arcadia Rural Study on Atrial Fibrillation. *Acta Cardiol*. 2012 Feb;67(1):65-9. doi: 10.2143/ac.67.1.2146567. PMID: 22455091. Exclusion Code: X4.

Appendix C. Excluded Studies

231. Ntaios G, Papavasileiou V, Diener HC, et al. Nonvitamin-K-antagonist oral anticoagulants in patients with atrial fibrillation and previous stroke or transient ischemic attack: a systematic review and meta-analysis of randomized controlled trials (Structured abstract). *Stroke*. 2012;43(12):3298-304. PMID: DARE-12013002704. Exclusion Code: X4.
232. Odutayo A, Wong CX, Hsiao AJ, et al. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. *BMJ*. 2016 Sep 06;354:i4482. doi: 10.1136/bmj.i4482. PMID: 27599725. Exclusion Code: X4.
233. Ogilvie IM, Welner SA, Cowell W, et al. Ischaemic stroke and bleeding rates in 'real-world' atrial fibrillation patients (Structured abstract). *Thromb Haemost*. 2011;106(1):34-44. PMID: DARE-12011004843. Exclusion Code: X4.
234. Ohara K, Inoue H, Nozawa T, et al. Accumulation of risk factors enhances the prothrombotic state in atrial fibrillation. *Int J Cardiol*. 2008 Jun 6;126(3):316-21. doi: 10.1016/j.ijcard.2007.06.020. PMID: 17689760. Exclusion Code: X5.
235. Okcun B, Yigit Z, Yildiz A, et al. What should be the primary treatment in atrial fibrillation: ventricular rate control or sinus rhythm control with long-term anticoagulation? *J Int Med Res*. 2009 Mar-Apr;37(2):464-71. PMID: 19383241. Exclusion Code: X4.
236. Okumura K, Hori M, Tanahashi N, et al. Special considerations for therapeutic choice of non-vitamin K antagonist oral anticoagulants for Japanese patients with nonvalvular atrial fibrillation. *Clin Cardiol*. 2017;40(2):126-31. doi: 10.1002/clc.22596. PMID: CN-01337693. Exclusion Code: X4.
237. Okumura K, Inoue H, Atarashi H, et al. Validation of CHA(2)DS(2)-VASc and HAS-BLED scores in Japanese patients with nonvalvular atrial fibrillation: an analysis of the J-RHYTHM Registry. *Circ J*. 2014;78(7):1593-9. PMID: 24759791. Exclusion Code: X4.
238. Oldgren J, Alings M, Darius H, et al. Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. *Ann Intern Med*. 2011 Nov 15;155(10):660-7. w204. doi: 10.7326/0003-4819-155-10-201111150-00004. PMID: 22084332. Exclusion Code: X4.
239. Oldgren J, Hijazi Z, Lindback J, et al. Performance and validation of a novel biomarker-based stroke risk score for atrial fibrillation. *Circulation*. 2017;134(22):1697-707. doi: 10.1161/CIRCULATIONAHA.116.022802. PMID: CN-01290304. Exclusion Code: X3.
240. Olesen JB, Lip GY, Lindhardtsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a 'real world' nationwide cohort study. *Thromb Haemost*. 2011 Oct;106(4):739-49. doi: 10.1160/th11-05-0364. PMID: 21789337. Exclusion Code: X7.
241. Ono A, Fujita T. Low-intensity anticoagulation for stroke prevention in elderly patients with atrial fibrillation: efficacy and safety in actual clinical practice. *J Clin Neurosci*. 2005 Nov;12(8):891-4. doi: 10.1016/j.jocn.2004.10.011. PMID: 16271478. Exclusion Code: X4.
242. Origasa H, Noma H, Teramukai S. Estimating an ICER with NOAC versus warfarin in atrial fibrillation. *Value Health*. 2017;19(7):A867. PMID: CN-01250651. Exclusion Code: X5.
243. Oswald N. Anticoagulation to prevent stroke in atrial fibrillation. Cohort was younger than many patients with atrial fibrillation in primary care. *BMJ*. 2000 Nov 4;321(7269):1156. PMID: 11203223. Exclusion Code: X7.
244. Pancholy SB, Sharma PS, Pancholy DS, et al. Meta-analysis of gender differences in residual stroke risk and major bleeding in patients with nonvalvular atrial fibrillation treated with oral anticoagulants (Provisional abstract). *Am J Cardiol*. 2014;113(3):485-90. PMID: DARE-12013071804. Exclusion Code: X4.

Appendix C. Excluded Studies

245. Park H, Hildreth A, Thomson R, et al. Non-valvular atrial fibrillation and cognitive decline: a longitudinal cohort study. *Age Ageing*. 2007 Mar;36(2):157-63. doi: 10.1093/ageing/af1164. PMID: 17259637. Exclusion Code: X5.
246. Parkash R, Wee V, Gardner MJ, et al. The impact of warfarin use on clinical outcomes in atrial fibrillation: a population-based study. *Can J Cardiol*. 2007 May 1;23(6):457-61. PMID: 17487290. Exclusion Code: X4.
247. Passman R. Time in therapeutic range in warfarin-treated patients is very good good enough? *JAMA*. 2017;316(8):872-3. doi: 10.1001/jamacardio.2016.0199. PMID: CN-01286287. Exclusion Code: X7.
248. Patti G, Lucerna M, Cavallari I, et al. Insulin-Requiring Versus Noninsulin-Requiring Diabetes and Thromboembolic Risk in Patients With Atrial Fibrillation: PREFER in AF. *J Am Coll Cardiol*. 2017;69(4):409-19. doi: 10.1016/j.jacc.2016.10.069. PMID: CN-01329702. Exclusion Code: X3.
249. Penado S, Cano M, Acha O, et al. Stroke severity in patients with atrial fibrillation. *Am J Med*. 2002 May;112(7):572-4. PMID: 12015250. Exclusion Code: X2.
250. Perez-Gomez F. Is computer-assisted, long-term warfarin therapy safe and efficacious for patients with nonrheumatic atrial fibrillation? *Nat Clin Pract Cardiovasc Med*. 2005 Feb;2(2):82-3. doi: 10.1038/ncpcardio01117. PMID: 16265377. Exclusion Code: X6.
251. Perez-Gomez F, Alegria E, Berjon J, et al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. *J Am Coll Cardiol*. 2004 Oct 19;44(8):1557-66. doi: 10.1016/j.jacc.2004.05.084. PMID: 15489085. Exclusion Code: X4.
252. Perula-de-Torres LA, Martinez-Adell MA, Gonzalez-Blanco V, et al. Opportunistic detection of atrial fibrillation in subjects aged 65 years or older in primary care: a randomised clinical trial of efficacy. DOFA-AP study protocol. *BMC Fam Pract*. 2012;13:106. doi: 10.1186/1471-2296-13-106. PMID: 23130754. Exclusion Code: X2.
253. Pfeilschifter W, Luger S, Brunkhorst R, et al. The gap between trial data and clinical practice -- an analysis of case reports on bleeding complications occurring under dabigatran and rivaroxaban anticoagulation. *Cerebrovasc Dis*. 2013;36(2):115-9. doi: 10.1159/000352062. PMID: 24029592. Exclusion Code: X7.
254. Plitt A, Ezekowitz M, Caterina R, et al. Cardioversion of atrial fibrillation in ENGAGE AF-TIMI 48. *Clin Cardiol*. 2016;39(6):345-6. doi: 10.1002/clc.22537. PMID: CN-01165738. Exclusion Code: X2.
255. Poli D, Antonucci E, Grifoni E, et al. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. *J Am Coll Cardiol*. 2009 Sep 8;54(11):999-1002. doi: 10.1016/j.jacc.2009.05.046. PMID: 19729116. Exclusion Code: X4.
256. Poli D, Antonucci E, Grifoni E, et al. Gender differences in stroke risk of atrial fibrillation patients on oral anticoagulant treatment. *Thromb Haemost*. 2009 May;101(5):938-42. PMID: 19404548. Exclusion Code: X4.
257. Poli D, Antonucci E, Grifoni E, et al. Stroke risk in atrial fibrillation patients on warfarin. Predictive ability of risks stratification schemes for primary and secondary prevention. *Thromb Haemost*. 2009 Feb;101(2):367-72. PMID: 19190823. Exclusion Code: X4.
258. Poli D, Antonucci E, Marcucci R, et al. The quality of anticoagulation on functional outcome and mortality for TIA/stroke in atrial fibrillation patients. *Int J Cardiol*. 2009 Feb 6;132(1):109-13. doi: 10.1016/j.ijcard.2007.10.041. PMID: 18180057. Exclusion Code: X4.
259. Poli D, Antonucci E, Pengo V, et al. Comparison of HAS-BLED and HAS-BED Versus CHADS2 and CHA2DS2VASC Stroke and Bleeding Scores in Patients With Atrial Fibrillation. *Am J Cardiol*. 2017 Apr 01;119(7):1012-6. doi: 10.1016/j.amjcard.2016.12.007. PMID: 28237286. Exclusion Code: X2.

Appendix C. Excluded Studies

260. Poli D, Antonucci E, Testa S, et al. The predictive ability of bleeding risk stratification models in very old patients on vitamin K antagonist treatment for venous thromboembolism: results of the prospective collaborative EPICA study. *J Thromb Haemost.* 2013 Jun;11(6):1053-8. doi: 10.1111/jth.12239. PMID: 23578305. Exclusion Code: X4.
261. Poli D, Antonucci E, Testa S, et al. Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian Centres for Anticoagulation. *Circulation.* 2011 Aug 16;124(7):824-9. doi: 10.1161/circulationaha.110.007864. PMID: 21810658. Exclusion Code: X4.
262. Poli D, Antonucci E, Zanazzi M, et al. Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics). *Thromb Haemost.* 2012 Jun;107(6):1100-6. doi: 10.1160/th11-10-0721. PMID: 22535516. Exclusion Code: X4.
263. Posada IS, Barriales V. Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. *Am Heart J.* 1999 Jul;138(1 Pt 1):137-43. PMID: 10385777. Exclusion Code: X12.
264. Potpara TS, Polovina MM, Marinkovic JM, et al. A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. *Int J Cardiol.* 2013 Oct 12;168(5):4744-9. doi: 10.1016/j.ijcard.2013.07.234. PMID: 23958417. Exclusion Code: X4.
265. Quinn GR, Severdija ON, Chang Y, et al. Wide Variation in Reported Rates of Stroke Across Cohorts of Patients With Atrial Fibrillation. *Circulation.* 2017 Jan 17;135(3):208-19. doi: 10.1161/circulationaha.116.024057. PMID: 27799272. Exclusion Code: X4.
266. Rasmussen LH, Larsen TB, Graungaard T, et al. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis. *BMJ.* 2012;345:e7097. doi: 10.1136/bmj.e7097. PMID: 23129490. Exclusion Code: X4.
267. Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). *J Am Coll Cardiol.* 2014 Feb 4;63(4):321-8. doi: 10.1016/j.jacc.2013.07.104. PMID: 24076487. Exclusion Code: X4.
268. Reynolds MR, Shah J, Essebag V, et al. Patterns and predictors of warfarin use in patients with new-onset atrial fibrillation from the FRACTAL Registry. *Am J Cardiol.* 2006 Feb 15;97(4):538-43. doi: 10.1016/j.amjcard.2005.09.086. PMID: 16461052. Exclusion Code: X5.
269. Rietbrock S, Plumb JM, Gallagher AM, et al. How effective are dose-adjusted warfarin and aspirin for the prevention of stroke in patients with chronic atrial fibrillation? An analysis of the UK General Practice Research Database. *Thromb Haemost.* 2009 Mar;101(3):527-34. PMID: 19277415. Exclusion Code: X5.
270. Rizzo MR, Sasso FC, Marfella R, et al. Autonomic dysfunction is associated with brief episodes of atrial fibrillation in type 2 diabetes. *J Diabetes Complications.* 2015 Jan-Feb;29(1):88-92. doi: 10.1016/j.jdiacomp.2014.09.002. PMID: 25266244. Exclusion Code: X4.
271. Romanelli RJ, Nolting L, Dolginsky M, et al. Dabigatran Versus Warfarin for Atrial Fibrillation in Real-World Clinical Practice: A Systematic Review and Meta-Analysis. *Circ Cardiovasc Qual Outcomes.* 2016 Mar;9(2):126-34. doi: 10.1161/circoutcomes.115.002369. PMID: 26812933. Exclusion Code: X4.
272. Rose G, Baxter PJ, Reid DD, et al. Prevalence and prognosis of electrocardiographic findings in middle-aged men. *Br Heart J.* 1978 Jun;40(6):636-43. PMID: 656238. Exclusion Code: X4.
273. Roskell NS, Lip GY, Noack H, et al. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. *Thromb Haemost.* 2010 Dec;104(6):1106-15. doi: 10.1160/th10-10-0642. PMID: 20967400. Exclusion Code: X11.

Appendix C. Excluded Studies

274. Roy B, Desai RV, Mujib M, et al. Effect of warfarin on outcomes in septuagenarian patients with atrial fibrillation. *Am J Cardiol*. 2012 Feb 1;109(3):370-7. doi: 10.1016/j.amjcard.2011.09.023. PMID: 22118824. Exclusion Code: X7.
275. Rozzini R, Sabatini T, Bellelli G, et al. Anticoagulation of older patients. *Age Ageing*. 2000 Sep;29(5):457-8; author reply 8-9. PMID: 11108422. Exclusion Code: X7.
276. Rozzini R, Sabatini T, Trabucchi M. Risk assessment and anticoagulation in atrial fibrillation in the elderly: malpractice or accuracy? *Stroke*. 1999 Oct;30(10):2239-40. PMID: 10512996. Exclusion Code: X7.
277. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials (Structured abstract). *Lancet*. 2014;383(9921):955-62. PMID: DARE-12013069847. Exclusion Code: X4.
278. Ruiz Ortiz M, Romo E, Mesa D, et al. Oral anticoagulation in nonvalvular atrial fibrillation in clinical practice: impact of CHADS(2) score on outcome. *Cardiology*. 2010;115(3):200-4. doi: 10.1159/000284450. PMID: 20160440. Exclusion Code: X4.
279. Ruiz Ortiz M, Romo E, Mesa D, et al. Outcomes and safety of antithrombotic treatment in patients aged 80 years or older with nonvalvular atrial fibrillation. *Am J Cardiol*. 2011 May 15;107(10):1489-93. doi: 10.1016/j.amjcard.2011.01.025. PMID: 21420049. Exclusion Code: X4.
280. Ruiz-Ortiz M, Romo E, Mesa D, et al. Effectiveness of oral anticoagulation in nonvalvular atrial fibrillation according to CHA(2)DS(2)-VASc score in patients with low-moderate embolic risk. *Rev Esp Cardiol (Engl Ed)*. 2012 Apr;65(4):382-3. doi: 10.1016/j.recesp.2011.05.021. PMID: 21840108. Exclusion Code: X4.
281. Runev NM, Dimitrov SM. Management of stroke prevention in Bulgarian patients with non-valvular atrial fibrillation (BUL-AF Survey). *Int J Cardiol*. 2015;187(1):683-5. doi: 10.1016/j.ijcard.2015.03.420. PMID: CN-01075331. Exclusion Code: X7.
282. Sahay S, Nombela-Franco L, Rodes-Cabau J, et al. Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation: a network meta-analysis from randomised trials. *Heart*. 2016 Sep 1;doi: 10.1136/heartjnl-2016-309782. PMID: 27587437. Exclusion Code: X11.
283. Salazar Carlos A, del Aguila D, Cordova Erika G. Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. *Cochrane Database of Systematic Reviews*. 2014(3)doi: 10.1002/14651858.CD009893.pub2. PMID: CD009893. Exclusion Code: X4.
284. Sanchez-Barba B, Navarrete-Reyes AP, Avila-Funes JA. Are geriatric syndromes associated with reluctance to initiate oral anticoagulation therapy in elderly adults with nonvalvular atrial fibrillation? *J Am Geriatr Soc*. 2013 Dec;61(12):2236-7. doi: 10.1111/jgs.12582. PMID: 24329827. Exclusion Code: X7.
285. Sandhu RK, Bakal JA, Ezekowitz JA, et al. Risk stratification schemes, anticoagulation use and outcomes: the risk--treatment paradox in patients with newly diagnosed non-valvular atrial fibrillation. *Heart*. 2011 Dec;97(24):2046-50. doi: 10.1136/heartjnl-2011-300901. PMID: 22076011. Exclusion Code: X7.
286. Sandhu RK, Connolly SJ, Hohnloser S, et al. Does the degree of left ventricular dysfunction or symptom status influence the risk of stroke or systemic embolism among patients with atrial fibrillation and heart failure?-Results from the ACTIVE study. *Circulation*. 2013;128(22 suppl. 1) PMID: CN-01062466. Exclusion Code: X2.
287. Sanofi. Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A). Bethesda, MD: National Library of Medicine (US); 2017. Exclusion Code: X4.
288. Sardar P, Chatterjee S, Chaudhari S, et al. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. *J Am Geriatr Soc*. 2014 May;62(5):857-64. doi: 10.1111/jgs.12799. PMID: 24786913. Exclusion Code: X2.

Appendix C. Excluded Studies

289. Sarvananthan S, Punjabi PP. In atrial fibrillation, dabigatran had similar efficacy to warfarin but caused less bleeding in higher GFR. *Ann Intern Med*. 2014;161(4):Jc7. doi: 10.7326/0003-4819-161-4-201408190-02007. PMID: CN-01014106. Exclusion Code: X4.
290. Scardi S, Mazzone C, Pandullo C, et al. Mortality and cause of death in patients with chronic non-rheumatic atrial fibrillation after a two-year follow-up. *G Ital Cardiol*. 1999 Jun;29(6):637-46. PMID: 10396667. Exclusion Code: X4.
291. Schauer DP, Moomaw CJ, Wess M, et al. Psychosocial risk factors for adverse outcomes in patients with nonvalvular atrial fibrillation receiving warfarin. *J Gen Intern Med*. 2005 Dec;20(12):1114-9. doi: 10.1111/j.1525-1497.2005.0242.x. PMID: 16423100. Exclusion Code: X7.
292. Schmiedl S, Rottenkolber M, Szymanski J, et al. Bleeding complications and liver injuries during phenprocoumon treatment: a multicentre prospective observational study in internal medicine departments. *Dtsch Arztebl Int*. 2013 Apr;110(14):244-52. doi: 10.3238/arztebl.2013.0244. PMID: 23616817. Exclusion Code: X3.
293. Schneeweiss S, Gagne JJ, Patrick AR, et al. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. *Circ Cardiovasc Qual Outcomes*. 2012 Jul 1;5(4):480-6. doi: 10.1161/circoutcomes.112.965988. PMID: 22787066. Exclusion Code: X4.
294. Schumann SA, Ewigman B. Stroke prevention: age alone does not rule out warfarin. *J Fam Pract*. 2007 Nov;56(11):902-6. PMID: 17976336. Exclusion Code: X7.
295. Schwartz JB. Dabigatran Compared With Rivaroxaban vs Warfarin. *JAMA Intern Med*. 2017 May 01;177(5):741-2. doi: 10.1001/jamainternmed.2017.0554. PMID: 28460097. Exclusion Code: X7.
296. Scott KA, Amirehsani KA. Dabigatran etexilate: an alternative to warfarin for patients with nonvalvular atrial fibrillation (Provisional abstract). *Database of Abstracts of Reviews of Effects*. 2014(2):epub. PMID: DARE-12014048325. Exclusion Code: X4.
297. Sherman D. Reducing stroke risk in atrial fibrillation patients. *Cleve Clin J Med*. 1991 May-Jun;58(3):203-4. PMID: 1893548. Exclusion Code: X7.
298. Shireman TI, Mahnken JD, Howard PA, et al. Development of a contemporary bleeding risk model for elderly warfarin recipients. *Chest*. 2006 Nov;130(5):1390-6. doi: 10.1378/chest.130.5.1390. PMID: 17099015. Exclusion Code: X4.
299. Simon TA, Jakouloff D, Mitchell SA, et al. Heterogeneity in published evidence for stroke prevention in patients with atrial fibrillation: A systematic review. *Pharmacoepidemiol Drug Saf*. 2012;21:247-8. doi: 10.1002/pds.3324. PMID: CN-01004059. Exclusion Code: X4.
300. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. *Ann Intern Med*. 2009 Sep 1;151(5):297-305. PMID: 19721017. Exclusion Code: X4.
301. Singer DE, Hughes RA, Gress DR, et al. The effect of aspirin on the risk of stroke in patients with nonrheumatic atrial fibrillation: The BAATAF Study. *Am Heart J*. 1992 Dec;124(6):1567-73. PMID: 1462916. Exclusion Code: X4.
302. Siu CW, Lip GY, Lam KF, et al. Risk of stroke and intracranial hemorrhage in 9727 Chinese with atrial fibrillation in Hong Kong. *Heart Rhythm*. 2014 Aug;11(8):1401-8. doi: 10.1016/j.hrthm.2014.04.021. PMID: 24747420. Exclusion Code: X7.
303. Siu CW, Pong V, Zhang X, et al. Risk of ischemic stroke after new-onset atrial fibrillation in patients with hyperthyroidism. *Heart Rhythm*. 2009 Feb;6(2):169-73. doi: 10.1016/j.hrthm.2008.10.023. PMID: 19187905. Exclusion Code: X6.
304. Siu CW, Tse HF. Net clinical benefit of warfarin therapy in elderly Chinese patients with atrial fibrillation. *Circ Arrhythm Electrophysiol*. 2014 Apr;7(2):300-6. doi: 10.1161/circep.113.000858. PMID: 24610776. Exclusion Code: X7.
305. Skjoth F, Larsen TB, Rasmussen LH, et al. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: An indirect comparison analysis. *Thromb Haemost*. 2014;111(5):981-8. doi: 10.1160/TH14-02-0118. PMID: CN-00988202. Exclusion Code: X4.

Appendix C. Excluded Studies

306. Sobieraj DM, White CM, Alikhanov S, et al. The impact of antiplatelet and anticoagulant therapies on gastrointestinal symptoms in patients with atrial fibrillation: a systematic review (Provisional abstract). *Ann Pharmacother*. 2012;46(9):1220-31. PMID: DARE-12012043698. Exclusion Code: X4.
307. Solomon MD, Yang J, Sung SH, et al. Incidence and timing of potentially high-risk arrhythmias detected through long term continuous ambulatory electrocardiographic monitoring. *BMC Cardiovasc Disord*. 2016 Feb 17;16:35. doi: 10.1186/s12872-016-0210-x. PMID: 26883019. Exclusion Code: X2.
308. Somerville S, Somerville J, Croft P, et al. Atrial fibrillation: a comparison of methods to identify cases in general practice. *Br J Gen Pract*. 2000 Sep;50(458):727-9. PMID: 11050790. Exclusion Code: X4.
309. Staszewski J, Staszewska M, Kotowicz J, et al. Cerebrovascular incidents differ in patients with permanent and paroxysmal atrial fibrillation. *Cerebrovasc Dis*. 2006;22(5-6):446-9. doi: 10.1159/000095288. PMID: 16931883. Exclusion Code: X2.
310. Steinberg BA, Hasselblad V, Atwater BD, et al. Dabigatran for periprocedural anticoagulation following radiofrequency ablation for atrial fibrillation: a meta-analysis of observational studies. *J Interv Card Electrophysiol*. 2013 Sep;37(3):213-21. doi: 10.1007/s10840-013-9813-7. PMID: 23881249. Exclusion Code: X4.
311. Steinberg BA, Peterson ED, Kim S, et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). *Circulation*. 2015 Feb 3;131(5):488-94. doi: 10.1161/circulationaha.114.011777. PMID: 25499873. Exclusion Code: X3.
312. Steinhubl SR, Mehta RR, Ebner GS, et al. Rationale and design of a home-based trial using wearable sensors to detect asymptomatic atrial fibrillation in a targeted population: The mHealth Screening to Prevent Strokes (mSToPS) trial. *Am Heart J*. 2016;175:77-85. doi: 10.1016/j.ahj.2016.02.011. PMID: CN-01142287. Exclusion Code: X5.
313. Stenestrand U, Lindback J, Wallentin L. Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: a prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). *Circulation*. 2005 Nov 22;112(21):3225-31. doi: 10.1161/circulationaha.105.552984. PMID: 16301355. Exclusion Code: X2.
314. Stergiou GS, Karpettas N, Protogerou A, et al. Diagnostic accuracy of a home blood pressure monitor to detect atrial fibrillation. *J Hum Hypertens*. 2009 Oct;23(10):654-8. doi: 10.1038/jhh.2009.5. PMID: 19279661. Exclusion Code: X4.
315. Stiffman MN. Risk of stroke in patients with atrial fibrillation. *J Fam Pract*. 1998 Jul;47(1):10-1. PMID: 9673595. Exclusion Code: X7.
316. Suarez-Pinilla M, Fernandez-Rodriguez A, Benavente-Fernandez L, et al. Vitamin K antagonist-associated intracerebral hemorrhage: lessons from a devastating disease in the dawn of the new oral anticoagulants. *J Stroke Cerebrovasc Dis*. 2014 Apr;23(4):732-42. doi: 10.1016/j.jstrokecerebrovasdis.2013.06.034. PMID: 23954605. Exclusion Code: X6.
317. Sudlow M, Rodgers H, Kenny RA, et al. Identification of patients with atrial fibrillation in general practice: a study of screening methods. *BMJ*. 1998 Aug 1;317(7154):327-8. PMID: 9685281. Exclusion Code: X5.
318. Suzuki M, Fukamizu S, Oyama J, et al. Rationale and design of the efficacy of rivaroxaban on renal function in patients with non-valvular atrial fibrillation and chronic kidney disease: The X-NOAC study. *Int J Cardiol*. 2015 Jun 1;188:52-3. doi: 10.1016/j.ijcard.2015.04.037. PMID: 25889327. Exclusion Code: X4.
319. Suzuki S, Otsuka T, Sagara K, et al. Nine-Year Trend of Anticoagulation Use, Thromboembolic Events, and Major Bleeding in Patients With Non-Valvular Atrial Fibrillation - Shinken Database Analysis. *Circ J*. 2016;80(3):639-49. doi: 10.1253/circj.CJ-15-1237. PMID: 26794283. Exclusion Code: X4.

Appendix C. Excluded Studies

320. Svennberg E, Engdahl J, Al-Khalili F, et al. Mass Screening for Untreated Atrial Fibrillation: The STROKESTOP Study. *Circulation*. 2015 Jun 23;131(25):2176-84. doi: 10.1161/circulationaha.114.014343. PMID: 25910800. Exclusion Code: X5.
321. Taillandier S, Olesen JB, Clementy N, et al. Prognosis in patients with atrial fibrillation and CHA2DS2-VASc Score = 0 in a community-based cohort study. *J Cardiovasc Electrophysiol*. 2012 Jul;23(7):708-13. doi: 10.1111/j.1540-8167.2011.02257.x. PMID: 22268375. Exclusion Code: X7.
322. Tawfik A, Bielecki JM, Krahn M, et al. Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation. *Clin Pharmacol*. 2016;8:93-107. doi: 10.2147/cpaa.s105165. PMID: 27570467. Exclusion Code: X11.
323. Testa L, Agnifili M, Latini RA, et al. Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation. *QJM*. 2012 Oct;105(10):949-57. doi: 10.1093/qjmed/hcs114. PMID: 22771555. Exclusion Code: X4.
324. Testa L, Agnifili M, Latini RA, et al. Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation (Structured abstract). *QJM*. 2012;105(10):949-57. PMID: DARE-12012048316. Exclusion Code: X4.
325. Thibault B, Talajic M, Dubuc M, et al. Thromboembolic events occur despite sinus rhythm maintenance in patients treated for atrial fibrillation: The Canadian Trial of Atrial Fibrillation experience. *Can J Cardiol*. 2004 Feb;20(2):195-9. PMID: 15010743. Exclusion Code: X3.
326. Thom H, Lu G. Rapid and automated test for connectedness of evidence networks in network meta analysis. *Value Health*. 2015;18(7):A727. PMID: CN-01126861. Exclusion Code: X3.
327. Thomson R. How can epidemiological studies help us to prevent stroke? The example of atrial fibrillation. *Age Ageing*. 2002 Nov;31 Suppl 3:9-16. PMID: 12450922. Exclusion Code: X7.
328. Thomson R, Eccles M, Wood R, et al. A cautionary note on data sources for evidence-based clinical decisions: warfarin and stroke prevention. *Med Decis Making*. 2007 Jul-Aug;27(4):438-47. doi: 10.1177/0272989x07302166. PMID: 17641140. Exclusion Code: X3.
329. Tsoukas GO, Blais C, Gagnon R, et al. The impact of pharmacotherapy on long-term survival and risk of re-hospitalization for stroke after hospitalization for atrial fibrillation. *Can J Cardiol*. 2014;30(10 suppl. 1):S132-s3. PMID: CN-01023554. Exclusion Code: X7.
330. Tu RH, Zhong GQ, Zeng ZY, et al. A meta-analysis on efficacy of anti-platelet agents and anticoagulants for preventing stroke in patients with nonvalvular atrial fibrillation (Provisional abstract). *Chinese Journal of Cardiology*. 2011;39(3):262-7. PMID: DARE-12012000421. Exclusion Code: X1.
331. Turakhia MP, Ullal AJ, Hoang DD, et al. Feasibility of extended ambulatory electrocardiogram monitoring to identify silent atrial fibrillation in high-risk patients: the Screening Study for Undiagnosed Atrial Fibrillation (STUDY-AF). *Clin Cardiol*. 2015 May;38(5):285-92. doi: 10.1002/clc.22387. PMID: 25873476. Exclusion Code: X2.
332. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. *Arch Intern Med*. 2012 Mar 12;172(5):397-402. doi: 10.1001/archinternmed.2011.1666. PMID: 22231617. Exclusion Code: X4.
333. Uittenbogaart SB, Verbiest-van Gorp N, Erkens PM, et al. Detecting and Diagnosing Atrial Fibrillation (D2AF): study protocol for a cluster randomised controlled trial. *Trials*. 2015;16:478. doi: 10.1186/s13063-015-1006-5. PMID: 26499449. Exclusion Code: X5.
334. Viitaniemi M, Eskola K, Kurunmaki H, et al. Anticoagulant treatment of patients with atrial fibrillation in primary health care. *Scand J Prim Health Care*. 1999 Mar;17(1):59-63. PMID: 10229996. Exclusion Code: X4.
335. Villines T, Peacock W. Safety of direct oral anticoagulants: insights from postmarketing studies. *Am J Med*. 2017;129(11 Supplement):S41-s6. doi: 10.1016/j.amjmed.2016.06.004. PMID: CN-01247709. Exclusion Code: X4.

Appendix C. Excluded Studies

336. Violi F, Davi G, Proietti M, et al. Ankle-Brachial Index and cardiovascular events in atrial fibrillation: the ARAPACIS study. *Thromb Haemost*. 2016;115(4):856-63. doi: 10.1160/TH15-07-0612. PMID: CN-01159711. Exclusion Code: X3.
337. Voller H, Glatz J, Taborski U, et al. Self-management of oral anticoagulation in nonvalvular atrial fibrillation (SMAAF study). *Z Kardiol*. 2005 Mar;94(3):182-6. doi: 10.1007/s00392-005-0199-0. PMID: 15747040. Exclusion Code: X4.
338. Vora AN, Alexander JH, Lopes RD. Dabigatran Compared With Rivaroxaban vs Warfarin. *JAMA Intern Med*. 2017 May 01;177(5):742-3. doi: 10.1001/jamainternmed.2017.0561. PMID: 28460098. Exclusion Code: X7.
339. Wagstaff AJ, Overvad TF, Lip GY, et al. Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis. *QJM*. 2014 Dec;107(12):955-67. doi: 10.1093/qjmed/hcu054. PMID: 24633256. Exclusion Code: X4.
340. Waldo AL, Becker RC, Tapson VF, et al. Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation. *J Am Coll Cardiol*. 2005 Nov 1;46(9):1729-36. doi: 10.1016/j.jacc.2005.06.077. PMID: 16256877. Exclusion Code: X7.
341. Walfridsson H, Johansson B, Englund A, et al. Effects of AZD0837, a novel direct thrombin inhibitor, on the electrophysiological properties of the human heart: a randomized, double-blind, parallel-group, placebo-controlled study. *Clin Drug Investig*. 2010;30(7):461-71. doi: 10.2165/11536300-000000000-00000. PMID: 20528001. Exclusion Code: X2.
342. Wandell P, Carlsson AC, Holzmann M, et al. Association between antithrombotic treatment and hemorrhagic stroke in patients with atrial fibrillation-a cohort study in primary care. *Eur J Clin Pharmacol*. 2017 Feb;73(2):215-21. doi: 10.1007/s00228-016-2152-8. PMID: 27826643. Exclusion Code: X7.
343. Wandell P, Carlsson AC, Sundquist K, et al. Effect of cardiovascular drug classes on all-cause mortality among atrial fibrillation patients treated in primary care in Sweden: a cohort study. *Eur J Clin Pharmacol*. 2013 Feb;69(2):279-87. doi: 10.1007/s00228-012-1395-2. PMID: 22990327. Exclusion Code: X7.
344. Wang TH, Bhatt DL, Fox KA, et al. An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial. *Eur Heart J*. 2007 Sep;28(18):2200-7. doi: 10.1093/eurheartj/ehm274. PMID: 17673448. Exclusion Code: X4.
345. Wang TJ, Massaro JM, Levy D, et al. A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study. *JAMA*. 2003 Aug 27;290(8):1049-56. doi: 10.1001/jama.290.8.1049. PMID: 12941677. Exclusion Code: X3.
346. Warkentin AE, Donadini MP, Spencer FA, et al. Bleeding risk in randomized controlled trials comparing warfarin and aspirin: a systematic review and meta-analysis (Structured abstract). *J Thromb Haemost*. 2012;10(4):512-20. PMID: DARE-12012020168. Exclusion Code: X4.
347. Wasserlauf G, Grandi SM, Filion KB, et al. Meta-analysis of rivaroxaban and bleeding risk (Structured abstract). *Am J Cardiol*. 2013;112(3):454-60. PMID: DARE-12013025396. Exclusion Code: X4.
348. Wheeldon NM. Atrial fibrillation and anticoagulant therapy. *Eur Heart J*. 1995 Mar;16(3):302-12. PMID: 7789371. Exclusion Code: X7.
349. Wheeldon NM, Tayler DI, Anagnostou E, et al. Screening for atrial fibrillation in primary care. *Heart*. 1998 Jan;79(1):50-5. PMID: 9505919. Exclusion Code: X4.
350. White RH, McBurnie MA, Manolio T, et al. Oral anticoagulation in patients with atrial fibrillation: adherence with guidelines in an elderly cohort. *Am J Med*. 1999 Feb;106(2):165-71. PMID: 10230745. Exclusion Code: X3.
351. Wieloch M, Sjalander A, Frykman V, et al. Anticoagulation control in Sweden: reports of time in therapeutic range, major bleeding, and thrombo-embolic complications from the national quality registry AuriculA. *Eur Heart J*. 2011 Sep;32(18):2282-9. doi: 10.1093/eurheartj/ehr134. PMID: 21616951. Exclusion Code: X4.

Appendix C. Excluded Studies

352. Wiesel J, Abraham S, Messineo FC. Screening for asymptomatic atrial fibrillation while monitoring the blood pressure at home: trial of regular versus irregular pulse for prevention of stroke (TRIIPS 2.0). *Am J Cardiol*. 2013 Jun 1;111(11):1598-601. doi: 10.1016/j.amjcard.2013.01.331. PMID: 23499278. Exclusion Code: X4.
353. Woodhouse L, Appleton J, Dineen R, et al. Comparisons of outcomes in patients with atrial fibrillation or requiring carotid endarterectomy: results from the triple antiplatelets for reducing dependency after ischaemic stroke (TARDIS) trial. *European Stroke Journal*. 2016;1(Suppl 1):678. PMID: CN-01164948. Exclusion Code: X2.
354. Wright J, Bibby J, Eastham J, et al. Multifaceted implementation of stroke prevention guidelines in primary care: cluster-randomised evaluation of clinical and cost effectiveness. *Qual Saf Health Care*. 2007 Feb;16(1):51-9. doi: 10.1136/qshc.2006.019778. PMID: 17301206. Exclusion Code: X4.
355. Wu J, Wang J, Jiang S, et al. The efficacy and safety of low intensity warfarin therapy in Chinese elderly atrial fibrillation patients with high CHADS2 risk score. *Int J Cardiol*. 2013 Sep 10;167(6):3067-8. doi: 10.1016/j.ijcard.2012.11.078. PMID: 23200268. Exclusion Code: X4.
356. Wyse DG. Bleeding while starting anticoagulation for thromboembolism prophylaxis in elderly patients with atrial fibrillation: from bad to worse. *Circulation*. 2007 May 29;115(21):2684-6. doi: 10.1161/circulationaha.107.704122. PMID: 17533193. Exclusion Code: X7.
357. Yamashita T, Koretsune Y, Yang Y, et al. Edoxaban vs. Warfarin in east asian patients with atrial fibrillation - An ENGAGE AF-TIMI 48 subanalysis. *Circ J*. 2016;80(4):860-9. doi: 10.1253/circj.CJ-15-1082. PMID: CN-01141783. Exclusion Code: X4.
358. Yamashita Y, Hamatani Y, Esato M, et al. Clinical Characteristics and Outcomes in Extreme Elderly (Age \geq 85 Years) Japanese Patients With Atrial Fibrillation: The Fushimi AF Registry. *Chest*. 2016 Feb;149(2):401-12. doi: 10.1378/chest.15-1095. PMID: 26181726. Exclusion Code: X4.
359. Yamashita Y, Takagi D, Hamatani Y, et al. Clinical characteristics and outcomes of dialysis patients with atrial fibrillation: the Fushimi AF Registry. *Heart Vessels*. 2017;31(12):2025-34. doi: 10.1007/s00380-016-0818-x. PMID: CN-01288574. Exclusion Code: X2.
360. Yang YM, Shao XH, Zhu J, et al. Risk factors and incidence of stroke and MACE in Chinese atrial fibrillation patients presenting to emergency departments: a national wide database analysis. *Int J Cardiol*. 2014 May 1;173(2):242-7. doi: 10.1016/j.ijcard.2014.02.040. PMID: 24630382. Exclusion Code: X6.
361. Yang YM, Shao XH, Zhu J, et al. One-Year Outcomes of Emergency Department Patients With Atrial Fibrillation: A Prospective, Multicenter Registry in China. *Angiology*. 2015 Sep;66(8):745-52. doi: 10.1177/0003319714553936. PMID: 25344528. Exclusion Code: X6.
362. Yoon CW, Kim SJ, Bang OY, et al. Premorbid warfarin use and lower D-dimer levels are associated with a spontaneous early improvement in an atrial fibrillation-related stroke. *J Thromb Haemost*. 2012 Nov;10(11):2394-6. doi: 10.1111/j.1538-7836.2012.04909.x. PMID: 22925077. Exclusion Code: X2.
363. Yu HC, Tsai YF, Chen MC, et al. Underuse of antithrombotic therapy caused high incidence of ischemic stroke in patients with atrial fibrillation. *Int J Stroke*. 2012 Feb;7(2):112-7. doi: 10.1111/j.1747-4949.2011.00667.x. PMID: 22103748. Exclusion Code: X7.
364. Zhao YJ, Lim WS. Dabigatran Compared With Rivaroxaban vs Warfarin. *JAMA Intern Med*. 2017 May 01;177(5):742. doi: 10.1001/jamainternmed.2017.0564. PMID: 28460099. Exclusion Code: X7.
365. Ziadeh M, Burcu M, Oehrlein E, et al. Novel oral anticoagulants and risk of gastrointestinal bleeding: a systematic review. *Pharmacoepidemiol Drug Saf*. 2017;25:571. doi: 10.1002/pds.4070. PMID: CN-01293654. Exclusion Code: X4.
366. Zolfaghari Jr S, Harenberg J, Marx S, et al. Indirect comparisons of the new oral anticoagulants in patients with non-valvular atrial fibrillation. *Blood*. 2012;120(21) PMID: CN-01008485. Exclusion Code: X4.

Appendix C. Excluded Studies

367. Zubaid M, Rashed W A, Alsheikh-Ali A A, et al. Management and 1-year outcomes of patients with atrial fibrillation in the Middle East: Gulf survey of atrial fibrillation events. *Angiology*. 2015 May;66(5):464-71. doi: 10.1177/0003319714536980. PMID: 24904179. Exclusion Code: X4.

Appendix D Table 1. Quality Assessment of Randomized, Controlled Trials (All KQs): Part 1

First Author, Year Trial Name	Was randomization adequate?	Was allocation concealment adequate?	Were groups similar at baseline?	What was the reported intervention fidelity?	What was the reported adherence to the intervention?	Did the study have cross-overs or contamination raising concern for bias?	What was the overall attrition?	What was the differential attrition?	Did the study have differential attrition or overall high attrition raising concern for bias?
Benito, 2015 ⁸³ EARLY pilot study	Unclear	Unclear	Yes, for those analyzed, but NR for those randomized; and not many characteristics reported (e.g., medications and smoking NR)	NR	NR	Unclear	77% of the 4,000 randomized were not included in analyses; the authors report an overall loss to follow up of 5.8% (using a smaller denominator around 900 that does not consider all of the post-randomization exclusions)	9.7% vs. 1.9%	Yes, very high overall attrition
Connolly, 1991 ⁸⁴ CAFA study	Unclear, method of sequence generation NR	NR	Yes	NA	NR	No (<3%)	Lost to follow up NR (implied 0 or very low); 25% discontinued medication	NR; 4%	No
Ezekowitz, 1992 ⁸⁵	Unclear	Unclear	Yes	NA	NR	NR	4% lost to follow up; 16% dropped out	2%; 3%	No
Fitzmaurice, 2014 ⁵³ ; Fitzmaurice, 2007 ⁴³ ; Mant, 2007 ⁸⁶ ; Hobbs, 2005 ⁸⁷ ; Swancutt, 2004 ⁸⁸ SAFE	Yes	No	Yes for age and sex; unclear otherwise	53% of patients invited for systematic screening underwent ECG	NA	NR, but not suspected	0.6% missing data	0.1%	No

Appendix D Table 1. Quality Assessment of Randomized, Controlled Trials (All KQs): Part 1

First Author, Year Trial Name	Was randomization adequate?	Was allocation concealment adequate?	Were groups similar at baseline?	What was the reported intervention fidelity?	What was the reported adherence to the intervention?	Did the study have cross-overs or contamination raising concern for bias?	What was the overall attrition?	What was the differential attrition?	Did the study have differential attrition or overall high attrition raising concern for bias?
Halcox, 2017 ⁸⁹ REHEARSE-AF	Unclear, method of sequence generation NR but was centralized process with interactive voice response	NR	Yes	NR	74% submitted single-lead ECG recordings every week	No	G1: 5/500 (1%) G2: NR	NR, but likely low	No
Morgan, 2002 ³⁶	Yes	Unclear	Yes for age and sex; unclear otherwise	73% of those invited for screening had pulse assessed	NA	NR	NR	NR	Unclear
Petersen, 1989 ⁹⁰ AFASAK	Yes	Unclear	Yes	NA	NR	No	Unable to determine amount of missing data (lost to follow up NR), Number of withdrawals is reported (222/1,007=22%) but it indicates that these subjects were still followed up for outcomes.	Unable to determine for missing data (lost to follow up); For withdrawals, 126 (38%) warfarin vs. 44 (12%) aspirin vs. 52 (16%) placebo and most of the difference was due to refusal to continue the medication.	Unclear

Appendix D Table 1. Quality Assessment of Randomized, Controlled Trials (All KQs): Part 1

First Author, Year Trial Name	Was randomization adequate?	Was allocation concealment adequate?	Were groups similar at baseline?	What was the reported intervention fidelity?	What was the reported adherence to the intervention?	Did the study have cross-overs or contamination raising concern for bias?	What was the overall attrition?	What was the differential attrition?	Did the study have differential attrition or overall high attrition raising concern for bias?
Posada, 1999 ⁹¹ LASAF Pilot Study	Unclear, method of sequence generation NR	NR	Yes for things in Table 1, but unclear for many risk factors for the outcomes that were NR (e.g., hypertension, smoking, medications)	NA	NR, although they report that 7% of those treated with aspirin withdrew because of GI discomfort or mild bleeding	NR	0% missing data; 18% dropped out (including due to adverse effects and events/outcomes)	0%; 8%	No
Sato, 2006 ⁹² JAST	Unclear, method of sequence generation NR	Yes	Yes	NA	NR	NR	0.3% missing data; 21.2% noncompleters (including due to side effects, cardiac and other diseases, and personal reasons)	0.7%; 2.5%	No
Stroke Prevention in Atrial Fibrillation Study Group, 1990 ⁹³ Stroke Prevention in Atrial Fibrillation Study Group, 1991 ⁹⁴ SPAF	Yes	Unclear	Yes	NA	88% of participants averaged over 80% adherence by pill count	NR	0% lost to follow up; 1.5% of scheduled follow up visits not completed	0%; NR; 11.2% discontinued w arfarin vs. 5% for aspirin, vs. 6.6% for placebo	No

Appendix D Table 1. Quality Assessment of Randomized, Controlled Trials (All KQs): Part 1

First Author, Year Trial Name	Was randomization adequate?	Was allocation concealment adequate?	Were groups similar at baseline?	What was the reported intervention fidelity?	What was the reported adherence to the intervention?	Did the study have cross-overs or contamination raising concern for bias?	What was the overall attrition?	What was the differential attrition?	Did the study have differential attrition or overall high attrition raising concern for bias?
The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators, 1990 ⁹⁵ BAATAF	Yes	Yes	Yes	NA	NR, although high time in therapeutic range over 80% suggests high adherence	Yes, aspirin allowed in control group (but not in warfarin group) and was being taken during 46% of all patient-years in control group	0% lost to follow up; 10% of warfarin group discontinued the medication (NA for control; no placebo control)	0%; NA	No

Abbreviations: AFASAK=Atrial Fibrillation, Aspirin and Anticoagulation study; BAATAF= Boston Area Anticoagulation Trial for Atrial Fibrillation; CAFA=Canadian Atrial Fibrillation Anticoagulation; EARLY=Early diagnosis of Atrial fibrillation: a Randomized trial in primary care; ECG=electrocardiogram; GI=gastrointestinal; JAST=Japan Atrial Fibrillation Stroke Trial; KQ=key question; LASAF= low-dose aspirin, stroke atrial fibrillation trial; NA=not applicable; NR=not reported; REHEARSE-AF=Assessment of REmote HEArt Rhythm Sampling using the AliveCor heart monitor to screen for Atrial Fibrillation; SAFE= Screening for AF in the elderly study; SPAF= Stroke Prevention in Atrial Fibrillation.

Appendix D Table 2. Quality Assessment of Randomized, Controlled Trials (All KQs): Part 2

First Author, Year Trial Name	Were outcome measurements equal, valid, and reliable?	Were patients masked?	Were providers masked?	Were outcome assessors masked?	Was the duration of follow up adequate to assess the outcome?	What was the method used to handle missing data?	Did the study use acceptable statistical methods?	Quality Rating	Comments
Benito, 2015 ⁸³ EARLY pilot study	No, outcomes measures were not equal between groups; IG had visits every 6 months that included an ECG, whereas CG only had outcomes based on clinical history from EHR and as needed phone calls	No, not feasible	Yes	Unclear	Yes	NR	Yes	Poor	High risk of selection bias, measurement bias, and confounding. Very high overall attrition (>70% of those randomized were not included in analyses), methods of outcome assessment differed between IG and CG, unclear methods of randomization and allocation concealment, and no information about handling of missing data, or masking of outcome assessors. We note that it is self-described as a pilot study (indicating that the purpose may be mainly for planning a future study).
Connolly, 1991 ⁸⁴ CAFA study	Yes	Yes	Yes, except for person seeing PT/INR and making dose adjustments	Yes	Yes (mean follow up 15.2months)	NR	Yes	Fair	Stopped early because of other positive studies with similar design and objectives; planned 630 participants and 2.5 years follow up (378 analyzed)
Ezekowitz, 1992 ⁸⁵	Yes	Yes	No, for those adjusting doses; yes for cardiologist and neurologist	Yes	Yes (mean follow up 1.7 to 1.8 years)	Censored	Yes	Fair	Warfarin vs. placebo; Stopped early with DSMB involvement and prespecified interim analyses showing benefit of warfarin and other similar studies being stopped early

Appendix D Table 2. Quality Assessment of Randomized, Controlled Trials (All KQs): Part 2

First Author, Year Trial Name	Were outcome measurements equal, valid, and reliable?	Were patients masked?	Were providers masked?	Were outcome assessors masked?	Was the duration of followup adequate to assess the outcome?	What was the method used to handle missing data?	Did the study use acceptable statistical methods?	Quality Rating	Comments
Fitzmaurice, 2014 ⁵³ ; Fitzmaurice, 2007 ⁴³ ; Mant, 2007 ⁸⁶ ; Hobbs, 2005 ⁸⁷ ; Swancutt, 2004 ⁸⁸ SAFE	Yes	No	No	Yes	Yes	Excluded; complete records only	Yes	Fair	Practices randomized to screening intervention or not (and randomization again within intervention group for opportunistic vs. systematic); no concealment of allocation; baseline comparison only provided for age and sex (no information on other variables or on practice characteristics, although randomization was stratified by practice size); good approach to determining when atrial fibrillation was previously diagnosed
Halcox, 2017 ⁸⁹ REHEARSE-AF	Uncertain but seems that approach to confirming AF may have differed between groups	No	No	No	Yes (for primary outcome of AF detection)	NR	Yes	Fair	Moderate risk of measurement bias with lack of any masking and uncertainty about what workup was done to confirm AF. Underpowered for KQ 1 outcomes.

Appendix D Table 2. Quality Assessment of Randomized, Controlled Trials (All KQs): Part 2

First Author, Year Trial Name	Were outcome measurements equal, valid, and reliable?	Were patients masked?	Were providers masked?	Were outcome assessors masked?	Was the duration of follow up adequate to assess the outcome?	What was the method used to handle missing data?	Did the study use acceptable statistical methods?	Quality Rating	Comments
Morgan, 2002 ³⁶	Unclear, single observer reviewed medical records	No	No	NR	Unclear (6 months and few new cases of atrial fibrillation)	NR	Yes	Fair	The main outcomes describe total numbers of atrial fibrillation cases detected (inclusive of both previously known atrial fibrillation and newly diagnosed atrial fibrillation), so their main outcomes are not relevant for our questions; they also report incident cases, but they give somewhat limited details on methods of medical record review process for determining whether patients had previously diagnoses atrial fibrillation, and it was done by a single person (and masking NR); given that there were only 12 vs. 7 new cases (few events) and the study only covered 6 months of screening, the study provides limited information, although it shows pretty good uptake/fidelity; Allocation concealment NR; baseline comparison only provided for age and sex
Petersen, 1989 ⁹⁰ AFASAK	Yes	No for warfarin Yes for ASA and placebo	No for warfarin Yes for ASA and placebo	Yes	Yes	NR	Yes	Fair	Thromboembolic endpoints were clinically confirmed, and also classified by a neurologist using a priori criteria. Information on missing data NR, unable to determine attrition; open-label for warfarin

Appendix D Table 2. Quality Assessment of Randomized, Controlled Trials (All KQs): Part 2

First Author, Year Trial Name	Were outcome measurements equal, valid, and reliable?	Were patients masked?	Were providers masked?	Were outcome assessors masked?	Was the duration of follow up adequate to assess the outcome?	What was the method used to handle missing data?	Did the study use acceptable statistical methods?	Quality Rating	Comments
Posada, 1999 ⁹¹ LASAF Pilot Study	Unclear	No	No	NR	Unclear (all followed a minimum 12 months)	NR	Yes	Poor	Open-label; stopped early because of results from other trials on aspirin being published; methods of randomization sequence generation and allocation concealment NR; methods of outcome ascertainment unclear and masking of outcome assessors NR; high risk of measurement bias
Sato, 2006 ⁹² JAST	Yes	No	No	Yes	Unclear, mean follow up of 2-3 years planned (stopped early)	NR	Yes	Fair	Open-label; trial stopped early because of interim analysis showing possibly higher risk of bleeding and aspirin unlikely to be superior to no treatment for benefits
Stroke Prevention in Atrial Fibrillation Study Group, 1990 ⁹³ Stroke Prevention in Atrial Fibrillation Study Group, 1991 ⁹⁴ SPAF	Yes	No	No	Yes	Yes (mean follow up 1.3 years)	NA	Yes	Fair	Placebo arm was stopped early (multi-arm trial, and the warfarin and aspirin arms continued); open-label warfarin (although aspirin and placebo were given in a double-blind fashion); allocation concealment unclear

Appendix D Table 2. Quality Assessment of Randomized, Controlled Trials (All KQs): Part 2

First Author, Year Trial Name	Were outcome measurements equal, valid, and reliable?	Were patients masked?	Were providers masked?	Were outcome assessors masked?	Was the duration of follow up adequate to assess the outcome?	What was the method used to handle missing data?	Did the study use acceptable statistical methods?	Quality Rating	Comments
The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators, 1990 ⁹⁵ BAATAF	Yes	No	No	Yes	Yes (mean follow up 2.2 years)	NA, reported no missing data	Yes	Fair	Stopped early because of evidence favoring warfarin over control (had already enrolled target number of participants, but had not reached the mean 4.1 years planned); contamination with aspirin in control group (might lead to underestimation of both benefits and harms of warfarin); no placebo; open-label

Abbreviations: AFASAK=Copenhagen Atrial Fibrillation, Aspirin and Anticoagulation study; ASA=aspirin; BAATAF= Boston Area Anticoagulation Trial for Atrial Fibrillation; CAFA=Canadian Atrial Fibrillation Anticoagulation; CG=control group; DSMB=Data and Safety Monitoring Board; EARLY=Early diagnosis of Atrial fibrillation: a Randomized trial in primary care; ECG=electrocardiogram; EHR=electronic health record; IG=intervention group; JAST=Japan Atrial Fibrillation Stroke Trial; LASAF=Low-dose Aspirin, Stroke Atrial Fibrillation trial; NR=not reported; PT/INR=prothrombin time/International Normalized Ratio; REHEARSE-AF=Assessment of Remote Heart Rhythm Sampling using the AliveCor heart monitor to screen for Atrial Fibrillation; SAFE=Screening for AF in the Elderly study; SPAF= Stroke Prevention in Atrial Fibrillation.

Appendix D Table 3. Quality Assessment of Randomized, Controlled Trials: Additional Questions for Studies Reporting Harms (KQs 3 and 5 Only)

First Author, Year Trial Name	Were harms pre- specified and defined?	Were ascertainment techniques for harms adequately described?	Were ascertainment techniques for harms equal, valid, and reliable?	Was duration of follow up adequate for harms assessment?	Quality Rating	Comments
Benito, 2015 ⁸³ EARLY pilot study	No	No	No	Yes	Poor	High risk of selection bias, measurement bias, and confounding
Connolly, 1991 ⁸⁴ Canadian Atrial Fibrillation Anticoagulation (CAFA) study	Yes	Yes	Yes	Yes (mean follow up 15.2 months)	Fair	Self-report of bleeding events
Ezekowitz, 1992 ⁸⁵	Yes	Yes	Yes	Yes (mean follow up 1.7 to 1.8 years)	Fair	
Fitzmaurice, 2014 ⁵³ ; Fitzmaurice, 2007 ⁴³ ; Mant, 2007 ⁸⁶ ; Hobbs, 2005 ⁸⁷ ; Swancutt, 2004 ⁸⁸ SAFE	Yes	Yes	NA (only measured for intervention group)	Yes	Fair	Limited information about harms, but protocol/methods paper prespecified measurement of anxiety (intervention group only) and evaluation of primary care provider accuracy of interpretation of ECGs (direct implications for mislabeling and potential harms); the anxiety information was only collected for those getting ECGs and was not collected for the control group (so unable to make any conclusions for anxiety that directly address our question)

Appendix D Table 3. Quality Assessment of Randomized, Controlled Trials: Additional Questions for Studies Reporting Harms (KQs 3 and 5 Only)

First Author, Year Trial Name	Were harms pre-specified and defined?	Were ascertainment techniques for harms adequately described?	Were ascertainment techniques for harms equal, valid, and reliable?	Was duration of follow up adequate for harms assessment?	Quality Rating	Comments
Halcox, 2017 ⁸⁹ REHEA RSE-AF	Yes	Yes	Yes, equal; uncertain validity and reliability for some outcomes	Yes	Poor	Potential harms of screening reported in the study included anxiety. High risk of measurement bias. No masking. Did not use a valid and reliable instrument. The question used was "Did participation in this study make you more anxious about your risk of heart rhythm abnormalities and / or stroke"? (response options were from 1 = No more anxious to 10 = More anxious). They also had a question about anxiousness using the device ("To what extent did you feel anxious in using the AliveCor device"?), but it was only asked of the intervention group.
Petersen, 1989 ⁹⁰ AFASAK	Yes	Yes	Yes	Yes	Fair	
Posada, 1999 ⁹¹ LASAF Pilot Study	Unclear whether prespecified; hemorrhagic stroke was defined, bleeding events were not	No	Unclear	Unclear (all followed a minimum of 12 months)	Poor	See comments for KQ 4 quality evaluation of this study
Sato, 2006 ⁹² JAST	Yes	Yes	Yes	Unclear	Fair	Open-label; stopped early
Stroke Prevention in Atrial Fibrillation Study Group, 1990 ⁹³ Stroke Prevention in Atrial Fibrillation Study Group, 1991 ⁹⁴ SPAF	Yes	Yes	Yes	Yes (mean follow up 1.3 years)	Fair	

Appendix D Table 3. Quality Assessment of Randomized, Controlled Trials: Additional Questions for Studies Reporting Harms (KQs 3 and 5 Only)

First Author, Year Trial Name	Were harms pre-specified and defined?	Were ascertainment techniques for harms adequately described?	Were ascertainment techniques for harms equal, valid, and reliable?	Was duration of follow up adequate for harms assessment?	Quality Rating	Comments
The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators, 1990 ⁹⁵ BAATAF	Yes	Yes	Yes	Yes (mean follow up 2.2 years)	Fair	

Abbreviations: AFASAK=Copenhagen Atrial Fibrillation, Aspirin and Anticoagulation study; BAATAF=Boston Area Anticoagulation Trial for Atrial Fibrillation; CAFA=Canadian Atrial Fibrillation Anticoagulation study; EARLY=Early diagnosis of Atrial fibrillation: a Randomized trial in primary care; ECG=electrocardiography; JAST=Japan Atrial Fibrillation Stroke Trial; KQ=key question; NA=not applicable; NR=not reported; REHEARSE-AF=Assessment of REMote HEArt Rhythm Sampling using the AliveCor heart monitor to screen for Atrial Fibrillation; SAFE= Screening for AF in the elderly study; SPAF=Stroke Prevention in Atrial Fibrillation Study; SPINAF=Stroke Prevention in Nonrheumatic Atrial Fibrillation study.

Appendix D Table 4. Quality Assessment of Cohort Studies (KQs 2, 3, 5 Only): Part 1

First Author, Year, Study Name	Were eligibility criteria clearly described?	Were groups similar at baseline?	What was the reported intervention fidelity?	What was the reported adherence to the intervention?	Did the study have cross-overs or contamination raising concern for bias?	What was the overall attrition?	What was the differential attrition?	Did the study have differential attrition or overall high attrition raising concern for bias?
Caro, 1999 ⁹⁶	Yes	No	NA	NR	Yes	NR	NR	Unclear
Forslund, 2014 ⁹⁷	Yes	No	NA	NR	Yes	NR	NR	Unclear
Humphries, 2001 ⁹⁸	Yes	NR for warfarin vs. no warfarin (only reported for men vs. women, and they were not similar)	NA	NR	Unclear	1% loss to follow up; 14% did not complete 3-year visit evaluation	NR	Unclear
Kodani, 2016 ⁹⁹ J-RHYTHM Registry 2	Yes	No	NR. Analysis based on final status of medication use (at time of an event or end of follow up).	NR. Analysis based on final status of medication use.	Yes	Loss to follow up: 0.7%	NR	NR for differential; no for overall

Abbreviations: KQ=key question; NA=not applicable; NR=not reported; vs=versus.

Appendix D Table 5. Quality Assessment of Cohort Studies (KQs 2, 3, 5 only): Part 2

First Author, Year	Was assessment of the drug exposure (dose and duration) valid and reliable?	Were outcome measurements equal, valid, and reliable?	Were outcome assessors masked?	Was the duration of follow up adequate to assess the outcome?	What was the method used to handle missing data?	Did the study use acceptable statistical methods?	Did the analysis adjust for potential confounders?	Quality Rating	Comments
Caro, 1999 ⁹⁶	Unclear for duration (self-report, but vague description of ascertainment methods); no assessment of dose	Yes equal, but uncertain validity and reliability (relied on patient recall, although they sought confirmation from charts)	No	Yes	Censored	Complete data only; and not ITT (reassigned to “blended” group if treatment changed)	No (Cox model but did not report adjusting for anything for the bleeding assessment)	Poor	High risk of confounding and selection bias; no adjustment for potential confounders; high risk of contamination; many baseline characteristics differ significantly between groups; not ITT analysis; sample size under 250 may be inadequate; attrition NR
Forslund, 2014 ⁹⁷	No	Unclear	No	Yes	NR	No	No	Poor	High risk of selection bias and confounding; no adjustment for potential confounders; not ITT; concern for cross-over and contamination; aspirin ascertainment based on prescriptions only; determined whether participants had atrial fibrillation based on 2005 to 2009 data, but treatment group assignment based on a 6-month window within the 2009 data or the 6 months prior to any event that occurred; 25% not assigned to warfarin group got warfarin prior to 2009

Appendix D Table 5. Quality Assessment of Cohort Studies (KQs 2, 3, 5 only): Part 2

First Author, Year	Was assessment of the drug exposure (dose and duration) valid and reliable?	Were outcome measurements equal, valid, and reliable?	Were outcome assessors masked?	Was the duration of follow up adequate to assess the outcome?	What was the method used to handle missing data?	Did the study use acceptable statistical methods?	Did the analysis adjust for potential confounders?	Quality Rating	Comments
Humphries, 2001 ⁹⁸	Yes, for warfarin vs. no warfarin; dose information NR and no assessment of INRs except for people with bleeding events	Yes equal, but uncertain validity and reliability (relied on patient recall, and no mention of verification)	No	Yes	None	Complete data only; no handling of missing data	No, only adjusted for age	Poor	High risk of confounding and selection bias; prospective cohort study focused on comparing sex differences for presentation, treatment, and outcomes; only potentially eligible for our KQ 5 for the information on major bleeds; analysis only adjusted for age, unclear how many in each group were on aspirin, did not report baseline characteristics for warfarin vs. no warfarin groups; and participants had very few major bleeding events (15 total events); differential attrition NR for our comparison of interest
Kodani, 2016 ⁹⁹ J-RHYTHM Registry 2	No (analysis based on final status of use)	Yes	Unclear	Yes	None, excluded from analyses (15% excluded because of unknown OAC status; NR how much missing/excluded for other reasons)	Yes	Adjusted for some potential confounders (CHA ₂ DS ₂ components and antiplatelet use)	Poor	High risk of selection bias and confounding; not an inception cohort, high likelihood of residual confounding and confounding by indication, exposure groups analyzed based on final exposure at end of observation period, not based on exposure at baseline or changes over time; inadequate handling of missing data; unclear masking.

Abbreviations: CHA₂DS₂-VAsC=Congestive heart failure, Hypertension, Age ≥75 years [doubled], Diabetes mellitus, prior Stroke or TIA or thromboembolism [doubled], Vascular disease, Age 65-74 years, Sex category; INR=international normalized ratio; ITT=intent to treat; KQ=key question; NA=not applicable; NR=not reported; OAC=oral anticoagulant; TIA=transient ischemic attack.

Appendix D Table 6. Quality Assessment of Systematic Reviews, Network Meta-analyses, and IPD Meta-analyses (KQs 4, 5)

First Author, Year	Was the review based on a focused question of interest?	Was a comprehensive literature search (including grey literature) clearly described?	Were there explicit a priori inclusion/exclusion criteria for the selection of studies?	Did at least 2 people independently review studies?	Were the characteristics of the included studies provided?	Was the internal validity (quality) of included studies adequately assessed?	Was heterogeneity assessed and addressed?	Was the approach used to synthesize the information adequate and appropriate?	Were the authors' conclusions supported by the evidence?	Was publication bias assessed?	Quality Rating
Aguilar Maria, 2005 ¹⁰⁰	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Good
Aguilar Maria, 2005 ¹⁰¹	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	No	Good
Coleman, 2012 ¹⁰²	Yes	Yes for published literature; no mention of grey literature	Yes	Unclear	Yes	Yes	Yes	Yes	Yes	Yes (some statistical tests reported, although not described in methods)	Fair
Atrial Fibrillation Investigators, 1994 ¹⁰³	Yes	No, but they identified all relevant known studies	Yes	NR	No	No	Yes (it is an IPD meta-analysis allowing greater assessment of heterogeneity) (e.g., analyses of women separated)	Yes	Yes	NR	Fair
Tereshchenko, 2016 ¹⁰⁴	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Good
The Atrial Fibrillation Investigators, 1997 ¹⁰⁵	Yes	No, but they identified all relevant known studies	Yes	NR	Partially	No	Yes (it is an IPD meta-analysis allowing greater assessment of heterogeneity) (e.g., analyses of women separated)	Yes	Yes	NR	Fair

Appendix D Table 6. Quality Assessment of Systematic Reviews, Network Meta-analyses, and IPD Meta-analyses (KQs 4, 5)

First Author, Year	Was the review based on a focused question of interest?	Was a comprehensive literature search (including grey literature) clearly described?	Were there explicit a priori inclusion/exclusion criteria for the selection of studies?	Did at least 2 people independently review studies?	Were the characteristics of the included studies provided?	Was the internal validity (quality) of included studies adequately assessed?	Was heterogeneity assessed and addressed?	Was the approach used to synthesize the information adequate and appropriate?	Were the authors' conclusions supported by the evidence?	Was publication bias assessed?	Quality Rating
van Walraven, 2009 ¹⁰⁶	Yes	No, but they identified all relevant known studies (IPD analysis of data from a central database of clinical trials on patients with AF)	Yes	NR	Partially	No	Yes	Yes	Yes	NR	Fair
Hart, 2007 ¹⁰⁷	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Good

Abbreviations: AF=atrial fibrillation; IPD=individual patient data; KQ=key question; NR=not reported.

Appendix D Table 7. Relevance of Systematic Reviews and Meta-Analyses for the Benefits and Harms of Anticoagulation or Antiplatelet Therapy (KQs 4, 5)

First Author, Year	Review type (IPD, aggregate data SR, NMA)?	Did the review meet our initial eligibility criteria?	Did the review focus only on studies of primary prevention (with no or few participants with history of stroke or TIA)?	Did the review include all relevant trials on aspirin?	Did the review include all relevant trials on warfarin?	If the review is an NMA, did it include the relevant trials for newer OACs?	Has the review been updated?	Was the review relevant and included in our current review?	Comments
Aguilar, 2009 ¹⁰⁰	SR with MA	Yes	Yes	NA	Yes	NA	No	Yes	Cochrane review. Focuses on patients without history of stroke or TIA and got unpublished results from the Atrial Fibrillation Investigators that removed the 3% to 8% of participants with prior TIA or stroke from the studies.
Aguilar, 2011 ¹⁰⁸	SR with MA	Yes	Yes	No, did not include JAST (JAST was not yet published)	NA	NA	No	Yes	Cochrane review. Focuses on patients without history of stroke or TIA and got unpublished results from the Atrial Fibrillation Investigators that removed the 6% of participants with prior TIA or stroke from the studies.
Assiri, 2013 ¹⁰⁹	NMA	Yes	No	Yes	No, did not include CAFA or BAATAF	No, did not include ENGAGE or JROCKET	No	No	Review excludes 2 warfarin trials and 2 trials of NOACs. Also combined studies of primary and secondary prevention.
Atrial Fibrillation Investigators, 1994 ¹⁰³	IPD	Yes	Yes	No, it did not include JAST or LASAF	Yes	NA	No	Yes	Used the Atrial Fibrillation Investigators database; used only the 5 warfarin trials (2 of those also included ASA)
Atrial Fibrillation Investigators, 1997 ¹⁰⁵	IPD	Yes	No, but it provides separate analyses in some places for the studies that were primary prevention	No, it did not include JAST or LASAF	NA	NA	No	Yes	Used the 3 ASA trials in Atrial Fibrillation Investigators database; 1 of those is secondary prevention (EAFT), but those data are not in all analyses in Tables 2 and 3 (and Table 4 provides data for patients with no clinical risk factors, one of which was prior stroke or TIA)
Cameron, 2014 ¹¹⁰	NMA	Yes	Yes	No, it did not include LASAF or SPAF-1	No, it did not include SPINAF, BAATAF, or SPAF-1	No, did not include AVERROES or JROCKET	No	No	Review excluded 2 of the aspirin trials, 3 of the warfarin trials, and 2 of NOCAS

Appendix D Table 7. Relevance of Systematic Reviews and Meta-Analyses for the Benefits and Harms of Anticoagulation or Antiplatelet Therapy (KQs 4, 5)

First Author, Year	Review type (IPD, aggregate data SR, NMA)?	Did the review meet our initial eligibility criteria?	Did the review focus only on studies of primary prevention (with no or few participants with history of stroke or TIA)?	Did the review include all relevant trials on aspirin?	Did the review include all relevant trials on warfarin?	If the review is an NMA, did it include the relevant trials for newer OACs?	Has the review been updated?	Was the review relevant and included in our current review?	Comments
Coleman, 2012 ¹⁰²	SR with MA	Yes	No, combines primary prevention and secondary prevention studies; studies in the review were not selected because of history of stroke/TIA	No, it did not include SPAF-1 or LASAF (but those did not report MGIB)	No, it did not include SPAF-1 or CAFA (but those did not report MGIB)	NA	No	Yes	Combined studies of primary and secondary prevention (participants had a TIA or stroke) and does not provide any analyses separating them; ^a possibly limiting applicability
Ezekowitz, 1999 ¹¹¹	IPD	Yes	No, included 1 secondary prevention trial (EAF), 1 with over a third having previous stroke or TIA (SPAF3), and 1 with around 20% secondary prevention (NASPEAF)	No, it did not include JAST or LASAF	Yes	NA	No	No	Relevant data were presented in a previous publication. This just reiterates those findings.
Hart, 2007 ¹¹²	SR with MA	Yes	No, but separated (primary vs. secondary prevention) results for absolute risk reduction of stroke	No, it did not include JAST	Yes	NA	Yes	No	Excluded, superseded by an updated publication
Hart, 2007 ¹⁰⁷	SR with MA	Yes	No, but separated (primary vs. secondary prevention) results for absolute risk reduction of stroke	Yes	Yes	NA	No (it is an update of a 1999 review) ¹¹²	Yes	Although the meta-analyses reporting relative reductions include both primary and secondary prevention studies, they stratify those for the absolute reduction data (in Tables 2 and 3)

Appendix D Table 7. Relevance of Systematic Reviews and Meta-Analyses for the Benefits and Harms of Anticoagulation or Antiplatelet Therapy (KQs 4, 5)

First Author, Year	Review type (IPD, aggregate data SR, NMA)?	Did the review meet our initial eligibility criteria?	Did the review focus only on studies of primary prevention (with no or few participants with history of stroke or TIA)?	Did the review include all relevant trials on aspirin?	Did the review include all relevant trials on warfarin?	If the review is an NMA, did it include the relevant trials for newer OACs?	Has the review been updated?	Was the review relevant and included in our current review?	Comments
Lapner, 2013 ¹¹³	SR with MA	No	Yes	No, it did not include JAST, LASAF, SPAF-1, AFASAK-1	No, it did not include SPINAF, CAFA, BAATAF, SPAF-1, AFASAK-1	NA	No	No	Excluded for wrong comparator
Roskell, 2010 ¹¹⁴	NMA	Yes	Yes	No, it did not include JAST or LASAF	No, it did not include SPINAF	No, published prior to ARISTOTLE, ENGAGE, ROCKET, and JROCKET	No	No	Excluded 2 of the aspirin trials, 1 of the warfarin trials, and 3 of the NOAC trials
Sahay, 2016 ¹¹⁵	NMA	Yes	Yes	No, it did not include JAST or LASAF	No, it did not include SPINAF, CAFA, or BAATAF	No, it did not include AVERROES	No	No	Excluded 2 of the aspirin trials, 3 of the warfarin trials, and 1 NOAC trial
Sardar, 2014 ¹¹⁶	SR and MA	No	Yes	No, it did not include JAST, LASAF, SPAF-1, or AFASAK-1	No, it did not include SPINAF, CAFA, BAATAF, SPAF-1, or AFASAK-1	NA	No	No	Wrong population; only placebo-controlled trials treated VTE
Tawfik, 2016 ¹¹⁷	NMA	Yes	Yes	Yes	No, it did not include SPINAF or BAATAF	No, it did not include JROCKET	No	No	Review excluded 2 of the warfarin trials

Appendix D Table 7. Relevance of Systematic Reviews and Meta-Analyses for the Benefits and Harms of Anticoagulation or Antiplatelet Therapy (KQs 4, 5)

First Author, Year	Review type (IPD, aggregate data SR, NMA)?	Did the review meet our initial eligibility criteria?	Did the review focus only on studies of primary prevention (with no or few participants with history of stroke or TIA)?	Did the review include all relevant trials on aspirin?	Did the review include all relevant trials on warfarin?	If the review is an NMA, did it include the relevant trials for newer OACs?	Has the review been updated?	Was the review relevant and included in our current review?	Comments
Tereshchenko, 2016 ¹⁰⁴	NMA	Yes	No, but most of the evidence is from trials focused mostly on primary prevention (4 of the 21 included trials had over 35% secondary prevention) ^b	Yes (although ultimately excluded LASAF for poor quality)	Yes	Yes, all the newer relevant trials included (although this excluded phase II trials of NOACs)	No	Yes	Includes some contribution of data from people with a history of TIA or stroke. NOAC phase II studies were excluded.
van Walraven, 2009 ¹⁰⁶ Atrial Fibrillation Investigators	IPD	Yes	No, included 1 secondary prevention trial (EAFT), 1 trial with over a third having previous stroke or TIA (SPAF3), and one with around 20% secondary prevention (NASPEAF) but sensitivity analyses provided serial exclusion of individual studies (and those did not alter estimates)	No, it did not include JAST or LASAF	Yes	NA	No	Yes	Used the Atrial Fibrillation Investigators database; included head-to-head studies and placebo-controlled

^aOne quarter studies in VKA meta-analysis, and one third in the aspirin meta-analysis were secondary prevention studies.

^b The percentage of participants with a history of TIA or stroke was 100% in EAFT (VKA vs. aspirin vs. placebo), 64% in JROCKET (rivaroxaban vs. VKA), 55% in ROCKET AF (rivaroxaban vs. VKA), and 38% in SPAF III. It was <10% in 9 trials (AFASAK I, BAATAF, SPAF I, CAFA, SPAF II, AFASAK II, PATAF, SAFT, and JAST) and ranged from 13% to 28% in the other 8 included trials.

Abbreviations: AFASAK=Copenhagen Atrial Fibrillation, Aspirin and Anticoagulation study; ARISTOTLE=Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; ASA=aspirin; AVERROS=Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment; BAATAF=Boston Area Anticoagulation Trial for Atrial Fibrillation; CAFA=Canadian Atrial Fibrillation Anticoagulation study; EAFT=European Atrial Fibrillation Trial Study Group; ENGAGE AF-TIMI=Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation - Thrombolysis in Myocardial Infarction 48; IPD=individual patient data; JAST=Japan Atrial Fibrillation Stroke Trial; JROCKET=Japanese Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; KQ=key question; LASAF=low-dose aspirin, stroke atrial

Appendix D Table 7. Relevance of Systematic Reviews and Meta-Analyses for the Benefits and Harms of Anticoagulation or Antiplatelet Therapy (KQs 4, 5)

fibrillation trial; MA=meta-analysis; MGIB=major gastrointestinal bleeding; NA=not applicable; NASPEAF=National Study for Prevention of Embolism in Atrial Fibrillation; NMA=network meta-analysis; NOAC=novel oral anticoagulant; OAC=oral anticoagulant; ROCKET AF=Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; SPAF=Stroke Prevention in Atrial Fibrillation Study; SPINAF=Stroke Prevention in Nonrheumatic Atrial Fibrillation study; SR=systematic review; TIA=transient ischemic attack; VKA=vitamin K antagonist; VTE=venous thrombosis.

Appendix E Table 1. Results of Included Randomized, Controlled Trials for KQs 4 and 5

First Author, Year Trial Name	G1 (N) G2 (N) G3 (N)	All-Cause Mortality G1 N (%) G2 N (%) ES (95% CI)	Stroke- or CV-Related Mortality G1 N (%) G2 N (%) ES (95% CI)	Any Stroke G1 N (%) G2 N (%) ES (95% CI)	Cardioembolic or Ischemic Stroke G1 N (%) G2 N (%) ES (95% CI)	Stroke-Related Morbidity G1 N (%) G2 N (%) ES (95% CI)	Other G1 N (%) G2 N (%) ES (95% CI)
Petersen, 1989 ⁹⁰ AFASAK	Warfarin, adjusted dose (335) Aspirin 75 mg daily (336) Placebo (336)	71 total deaths Total mortality by group NR	<u>Stroke-related mortality</u> 1 (0.3) 3 (0.9) 4 (1.2) NR <u>Vascular deaths</u> 3 (0.9) 12 (3.6) 15 (4.5) p<0.02	NR	<u>Cumulative incidence of thromboembolic related complications</u> 5 (1.5) 15 (6.0) 16 (6.3) p<0.05 <u>Annual incidence of thromboembolic complications</u> 2.0%/year (0.6 to 4.8%) 5.5%/year (2.9 to 9.4%) 5.5%/year (2.9 to 9.4%)	<u>Minor stroke</u> 0 (0) 1 (0.3) 2 (0.6) NR <u>Nondisabling stroke</u> 0 (0) 7 (2.1) 3 (0.9) NR <u>Disabling stroke</u> 4 (1.2) 4 (1.2) 7 (2.1) NR	<u>TIA</u> 0 (0) 2 (0.6) 3 (0.9) NR <u>Visceral emboli</u> 0 (0) 2 (0.6) 2 (0.6) NR <u>Emboli in both extremities</u> 0 (0) 1 (0.3) 0 (0) NR
The Boston Area Trial for Atrial Fibrillation Investigators, 1990 ⁹⁵ BAATAF	Warfarin, adjusted dose (212) Control (208)	<u>Total death</u> 11 (5.2) 26 (12.5) Rate ratio: 0.38 (0.17 to 0.82) p=0.005 <u>Noncardiac death (includes stroke-related mortality)</u> 4 (1.9) 14 (6.7) p=0.008	<u>Stroke-related mortality</u> 0 (0) 1 (0.5) NR <u>CV-related mortality</u> 7 (3.3) 12 (5.8) p=0.17	NR	<u>Ischemic/cardioembolic stroke</u> 2 (0.9) 13 (6.3) Incidence ratio: 0.14 (0.04 to 0.49) Risk reduction: 86% (96 to 51)	<u>Mild</u> 0 (0) 4 (1.9) NR <u>Moderate</u> 1 (0.5) 3 (1.4) NR <u>Severe</u> 1 (0.5) 5 (2.4) NR	<u>Possible ischemic stroke</u> 1 (0.5) 2 (1) NR <u>TIA</u> 2 (0.9) 3 (1.4) NR

Appendix E Table 1. Results of Included Randomized, Controlled Trials for KQs 4 and 5

First Author, Year Trial Name	G1 (N) G2 (N) G3 (N)	All-Cause Mortality G1 N (%) G2 N (%) ES (95% CI)	Stroke- or CV-Related Mortality G1 N (%) G2 N (%) ES (95% CI)	Any Stroke G1 N (%) G2 N (%) ES (95% CI)	Cardioembolic or Ischemic Stroke G1 N (%) G2 N (%) ES (95% CI)	Stroke-Related Morbidity G1 N (%) G2 N (%) ES (95% CI)	Other G1 N (%) G2 N (%) ES (95% CI)
Stroke Prevention in Atrial Fibrillation Investigators, 1990 & 1991 Stroke Prevention in Atrial Fibrillation Investigators, 1990 & 1991 ^{93, 94} SPAF I	<u>Group 1 (anti-coagulation candidates)</u> Warfarin, adjusted dose (210) Aspirin 325 mg/day (206) Placebo (211) <u>Group 2 (non-anticoagulation candidates)</u> Aspirin 325 mg/day (346) Placebo (357)	<u>Total mortality warfarin vs. placebo (Group 1)</u> Warfarin: 6 (2.2%/year) Placebo: 8 (3.1%/year) Risk reduction: 0.25 (-1.11 to .73), p=0.56 <u>Total mortality aspirin vs. placebo (Groups 1 and 2 combined)</u> Aspirin: 39 (5.3%/year) Placebo: 50 (6.5%/year) Risk reduction: 0.20 (-0.20 to 0.46), p=0.37	<u>Fatal ischemic stroke (Group 1)</u> Warfarin: 0 Placebo: 0 NA <u>Fatal ischemic stroke (Groups 1 and 2 combined)</u> Aspirin: 3 (0.5) Placebo: 2 (0.4) NR <u>Vascular death (Group 1)</u> Warfarin: 3 (1.4) Placebo: 5 (2.4) NA <u>Vascular death (Groups 1 and 2 combined)</u> Aspirin: 18 (3.3) Placebo: 19 (3.3) NR <u>Probable vascular death (Group 1)</u> Warfarin: 1 (0.5) Placebo: 2 (0.9) NA <u>Probable vascular death (Groups 1 and 2 combined)</u> Aspirin: 5 (0.9) Placebo: 8 (1.4) NR	NR	<u>Ischemic stroke or systemic embolism warfarin vs. placebo (Group 1)</u> Warfarin: 6 (2.3%/year) Placebo: 18 (7.4%/year) Risk reduction: 0.67 (0.27 to 0.85), p=0.01 <u>Ischemic stroke or systemic embolism vs. placebo (Groups 1 and 2 combined)</u> Aspirin: 26 (3.6%/year) Placebo: 46 (6.3%/year) Risk reduction: 0.42 (-0.09 to 0.63), p=0.02	<u>Minimally disabling ischemic stroke (Group 1)</u> Warfarin: 4 (1.9) Placebo: 10 (4.7) NA <u>Minimally disabling ischemic stroke (Groups 1 and 2 combined)</u> Aspirin: 10 (1.8) Placebo: 24 (4.2) NR <u>Moderate to severely disabling ischemic stroke (Group 1)</u> Warfarin: 2 (1.0) Placebo: 7 (3.3) NA <u>Moderate to severely disabling ischemic stroke (Groups 1 and 2 combined)</u> Aspirin: 10 (1.8) Placebo: 16 (2.8) NR	<u>TIA without ischemic stroke or systemic embolism (Group 1)</u> Warfarin: 3 (1.1%/year) Placebo: 4 (1.6%/year) NR <u>TIA without ischemic stroke or systemic embolism (Group 2)</u> Aspirin: 7 (1.0%/year) Placebo: 13 (1.7%/year) Risk reduction: 0.45 (-0.32 to 0.77), p=0.19 <u>Myocardial infarction (Group 1)</u> Warfarin: 2 (0.8%/year) Placebo: 2 (0.8%/year) NR <u>Myocardial infarction (Group 2)</u> Aspirin: 7 (0.9%/year) Placebo: 12 (1.6%/year) Risk reduction: 0.40 (-0.46 to 0.75), p=0.29 <u>Primary event or death Warfarin vs. placebo (Group 1)</u> Warfarin: 10 (3.8%/year) Placebo: 24 (9.8%/year) Risk reduction: 0.58 (0.20 to 0.78), p=0.01 <u>Primary event or death aspirin vs. placebo (Groups 1 and 2 combined)</u> Aspirin: 57 (7.9%/year) Placebo: 86 (11.8%/year) Risk reduction: 0.32 (0.07 to 0.50), p=0.02

Appendix E Table 1. Results of Included Randomized, Controlled Trials for KQs 4 and 5

First Author, Year Trial Name	G1 (N) G2 (N) G3 (N)	All-Cause Mortality G1 N (%) G2 N (%) ES (95% CI)	Stroke- or CV-Related Mortality G1 N (%) G2 N (%) ES (95% CI)	Any Stroke G1 N (%) G2 N (%) ES (95% CI)	Cardioembolic or Ischemic Stroke G1 N (%) G2 N (%) ES (95% CI)	Stroke-Related Morbidity G1 N (%) G2 N (%) ES (95% CI)	Other G1 N (%) G2 N (%) ES (95% CI)
Connolly, 1991 ⁸⁴ CAFA	Warfarin, adjusted dose (187) Placebo (191)	<u>All-cause mortality</u> NR <u>Other deaths & vascular deaths</u> (Efficacy analysis) 7 (4) 6 (3) (ITT analysis) 10 (5) 8 (4)	<u>Vascular death</u> (Efficacy analysis) 6 (3.2) 6 (3.1) NR (ITT analysis) 9 (4.8) 6 (3.1) NR	NR	<u>Lacunar stroke</u> (Efficacy analysis) 1 (0.5) 0 (0) NR (ITT analysis) 1 (0.5) 0 (0) NR <u>Non-lacunar stroke</u> (Efficacy analysis) 4 (2.1) 9 (4.7) NR (ITT analysis) 5 (2.7) 9 (4.7) NR	<u>Severe non-lacunar stroke</u> (ITT analysis) 2 (1.1) 4 (2.1) NR <u>Mild non-lacunar stroke</u> (ITT analysis) 3 (1.6) 5 (2.6) NR	<u>TIA</u> (Efficacy analysis) 1 (0.5) 2 (1.0) NR (ITT analysis) 2 (1.1) 2 (1.0) NR <u>Non-CNS embolic event</u> (Efficacy analysis) 1 (0.5) 2 (1.0) NR (ITT analysis) 1 (0.5) 2 (1.0) NR
Ezekowitz et al, 1992 ⁸⁵ SPINAF	Warfarin 4 mg/day and adjusted to meet PT ratios (260) Placebo (265)	15 (5.8) (3.3%/year) 22 (8.3) (5.0%/year) Risk reduction: 0.31 (-0.29 to 0.63) p=0.19	<u>Cardiac cause (not related to cerebral outcome)</u> 7 (2.7) 6 (2.3) ES NR <u>Fatal stroke</u> 1 (0.4) 1 (0.4) ES NR	4 (1.5) (0.9%/year) 19 (7.2) (4.3%/year) Risk reduction: 0.79 (0.52 to 0.90) p=0.001	4 (1.5) (0.9%/year) 19 (7.2) (4.3%/year) Risk reduction: 0.79 (0.52 to 0.90) p=0.001	<u>Stroke with no impairment</u> 0 9 (3.4) NR <u>Stroke with minor impairment</u> 3 (1.2) 7 (2.6) NR <u>Stroke with major impairment</u> 0 (0) 2 (0.8) NR	<u>Cerebral infarction or death</u> 19 (7.3) (4.2%/year) 41 (15.5) (9.3%/year) Risk reduction: 0.53 (0.24 to 0.71) p=0.003 <u>Thrombotic vascular events</u> 9 (3.5) (2.0%/year) 16 (6.0) (3.6%/year) Risk reduction: 0.43 (-0.22 to 0.74) p=0.16

Appendix E Table 1. Results of Included Randomized, Controlled Trials for KQs 4 and 5

First Author, Year Trial Name	G1 (N) G2 (N) G3 (N)	All-Cause Mortality G1 N (%) G2 N (%) ES (95% CI)	Stroke- or CV-Related Mortality G1 N (%) G2 N (%) ES (95% CI)	Any Stroke G1 N (%) G2 N (%) ES (95% CI)	Cardioembolic or Ischemic Stroke G1 N (%) G2 N (%) ES (95% CI)	Stroke-Related Morbidity G1 N (%) G2 N (%) ES (95% CI)	Other G1 N (%) G2 N (%) ES (95% CI)
Sato et al, 2006 ⁹² JAST	Aspirin 150–200 mg/day (426) Control (445)	<u>Cardiovascular death</u> 3 (.7) 3 (.67) p=1.00 <u>Noncardio-vascular death</u> 7 (1.6) 6 (1.35) p=0.720	NR	17 (4) 18 (4.04) p=0.967	NR	NR	<u>TIA</u> 7 (1.64) 2 (.45) p=0.101 <u>Cardiogenic embolism</u> 14 (3.29) 12 (2.70) p=0.609 <u>Peripheral emboli</u> 0 (0) 1 (.22) p=1.000 <u>Thrombotic infarction</u> 3 (.70) 2 (.45) p=0.959 <u>Lacunar infarction</u> 0 (0) 4 (.9) p=0.135

Abbreviations: AFASAK=Copenhagen Atrial Fibrillation, Aspirin and Anticoagulation study; BAATAF=Boston Area Anticoagulation Trial for Atrial Fibrillation; CAFA=Canadian Atrial Fibrillation Anticoagulation study; CI=confidence interval; CNS=central nervous system; CV=cardiovascular; ES=effect size; G=group; ITT=intent to treat; JAST=Japan Atrial Fibrillation Stroke Trial; KQ=key question; N=sample size; NA=not applicable; NR=not reported; PT=prothrombin time; SPAF=Stroke Prevention in Atrial Fibrillation Study; SPINAF=Stroke Prevention in Nonrheumatic Atrial Fibrillation study; TIA=transient ischemic attack.

Appendix E Table 2. Results of Included Studies for KQ 5: Harms of Treatment

First Author, Year Trial Name	G1 (N) G2 (N)	Major Bleeding G1 N (%) G2 N (%) ES (95% CI)	Major GI Bleeding G1 N (%) G2 N (%) ES (95% CI)	Allergic Reaction G1 N (%) G2 N (%) ES (95% CI)	Hemorrhagic Stroke G1 N (%) G2 N (%) ES (95% CI)	Subarachnoid Hemorrhage G1 N (%) G2 N (%) ES (95% CI)	Intracerebral Hemorrhage G1 N (%) G2 N (%) ES (95% CI)	Subdural Hemorrhage/ Hematoma G1 N (%) G2 N (%) ES (95% CI)	Minor Bleeding G1 N (%) G2 N (%) ES (95% CI)	Other Harms G1 N (%) G2 N (%) ES (95% CI)
Petersen, 1989 ⁹⁰ The Copenhagen AFASAK Study	Warfarin dose adjusted per subject (335) Aspirin 75 mg 1x daily (336) Placebo (336)	<u>Bleeding (non- fatal) causing withdrawal from study</u> 21 (6.3) 2 0 <u>Respiratory tract bleeding</u> 4 (1.2) 1 (0.3) 0 (0) NR <u>Urogenital bleeding</u> 6 (1.8) 0 (0) 0 (0) NR <u>Other bleeding</u> 0 (0) 2 (0.6) 0 (0) NR	GI bleeding 4 (1.2) 1 (0.3) 0 (0) NR	0 (0) 2 (0.6) 0 (0) NR	NR	NR	1 (0.3) NR NR	NR	All bleeding reported in other columns (no definitions of severity)	<u>GI discomfort</u> 0 (0) 4 (1.2) 3 (0.9) NR

Appendix E Table 2. Results of Included Studies for KQ 5: Harms of Treatment

First Author, Year Trial Name	G1 (N) G2 (N)	Major Bleeding G1 N (%) G2 N (%) ES (95% CI)	Major GI Bleeding G1 N (%) G2 N (%) ES (95% CI)	Allergic Reaction G1 N (%) G2 N (%) ES (95% CI)	Hemorrhagic Stroke G1 N (%) G2 N (%) ES (95% CI)	Subarachnoid Hemorrhage G1 N (%) G2 N (%) ES (95% CI)	Intracerebral Hemorrhage G1 N (%) G2 N (%) ES (95% CI)	Subdural Hemorrhage/Hematoma G1 N (%) G2 N (%) ES (95% CI)	Minor Bleeding G1 N (%) G2 N (%) ES (95% CI)	Other Harms G1 N (%) G2 N (%) ES (95% CI)
The Boston Area Trial for Atrial Fibrillation Investigators, 1990 ⁹⁵ Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)	Warfarin, low dose NR (212) Control (208)	2 (0.9) 1 (0.5) NR	1 (0.5) 0 (0) NR	NR	NR	NR	0 (0) 0 (0) NR	NR	Total 38 (17.9) 21 (10.1) Incidence Ratio: 1.62 (95% CI, 0.95 to 2.74) Leading to hospitalization 4 (1.9) 6 (2.9) NR Leading to transfusion 2 (0.9) 1 (0.5) NR	Transient Monocular Vision Loss 2 (0.9) 1 (0.5) NR Fatal pulmonary hemorrhage 0 (0) 1 (0.5) NR Fatal intracranial hemorrhage (due to loss of consciousness then falling) 1 (0.5) 0 (0) NR

Appendix E Table 2. Results of Included Studies for KQ 5: Harms of Treatment

First Author, Year Trial Name	G1 (N) G2 (N)	Major Bleeding G1 N (%) G2 N (%) ES (95% CI)	Major GI Bleeding G1 N (%) G2 N (%) ES (95% CI)	Allergic Reaction G1 N (%) G2 N (%) ES (95% CI)	Hemorrhagic Stroke G1 N (%) G2 N (%) ES (95% CI)	Subarachnoid Hemorrhage G1 N (%) G2 N (%) ES (95% CI)	Intracerebral Hemorrhage G1 N (%) G2 N (%) ES (95% CI)	Subdural Hemorrhage/Hematoma G1 N (%) G2 N (%) ES (95% CI)	Minor Bleeding G1 N (%) G2 N (%) ES (95% CI)	Other Harms G1 N (%) G2 N (%) ES (95% CI)
Stroke Prevention in Atrial Fibrillation Investigators, 1990 & 1991 ^{93, 94} Stroke Prevention in Atrial Fibrillation (SPAF) Study	<u>Group 1 (anti-coagulation candidates)</u> Warfarin-adjusted dose (210) Aspirin 325 mg/day (206) Placebo (211) <u>Group 2 (non-anticoagulation candidates)</u> Aspirin 325 mg/day (346) Placebo (357)	<u>Major bleeding complications intention to treat population (Group 1)</u> Warfarin: 4 (1.5%/year) Placebo: 4 (1.6%/year) NR <u>(Groups 1 and 2)</u> Aspirin: 10 (1.4%/year) Placebo: 14 (1.9%/year) NR <u>Major bleeding complications relevant bleeding (Group 1)</u> Warfarin: 3 (1.4) Placebo: 1 (0.5) NR <u>(Groups 1 and 2)</u> Aspirin: 5 (0.9) Placebo: 4 (0.7) NR	NR	<u>Severe allergic reactions</u> 0 (0) 0 (0) NR	NR	NR	<u>Group 1</u> Warfarin: 1 (0.5) Placebo: 0 (0) NR <u>Group 1 and 2</u> Aspirin: 1 (0.2) Placebo: 0 (0) NR	<u>Subdural hematoma (Group 1)</u> Warfarin: 1 (0.5) Placebo: 2 (0.9) NR <u>Subdural hematoma (Groups 1 and 2)</u> Aspirin: 1 (0.2) Placebo: 2 (0.4) NR	<u>Minor bleeding leading to therapy withdrawal (Group 1)</u> Warfarin: 4 (1.9) Placebo: 1 (0.5) NR <u>(Groups 1 and 2)</u> Aspirin: 0 (0) Placebo: 2 (0.4) NR	Intracerebral Fatal Hemorrhage Warfarin: 1 Placebo: 0 <u>(Groups 1 and 2)</u> Aspirin: 1 Placebo: 0

Appendix E Table 2. Results of Included Studies for KQ 5: Harms of Treatment

First Author, Year Trial Name	G1 (N) G2 (N)	Major Bleeding G1 N (%) G2 N (%) ES (95% CI)	Major GI Bleeding G1 N (%) G2 N (%) ES (95% CI)	Allergic Reaction G1 N (%) G2 N (%) ES (95% CI)	Hemorrhagic Stroke G1 N (%) G2 N (%) ES (95% CI)	Subarachnoid Hemorrhage G1 N (%) G2 N (%) ES (95% CI)	Intracerebral Hemorrhage G1 N (%) G2 N (%) ES (95% CI)	Subdural Hemorrhage/ Hematoma G1 N (%) G2 N (%) ES (95% CI)	Minor Bleeding G1 N (%) G2 N (%) ES (95% CI)	Other Harms G1 N (%) G2 N (%) ES (95% CI)
Connolly, 1991 ⁸⁴ Canadian Atrial Fibrillation Anticoagulation (CAFA) Study ⁷⁸	Warfarin dose adjusted per subject (187) Placebo (191)	<u>Life-threatening or major bleeding</u> 5 (2.7) 1 (0.5) NR <u>Other major bleeding after permanent discontinuation of medication</u> 0 1	NR	NR	NR	NR	NR	NR	30 (16) 18 (9.4) NR	<u>Intracranial hemorrhage</u> (Efficacy analysis) 1 (0.5) 0 (0) NR (Intention to treat analysis) 1 (0.5) 0 (0) NR <u>Other fatal hemorrhage</u> (Efficacy analysis) 1 (0.5) 0 (0) NR (Intention to treat analysis) 1 (0.5) 0 (0) NR <u>Annual rate of fatal or major hemorrhage</u> 2.5%/year 0.5%/year NR

Appendix E Table 2. Results of Included Studies for KQ 5: Harms of Treatment

First Author, Year Trial Name	G1 (N) G2 (N)	Major Bleeding G1 N (%) G2 N (%) ES (95% CI)	Major GI Bleeding G1 N (%) G2 N (%) ES (95% CI)	Allergic Reaction G1 N (%) G2 N (%) ES (95% CI)	Hemorrhagic Stroke G1 N (%) G2 N (%) ES (95% CI)	Subarachnoid Hemorrhage G1 N (%) G2 N (%) ES (95% CI)	Intracerebral Hemorrhage G1 N (%) G2 N (%) ES (95% CI)	Subdural Hemorrhage/Hematoma G1 N (%) G2 N (%) ES (95% CI)	Minor Bleeding G1 N (%) G2 N (%) ES (95% CI)	Other Harms G1 N (%) G2 N (%) ES (95% CI)
Ezekowitz et al, 1992 ⁸⁵ Veterans Affairs Cooperative Study SPINAF	Patients without previous cerebral infarction: Warfarin: 4 mg/day and adjusted to meet PT ratios (260) Control (265) Patients with previous cerebral infarction: Warfarin: 4 mg/day and adjusted to meet PT ratios (21) Control (25)	Without previous cerebral infarction: Major hemorrhage 6 (2.3) (1.3%/year) 4 (1.5) (0.9%/year) Risk reduction: -0.53 (-4.22 to 0.55) p=0.54 With previous cerebral infarction: 0 (0) 0 (0)	Without previous cerebral infarction: Major hemorrhage 6 (2.3) (1.3%/year) 4 (1.5) (0.9%/year) Risk reduction: -0.53 (-4.22 to 0.55) p=0.54 With previous cerebral infarction: 0 (0) 0 (0)	NR	NR	NR	Without previous cerebral infarction: Cerebral hemorrhage 1 (0.4) (0) ES NR With previous cerebral infarction: Cerebral hemorrhage 0 (0) 0 (0)	NR	Without previous cerebral infarction: Minor hemorrhage 64 (24.6) (14.0%/year) 46 (17.4) (10.5%/year) Risk reduction: -0.42 (-0.98 to -0.02) p=0.04 With previous cerebral infarction: Minor hemorrhage 3 (14.3) (9.2%/year) 7 (28.0) (16.2%/year) Risk reduction: 0.49 (-0.53 to 0.83) p=0.31	NR

Appendix E Table 2. Results of Included Studies for KQ 5: Harms of Treatment

First Author, Year Trial Name	G1 (N) G2 (N)	Major Bleeding G1 N (%) G2 N (%) ES (95% CI)	Major GI Bleeding G1 N (%) G2 N (%) ES (95% CI)	Allergic Reaction G1 N (%) G2 N (%) ES (95% CI)	Hemorrhagic Stroke G1 N (%) G2 N (%) ES (95% CI)	Subarachnoid Hemorrhage G1 N (%) G2 N (%) ES (95% CI)	Intracerebral Hemorrhage G1 N (%) G2 N (%) ES (95% CI)	Subdural Hemorrhage/ Hematoma G1 N (%) G2 N (%) ES (95% CI)	Minor Bleeding G1 N (%) G2 N (%) ES (95% CI)	Other Harms G1 N (%) G2 N (%) ES (95% CI)
Sato et al, 2006 ⁹² Japan Atrial Fibrillation Stroke Trial (JAST)	Aspirin 150–200 mg/day (426) Control (445)	Major bleeding 7 (1.64) 2 (0.45) p=0.101	NR	NR	NR	NR	NR	NR	NR	Intracranial bleeding 4 (0.94) 2 (0.45) NR

AFASAK did not specify bleeding severity and was therefore not included in this analysis. It reported bleeding events leading to withdrawal from study, 21 for warfarin and 0 for placebo.

BAATAF, minor bleeding was defined as bleeding that did not include intracranial bleeding, fatal bleeding, or bleeding that required a blood transfusion (four or more units of blood within 48 hours).

SPAF I, minor bleeding defined as bleeding that did not involve the central nervous system, management requiring hospitalization with transfusion and/or surgery, or permanent residual impairment.

CAFA, minor bleeding defined as non-life-threatening bleeding.

SPINAF, minor bleeding defined as bleeding that did not require a blood transfusion, an emergency procedure, removal of a hematoma, or ICU admission.

Abbreviations: AFASAK=Copenhagen Atrial Fibrillation, Aspirin and Anticoagulation study; BAATAF=Boston Area Anticoagulation Trial for Atrial Fibrillation;

CAFA=Canadian Atrial Fibrillation Anticoagulation study; CI=confidence interval; ES=effect size; G=group; JAST=Japan Atrial Fibrillation Stroke Trial; KQ=key question;

N=sample size; NA=not applicable; NR=not reported; PT=prothrombin time; SPAF=Stroke Prevention in Atrial Fibrillation Study; SPINAF=Stroke Prevention in Nonrheumatic Atrial Fibrillation study.

Appendix E Table 3. Summary of Included Systematic Reviews, Individual Patient Data Meta-Analyses, and Network Meta-Analyses on Benefits and Harms of Treatment for Atrial Fibrillation

Author, Year Intervention vs. Comparison	Review Type	Total N	Characteristics of Participants	Main Findings
Aguilar, 2009 ¹⁰⁰ Warfarin vs. Placebo	SR with MA	2,313	Mean age: 69 Female: 26% Nonwhite: NR History of HF: 45% Diabetes: 15% Prior MI: 15% HTN: 45% Prior stroke or TIA: 3 to 8% in published results of the included studies, but they report obtaining the unpublished results without those 3 to 8%	Included same RCTs as our report Odds ratio (95% CI) All strokes (including ischemic and hemorrhagic): 0.39 (0.26 to 0.59) All ischemic strokes: 0.34 (0.23 to 0.52) ^a Disabling or fatal strokes (including ischemic and hemorrhagic): 0.47 (0.28 to 0.80) MI: 0.87 (0.32 to 2.42) All systemic emboli: 0.45 (0.13 to 1.57) Intracranial hemorrhage: 2.38 (0.54 to 10.5) Major extracranial bleeding: 1.07 (0.53 to 2.12) ^b Vascular death: 0.84 (0.56 to 1.27) Stroke, MI, or vascular death: 0.56 (0.42 to 0.76) All-cause mortality: 0.69 (0.50 to 0.94)
Aguilar, 2011 ¹⁰⁸ AP vs. Placebo	SR with MA	2,622	Mean age: 70 Female: 38% % nonwhite: NR History of HF: NR Diabetes and prior MI: NR Prior stroke or TIA: NR HTN: NR	Included AFASAK I, SPAF I, and LASAF (not JAST) Odds ratio (95% CI) All strokes (including ischemic and hemorrhagic): 0.70 (0.47 to 1.07) Ischemic strokes: 0.70 (0.46 to 1.07) All disabling or fatal strokes (including ischemic and hemorrhagic): 0.86 (0.50 to 1.49) MI: 0.47 (0.19 to 1.14) Systemic emboli: 0.67 (0.19 to 2.3) Intracranial hemorrhage: 1.32 (0.22 to 7.80) Major extracranial bleeding: 1.14 (0.44 to 2.98) Vascular death: 0.82 (0.54 to 1.25) Composite outcome: all stroke, MI, or vascular death: 0.71 (0.51 to 0.97) All-cause mortality: 0.75 (0.54 to 1.04)

Appendix E Table 3. Summary of Included Systematic Reviews, Individual Patient Data Meta-Analyses, and Network Meta-Analyses on Benefits and Harms of Treatment for Atrial Fibrillation

Author, Year Intervention vs. Comparison	Review Type	Total N	Characteristics of Participants	Main Findings
Atrial Fibrillation Investigators, 1997 ¹⁰⁵ Aspirin vs. Placebo	IPD	2,574	Mean age: 70 Female: 38% Nonwhite: NR History of HF: 28 Diabetes: 14% Prior MI: 10% Prior stroke or TIA: 35% HTN: 46%	Included AFASAK I and SPAF I, and a secondary prevention trial (EAST). Relative risk reduction (95% CI) Stroke: 21% (0% to 38%); p=0.05 Disabling stroke: 17% (-12% to 38%; p=0.23) Nondisabling stroke occurrence: 27% (-7% to 51%; p=0.10) Subgroups Age: 1.02 (0.99 to 1.05) Age ≤75: 0.73 (0.54 to 0.99) Male: 0.80 (0.58 to 1.11) Female: 0.80 (0.56 to 1.13) SBP>160 mm Hg: 0.75 (0.48 to 1.18) SBP<160 mm Hg: 0.81 (0.61 to 1.07) History of hypertension: 0.64 (0.46 to 0.89), p=0.09; interaction NS, p=.08 No history of hypertension: 0.98 (0.70 to 1.39) History of CHF: 0.54 (0.33 to 0.89) No history of CHF: 0.89 (0.68 to 1.16) History of diabetes: 0.60 (0.34 to 1.06) No history of diabetes: 0.84 (0.65 to 1.09) Risk stratification No clinical risk factors: 1.33 (0.66 to 2.68) >1 clinical risk factors: 0.72 (0.56 to 0.93) (interaction between aspirin and risk factor NS, p=0.10) History of hypertension or diabetes but with no previous stroke or TIA: 54% (17% to 74%; p=0.009; interaction term, p=0.02) Except for patients younger than 65 years, the absolute risk of stroke with aspirin therapy did not decrease below 3.0% per year for any of the risk strata

Appendix E Table 3. Summary of Included Systematic Reviews, Individual Patient Data Meta-Analyses, and Network Meta-Analyses on Benefits and Harms of Treatment for Atrial Fibrillation

Author, Year Intervention vs. Comparison	Review Type	Total N	Characteristics of Participants	Main Findings
<p>Atrial Fibrillation Investigators, 1994¹⁰³</p> <p>Warfarin vs. Placebo</p> <p>Aspirin vs. Placebo</p>	IPD	4,174	<p>Mean age: 69</p> <p>Female: 26%</p> <p>Nonwhite: 7%</p> <p>History of HF: 20%</p> <p>Diabetes: 14%</p> <p>Prior MI: 14%</p> <p>Prior stroke or TIA: 6%</p> <p>HTN: 45%</p>	<p>Included same RCTs as our report for warfarin; only included AFASAK and SPAF for aspirin (JAST was not yet published)</p> <p><i>Warfarin (1889 patient-years receiving warfarin)</i></p> <p>Relative risk reduction (95% CI)</p> <p>Stroke: 68% (50% to 79%); 3.1% Absolute annual reduction, $p<0.001$</p> <p>Stroke with residual deficit: 68% (39% to 83%); 1.4% absolute annual reduction, $p<0.001$</p> <p>Death: 33% (9% to 51%); $p=0.010$</p> <p>Stroke, systemic embolism, or death: 48% (34% to 60%); $p<0.001$</p> <p>Annual frequency of major bleeding events: 1.3% (vs. 1.0% for controls).</p> <p>Patients taking warfarin who had intracranial bleeding ($n=6$) had a higher systolic ($p=0.001$) and diastolic ($p=0.016$) blood pressure at entry to study than patients taking warfarin who did not have intracranial bleeding (mean 169/93 vs. 141/83)</p> <p>Mean age of those with and without intracranial bleeding as 73 and 69, NS</p> <p><i>Effect of Warfarin on Stroke by Subgroup</i></p> <p>Women: 84% (55% to 95%), $p<0.001$</p> <p>Men: 60% (35% to 76%), $p<0.001$</p> <p><i>Aspirin 1,132 (patient-years receiving aspirin)</i></p> <p>Relative risk reduction (95% CI)</p> <p>Stroke: 36% (4% to 57%); $p=0.03$</p> <p>Stroke with residual deficit: 30% (20% to 60%); NS</p> <p>Rate of death: 17% (20% to 40%); NS</p> <p>Combination of stroke, systemic embolism, or death: 28% (6% to 45%); $p=0.02$</p> <p>Annual frequency of major bleeding events: 1.0%</p> <p><i>Effect of Aspirin on Stroke by Subgroup</i></p> <p>History of hypertension: 59% (28% to 77%); $p=0.002$</p> <p>No history of hypertension: 10% (40% to 100%); $p=0.76$</p> <p>$p=0.02$ for difference in effectiveness between those with and without hypertension</p> <p><i>Effect of Aspirin on Stroke by Subgroup</i></p> <p>Women: 23% (40% to 58%), $p=0.38$</p> <p>Men: 44% (3% to 68%), $p=0.04$</p>

Appendix E Table 3. Summary of Included Systematic Reviews, Individual Patient Data Meta-Analyses, and Network Meta-Analyses on Benefits and Harms of Treatment for Atrial Fibrillation

Author, Year Intervention vs. Comparison	Review Type	Total N	Characteristics of Participants	Main Findings
<p>Coleman, 2012¹⁰²</p> <p>Warfarin vs. Placebo</p> <p>Aspirin vs. Placebo</p> <p>VKA vs. Aspirin</p>	SR with MA	42,983	<p>Mean age: 65–75</p> <p>Female: 0–59%</p> <p>% nonwhite: NR</p> <p>History of HF: NR</p> <p>Diabetes and prior MI: NR</p> <p>Prior stroke or TIA: NR</p> <p>Target range of INRs: NA</p> <p>Median follow up: 2 years</p>	<p>Combines studies of primary and secondary prevention (participants had a TIA or stroke) and does not provide any analyses separating them, possibly limiting applicability; did not include SPAF-1, CAFA, or LASAF (but those did not report major gastrointestinal bleeding); also included studies of combinations of medications (e.g., aspirin plus low-dose VKA)</p> <p>Major gastrointestinal bleeding odds ratio (95% CI), 4 trials (including EAFT), 2,219 participants</p> <p>Adjusted-dose warfarin vs. placebo/control: 3.21 (1.32 to 7.82)</p> <p>Aspirin vs. placebo/control: 3.23 (0.56 to 18.66); 3 trials (AFASAK I, JAST, and EAFT), 2,325 participants</p> <p>Adjusted-dose VKA vs. aspirin: 1.92 (1.08 to 3.41); 7 trials, 4,819 participants</p>
<p>Hart, 2007¹⁰⁷</p> <p>Warfarin vs. Placebo</p> <p>Aspirin vs. Placebo</p> <p>Warfarin vs. Aspirin</p>	SR with MA	28,044 (but most of those from secondary prevention trials)	<p>Warfarin</p> <p>Mean age: 69</p> <p>Female: 29%</p> <p>Prior stroke or TIA: 20%</p> <p>Aspirin</p> <p>Mean age: 69</p> <p>Female: 37%</p> <p>Prior stroke or TIA: 29%</p> <p>Median follow up: 1.6 to 1.7 years overall</p>	<p>Included secondary prevention RCTs in addition to primary prevention RCTs for most analyses; only separated primary prevention results (using the same trials we included) when reporting absolute risk reduction and NNT</p> <p>Warfarin vs. placebo or no treatment for primary prevention:</p> <p>Stroke, ARR: 2.7%/year (vs. 8.4% for secondary prevention); NNT 40</p> <p>Aspirin vs. placebo or no treatment for primary prevention:</p> <p>Stroke, ARR: 0.8%/year (vs. 2.5% for secondary prevention); NNT 111</p> <p>Warfarin vs. aspirin for primary prevention:</p> <p>Stroke, ARR: 0.7%/year (vs. 7% for secondary prevention); NNT 81</p> <p>Safety outcomes included all trials identified (not limited to primary prevention):</p> <p>Warfarin vs. placebo or no treatment</p> <p>Intracranial hemorrhage: 6 vs. 3 events (RR not calculated)</p> <p>Major extracranial hemorrhage: -66 (-235 to 18); -0.3%/year ARR</p> <p>All-cause mortality: 26 (3 to 43); 1.6%/year ARR</p> <p>Aspirin vs. placebo or no treatment</p> <p>Intracranial hemorrhage: 8 vs. 4 events (RR not calculated)</p> <p>Major extracranial hemorrhage: -2 (-98 to 52); -0.2%/year ARR</p> <p>All-cause mortality: 14 (-7 to 31); 0.5 %/year ARR</p>

Appendix E Table 3. Summary of Included Systematic Reviews, Individual Patient Data Meta-Analyses, and Network Meta-Analyses on Benefits and Harms of Treatment for Atrial Fibrillation

Author, Year Intervention vs. Comparison	Review Type	Total N	Characteristics of Participants	Main Findings
Tereshchenko, 2016 ¹⁰⁴ All comparisons	NMA	96,017	<p>Mean age: 71.5 Female: 35% Nonwhite: NR Prior stroke or TIA: NR overall, but ranged from 0% to 100%; 4 (of 21) included trials had over 35% secondary prevention; and both trials of rivaroxaban, JROCKET and ROCKET AF, included more than 50% for secondary prevention.</p> <p>Median follow up: 1.7 years</p>	<p>Included 21 RCTs of treatment for nonvalvular AF. Not limited to primary prevention. Results below were unadjusted unless otherwise noted (for the major bleeding outcome, unadjusted data were not provided in the published article but were obtained from the author).</p> <p><i>VKAs vs. placebo/control odds ratio (95% CI)</i> Stroke or systemic embolism: 0.38 (0.29 to 0.49) All-cause mortality: 0.69 (0.57 to 0.85)</p> <p><i>Placebo/control vs. VKA</i> Unadjusted; adjusted for population characteristics (CHADS₂ scores, TTR, duration of follow up) Stroke or systemic embolism: 2.65 (2.03 to 3.46); 2.30 (1.50 to 3.54) All-cause mortality: 1.44 (1.17 to 1.76); 1.33 (0.90 to 1.95); Major bleeding: 0.40 (0.24 to 0.68); 0.47 (0.22 to 1.00)</p> <p><i>Aspirin vs. placebo/control odds ratio (95% CI)</i> Unadjusted; adjusted for population characteristics (CHADS₂ scores, TTR, duration of follow up) Stroke or systemic embolism: 0.75 (0.60 to 0.95); 0.77 (0.53, 1.11) All-cause mortality: 0.82 (0.68 to 0.99); 0.82 (0.57, 1.17) Major bleeding: 1.79 (1.06 to 3.04); 1.65 (0.77 to 3.51)</p> <p><i>NOACs vs. placebo/control odds ratio (95% CI) for stroke or systemic embolism</i> Unadjusted; Adjusted for population characteristics (CHADS₂ scores, TTR, duration of follow up) Apixaban 0.31 (0.22 to 0.45); 0.35 (0.21 to 0.58) Dabigatran 0.29 (0.20 to 0.43); 0.34 (0.19 to 0.60) Edoxaban 0.38 (0.26 to 0.54); 0.44 (0.25 to 0.77) Rivaroxaban 0.27 (0.18 to 0.42); 0.32 (0.16 to 0.66)</p> <p><i>Comparison of NOACs: no statistically significant differences in effectiveness for each of the 4 NOACs in comparison to one another</i></p> <p><i>NOACs vs. VKA: risk of stroke or systemic embolism; OR (95% CI)</i> Unadjusted; adjusted for population characteristics (CHADS₂ scores, TTR, duration of follow up) Apixaban 0.82 (0.62 to 1.10); 0.81 (0.57 to 1.15) Dabigatran 0.78 (0.60 to 1.01); 0.78 (0.53 to 1.14) Edoxaban 1.00 (0.79 to 1.27); 1.01 (0.70 to 1.45) Rivaroxaban 0.72 (0.51 to 1.00); 0.74 (0.42 to 1.31)</p>

Appendix E Table 3. Summary of Included Systematic Reviews, Individual Patient Data Meta-Analyses, and Network Meta-Analyses on Benefits and Harms of Treatment for Atrial Fibrillation

Author, Year Intervention vs. Comparison	Review Type	Total N	Characteristics of Participants	Main Findings
Tereshchenko, 2016 ¹⁰⁴ (continued)				<p>NOACs vs. VKA: <i>risk of all-cause mortality; OR (95% CI)</i> Unadjusted; Adjusted for population characteristics (CHADS₂ scores, TTR, duration of follow up) Apixaban 0.89 (0.80 to 0.99); 0.89 (0.71 to 1.13) Dabigatran 0.90 (0.82 to 0.99); 0.88 (0.70 to 1.12) Edoxaban 0.89 (0.82 to 0.96); 0.90 (0.71 to 1.14) Rivaroxaban 0.84 (0.70 to 1.01); 0.84 (0.48 to 1.48)</p> <p>NOACs vs. VKA: major bleeding Edoxaban 0.61 (0.36 to 1.01); 0.64 (0.46 to 0.90) Only edoxaban was significantly different (adjusted ORs from 0.74 to 0.85 for the others but CIs go up to 1.02 through 1.57 for the various NOACs)</p>
van Walraven, 2008 ¹⁰⁶ Oral anticoagulant (mostly warfarin) ^c vs. Placebo Antiplatelet (mostly Aspirin) vs. Placebo	IPD	8,932	<p>Mean age: 70.9 for all studies except for BAFTA with was 81.5 Female: 37% History of HF: 20% Diabetes and prior MI: 15 Prior stroke or TIA: 22% HTN: 50% AP dose range: 75 mg to 325 mg daily Median follow up: 2.0 years</p>	<p>Included secondary prevention RCTs in addition to primary prevention RCTs; did not separate primary prevention results</p> <p>OAC hazard ratio (95% CI) Ischemic stroke: 0.36 (0.29 to 0.45) Systemic or intracranial hemorrhage: 1.56 (1.03 to 2.37) Cardiovascular event: 0.59 (0.52 to 0.66)</p> <p>Interaction of age and OAC Ischemic stroke: $X^2=3.2$, $p=0.07$; trend toward decreasing relative benefit of OAC (HR moved toward 1 as patients age. HR 0.22 [95% CI, 0.11, 0.41] for 50-year-olds and HR 0.53 [0.35, 0.81] for 90-year-olds) Serious hemorrhage: NS Cardiovascular events: NS</p> <p>AP hazard ratio (95% CI) Ischemic stroke: 0.81 (0.72 to 0.90) Systemic or intracranial hemorrhage: 1.03 (0.71 to 1.49) Cardiovascular event: 0.81 (0.75 to 0.88)</p> <p>Interaction of age and AP Ischemic stroke: $X^2=6.5$, $p=0.01$; relative benefit of AP for preventing stroke decreased significantly with age; HR, 0.40; 95% CI, 0.22 to 0.72 at age 50; by age 77, the HR no longer excluded the null; at age 82, the HR exceeded 1. Serious hemorrhage: NS Cardiovascular events: NS</p>

^a Subgroup analysis was performed for the outcome “ischemic stroke (fatal and nonfatal).” There was no evidence of a difference in the treatment effect between double-blind trials and open-label trials, $p=0.92$.

^b In the text, they also report that meta-analysis of data from six trials in which 20% had prior stroke, TIA, or both, major extracranial bleeding was increased in those assigned to OAC (OR 1.80, 95% CI, 1.01 to 3.18), presumably that was by adding EAFT (in which all participants had a history of stroke or TIA).


^c Some secondary prevention studies used 4-hydroxycoumarin instead of warfarin.

Appendix E Table 3. Summary of Included Systematic Reviews, Individual Patient Data Meta-Analyses, and Network Meta-Analyses on Benefits and Harms of Treatment for Atrial Fibrillation

^d One secondary prevention study used triflusal.


Abbreviations: AFASAK=Copenhagen Atrial Fibrillation, Aspirin and Anticoagulation study; AP= antiplatelet therapy; ARR=absolute risk reduction; BAFTA=Birmingham Atrial Fibrillation in the Aged; CAFA=Canadian Atrial Fibrillation Anticoagulation study; CHADS₂=Congestive heart failure, Hypertension, Age≥75 years, Diabetes mellitus, Prior stroke or TIA or thromboembolism; CHF=cardiac heart failure; CI=confidence interval; EAFT=European Atrial Fibrillation Trial Study Group; G=group; HF=heart failure; Hg=hemoglobin; HR=hazard ratio; HTN: hypertension; INR=International Normalized Ratio, assay used to determine clotting tendency; IPD=individual patient data meta-analysis; JAST=Japan Atrial Fibrillation Stroke Trial; JROCKET=Japanese Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; LASAF=low-dose aspirin, stroke atrial fibrillation trial; MA=meta-analysis; MI=myocardial infarction; N=sample size; NA=not applicable; NR=not reported; NS=not significant; NMA=network meta-analysis; NNT=number-needed-to-treat; NOAC=novel oral anticoagulants; OAC=oral anticoagulant; OR=odds ratio; RCT=randomized, controlled trial; ROCKET AF=Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; RR=relative risk; SBP=systolic blood pressure; SPAF=Stroke Prevention in Atrial Fibrillation Study; SR=systematic review; TIA=transient ischemic attack; TTR=time in therapeutic range; VKA=vitamin K antagonists.

Appendix F Figure 1. Warfarin vs. Placebo/Control, TIA



$Q = 1.25$, $df=3$, $p= 0.74$, $I-sq= 0.00$

Appendix F Figure 2. Warfarin vs. Placebo/Control, Minor Bleeding



AFASAK did not specify bleeding severity and was therefore not included in this analysis. It reported bleeding events leading to withdrawal from study, 21 for warfarin and 0 for placebo.


BAATAF, minor bleeding was defined as bleeding that did not include intracranial bleeding, fatal bleeding, or bleeding that required a blood transfusion (four or more units of blood within 48 hours).

SPAF I, minor bleeding defined as bleeding that did not involve the central nervous system, management requiring hospitalization with transfusion and/or surgery, or permanent residual impairment.

CAFA, minor bleeding defined as non-life-threatening bleeding.


SPINAF, minor bleeding defined as bleeding that did not require a blood transfusion, an emergency procedure, removal of a hematoma, or ICU admission.

Appendix F Figure 3. Aspirin vs. Placebo/Control, All-Cause Mortality Sensitivity Analyses




$Q=1.62$, $df=3$, $p=0.65$, $I^2=0.00$; AFASAK, includes data from a previously published meta-analysis that obtained data from the original study authors.


Appendix F Figure 4. Aspirin vs. Placebo/Control, Cardiovascular-Related Mortality Sensitivity Analyses




Appendix F Figure 5. Aspirin vs. Placebo/Control, All Ischemic Stroke



Appendix F Figure 6. Aspirin vs. Placebo/Control, All Ischemic Stroke or Intracranial Hemorrhage Sensitivity Analyses




Appendix F Figure 7. Aspirin vs. Placebo/Control, Moderately to Severely Disabling Stroke



Q =3.06 df=3, p= 0.87, I-sq= 0.00


AFASAK reported disabling stroke which was defined as a stroke leaving definite functional disability a month after onset. SPAF I reported moderately to severely disabling stroke which was defined as a stroke requiring assistance to perform basic activities of daily living after onset.

Appendix F Figure 8. Aspirin vs. Placebo/Control, TIA



$Q = 4.25$ $df=2$, $p= 0.12$, $I-sq= 52.98$

Appendix F Figure 9. Aspirin vs. Placebo/Control, Intracranial Bleeding



$Q = 0.29$ $df=1$, $p= 0.59$, $I-sq= 0.00$

For AFASAK: zero for aspirin and zero for placebo. For SPAF I: aspirin, one fatal intracerebral hemorrhage and one fatal subdural hematoma; placebo, two subdural hematomas with full recovery.

Appendix References

1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. *JAMA*. 2001 May 9;285(18):2370-5. PMID: 11343485.
2. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. *JAMA*. 2001 Jun 13;285(22):2864-70. PMID: 11401607.
3. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. *Chest*. 2010 Feb;137(2):263-72. doi: 10.1378/chest.09-1584. PMID: 19762550.
4. Piccini JP, Stevens SR, Chang Y, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. *Circulation*. 2013 Jan 15;127(2):224-32. doi: 10.1161/circulationaha.112.107128. PMID: 23212720.
5. Hippisley-Cox J, Coupland C, Brindle P. Derivation and validation of QStroke score for predicting risk of ischaemic stroke in primary care and comparison with other risk scores: a prospective open cohort study. *BMJ*. 2013;346:f2573. doi: 10.1136/bmj.f2573. PMID: 23641033.
6. Singer DE, Chang Y, Borowsky LH, et al. A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score. *J Am Heart Assoc*. 2013 Jun 21;2(3):e000250. doi: 10.1161/JAHA.113.000250. PMID: 23782923.
7. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest*. 2010 Nov;138(5):1093-100. doi: 10.1378/chest.10-0134. PMID: 20299623.
8. Gage BF, Yan Y, Milligan PE, et al. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). *Am Heart J*. 2006 Mar;151(3):713-9. doi: 10.1016/j.ahj.2005.04.017. PMID: 16504638.
9. Fang MC, Go AS, Chang Y, et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. *J Am Coll Cardiol*. 2011 Jul 19;58(4):395-401. doi: 10.1016/j.jacc.2011.03.031. PMID: 21757117.
10. Lopes RD, Crowley MJ, Shah BR, et al. Stroke Prevention in Atrial Fibrillation Agency for Healthcare Research and Quality. Rockville (MD): 2013. PMID: 24049843. <http://www.ncbi.nlm.nih.gov/pubmed/24049843>
11. Cairns JA, Connolly S, McMurry S, et al. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. *Can J Cardiol*. 2011 Jan-Feb;27(1):74-90. doi: 10.1016/j.cjca.2010.11.007. PMID: 21329865.
12. Lip GY, Andreotti F, Fauchier L, et al. Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm

Appendix References

- Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. *Europace*. 2011 May;13(5):723-46. doi: 10.1093/europace/eur126. PMID: 21515596.
13. National Institute for Health and Care Excellence. Atrial Fibrillation: The Management of Atrial Fibrillation National Institute for Health and Care Excellence (UK). London: 2014.
14. Freedman B, Camm J, Calkins H, et al. Screening for Atrial Fibrillation: A Report of the AF-SCREEN International Collaboration. *Circulation*. 2017 May 09;135(19):1851-67. doi: 10.1161/circulationaha.116.026693. PMID: 28483832.
15. Murphy A, Banerjee A, Breithardt G, et al. The World Heart Federation Roadmap for Nonvalvular Atrial Fibrillation. *Glob Heart*. 2017 Dec;12(4):273-84. doi: 10.1016/j.gheart.2017.01.015. PMID: 28336387.
16. Kirchhof P, Breithardt G, Bax J, et al. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. *Europace*. 2016 Jan;18(1):37-50. doi: 10.1093/europace/euv304. PMID: 26481149.
17. Mairesse GH, Moran P, Van Gelder IC, et al. Screening for atrial fibrillation: a European Heart Rhythm Association (EHRA) consensus document endorsed by the Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE). *Europace*. 2017 Oct 1;19(10):1589-623. doi: 10.1093/europace/eux177. PMID: 29048522.
18. Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*. 2016 Oct 7;37(38):2893-962. doi: 10.1093/eurheartj/ehw210. PMID: 27567408.
19. Hobbs FR, Taylor CJ, Jan Geersing G, et al. European Primary Care Cardiovascular Society (EPCCS) consensus guidance on stroke prevention in atrial fibrillation (SPAF) in primary care. *Eur J Prev Cardiol*. 2016 Mar;23(5):460-73. doi: 10.1177/2047487315571890. PMID: 25701017.
20. Huisman M, Rothman K, Paquette M, et al. The Changing Landscape for Stroke Prevention in AF: findings From the GLORIA-AF Registry Phase 2. *J Am Coll Cardiol*; 2017. p. 777-85.
21. National Screening Committee. The UK NSC recommendation on Atrial Fibrillation screening in adults National Health Service (UK). London: 2014.
<https://legacyscreening.phe.org.uk/atrialfibrillation>
22. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. 2014 Dec 2;64(21):e1-76. doi: 10.1016/j.jacc.2014.03.022. PMID: 24685669.
23. Meschia JF, Bushnell C, Boden-Albala B, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2014 Dec;45(12):3754-832. doi: 10.1161/STR.0000000000000046. PMID: 25355838.
24. Culebras A, Messe SR, Chaturvedi S, et al. Summary of evidence-based guideline update: prevention of stroke in nonvalvular atrial fibrillation: report of the Guideline

Appendix References

- Development Subcommittee of the American Academy of Neurology. *Neurology*. 2014 Feb 25;82(8):716-24.
25. Verma A, Cairns JA, Mitchell LB, et al. 2014 focused update of the Canadian Cardiovascular Society Guidelines for the management of atrial fibrillation. *Can J Cardiol*. 2014;30(10):1114-30.
26. Antithrombotic Agents for the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation Canadian Agency for Drugs and Technologies in Health. Ottawa (ON): 2013.
27. Scottish Intercollegiate Guidelines Network (SIGN). SIGN 129: Antithrombotics: Indications and Management. Edinburgh: Healthcare Improvement Scotland; 2013.
28. You JJ, Singer DE, Howard PA, et al. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012;141(2 Suppl):e513S-75S.
29. Furie KL, Goldstein LB, Albers GW, et al. Oral antithrombotic agents for the prevention of stroke in nonvalvular atrial fibrillation: a science advisory for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2012;43(12):3442-53.
30. Stott DJ, Dewar RI, Garratt CJ, et al. RCPE UK Consensus Conference on 'Approaching the comprehensive management of atrial fibrillation: evolution or revolution?'. *J R Coll Physicians Edinb*. 2012;42(Suppl 18):3-4. doi: 10.4997/JRCPE.2012.S01. PMID: 22518389.
31. Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2010 Dec 14;56(25):e50-103. doi: 10.1016/j.jacc.2010.09.001. PMID: 21144964.
32. Lindsay MP, Gubitz G, Bayley M, et al. Canadian Best Practice Recommendations for Stroke Care (Update 2010). On behalf of the Canadian Stroke Strategy Best Practices and Standards Writing Group Canadian Stroke Network. Ottawa (ON): 2010.
33. Chan N-y, Choy C-c. Screening for atrial fibrillation in 13 122 Hong Kong citizens with smartphone electrocardiogram. *Heart*. 2016 October 12, 2016doi: 10.1136/heartjnl-2016-309993.
34. Doliwa PS, Frykman V, Rosenqvist M. Short-term ECG for out of hospital detection of silent atrial fibrillation episodes. *Scand Cardiovasc J*. 2009 Jun;43(3):163-8. doi: 10.1080/14017430802593435. PMID: 19096977.
35. Kaasenbrood F, Hollander M, Rutten FH, et al. Yield of screening for atrial fibrillation in primary care with a hand-held, single-lead electrocardiogram device during influenza vaccination. *Europace*. 2016 Oct;18(10):1514-20. doi: 10.1093/europace/euv426. PMID: 26851813.
36. Morgan S, Mant D. Randomised trial of two approaches to screening for atrial fibrillation in UK general practice. *Br J Gen Pract*. 2002 May;52(478):373-4, 7-80. PMID: 12014534.
37. Lowres N, Neubeck L, Salkeld G, et al. Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in

Appendix References

- pharmacies. The SEARCH-AF study. *Thromb Haemost.* 2014 Jun;111(6):1167-76. doi: 10.1160/th14-03-0231. PMID: 24687081.
38. Claes N, Van Laethem C, Goethals M, et al. Prevalence of atrial fibrillation in adults participating in a large-scale voluntary screening programme in Belgium. *Acta Cardiol.* 2012 Jun;67(3):273-8. doi: 10.2143/ac.67.3.2160714. PMID: 22870733.
39. Deif B, Lowres N, Freedman SB. Screening for atrial fibrillation above age 65 detects an asymptomatic subset at high risk of stroke. *Int J Cardiol.* 2013 Apr 15;164(3):371-2. doi: 10.1016/j.ijcard.2012.08.002. PMID: 22964080.
40. Schnabel RB, Wilde S, Wild PS, et al. Atrial fibrillation: its prevalence and risk factor profile in the German general population. *Dtsch Arztebl Int.* 2012 Apr;109(16):293-9. doi: 10.3238/arztebl.2012.0293. PMID: 22577476.
41. Meschia JF, Merrill P, Soliman EZ, et al. Racial disparities in awareness and treatment of atrial fibrillation: the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. *Stroke.* 2010 Apr;41(4):581-7. doi: 10.1161/strokeaha.109.573907. PMID: 20190000.
42. Clua-Espuny JL, Lechuga-Duran I, Bosch-Princep R, et al. Prevalence of undiagnosed atrial fibrillation and of that not being treated with anticoagulant drugs: the AFABE study. *Rev Esp Cardiol (Engl Ed).* 2013 Jul;66(7):545-52. doi: 10.1016/j.rec.2013.03.003. PMID: 24776203.
43. Fitzmaurice DA, Hobbs FD, Jowett S, et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. *BMJ.* 2007 Aug 25;335(7616):383. doi: 10.1136/bmj.39280.660567.55. PMID: 17673732.
44. Frewen J, Finucane C, Cronin H, et al. Factors that influence awareness and treatment of atrial fibrillation in older adults. *QJM.* 2013 May;106(5):415-24. doi: 10.1093/qjmed/hct060. PMID: 23504411.
45. Furberg CD, Psaty BM, Manolio TA, et al. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). *Am J Cardiol.* 1994 Aug 01;74(3):236-41. PMID: 8037127.
46. Hill JD, Mottram EM, Killeen PD. Study of the prevalence of atrial fibrillation in general practice patients over 65 years of age. *J R Coll Gen Pract.* 1987 Apr;37(297):172-3. PMID: 3694577.
47. Wheeldon NM, Tayler DI, Anagnostou E, et al. Screening for atrial fibrillation in primary care. *Heart.* 1998 Jan;79(1):50-5. PMID: 9505919.
48. Svennberg E, Engdahl J, Al-Khalili F, et al. Mass screening for untreated atrial fibrillation: the STROKESTOP Study. *Circulation.* 2015 Jun 23;131(25):2176-84. doi: 10.1161/circulationaha.114.014343. PMID: 25910800.
49. Engdahl J, Andersson L, Mirskaya M, et al. Stepwise screening of atrial fibrillation in a 75-year-old population: implications for stroke prevention. *Circulation.* 2013 Feb 26;127(8):930-7. doi: 10.1161/circulationaha.112.126656. PMID: 23343564.
50. Turakhia MP, Ullal AJ, Hoang DD, et al. Feasibility of extended ambulatory electrocardiogram monitoring to identify silent atrial fibrillation in high-risk patients: the Screening Study for Undiagnosed Atrial Fibrillation (STUDY-AF). *Clin Cardiol.* 2015 May;38(5):285-92. doi: 10.1002/clc.22387. PMID: 25873476.
51. Bury G, Swan D, Cullen W, et al. Screening for atrial fibrillation in general practice: a national, cross-sectional study of an innovative technology. *Int J Cardiol.* 2015 Jan 15;178:247-52. doi: 10.1016/j.ijcard.2014.10.037. PMID: 25464263.

Appendix References

52. Martinez C, Katholing A, Freedman SB. Adverse prognosis of incidentally detected ambulatory atrial fibrillation. A cohort study. *Thromb Haemost*. 2014 Aug;112(2):276-86. doi: 10.1160/th4-04-0383. PMID: 24953051.
53. Fitzmaurice DA, McCahon D, Baker J, et al. Is screening for AF worthwhile? Stroke risk in a screened population from the SAFE study. *Fam Pract*. 2014 Jun;31(3):298-302. doi: 10.1093/fampra/cmu011. PMID: 24728774.
54. Boriani G, Laroche C, Diemberger I, et al. Asymptomatic atrial fibrillation: clinical correlates, management, and outcomes in the EORP-AF Pilot General Registry. *Am J Med*. 2015 May;128(5):509-18.e2. doi: 10.1016/j.amjmed.2014.11.026. PMID: 25534423.
55. Potpara TS, Polovina MM, Marinkovic JM, et al. A comparison of clinical characteristics and long-term prognosis in asymptomatic and symptomatic patients with first-diagnosed atrial fibrillation: the Belgrade Atrial Fibrillation Study. *Int J Cardiol*. 2013 Oct 12;168(5):4744-9. doi: 10.1016/j.ijcard.2013.07.234. PMID: 23958417.
56. Tsang TS, Barnes ME, Pellikka PA, et al. Silent atrial fibrillation in Olmsted County: a community-based study. *Can J Cardiol*. 2011;27(5):S122-S.
57. Siontis KC, Gersh BJ, Killian JM, et al. Typical, atypical, and asymptomatic presentations of new-onset atrial fibrillation in the community: Characteristics and prognostic implications. *Heart Rhythm*. 2016 Jul;13(7):1418-24. doi: 10.1016/j.hrthm.2016.03.003. PMID: 26961300.
58. Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. *Am J Cardiol*. 1986 Mar 01;57(8):563-70. PMID: 3953440.
59. Nerheim P, Birger-Botkin S, Piracha L, et al. Heart failure and sudden death in patients with tachycardia-induced cardiomyopathy and recurrent tachycardia. *Circulation*. 2004 Jul 20;110(3):247-52. doi: 10.1161/01.CIR.0000135472.28234.CC. PMID: 15226218.
60. Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. *N Engl J Med*. 2008 Jun 19;358(25):2667-77. doi: 10.1056/NEJMoa0708789. PMID: 18565859.
61. Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. *J Am Coll Cardiol*. 2004 Apr 7;43(7):1201-8. doi: 10.1016/j.jacc.2003.11.032. PMID: 15063430.
62. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. *Lancet*. 2000 Nov 25;356(9244):1789-94. PMID: 11117910.
63. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. 2014 Dec 02;64(21):e1-76. doi: 10.1016/j.jacc.2014.03.022. PMID: 24685669.
64. Caldeira D, David C, Sampaio C. Rate versus rhythm control in atrial fibrillation and clinical outcomes: updated systematic review and meta-analysis of randomized controlled trials. *Arch Cardiovasc Dis*. 2012 Apr;105(4):226-38. doi: 10.1016/j.acvd.2011.11.005. PMID: 22633297.

Appendix References

65. Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med*. 2002 Dec 5;347(23):1825-33. doi: 10.1056/NEJMoa021328. PMID: 12466506.
66. Shariff N, Desai RV, Patel K, et al. Rate-control versus Rhythm-control Strategies and Outcomes in Septuagenarians with Atrial Fibrillation. *Am J Med*; 2013. p. 887-93.
67. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. *Europace*. 2012 Oct;14(10):1385-413. doi: 10.1093/europace/eus305. PMID: 22923145.
68. National Clinical Guideline Centre. National Institute for Health and Clinical Excellence: Guidance. Atrial Fibrillation: The Management of Atrial Fibrillation. London: National Institute for Health and Care Excellence; 2014.
69. Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. *N Engl J Med*. 2002 Dec 5;347(23):1834-40. doi: 10.1056/NEJMoa021375. PMID: 12466507.
70. Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. *N Engl J Med*. 2010 Apr 15;362(15):1363-73. doi: 10.1056/NEJMoa1001337. PMID: 20231232.
71. Mead GE, Elder AT, Flapan AD, et al. Electrical cardioversion for atrial fibrillation and flutter. *Cochrane Database Syst Rev*. 2005(3):Cd002903. doi: 10.1002/14651858.CD002903.pub2. PMID: 16034878.
72. Van Gelder IC, Crijns HJ, Van Gilst WH, et al. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. *Am J Cardiol*. 1991 Jul 01;68(1):41-6. PMID: 2058558.
73. Mancini GB, Goldberger AL. Cardioversion of atrial fibrillation: consideration of embolization, anticoagulation, prophylactic pacemaker, and long-term success. *Am Heart J*. 1982 Sep;104(3):617-21. PMID: 7113903.
74. Lafuente-Lafuente C, Valembois L, Bergmann J-F, et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. *Cochrane Database of Systematic Reviews*: John Wiley & Sons, Ltd; 2015.
75. Tracy CM, Akhtar M, DiMarco JP, et al. American College of Cardiology/American Heart Association 2006 update of the clinical competence statement on invasive electrophysiology studies, catheter ablation, and cardioversion: a report of the American College of Cardiology/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training developed in collaboration with the Heart Rhythm Society. *J Am Coll Cardiol*. 2006 Oct 03;48(7):1503-17. doi: 10.1016/j.jacc.2006.06.043. PMID: 17010821.
76. Chen Huai S, Wen Jun M, Wu Sheng N, et al. Catheter ablation for paroxysmal and persistent atrial fibrillation. *Cochrane Database of Systematic Reviews*: John Wiley & Sons, Ltd; 2012.
77. Nyong J, Amit G, Adler AJ, et al. Efficacy and safety of ablation for people with non-paroxysmal atrial fibrillation. *Cochrane Database Syst Rev*. 2016 Nov 22;11:Cd012088. doi: 10.1002/14651858.CD012088.pub2. PMID: 27871122.

Appendix References

78. Liu J, Sylwestrzak G, Barron J, et al. Evaluation of practice patterns in the treatment of atrial fibrillation among the commercially insured. *Curr Med Res Opin.* 2014 Sep;30(9):1707-13. doi: 10.1185/03007995.2014.922061. PMID: 24809834.
79. Allen LaPointe NM, Governale L, Watkins J, et al. Outpatient use of anticoagulants, rate-controlling drugs, and antiarrhythmic drugs for atrial fibrillation. *Am Heart J.* 2007 Nov;154(5):893-8. doi: 10.1016/j.ahj.2007.06.035. PMID: 17967595.
80. Kneeland PP, Fang MC. Trends in catheter ablation for atrial fibrillation in the United States. *J Hosp Med.* 2009 Sep;4(7):E1-5. doi: 10.1002/jhm.445. PMID: 19753578.
81. U.S. Preventive Services Task Force. U.S. Preventive Services Task Force, Procedure Manual, Appendix VI. Rockville, MD: U.S. Preventive Services Task Force; 2015. <https://www.uspreventiveservicestaskforce.org/Page/Name/methods-and-processes> Accessed May 17, 2017.
82. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. *Am J Prev Med.* 2001 Apr;20(3 Suppl):21-35. PMID: 11306229.
83. Benito L, Coll-Vinent B, Gómez E, et al. EARLY: a pilot study on early diagnosis of atrial fibrillation in a primary healthcare centre. *Europace.* 2015;17(11):1688-93. doi: 10.1093/europace/euv146. PMID: CN-01257576.
84. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. *J Am Coll Cardiol.* 1991 Aug;18(2):349-55. PMID: 1856403.
85. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. *N Engl J Med.* 1992 Nov 12;327(20):1406-12. doi: 10.1056/nejm199211123272002. PMID: 1406859.
86. Mant J, Fitzmaurice DA, Hobbs FD, et al. Accuracy of diagnosing atrial fibrillation on electrocardiogram by primary care practitioners and interpretative diagnostic software: analysis of data from screening for atrial fibrillation in the elderly (SAFE) trial. *BMJ.* 2007 Aug 25;335(7616):380. doi: 10.1136/bmj.39227.551713.AE. PMID: 17604299.
87. Hobbs FD, Fitzmaurice DA, Mant J, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. *Health Technol Assess.* 2005 Oct;9(40):iii-iv, ix-x, 1-74. PMID: 16202350.
88. Swancutt D, Hobbs R, Fitzmaurice D, et al. A randomised controlled trial and cost effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in the over 65s: (SAFE) [ISRCTN19633732]. *BMC Cardiovasc Disord.* 2004 Jul 29;4:12. doi: 10.1186/1471-2261-4-12. PMID: 15283871.
89. Halcox JPJ, Wareham K, Cardew A, et al. Assessment of Remote Heart Rhythm Sampling Using the AliveCor Heart Monitor to Screen for Atrial Fibrillation: The REHEARSE-AF Study. *Circulation.* 2017 Nov 7;136(19):1784-94. doi: 10.1161/circulationaha.117.030583. PMID: 28851729.
90. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. *Lancet.* 1989 Jan 28;1(8631):175-9. PMID: 2563096.

Appendix References

91. Posada IS, Barriaes V. Alternate-day dosing of aspirin in atrial fibrillation. LASAF Pilot Study Group. *Am Heart J*. 1999 Jul;138(1 Pt 1):137-43. PMID: 10385777.
92. Sato H, Ishikawa K, Kitabatake A, et al. Low-dose aspirin for prevention of stroke in low-risk patients with atrial fibrillation: Japan Atrial Fibrillation Stroke Trial. *Stroke*. 2006 Feb;37(2):447-51. doi: 10.1161/01.STR.0000198839.61112.ee. PMID: 16385088.
93. Stroke Prevention in Atrial Fibrillation Study Group Investigators. Preliminary report of the Stroke Prevention in Atrial Fibrillation Study. *N Engl J Med*. 1990 Mar 22;322(12):863-8. doi: 10.1056/nejm199003223221232. PMID: 2407959.
94. Stroke Prevention in Atrial Fibrillation Study. Final results. *Circulation*. 1991 Aug;84(2):527-39. PMID: 1860198.
95. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. *N Engl J Med*. 1990 Nov 29;323(22):1505-11. doi: 10.1056/nejm199011293232201. PMID: 2233931.
96. Caro JJ, Flegel KM, Orejuela ME, et al. Anticoagulant prophylaxis against stroke in atrial fibrillation: effectiveness in actual practice. *CMAJ*. 1999 Sep 7;161(5):493-7. PMID: 10497604.
97. Forslund T, Wettermark B, Wandell P, et al. Risks for stroke and bleeding with warfarin or aspirin treatment in patients with atrial fibrillation at different CHA(2)DS(2)VASc scores: experience from the Stockholm region. *Eur J Clin Pharmacol*. 2014 Dec;70(12):1477-85. doi: 10.1007/s00228-014-1739-1. PMID: 25219360.
98. Humphries KH, Kerr CR, Connolly SJ, et al. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. *Circulation*. 2001 May 15;103(19):2365-70. PMID: 11352885.
99. Kodani E, Atarashi H, Inoue H, et al. Beneficial Effect of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation- Results of the J-RHYTHM Registry 2. *Circ J*. 2016;80(4):843-51. doi: 10.1253/circj.CJ-16-0066. PMID: 27001190.
100. Aguilar Maria I, Hart R. Oral anticoagulants for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. *Cochrane Database of Systematic Reviews*. 2005(3)doi: 10.1002/14651858.CD001927.pub2. PMID: CD001927.
101. Aguilar Maria I, Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. *Cochrane Database of Systematic Reviews*. 2005(4)doi: 10.1002/14651858.CD001925.pub2. PMID: CD001925.
102. Coleman CI, Sobieraj DM, Winkler S, et al. Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation (Structured abstract). *Int J Clin Pract*. 2012;66(1):53-63. PMID: DARE-12012000802.
103. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. *Arch Intern Med*. 1994 Jul 11;154(13):1449-57. PMID: 8018000.
104. Tereshchenko LG, Henrikson CA, Cigarroa J, et al. Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis. *J Am Heart Assoc*. 2016 May;5(5)doi: 10.1161/jaha.116.003206. PMID: 27207998.

Appendix References

105. Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. *Arch Intern Med*. 1997 Jun 9;157(11):1237-40. PMID: 9183235.
106. van Walraven C, Hart RG, Connolly S, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. *Stroke*. 2009 Apr;40(4):1410-6. doi: 10.1161/strokeaha.108.526988. PMID: 19182090.
107. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med*. 2007 Jun 19;146(12):857-67. PMID: 17577005.
108. Aguilar M, Hart R. Antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks. *Cochrane Database Syst Rev*. 2005 Oct 19(4):CD001925. doi: 10.1002/14651858.CD001925.pub2. PMID: 16235290.
109. Assiri A, Al-Majzoub O, Kanaan AO, et al. Mixed treatment comparison meta-analysis of aspirin, warfarin, and new anticoagulants for stroke prevention in patients with nonvalvular atrial fibrillation (Provisional abstract). *Clin Ther*. 2013;35(7):967-84.e2. PMID: DARE-12013042121.
110. Cameron C, Coyle D, Richter T, et al. Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation (Provisional abstract). *Database of Abstracts of Reviews of Effects*. 2014(2):e004301. PMID: DARE-12014036609.
111. Ezekowitz MD, Levine JA. Preventing stroke in patients with atrial fibrillation. *JAMA*. 1999 May 19;281(19):1830-5. PMID: 10340371.
112. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. *Ann Intern Med*. 1999 Oct 05;131(7):492-501. PMID: 10507957.
113. Lapner S, Cohen N, Kearon C. Influence of sex on risk of bleeding in anticoagulated patients: a systematic review and meta-analysis. *J Thromb Haemost*. 2014 May;12(5):595-605. PMID: 24977286.
114. Roskell NS, Lip GY, Noack H, et al. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate. *Thromb Haemost*. 2010 Dec;104(6):1106-15. doi: 10.1160/th10-10-0642. PMID: 20967400.
115. Sahay S, Nombela-Franco L, Rodes-Cabau J, et al. Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation: a network meta-analysis from randomised trials. *Heart*. 2016 Sep 1doi: 10.1136/heartjnl-2016-309782. PMID: 27587437.
116. Sardar P, Chatterjee S, Chaudhari S, et al. New oral anticoagulants in elderly adults: evidence from a meta-analysis of randomized trials. *J Am Geriatr Soc*. 2014 May;62(5):857-64. doi: 10.1111/jgs.12799. PMID: 24786913.
117. Tawfik A, Bielecki JM, Krahn M, et al. Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation. *Clin Pharmacol*. 2016;8:93-107. doi: 10.2147/cpaa.s105165. PMID: 27570467.